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Abstract
Papillomaviruses (PY) are small DNA tumour viruses that infect mucosal and
cutaneous epithelium where they induce benign hyperproliferative lesions. In the
great majority of cases, papillomavirus infections are usually cleared, after several
months by a cell mediated immune response directed against viral antigens (Frazer
and Tindle 1996). Occasionally, however, the lesions do not regress and can progress
to cancer under appropriate environmental conditions. Failure of virus clearance is
attributed to a poor immunological response and persistent viral infection poses a
greater risk of neoplastic progression.
Together with E6 and E7, E5 is a transforming protein of PY. While E6 and E7 are
the main oncoproteins of mucosal human papillomavirus (HPYs) (Munger et af. 2001;
Mantovani and Banks 2001), E5 is the major oncoprotein of bovine papillomaviruses
(BPY s), particularly of BPY -1 (DiMaio and Mattoon 2001). The E5 protein is a small
hydrophobic peptide (from 83 amino acid residues in HPY-16 to 42 residues in BPY-
4) which is expressed during the early stages of infection in the deep layers of the
infected epithelium and its expression is extinguished as the lesion progresses
(Burnett et al. 1992; Anderson et al. 1997; Chang et al. 2001).
In agreement with its hydrophobic nature, E5 is localized in the endomembrane
compartments of the endoplasmic reticulum (ER) and Golgi apparatus (GA) of the
host cell (Burkhardt et al. 1989; Pennie et al. 1993). The function of E5 in vivo is not
known, but in vitro cell transformation is brought about by the activation of several
kinases, from growth factor receptors to cyclins-cdks (Morgan and Campo 2000). E5
interacts physically with the cellular protein 16k ductinlsubunit c, a component of the
gap junction and of the YO sector of the vacuolar H+-ATPase (Goldstein et al. 1991;
Conrad et al. 1993; Finbow et af. 1995; Faccini et al. 1996). This physical interaction
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has been deemed responsible for the down-regulation of gap junction communication
(Oelze et al. 1995; Faccini et al. 1996; Ashrafi et al. 2000) and for the lack of
acidification of endosomes and GA and the consequent impaired functions of these
organelles (Straight et al. 1995; Schapiro et al. 2000). Previous studies have shown
that transformed cells expressing BPV-1 E5 or BPV-4 E5 retain major
histocompatibility class I (MHC I) molecules in the Golgi apparatus and cause the
inhibition of transport of the complex to the cell surface (Marchetti et al. 2002;
Ashrafi et al. 2002).
This effect can be ascribed to a failure of acidification of the Golgi apparatus, as
similar effects are observed in control cells treated with the ionophore monensin.
In addition, the total amount of both MHC I protein and mRNA is reduced in E5-
transformed cells (Ashrafi et al. 2002).
Results from this thesis show that:
a) Transcription inhibition can be alleviated by interferon treatment and the
degradation of MHC Iheavy chain (HC) can be reversed by treatment with inhibitors
of proteasomes and lysosomes. However, the inhibition of transport of MHC I to the
cell surface is irreversible.
b) E5 is capable of physically interacting with heavy chain. Together with the
inhibition of the vacuolar ATPase (due to the interaction between E5 and 16k subunit
c), the interaction between E5 and heavy chain is likely to be responsible for retention
of MHC Iin the Golgi apparatus.
c) C-terminus deletion mutants of E5 are incapable of either down-regulating surface
MHC class Ior interacting with heavy chain, establishing that the C-terminus domain
of E5 is important in the inhibition of MHC I.
d) Other two PV E5 proteins, BPV-1 E5 and HPV-16 E5 are able to interact
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physically with heavy chains from different alleles. BPV-1 E5 interacts with two
equine classical class I heavy chains (EqB2 and EqB4) in vitro and the HPV-16 E5
interacts with classical HLA-A1, A2 and B8 in vitro and with HLA-A3 in vivo
(Ashrafi et al. 2006b).
e) Like HPV-16 E5, BPV-4 E5 is incapable of down-regulating certain non-classical
MHC genes (Araibi et at. 2006).
These observations lead to a deeper understanding of the general down-regulation of
MHC class I by the E5 proteins. Lack of surface classical MHC class I and presence
of non-classical MHC class I in infected cells expressing E5 would allow evasion of
cytotoxic T lymphocyte and NK killing and thus establishment of viral infection.
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Chapter 1 INTRODUCTION
CHAPTER 1: INTRODUCTION
1.1 IMMUNE RESPONSE
The mammalian body is susceptible to infection by many pathogens, which must first
make contact with the host and then establish a focus of infection in order to cause
disease. These pathogens differ greatly in their lifestyles, the structures of their
surfaces, and means of pathogenesis, which therefore requires an equally diverse set
of defensive responses from the host immune system (Mandell et al. 2000). The first
phase of host defence consists of those mechanisms that are present and ready to resist
an invader at any time. The epithelial surfaces of the body keep pathogens out, and
protect against colonization and against viruses and bacteria that enter through
specialized cell-surface interactions, by preventing pathogen adherence and by
secreting antimicrobial enzymes and peptides (Gibbons R.J. 1992; Podolsky 1999;
Ouellette 1999; Krisanaprakornkit et al. 2000). Bacteria, viruses, and parasites that
overcome this barrier are faced immediately by components of the innate immune
system. The innate immune responses rely on the ability of the body to recognize
conserved features of pathogens (i.e., LPS, dsDNA, ssRNA) that are absent in the host
cell. These pathogen-associated molecules stimulate two types of immune responses,
inflammatory responses and phagocytosis by cells such neutrophil and macrophages,
which in tum produce chemokines that recruit other inflammatory cells and secrete
cytokines that orchestrate the outcome of the inflammatory process. Innate immunity
provides a front line of host defence through effector mechanisms that engage the
pathogen directly, act immediately on contact with it, and are unaltered in their ability
to resist a subsequent challenge with either the same or a different pathogen. These
mechanisms often succeed in preventing an infection from becoming established. If
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not, they are reinforced through the recruitment and increased production of further
effector molecules and cells in a series of induced responses. These induced innate
responses often fail to clear the infection. In that case, macrophages and other cells
activated in the early innate response help to initiate the development of an adaptive
immune response (Janeway et al. 2001,2005).
1.1.1 Innate and adaptive response
Both innate immunity and adaptive immune responses depend upon the activities of
white blood cells, or leukocytes. Innate immunity largely involves granulocytes and
macrophages among other cell lines (see table 1). Adaptive immune responses depend
upon lymphocytes, which provide the lifelong immunity that can follow exposure to
disease or vaccination. The innate and adaptive immune systems together provide a
remarkably effective defence system. Many infections are handled successfully by the
innate immune system and cause no disease; others that cannot be resolved by innate
immunity trigger adaptive immunity and are then overcome successfully, followed by
lasting immunological memory (Fearon et al. 1996; Alan et al. 1998; Medzhitov et al.
1998; Caroll et al. 1998; Ploegh and Watts 1998). The macrophages and neutrophils
of the innate immune system provide a first line of defence against many common
microorganisms and are essential for the control of common bacterial infections.
However, they cannot always eliminate infectious organisms, and there are some
pathogens that they cannot recognize. The lymphocytes of the adaptive immune
system have evolved to provide a more versatile means of defence which, in addition,
provides increased protection against subsequent reinfection with the same pathogen
(Picker and Butcher 1992; Butcher and Picker 1996; Paul 1998; Mandell et al. 2000).
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Pathogens are accessible to antibodies only in the blood and the extracellular spaces.
However, some bacterial pathogens and parasites, and all viruses, replicate inside
cells where they cannot be detected by antibodies. The destruction of these invaders is
the function of the T lymphocytes, or T cells, which are responsible for the cell-
mediated immune responses of adaptive immunity. Cell-mediated reactions depend on
direct interactions between T lymphocytes and cells bearing the antigen that the T
cells recognize. The actions of cytotoxic T cells (CTL) are the most direct. These
recognize any of the body's cells that are infected with viruses, which replicate inside
cells, using the biosynthetic machinery of the cell itself. The replicating virus
eventually kills the cell, releasing new virus particles. Antigens derived from the
replicating virus are, however, displayed on the surface of infected cells, where they
are recognized by cytotoxic T cells. These cells can then control the infection by
killing the infected cell before viral replication is complete (Paul 1998; Mandell et al.
2000).
All the effects of T lymphocytes depend upon interactions with target cells containing
foreign proteins. Cytotoxic T cells and T helper type-I (THI) cells interact with
antigens produced by pathogens that have infected the target cell or that have been
ingested by it. T helper Type-2 (TH2) cells, in contrast, recognize and interact with B
cells that have bound and internalized foreign antigen by means of their surface
immunoglobulin. In all cases, T cells recognize their targets by detecting peptide
fragments derived from the foreign proteins, after these peptides have been captured
by specialized molecules in the host cell and displayed by them at the cell surface
(Figure 1) (Paul 1998; Janeway et al. 2001).
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Innate immunity elements Function
Complement components Many distinct plasma proteins that can be
activated by pathogens and induce a
series of inflammatory responses
Dendritic cells Phagocytic cells that when immature can
take up pathogens; when mature they act
as antigen- presenting cells to T cells,
initiating adaptive immune responses
Eosinophils Are thought to be involved in the killing
of antibody-coated parasites (worms)
Macrophages Primary phagocytic cells that engulf
pathogens and destroy them III
intracellular vesicles; also present
antigens to T cells and can activate them
Mast cells Tissue cells that trigger a local
inflammatory response by releasing
substances that act on local blood vessels
Neutrophils Primary phagocytic cells that engulf
pathogens and destroy them In
intracellular vesicles
NLRs (nucleotide-binding oligomerization Family of receptors that sense pathogens
domain (Nod)-like receptors) in the cytosol and induce host defence
signaling pathways upon activation
NK cells Activated in response to interferons or
macrophage-derived cytokines. Killing of
virus infected and tumour cells while the
adaptive immune response is generating
antigen-specific cytotoxic T cells
TLRs (Toll-like receptors) Family of receptors for many bacterial
and viral components (i.e.LPS, dsRNA,
ssRNA etc.) expressed by macrophages
and dendritic cells that mediate
extracellular recognition of pathogens
Table 1 The elements of innate immunity
Summary adapted from Franchi et aI., 2006, Kawai and Akira 2006, Janeway et aI.,
2005.
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Figure 1. CD8 and CD4 T cells. The CD8 cytotoxic T cells (left panels) interact
with antigenic peptides produced by cytosolic pathogens and are presented by MBC
class I molecules at the cell surface of the infected cells. THI cells (middle panels)
and TH2 cells (right panels) which express the CD4 co-receptor recognize fragments
of antigenic peptides derived from pathogens taken up into intracellular vesicles and
displayed at the cell surface by MBC class II molecules.
TH I are able to activate macrophages and they can also activate B cells to produce
antibodies belonging to certain IgG subclasses. TH2 cells stimulate B cells to
differentiate and produce immunoglobulins of all other types, and also activate naive
B cells to proliferate and secrete IgM. The different types of immunoglobulin
together form the effector molecules of the humoral immune response. (Picture
courtesy of Charles A Janeway, Paul Travers, Mark Walport, Mark Shlomchik in
Immunobiology © 200 I by Garland Publishing).
apoptotic cell
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The molecules that display peptide antigen to T cells are membrane glycoproteins
encoded in a cluster of genes named major histocompatibility complex, abbreviated to
MHC.
There are two types of MHC molecule, called MHC class I and MHC class II (figure
1.1). These differ in several subtle ways but share most of their major structural
features (Bjorkman et al. 1987a; Brown et al. 1993; Jones 1997). The most important
of these is formed by the two outer extracellular domains of the molecule, which
combine to create a long cleft in which a single peptide fragment is trapped during the
synthesis and assembly of the MHC molecule inside the cell (Madden et al. 1992;
Stem and Wiley 1994; Murthy and Stem 1997). The MHC molecule bearing its cargo
of peptide is then transported to the cell surface, where it displays the peptide to T
cells. The antigen receptors of T lymphocytes are specialized to recognize a foreign
antigenic peptide fragment bound to an MHC molecule. A T cell with a receptor
specific for the complex formed between that particular foreign peptide and MHC
molecule can then recognize and respond to the antigen-presenting cell (Paul 1998).
The most important differences between the two classes of MHC molecule lie not in
their structure but in the source of the peptides that they trap and carry to the cell
surface. MHC class I molecules collect peptides derived from proteins synthesized in
the cytosol, and are thus able to display fragments of viral proteins on the cell surface.
MHC class II molecules bind peptides derived from proteins in intracellular vesicles,
and thus display peptides derived from pathogens living in macrophage vesicles or
internalized by phagocytic cells and B cells (Morrison et al. 1986).
Having reached the cell surface with their peptide cargo, the two classes of MHC
molecule are recognized by different functional classes of T cell. MHC class I
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molecules bearing viral peptides are recognized by cytotoxic T cells, which then kill
the infected cell; MHC class II molecules bearing peptides derived from pathogens
taken up into vesicles are recognized by helper T cells THI, which activate
macrophages and can release cytokine and chemokines or helper T cells TH2 that
activate B cells.
The antigen-specific activation of these effector T cells is aided by co-receptors that
distinguish between the two classes of MHC molecule; cytotoxic cells express the
CD8 co-receptor that binds MHC class I molecules, whereas THI and TH2 cells
express the CD4 co-receptor with specificity for MHC class II molecules. On
recognizing their targets, the three types of T cell are stimulated to release different
sets of effector molecules. These effector molecules include many cytokines, which
have a crucial role in the clonal expansion of lymphocytes as well as in innate
immune responses and in the effector actions of most immune cells (Paul 1998;
Janeway et af. 2001).
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Fig 1.1 MHC class I and class II proteins. (A) The class I MBC proteins consists of
an a chain with an extracellular region composed by three domains, a l, a2 and a3
which are encoded by separate exons. The al and a2 domains are highly
polymorphic. The a3 domain is Ig-like. ~-2 microglobulin is a small non glycosylated
protein that is associated noncovalently with the a chain. (B) The class II MBC
proteins consist of two chains a and ~ which are highly polymorphic in the al and ~l
domains whereas the a2 and ~2 domains are Ig-like. The al and a2 domains of the
class I proteins and o.l and ~1 domains of class II proteins interact to create a long
cleft (shaded in blue) in which peptide fragments of foreign proteins are trapped and
then presented to T cells. (Picture courtesy of Molecular Biology of The Cell © 2002
by Bruce Alberts, Alexander Johnson, Julian Lewis, Martin Raff, Keith Roberts, and
Peter Walter).
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1.1.2 CD4 and CD8 co-receptors
T cells fall into two major classes that have different effector functions. The two
classes are distinguished by the expression of the cell-surface proteins CD4 and CD8
(Swain 1983; Norment et al. 1988; Salter et al. 1990; Cammarota et al. 1992; Konig
etal.1992).
CD4 is a single-chain molecule composed of four immunoglobulin-like domains
(Figure 1.2). The first two domains (01 and O2) of the CD4 molecule are packed
tightly together to form a rigid rod some 60 A long, which is joined by a flexible
hinge to a similar rod formed by the third and fourth domains (03 and 04) (Ryu et al.
1990; Wang et al. 1990; Wu et al. 1997). CD4 binds MHC class II molecules through
a region that is located mainly on a lateral face of the first domain, 01. Because CD4
binds to a site on the P domain of the MHC class II molecule that is well away from
the site where the T-cell receptor binds, the CD4 molecule and the T-cell receptor can
bind the same peptide:MHC class II complex (Janeway 1992; Reich et al. 1997).
When CD4 and the T-cell receptor can simultaneously bind to the same MHC class
II:peptide complex, the sensitivity of a T cell to antigen presented by MHC class II
molecules is markedly increased; the T-cell in this case requires lOO-foldless antigen
for activation (Zamoyska 1998; Gao G.F. et al. 2002).
The CD8 molecule is a disulfide-linked heterodimer consisting of an a and a p chain,
each containing a single immunoglobulin-like domain linked to the membrane by a
segment of extended polypeptide chain (Figure 1.2) (Parnes 1989; Leahy et al. 1992).
This segment is extensively glycosylated, which is thought to be important in
maintaining this polypeptide in an extended conformation and protecting it from
cleavage by proteases. CD8a chains can also form homo-dimers, although these are
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not found when the CD8P chains are present. CD8 binds weakly to an invariant site in
the U3 domain of an MHC class I molecule, which is equivalent to the site in MHC
class II molecules to which CD4 binds (Sun et al. 1995). Although only the
interaction of the CD8u homodimer with MHC class I is so far known in detail (Gao
et al. 1997), it is clear from this that the MHC class I binding site of the CD8 u:p
heterodimer will be formed by the interaction of the CD8u and p chains. In addition,
CD8 (most probably through the u chain) interacts with residues in the base of the U2
domain of the MHC class I molecule (Sun et al. 1995; Gao et al. 2000b). Binding in
this way, CD8 leaves the upper surface of the MHC class I molecule exposed and free
to interact simultaneously with a T-cell receptor (Gao et al. 2000a; Gao et al. 2002).
And as with CD4, the presence of CD8 increases the sensitivity of T cells to antigen
presented by MHC class I molecules by about lOO-fold. Thus, CD4 and CD8 have
similar functions and bind to the same approximate location in MHC class I and MHC
class II molecules even though the structures of the two co-receptor proteins are only
distantly related (Gao et al. 2002).
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CD4
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Figure 1.2 The CD4 and CD8 co-receptor molecules. CD4 is a single-chain molecule
composed of four immunoglobulin-like domains. The Dl and D2 domains are packed
tightly together to form a rigid rodlike structure that is linked to the carboxy-terminal
domains (D3 and D4) by a flexible link. It is thought that the binding site for MHC class
II molecules involve both the D1 and D2 domains. CD8 consists of an a and a b chain
covalently linked by a disulfide bond; it can also exist as an homodimer of a chains.
CD8a and CD8b immunoglobulin-like domains are linked to the membrane by an
extended polypeptide chain. The binding site for MHC class I molecules is thought to
involve the CD8a chain (Picture courtesy of Charles A Janeway, Paul Travers, Mark
Walport, Mark Shlomchik in Immunobiology © 2001 by Garland Publishing).
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1.1.3 The Major Histocompatibility Complex Class I (MHC I)
The major histocompatibility complex (MHC) is located on chromosome 6 in
humans, chromosome 17 in mouse and chromosome 23 in cattle. The MHC spans
approximately 4 Mbp of the human genome, 1.5 Mbp in mice and approximately 2.5
Mbp in cattle (Gellin et al. 2000). In mammals it contains more than 260 genes that in
humans are called Human Leukocyte Antigen or HLA genes, as they were first
discovered through antigenic differences between white blood cells from different
individuals; in mouse they are known as the H-2 genes and in cattle as bovine
leukocyte antigen (BoLA) genes (Beisel et al. 1980; Demant et al. 1981; The MHC
sequencing consortium 1999; Beck et al. 2000; Horton et al. 2004). The structure and
organization of the MHC genes of cattle, are very similar to those of the human. The
major difference between their organization is that the BoLA class II loci are found in
two separate regions of the chromosome rather than in a single cluster of genes as
seen in most mammals (Andersson et al. 1988; van Eijk et al. 1993; Childers et al.
2006). The mature MHC class I complexes consist of three noncovalently associated
components: a 45-kDa heavy chain (HC); a 12-kDa light chain, Prmicroglobulin (P2-
m); and a short peptide antigen (Jones 1997). There are three class la loci in humans
called HLA-A, B, and C; in mice, H-2K, H-2D, and H2L (Ploegh et al. 1981). There
are also many class Ib (Shawar et al. 1994) and MIC (MHC class I-chain related) loci
(Bahram et al. 1994). The class la HC genes are extremely polymorphic (Parham et
al. 1995). These genes encode type Iglycoproteins of approximately 340 amino acids,
consisting of a cytoplasmic region (about 30 residues), a transmembrane region, and
an extracellular region composed of three domains (o l , a2, and a3) with one to three
N-linked glycosylation sites (Bjorkman et al. 1987a). P2-m is a nonglycosylated
protein of about 100 amino acids encoded on chromosome 15 in humans and 2 in
12
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mice. This protein has no transmembrane domain and remains associated with cells
by interacting with the extracellular region of HC. The structure of a number of MHC
I molecules has been solved (Bjorkman et al. 1987a; Bjorkman et al. 1987b; Wilson
et al. 1993; Young et al. 1995). P2-m makes extensive contacts with all three domains
of the HC (Bjorkman et al. 1987a). Because of this, the conformation of the HC is
very dependent on the presence or absence of Prm. The membrane-proximal a3
region of the HC is an immunoglobulin-like domain that contains a binding site for
the CDS receptor on CTL. The a 1 and a2 domains, which are distal to the membrane
and interact with the T cell receptor on CTL, fold together to form a groove that binds
and displays peptides. A beta-pleated sheet forms the base of the cleft, and the walls
are made of two alpha helices. The allelic polymorphisms in HC primarily occur in
those residues in and around this cleft, and in this manner, they alter the peptide-
binding specificity of the class I molecules (Bjorkman et al. 1987b; Parham et al.
1995; York et al. 1996).
The solution of the crystal structure of the class I proteins also provided insight into
the problem of how a single type of molecule could bind and present so many
different peptides. Many of the molecular interactions are with the peptide main chain
atoms and amino and carboxy termini, which are features common to all peptides.
The groove is generally long enough to accommodate 8 or 9 residues in an extended
conformation (Madden et al. 1992). Longer peptides can also fit by bulging partly out
of the groove or by zigzagging within the cleft (Madden et al. 1993; Madden 1995).
In some cases the ends of the peptide may extend out of the groove, although this
decreases the stability of interaction (Chen et al. 1994; Collins et al. 1994).
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1.1.3.1 The antigen processing and presentation
An effector cytotoxic T cell kills a virus-infected cell when it recognizes fragments of
viral proteins bound to MHC class I on the surface of the infected cell (Figure 1.3).
The major pathway for degrading proteins in the cytosol is ATP-dependent and highly
conserved from yeast to mammals (Goldberg et al. 1976). In this process proteins are
hydrolyzed to oligopeptides by a large multicatalytic proteolytic particle, the
proteasome (Rechsteiner et al. 1993; Peters 1994). One form of the proteasome is a
20S (700 kDa) cylindrical particle composed of four rings (Lowe et at. 1995).
Another form of the proteasome is a 26S (1500 kDa) particle, which contains as its
proteolytic core the 20S structure associated with many additional subunits that
regulate its activity (Rechsteiner et al. 1993; Peters 1994). This larger particle
degrades some protein substrates directly in an ATP-dependent manner. In addition,
the 26S structure binds polyubiquitin chains (Deveraux et al. 1994) and is responsible
for degrading ubiquitin-conjugated proteins. The degradation of many cellular
proteins is initiated by their modification with the small polypeptide ubiquitin that is
attached via an isopeptide bond to lysines on the substrate and on other ubiquitins
(Ciechanover 1994; Hershko and Ciechanover 1998).
Many unfolded proteins and polypeptides, can be ubiquitinated and degraded by the
proteasome. Thus, is not surprising that the proteasome is the major source of peptide
supply to class I molecules (Rock and Goldberg 1999).
It has been shown that when cells are stimulated with IFN-y, a cytokine that is
commonly produced after virus infection, the synthesis of three proteasome subunits,
low-molecular mass polypeptide-2 (LMP2), -7 (LMP7), and multicatalytic
endopeptidase complex-like-l (MECL-l) are induced (Brown et al. 1991;Nandi et al.
1996; Rock and Goldberg 1999). Furthermore the genes encoding LMP2 and LMP7
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are MHC-linked, suggesting that these subunits of the proteasome have co-evolved
with MHC class I molecules (Glynne et al. 1991; Kelly et al. 1991).
Proteasomes that contain IFN-y inducible subunits are termed immunoproteasomes
and represent the predominant form found in antigen presenting cells (APCs) and
inflamed tissues (Stohwasser et al. 1997; Macagno et al. 1999). Data suggest that
IFN-y induces formation of immunoproteasomes and the synthesis of the proteasome
activator PA28 (Nandi et al. 1996; Macagno et al. 1999; Strehl et al. 2005). Both alter
the proteolytic properties of the proteasome complex and enhance proteosomal
function in antigen presentation (Aki et al. 1994; Eleuteri et al. 1997; Hendil et al.
1998; Kloetzel 2004).
Some peptides produced in the cytosol are further degraded by endopeptidases and
aminopeptidases into amino acids, which may be used for protein synthesis or energy
production (Hershko and Ciechanover 1998). A fraction of these peptides must pass
into the lumen of the ER before they can bind to MHC Imolecules that are assembled
in this organelle. This process is made possible by TAP (transporter associated with
antigen presentation) that is a member of the ATP-binding cassette (ABC) family of
transporters, which share a common architecture and require ATP for their transport
activity (Monaco 1992; Townsend et al. 1993; Reits et al. 2000). The members of this
family transport across cell membranes a wide range of molecules, ranging from ions
to large proteins. They have either 6 or 12 membrane spanning domains; those with 6
transmembrane domains, such as the TAP proteins, function as heterodimers or
homodimers. The two subunits of TAP are approximately 76 (TAPl) and 70 (TAP2)
kDa and are noncovalently associated. Although one study suggests that TAPI might
also be able to function as a homodimer (Gabathuler et al. 1994), TAPI and TAP2
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generally seem nonfunctional when expressed alone (Meyer T.H. et al. 1994; Russ et
al. 1995). Immunoelectron microscopy and confocal analysis have localized TAP to
the ER (Russ et al. 1995) and the eis-Golgi (Kleijmeer et al. 1992). This subcellular
distribution is consistent with the location in cells where MHC molecules bind
peptides. The sequence of both the TAP1 and TAP2 subunits shows consensus ATP
binding sites in the cytoplasmic domain, near the C-terminus. The peptide-binding
site is also in the cytoplasmic region and is probably formed by both subunits (van
Endert et al. 1995) (van Endert et al. 1994). Peptide binds to the TAP complex
independently of ATP (van Endert et al. 1994) while peptide translocation is ATP-
dependent (Androlewicz et al. 1993).
TAP effectively binds peptides ranging from 8 to 13 residues in leght, but peptides of
up to 40 residues can be translocated (Pamer and Cresswell 1998).
The finding that many of the transported peptides are longer than the optimal length
(8-10 residues) for binding to MHC molecules is consistent with the notion that some
peptides require further N-terminal trimming in the ER (Stoltze et al. 2000). In mice,
MHC I molecules show preferences for binding peptides containing hydrophobic
residues at the C-terminus, and human MHC I mainly binds peptides with
hydrophobic and basic C-termini; the TAP transporters in each case show a similar
bias (Schumacher et al. 1994; Momburg et al. 1994).
Studies with TAP-deficient cell lines (Townsend et al. 1989), TAPI-deficient mice
(Van Kaer et al. 1992) and TAP-deficient humans (de la Salle H. et al. 1994) have
provided strong evidence that TAP is the major source of peptide supply to the ER
lumen.
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Figure 1.3 Viral protein processing for presentation to CTL cells.
After the entry of a virus in a target cell (here is shown an enveloped RNA virus)
some of the viral proteins synthesized are degraded by the proteasome. A fraction of
these peptides are then transported into the lumen of the ER where they can bind to
the MHC class I associated in the loading complex. This consists of several chaperone
proteins only one of which is shown in black. After peptide binding the MHC I loaded
complex is transported through the GA to the cell surface for presentation to cytotoxic
T cells. (Picture courtesy of Molecular Biology of The Cell © 2002 by Bruce Alberts,
Alexander Johnson, Julian Lewis, Martin Raff, Keith Roberts, and Peter Walter)
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The MHC I heavy and light chains are synthesized separately on the rough ER and are
cotranslationally transported into the ER. The loading of MHC class I molecules with
peptides in the ER is a highly regulated process that involves a variety of accessory
proteins (Figure 1.4) (Pamer and Cresswell 1998; Cresswell 2000; Van Kaer 2001).
The initial steps of class Iassembly are largerly controlled by chaperones with general
housekeeping functions, whereas dedicated proteins participate in the later stages of
class Iassembly (Van Kaer 2001). The initial steps of class I assembly are controlled
by the lectin-like chaperones calnexin and calreticulin, both of which recognize
monoglucosylated N-linked glycans (Pamer and Cresswell 1998; Van Kaer 2001).
Soon after their synthesis class Iheavy chains bind with calnexin. Binding of class I
heavy chain with ~2-m induces the exchange of calnexin for the chaperone
calreticulin, at least in human cells. In murine cells, interaction of calnexin with class
I heavy chains may persist after ~2-m binding, but the significance of this species
difference remains unknown. Although the association of calnexin with class Iheavy
chains is undisputed, its importance for class I assembly is unclear because this
process proceeds normally in a human calnexin-deficient cell line (Sadasivan et at.
1995). One possible explanation for this finding is that, in human cells, other
chaperones such as immunoglobulin heavy chain binding protein (BiP) can
compensate for the loss of calnexin. There is indeed evidence that BiP binds with
human class I heavy chains during the early steps of class I assembly (Nossner and
Parham 1995).
Class Iheterodimers that bind with calreticulin are typically found in association with
a variety of other ER-resident proteins, including Erp57, the two subunits of the TAP
peptide transporter, and TAP-associated glycoprotein (tapasin) (Cresswell 2000;
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Grandea et al. 2001). This multifactorial protein complex is called the MHC class I
peptide-loading complex.
Tapasin is a transmembrane protein with an ER retention signal in its cytoplasmic
domain (Cresswell 2000), is encoded by an MHC-linked gene, and its expression is
up-regulated by IFN-y. It has been suggested that tapasin is in fact an MHC class 1-
like protein (Mayer and Klein 2001). Tapasin forms a physical link between the two
subunits of the TAP transporter and the class I heterodimers (Suh et al. 1994;
Ortmann et al. 1997).
Erp57 is a member of the protein disulfide isomerase family and mediates disulfide
bond rearrangements in glycoproteins to which it is recruited by calnexin or
calreticulin (Cresswell et al. 1999), moreover it interacts with tapasin, via an
interchain disulfide bond (Dick et al. 2002).
Emerging evidence indicates that TAP heterodimers initially interact with tapasin and
Erp57, assisted by calnexin. This intermediate complex then binds with classl/Bj-m
heterodimers, with release of calnexin and recruitment of calreticulin, to generate the
mature loading complex (Diedrich et al. 2001). It has been shown that Erp57 and
tapas in are covalently linked by a disulfide bond within the loading complex, and that
this interaction is critical for complete oxidation of class I heavy chain (Dick et al.
2002).
The role of calreticulin in class I assembly was recently evaluated with fibroblast cells
derived from mouse embryos that carry a lethal, homozygous mutation in their
calreticulin gene. Class I molecules in these cells fail to load with optimal peptide
ligands but these molecules are released into the secretory pathway at a normal or
even enhanced rate. Calreticulin-deficient cells have moderately reduced class I
surface levels and are defective in antigen presentation to class l-restricted CTLs (Gao
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et al. 2002). These findings indicate that tapas in, Erp57 and calreticulin play
cooperative and non-redundant roles in class I assembly.
Peptide translocation into the ER by TAP induces the release of classVp2-m
heterodimers from the peptide-loading complex (Pamer and Cresswell 1998;
Cresswell et al. 2005). In mouse cells it has been shown that release from calnexin
occurs after dissociation from TAP, so it appears that calnexin ultimately determines
if a class I molecule is to be exported from the ER (Suh et al. 1996; Marguet et al.
1999). Exit of peptide-loaded class I molecules from the ER occurs by selective
mechanism involving association with transport receptors (Herrmann et al. 1999;
Spiliotis et al. 2001).
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Fig. 1.4 The major histocompatibility complex (MHC) class I assembly and loading
pathway. The initial step of MHC class I complex assembly starts with the association
between the MHC class I heavy chain and the chaperone calnexin (CNX). After binding
the f32-microglobulin(f32-m)the folded MHC heavy chain becomes associated with the
peptide-loading complex, consisting of the transporter associated with antigen
presentation (TAP), tapasin, ErpS7 and calreticulin (CRT). The peptides derived form
degradation of viral proteins in the cytosol are then transported into the endoplasmic
reticulum (ER) lumen via TAP. Some peptides in the ER may require further trimming by
an ER-associated aminopeptidase (ERAP-1) to reach the optimal length of 8-10 amino
acids necessary for binding to MHC I molecules. The binding of a peptide of the
appropriate sequence to the class I molecule initiates its dissociation from the peptide-
loading complex. (Picture courtesy of Cresswell et al. 2005, Immunological Reviews vol.
207:145-157)
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1.1.4 NK cells and non-classical MHCIHLA
Natural Killer cells (NK) develop in the bone marrow from the common lymphoid
progenitor cell and circulate in the blood.
The mechanism of NK cell killing is the same as that used by cytotoxic T cells
generated in an adaptive immune response; cytotoxic granules are released onto the
surface of the bound target cell, and the proteins they contain penetrate the cell
membrane and induce programmed cell death. NK cells also secrete cytokines such as
interferon-y (IFN-y) and tumor necrosis factor-a (TFN-a) during infection and
inflammation (Salazar-Mather et al. 2000). NK cells are activated in response to
interferon-a (IFN-a) and interferon-B (IFN-~) or macrophage-derived cytokines such
as interleukin-2 (IL-2), which is one of the cytokines produced early in many
infections (Biron et al. 1999). Activated NK cells serve to contain virus infections
while the adaptive immune response generates antigen-specific cytotoxic T cells that
can clear the infection.
NK cells have two types of surface receptor that control their cytotoxic activity. One
type is an 'activating receptor' which triggers killing by the NK cells. Several types of
receptor provide this activation signal, including calcium-binding C-type lectins that
recognize a wide variety of carbohydrate ligands present on many cells. In human the
identified cytotoxic receptors are NKp30, NKp44, NKp46 (Biassoni et al. 2001) and
in mouse Ly49D and Ly42H (Smith et al. 2001).
A second set of receptors inhibit activation and prevent NK cells from killing normal
host cells. These 'inhibitory receptors' are specific for MHC class I alleles, which
helps to explain why NK cells selectively kill target cell bearing low level of MHC
class Imolecules. Various inhibitory receptors are consistently expressed by subsets
of NK cells including killer-cell immunoglobulin-like receptors (KIRs),
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immunoglobulin-like inhibitory receptors (lLT) and the lectin-like heterodimer CD94-
NKG2 (Biassoni et al. 2001). Also found in mice the CD94-NKG2 receptor interacts
with non-polymorphic MHC-like molecules, HLA-E in human and Qa-l m mice
(Renard et al. 1997; Lanier 1998; Vales-Gomez et al. 2000a).
In fact, in addition to the highly polymorphic "classical" MHC class I and class II
genes, there are many genes encoding MHC class I-type molecules that show little
polymorphism. These gene have been termed MHC class Ib genes (Bahram et al.
1994). Some class Ib genes, for example the members of the MIC gene family, are
under a different regulatory control from the classical MHC class I genes and are
induced in response to cellular stress. There are five MIC genes, but only two, MIC A
and MIC B, are expressed and produce protein products. They are expressed in
fibroblasts and epithelial cells, particularly in intestinal epithelial cells, and may play
a part in innate immunity (Groh et at. 1998).
The MIC A and MIC B molecules are recognized by a receptor that is present on NK
cells and is capable of activating these cells to kill MIC-expressing targets. The MIC
receptor is composed of two chains. One is NKG2D, an 'activating' member of the
NKG2 family of NK-cell receptors the other is a protein called DAPlO, which
transmits the signal into the interior of the cell by interacting with an activating
intracellular protein tyrosine kinase (Wu et al. 1999; Moretta et al. 2001).
Other MHC class Ib molecules may inhibit cell killing by NK cells. Such a role has
been suggested for the MHC class Ib molecule HLA-G, which is expressed on foetus-
derived placental cells that migrate into the uterine wall. These cells express no
classical MHC class I molecules and cannot be recognized by CD8+ T cells but,
unlike other cells lacking classical MHC class I molecules, they are not killed by NK
cells (Verma et al. 1997; Pende et al. 1997; Braud et al. 1999a).
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Another MHC class Ib molecule, HLA-E, also has a specialized role in cell
recognition by NK cells. HLA-E binds a very restricted subset of peptides, derived
from the leader sequence of other HLA class I molecules. These peptideslHLA-E
complexes can bind to the receptor NKG2A, which is present on NK cells in a
complex with the cell-surface molecule CD94. NKG2A is an inhibitory member of
the NKG2 family, and on stimulation inhibits the cytotoxic activity of the NK cell
(Braud et al. 1998) (Braud and McMichael 1999b) (Lopez-Botet et al. 2000; Vales-
Gomez et al. 2000a; Vales-Gomez et al. 2000b). Thus a cell that expresses either
HLA-E or HLA-G is not killed by NK cells.
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1.2 PAPILLOMA VIRUSES
The Papillomaviruses (PVs) had been originally grouped with the polyomaviruses in
one family, the Papovaviridae. This was based on similar, nonenveloped capsids and
the common circular double-stranded DNA genomes. As it was later recognized that
the two virus groups have different genomes sizes, completely different genome
organizations, and no major nucleotide or aminoacid sequence similarities, they are
now officially recognized by the International Committee on the Taxonomy of
Viruses (ICTV) as two separate families, Papillomaviridae and Polyomaviridae (de
Villiers et al. 2004).
One hundred eighteen papillomavirus type have been completely described, and a yet
higher number of presumed new types have been detected by preliminary data (de
Villiers et al. 2004).
PVs are a diverse group of viruses that have been found in more then 20 different
mammalian species, as well as in birds and reptiles. They are strictly species specific
and are not known to cross the species barriers with the exception of Bovine
Papillomaviruses (BPVs), which can infect horses and induce equine sarcoid (Olson
and Cook 1951; Ragland et al. 1969; Lancaster et al. 1977; Chambers et al. 2003a;
Chambers et al. 2003b).
PVs are non enveloped viruses with icosahedral capsids that replicate their genomes
within the nuclei of infected host cells. They have circular double-stranded DNA
genomes with sizes close to 8Kb. In spite of their small size, their molecular biology
is very complex. Briefly, three oncoproteins, E5, E6, and E7, modulate the
transformation process, two regulatory proteins, El and E2, modulate transcription
and replication, and three late proteins of which L1 and L2, compose the viral capsid
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and EI"E4 has several possible functions late in infection (i.e., collapse of cytokeratin
matrix, G2 cell cycle arrest) (Doorbar et al.,1991,1997, 2006; Munger et al. 2002;
Davy et al. 2005). The El, E2, L1 and L2 ORFs are particularly well conserved
among all members of the family. Most cis-responsive elements are in the long
control region (LCR) between L1 and E6, a segment with little sequence
conservation.
The direct link between papillomavirus infection and neoplasia, and the relationship
between malignant progression and environmental or genetic cofactors was first
established for animal papillomaviruses particularly cottontail rabbit papillomavirus
(CRPV) (Kreider et al. 1985), bovine papillomavirus (BPV) (Jarrett et al. 1978;
Campo 1992; Campo et al. 1994a), and canine oral papillomavirus (COPV) (Watrach
1969) (reviewed in Campo 2002).
The canine, cottontail rabbit and bovine papillomaviruses have been used as model
systems in which to study the interaction of a papillomavirus with its natural host and
with environmental cofactors (Jarrett et at. 1978; Campo et al. 1994b; Nicholls and
Stanley 1999) and have been for many years the model system with which to study
the biology of human papillomaviruses (HPV).
1.2.1 BOVINE PAPILLOMA VIRUSES
Bovine papillomaviruses fall into two subgroups (Jarrett et al. 1984): subgroup A and
B. The subgroup A comprises the fibropapillomaviruses BPV-I, -2 (also known as
delta-papillomavirus (Figure 1.5) (de Villiers et al. 2004) and BPV-5 (or epsilon-
papillomavirus) (Figure 1.5) (de Villiers et al. 2004) that also causes cutaneous
papillomas.
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The subgroup B (or Xi-papillornavirus) (Figure 1.5) (de Villiers et al. 2004)
comprises the epitheliotrophic papillomaviruses BPV-3, -4,- 6.
The fibropapillomaviruses have a larger genome (approximately 7.9Kb) than the
epithelial papillomaviruses, whose genome is approximately 7.3Kb.
In cattle BPV infection causes skin warts (BPV-1 and -2), papillomatosis and cancer
of the upper gastrointestinal (01) tract (BPV-4), papillomatosis of teats and udder
(BPV-l, -5 and -6) and penis (BPV-l) and cancer of the urinary bladder (BPV-l and
-2) (Campo 1997). Cancer of the upper OI tract and urinary bladder develop as a
result of the interactions between the virus, chemical carcinogens and
immunosuppressant present in bracken fern (Campo 1997; Beniston et al. 2001;
Beniston et al. 2003; Beniston et al. 2005).
Sequencing of the viral genomes has permitted molecular and genetic analysis, with
type 1 and 4 being used as representatives for each group in the following discussion.
1.2.1.1 Bovine papillomavirus type 1
BPV-1 is a fibropapillomavirus that infects both epidermal keratinocytes and the
underlying dermal fibroblast, resulting in the production of benign tumours.
Those papillomaviruses that are associated with fibropapillomas such as BPV-1 have
the capacity to transform a variety of rodent cells in tissue culture. The transformation
capacity of BPV in tissue culture was first demonstrated in the early 1960s (Black et
al. 1963; Boiron et al. 1964; Thomas et al. 1964). In the early 1980s, quantitative
focus assays were developed for BPV-1 using mouse and hamster cell culture
(Dvoretzky et al. 1980). This transformation property has permitted investigators to
study the viral functions involved in cellular transformation and in the induction of
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cellular proliferation, even in the absence of a tissue culture system for the productive
replication of the virus. Most of our knowledge of BPY-1 genetics has relied upon
this capacity of BPY-l to transform rodent cells, particularly mouse C127 cells
(Lambert et al. 1988).
The DNA of BPY -1 was the first to be completely sequenced (Chen et al. 1982).
Sequence analysis has identified the position of large open reading frames (ORPs)
that revealed a genetic organization common to the human papillomavirus type 1a
(HPY-la) (Danos et al. 1982).
1.2.1.2 Bovine papillomavirus type-4
Bovine papillomavirus type 4 (BPY-4) infects the mucous epithelium of the
alimentary canal of cattle and causes papillomas, which can progress to malignancy in
animals that feed on braken fern (Jarrett et af.1978; Campo et al. 1994a). It has been
shown that in naturally occurring bovine alimentary cancers the ras gene is rearranged
and activated (McCaffery et af. 1989; Campo et al. 1990), pS3 gene is mutated
(Scobie et al. 1997) and the level of EGF receptors is increased (Smith 1987). These
observations support the hypothesis that multiple independent events are necessary for
the development of cancer. Early studies of the transforming properties of BPY -4 in
vitro were conducted in established mouse fibroblast cells. The virus was found to
transform both NIH3T3 and C127 established cells in vitro (Campo et al. 1983;
Smith and Campo 1988). Work on C127 cell lines defined the BPY -4 E7 and BPY-4
ES (described in further details in sections 1.2.4.S and 1.2.S.2, respectively) as the
transforming proteins of BPY -4 (Smith and Campo 1988). Later work looked at BPY-
4 transformation of primary bovine fibroblasts (PalF) from the foetal palate (Jaggar et
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al. 1990). BPV -4 is incapable of transforming PalF cells by itself and requires the
cooperation of an activated ras gene to morphologically transform them. The partially
transformed PalFs have an extended life span and are capable of anchorage-
independent growth but are not immortal or tumorigenic in nude mice (Jag gar et al.
1990). In those cells it is the combination of BPV-4 E7, BPV-4 E5 and activated ras
that induce cell transformation (O'Brien et al. 1999; Ashrafi et al. 2000) but
immortalisation is conferred by HPV -16 E6 (Pennie et at. 1993), as the BPV-4
genome does not encode an E6 protein (Jackson et al. 1991).
BPV -4 shares many of the features of BPV -1, size and genome organisation are very
similar (Patel et at. 1987), the only major difference is the substitution of the ORF
encoding the transforming protein E6 with the ORF encoding the E5 oncoprotein
(formerly known as E8) (Jackson et at. 1991).
1.2.2 HUMAN PAPILLOMA VIRUSES
The Human Papillomaviruses (HPVs) are divided into two main groups: those that
infect cutaneous epithelia and produce skin warts, and those that infect mucosal
epithelia, which give rise to laryngeal and anogenital warts. Of the more than 100
identified types of HPVs, approximately 30 specifically infect the genital epithelium
(zur Hausen 2002). Recently all grouped in the Alpha-papiIIomavirus genus (de
ViIIiers et at. 2004) these viruses are subdivided into Iow-risk (HPV-6 and HPV-ll)
as they induce lesions at low-risk for progression to malignancy and high-risk (HPV-
16, HPV-18, HPV-31, HPV-33, HPV-45), associated at a high frequency with the
development of malignant lesions. Approximately 99% of cervical cancers contain
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HPV DNA of the high-risk types (Walboomers et al. 1999). The World Health
Organization (WHO) in 1995 recognized HPV-16 (Human papillomavirus-type 16)
and HPV-18 as carcinogenic to humans and HPV-31 and HPV-33 as possibly
carcinogenic to humans. Later in February 2005 twenty-five scientists from 13
countries met to re-assess the carcinogenicity of HPVs. They concluded that HPV
types 16,18,31,33,35,39,45,51,52,56,58,59,66 (grouped in the genus alpha) (de
Villiers et al. 2004) (Figure I.S) are carcinogenic to humans and HPV-6, -11 (genus
alpha) and some HPV types of genus beta (including HPV-S and HPV-8) are possibly
carcinogenic to humans (fARe Monographs on the evaluation of carcinogenic risks
to human 2005).
The Beta-papillomaviruses include some HPV types (among them HPV-S, HPV-8)
associated with epidermodysplasia verruciformis (EV), a cutaneous neoplastic disease
with a genetic component (Orth et al. 1978; Ramoz et al. 2002). In carriers who are
not genetically predisposed, beta-, and the related gamma-papillomaviruses normally
seem to establish asymptomatic infections or, at worst, induce small benign cutaneous
lesions. However, it is thought that some EV HPV types viruses may be involved in
the development of non-melanoma skin cancer (NMSC) also in the general population
(Harwood et al. 2004).
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Figure 1.5 Phylogenetic tree containing the sequence of 118 papillomavirus
types (Picture modified from de Villiers et af. 2004)
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1.2.3 VIRUS AND CELL DIFFERENTIATION
The initial viral infection requires access of infectious particles to cells, presumably
epithelial stem cells, in the basal layer of stratified epithelium, which for some HPV
types is thought to require a microlesion at this site. Following infection and
uncoating, it is thought that the virus maintains its genome as extrachromosomal
elements in the nucleus of the basal cells of the epithelium and is maintained at
around 10-200 copies per cell. The expression of viral proteins is regulated in line
with cell differentiation so that viral genome replication is carried out in the cells of
the spinous and granular layers, and capsid proteins are made only in the granular and
squamous cells of the upper layers, and the mature virus is then released from the
upper squamous layer. As infected cells divide, viral DNA is distributed between both
daughter cells. One of the daughter cells migrates away from the basal layer and
initiates a program of differentiation. The other daughter cell continues to divide in
the basal layer and provides a reservoir of viral DNA for further cell divisions. Since
production of papillomaviruses is restricted to suprabasal cells, the cells in the basal
layer are not lysed by virion production but continue to proliferate. This
differentiation-dependence allows the infected cells to persist in the basal layers for
periods as long as several years (Figure 1.6). Reviewed in (Stubenrauch and Laimins
1999; Doorbar 2005).
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Figure 1.6 Human papillomavirus life-cycle. Papillomavirus generally enters the
epithelium through micro-trauma and infects the basal layer cells. When a basal cell
divides, a daughter cell will migrate into the suprabasal differentiating cell layers,
where viral genes are activated in line with cell differentiation. Viral genome
replication is carried out in the cells of the spinous and granular layers, and capsid
proteins are made only in the granular and squamous cells of the upper layers, and
the mature virus is then released from the upper squamous layer.
(Picture courtesy of Harald zur Hausen 2002, Nature Reviews Cancer 5, 342-350).
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1.2.4 PAPILLOMA VIRUS GENOME ORGANISATION
The PVs genome can be divided into three regions, the early and late open reading
frames separated by a long control region (LCR) or upstream regulatory region
(URR). The early (E) proteins are those involved in cell transformation and viral
replication whereas the two late (L) proteins are the capsid proteins for packaging the
virus before release. The LCR or URR between late and early open reading frames
contains the origin of replication, and regulatory elements that coordinate the
expression of the viral proteins via proximal and distal promoters. In the viral LCRs
are present multiple E2 DNA binding sites (BS) (12 in BPV-I, 4 in BPV-4 and 4 in
HPV-16). E2 is the viral transcription regulator, and its binding to palindromic
consensus sequence ACCGN4CGGT, that differ in the sequences of the central N4
"spacer nucleotides", in the viral LCRs activates or represses transcription of the viral
genes (described in details in section 1.2.4.2) (Romanczuk et al. 1990; Bouvard et al.
1994b). The majority of mRNA species are initiated at promoters inside or near to the
LCR, with gene expression largely controlled post-transcriptionally (reviewed by
Lambert et al. 1988; Longworth and Laimins 2004) (Figure 1.7).
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Figure 1.7 Diagrammatic genomic organisation of BPV-I, BPV-4 and HPV-I6.
A, B, C) The viral genomes are represented as linear, with the open reading frames (ORF)
as rectangles. The function of the proteins encoded by the individual ORF is indicated.
(Picture courtesy of Papillomavirus Research: From Natural History to Vaccines and
Beyond, 2006).
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1.2.4.1 El ORF
El proteins, In conjunction with their cognate viral E2 proteins, are the origin
recognition proteins for papillomaviruses (Ustav et al. 1991; Wilson and Ludes-
Meyers 1991; Yang et al. 1991), recruit host cell replication proteins to the origin
(Park et al. 1994; Bonne-Andrea et al. 1995; Conger et al. 1999; Han et al. 1999;
Amin et al. 2000), and have intrinsic A'TPase/helicase activity (Hughes and Romanos
1993; Yang et al. 1993; Seo et al. 1993) that functions in origin unwinding and fork
progression (Gillette et al. 1994; Liu et al. 1995) reviewed by (Wilson et al. 2002).
1.2.4.2 E2 ORF
BPV 1 encodes three E2 proteins, the major transcription transactivator (E2TA), the
product of the full-length E2 ORF, which activates viral promoters by binding to E2
responsive elements. The function of the E2TA is repressed by two other E2 proteins;
the E2 transcriptional repressor (E2TR) encoded by the 3' half of the E2 ORF and
E81E2 transcriptional repressor (E81E2TR), a translation product of a viral spliced
RNA which fuses the upstream E8 ORF to the 3' end of the E2 ORF (Lambert et al.
1987; Choe et al. 1989; Lambert et al. 1990).The E2TA transactivator protein can be
divided into three domains. The amino-terminal -200 aminoacids comprise the
transactivation domain of E2, and the carboxy-terminal -100 aminoacids mediate
DNA binding and dimerization. These domains are linked by a variable region called
the hinge (Me Bride et al. 1997). The transactivation domain is critical for the
segregation of the viral genome to daughter nuclei, DNA replication, and
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transcriptional regulatory functions of the E2 protein (McBride et al. 1989; Winokur
et al. 1996; Skiadopoulos and McBride 1998; Bastien and McBride 2000). The
segregation of viral genome requires the interaction of the amino-terminal
transactivation domain of E2 with mitotic chromosomes (Bastien and McBride 2000).
E2 interacts with a cellular bromodomain protein, Brd4, to mediate the segregation of
viral genomes into daughter cells. Brd4 binds acetylated histones and has been
observed to diffusely coat mitotic chromosomes in several cell types (McPhillips et
al.2005).
Mutation of just two amino acids, in the region of the transactivation domain that is
crucial for the mitotic chromosome binding function of E2, eliminates chromosome
binding activity but retains the ability to support DNA replication in cooperation with
the viral El helicase (Baxter et al. 2005).
Also the E2 protein of BPY-4 is a transcription regulator, which acts on the BPY-4
long control region (LCR) to regulate transcription. There are four binding sites in the
BPY-4 LCR, binding site 1 (BS1), 2 (BS2), 3 (BS3), and 4 (BS4) of which BS4 and
BS2 mediate transactivation by E2, whereas BS1 and BS3 are responsible for
repression by elevated levels of E2 (Jackson et al. 1995; Morgan et al. 1998).These
data suggest that each of the four E2 sites performs different functions in the control
of transcription and that competition between cellular transcription factors and viral
E2 protein is essential in regulating the level of viral gene expression during
papilloma development (Jackson and Campo 1995).
The DNA-binding domain of HPY-16 E2 has been shown to make functional
interactions with the replication protein EI and several proteins have been identified
that interact with E2 proteins including TBP (Steger et al. 1995), AMFI (Breiding et
al. 1997), p300/CBP (Lee et al. 2000), SMN (Strasswimmer et al. 1999), TFIIB
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(Rank and Lambert 1995; Benson et al. 1997), TopBP1, RACK1, POMP, p27BBP
(Boner and Morgan 2002) and several of these can modulate the transcription and
replication properties of E2.
1.2.4.3 E4 ORF
Mutational analysis that prevented synthesis of the BPV-1 E4 ORF showed no effect
on transcription, replication of viral genome, or cell transformation (Neary et al.
1987) confirming the observation of others (Doorbar et al. 1986) that the E4 open
reading frame of papillomavirus is associated with late gene expression during
papilloma formation. The E4 gene product is found predominantly in the cytoplasm of
cells of the suprabasal epithelium (Doorbar et al. 1986; Chow et al. 1987; Crum et al.
1990).
The BPV-4 E4 ORF is transcribed into several RNA species (Stamps and Campo
1988). Two of these 7E11 and 1.6Kb transcripts, encode a potential E I1\E4 fusion
protein, although a different region of El is found in these two transcripts. The 7E11
transcript is most likely to encode the E11\E4 fusion peptide described for HPV-1a
(Doorbar et al. 1988). The expression of BPV-4 E4 is greatest in the differentiated
layers of papillomas (Anderson et at. 1997).
HPV encodes three late proteins, which are produced only in terminally
differentiating keratinocytes, two of which L1 and L2 are structural components of
the virion. The third, ElI\E4, is derived primarily from the E4 ORF, which represents
a region of maximal divergence between different HPV types. The expression of the
HPV 16-E11\E4 protein in human keratinocytes results in the total collapse of
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cytokeratin matrix (Doorbar et at. 1991). Expression of the viral El "E4 protein is lost
during malignant progression, but in premalignant lesions, El "E4 is abundant in cells
supporting viral DNA amplification. Expression of 16-El "E4 in cell culture causes
02 cell cycle arrest using a novel mechanism in which it sequesters CdkIlcyclin B1
onto the cytokeratin network preventing their accumulation in the nucleus and hence
prevents mitosis probably playing a role in creating an environment optimal for viral
DNA replication (Davy et al. 2005).
1.2.4.4 E6 ORF
Since the complete sequencing of the BPV -1 DNA (Chen et al. 1982) further genetic
dissection has identified E5 and E6 as the major transforming proteins of BPV-l
(Schiller et al. 1984; Yang et al. 1985; Neary and DiMaio 1989). Both E5 and E6
protein have been found in transformed cells (Androphy et at. 1985; Schlegel et al.
1986).
The 15.5kDa E6 protein is localised in both nuclear and membrane fractions of
transformed cells (Androphy et al. 1985). (The E5 protein is described in further
detail in section 1.2.5.1).
E6 it is capable of binding zinc through Cys-X-X-Cys motifs (Barbosa et al. 1989)
and stimulates transcription when targeted to a promoter (Lamberti et al. 1990). It is
capable of causing cell transformation in vitro (Androphy et al. 1985), but through a
mechanism involving both transcriptional activation (Vousden et at. 1989; Chen et al.
1997; Ned et al. 1997) and binding to cytoskeletal and vescicular proteins (Tong et al.
1997; Tong et al. 1998). It does not bind or promote degradation of p53 (Chen et al.
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1997). Furthermore, BPV -1 E6 sensitises mouse cells to tumour necrosis factor a
(TNF)-induced apoptosis (Rapp et al. 1999). Viral protein may suppress or delay
programmed cell death (PCD) (Lock shin et al. 1965) long enough for the production
of virus progeny. On the other hand, induction of PCD at late stages of infection by
viruses may represent a final and important step in spreading progeny to neighbouring
cells. Regulation of PCD is important in terms of pathogenesis of diseases.
BPV -1 E6 also reduces surface Fas expression decreasing the transduction of
apoptotic signals upon cross-linking with Fas ligand hence reducing Fas-mediated
apoptosis (Liu et al. 2005).
An unusual feature of BPVs of subgroup B, such as BPV-4, is their lack of the E6
ORF which has apparently been replaced by the E5 ORF (Jackson et al. 1991)
described in detail in section 1.2.5.2.
The HPV E6 ORF has been characterised most extensively, it encodes a 16-19kDa
cell transforming protein. Its transforming ability was discovered by viral expression
studies in human primary fibroblasts (Watanabe et al. 1989). In murine cells
persistent E6 expression is capable of causing transformation, and in K14E6
transgenic mice, in which the HPV -16 E6 gene is directed in its expression by the
human keratin 14 promoter (hKI4) to the basal layer of the epidermis, E6 induced
cellular hyperproliferation and epidermal hyperplasia and caused skin tumours in
adult mice (Song et al. 1999). E6 alone is not capable of immortalising primary
human foreskin keratinocytes (HFK) but can efficiently immortalise human mammary
epithelial cells (MECs) (Kiyono et al. 1997; Liu et al. 1999). In high-risk HPVs such
as HPV -16 however, E6 and E7 proteins are necessary and sufficient to immortalise
human squamous epithelial cells (Watanabe et al. 1989; Hawley-Nelson et al. 1989;
Munger et al. 1989).
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The E6 protein is capable of binding zinc through four Cys-X-X-Cys motifs that form
two zinc finger domains (Barbosa et al. 1989) and it may also act as a nucleic acid
binding protein. In high-risk HPV s it has been shown to complex with pS3 and to
promote its degradation via the ubiquitin pathway (Scheffner et al. 1990), while low
risk HPV E6 protein binds p53 less efficiently. p53 normally protects the cell from
mutations by causing cell cycle arrest or apoptosis in the event of DNA damage.
Chromosome damage has been found in E6-transformed cells (Coursen et al. 1997),
and E6 expression has been shown to abrogate checkpoints in the cell cycle in a
manner dependent upon pS3 binding and degradation (Thompson et al. 1997). It has
been shown to activate telomerase (Klingelhutz et al. 1996) a chromosome repair
enzyme that is typically upregulated in immortal cell lines. E6 protein has also been
shown to interact with cellular mini chromosome maintenance proteins which are
believed to playa key role in regulating cellular DNA replication (Kuhne and Banks
1998; Zimmermann et al. 2000). In addition to interacting with pS3, E6 may impact
on apoptosis through pS3-independent pathways. E6 can interact with and inhibit Bak,
a proapoptotic protein expressed at high levels in the upper layers of differentiating
epithelium (Thomas et al. 1998). The viral antiapoptotic function coupled with the
growth promoting functions, can contribute to uncontrolled growth and oncogenesis.
HPV E6 proteins target the PDZ-domain containing proteins such as the membrane-
associated guanylate kinases (MGUKs) for proteasome-mediated degradation
(Glaunsinger et al. 2000; Nakagawa et al. 2000). MAGUKs include the tumour
suppressor proteins hDlg and hScrib, involved in controlling cell polarity and also the
membrane associated guanylate kinase with inverted domain (MAGI-I) which is
believed to be involved in the regulation of cellular signal transduction pathways. The
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E6 proteins from high-risk HPV s differ in their ability to target these proteins in a
manner that correlates with their malignant potential (Thomas et al. 2001).
In a study in K14E6 transgenic mice, in which a mutated HPV-16 E6 gene lacking the
PDZ ligand motif was directed in its expression by human keratin 14 promoter
(hKI4) to the stratified squamous epithelia, it has been shown that the PDZ ligand
domain of HPV -16 E6 is necessary for the induction of epithelial hyperplasia in mice
(Nguyen et al. 2003) .
1.2.4.5 E7 ORF
Early studies in NIH3T3 cells established the product of the E7 ORF as the major
transforming protein of HPV -16 (Vousden et al. 1988).
Three domains have been identified: a retinoblastoma protein (Rb) binding domain
(Dyson et al. 1989), one zinc finger structure (Barbosa et al. 1989) and substrate sites
for protein kinase C and casein kinase II (CKII) (Firzlaff et al. 1989; Armstrong and
Roman 1995). The E7 protein blocks the negative regulation of retinoblastoma
tumour suppressor protein by binding to hypophosphorylated Rb and Rb-related
proteins and may also degrade Rb family members such as p107 and p130 (Boyer et
al. 1996).
The E7 protein of high-risk HPV -16 and HPV -18 bind hypophosphorylated Rb with
higher affinity than low-risk HPV -6 and HPV -11 (Griffiths and Mellon 1999).
Furthermore E7 has also been associated with AP-l transcription factor (Antinore et
al. 1996), the TATA box binding protein and members of the cyclin system
(Tommasino et al. 1993; Massimi et al. 1997). These associations contribute to the
ability of E7 to induce cellular proliferation, immortalization and transformation.
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The E7 protein of BPV-1 contains neither Rb-binding domain or CKII sites and is
consequently non-transforming. It has been reported that BPV-1 E7 contributes to the
control of viral DNA replication and copy number of viral genomes (Lusky and
Botchan 1985; Jareborg et al. 1992) rather than transformation per se.
A recent work correlates the lack of the canonical pRb-binding domain in the E7 ORF
of artiodactyl papillomaviruses such as BPV-1, -2, -5, european elk PV (EEPV), deer
PV (DPV), ovine PVs typesl and 2 (OvPV-l and -2) with the development of
fibropapillomas. Nevertheless, only when the presence of the E5 protein is coupled to
the absence of an E7 pRb-binding domain, does PV infection trigger the exclusive
development of fibropapillomas suggesting a role for E5 in the pathogenic mechanism
of fibropapilloma development (Narechania et al. 2004).
The BPV-4 E7 is one of the major transforming protein, capable of inducing
morphological transformation of primary bovine fibroblast (PaIF) cells in the presence
of activated ras (Pennie et al. 1993). It is expressed in all layers of papillomas at all
stages, consistent with is pivotal role in cell transformation. Its cellular localization
however appears to change, being nuclear in the basal and suprabasal layers, and
cytoplasmic in the more differentiated upper layers (Pennie et al. 1993; Anderson et
al. 1997; Campo 1997). It possesses DNA-binding zinc finger and an Rb-binding
domain but lacks the CKII site which is the main feature of the E7 protein of the high-
risk HPVs (Jaggar et al. 1990).
1.2.4.6 r.r and L2 ORFs
These ORFs encode the two capsid proteins Ll and L2 that are expressed before the
virus is shed from the squamous layer (Zhao et al. 1998). They have been useful for
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the production of a BPV-4 vaccine (Chandrachud et al. 1995) and encode virus
neutralizing epitopes that are effective prophylactic vaccines which prevent infection
(Kimbauer et al. 1996; Campo et al. 1997). The major capsid protein L1 has the
intrinsic capacity to self-assembles into virus-like particles (VLP). When L2, which is
not required for assembly, is coexpressed with Ll, in eukaryotic cells by recombinant
baculovirus or vaccinia virus, both Ll and L2 are incorporated into the particles
(Hagensee et al. 1993; Kimbauer et al. 1993).
Several groups have begun to assess VLP vaccines in clinical trials with encouraging
results suggesting the possibility to develop effective prophylactic vaccines (reviewed
in Galloway 2003).
The Ll ORF encodes the 56-60 kDa major capsid protein, the minor capsid protein
L2 has a molecular weight of 52-58 kDa. The Ll ORF is the most conserved gene
within the PVs genome and has therefore been used for the identification of new PV
types over the past 15 years (de Villiers et al. 2004). Also the N-terminal domain of
the L2 proteins is highly conserved among different papillomaviruses. Differentiation
of the epithelium triggers a coordinate increase in the replication of the viral genome
and expression of the L1 and L2 structural viral proteins leading to the assembly of
infectious viral particles in the nucleus.
The L2 protein is believed to be involved m encapsidation of the viral DNA,
generation and infectivity of PV virions as well as interaction with cell surface
receptors (Kawana et al. 2001; Okun et al. 2001). The L2 protein of HPV 16 contain
nuclear localisation signal (NLS), can interact with several cellular host proteins, and
has the ability to recruit them to the nucleus (Gomemann et al. 2002). It has been
shown that HPV-16 L2 selectively inhibits the transcriptional activation property of
E2 and that there is a direct interaction between the two proteins, although this is not
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sufficient to mediate the transcriptional repression (Okoye et al. 2005). The HPV -16
L2 has also been shown to bind ~-actin (Yang et al. 2003) causing cell retraction and
disruption of the microfilament network possibly assisting in the release of mature
VIruS.
1.2.5 The E5 proteins of Papillomaviruses: common and different features
All the PV s share a similar genome organisation and encodes at least one
transforming protein. They also possess an early open reading frame that encode for a
small hydrophobic transforming protein, the E5. Whatever the function of E5 in vivo,
its role in vitro cell transformation is being rapidly elucidated and it has become clear
that despite its small size, the protein has wide pleiotropic effects. Here it is reviewed
what is known about the products of the E5 open reading frames from BPV -I, BPV-4
and HPV-16.
1.2.5.1 BPV-l E5
E5 is the major transforming protein of BPV -I. The E5 ORF encodes a 44 amino
acids long highly hydrophobic protein that contains two distinct domains: an amino
terminal hydrophobic region that spans the cell membrane and a 14 amino acids
hydrophilic carboxy terminal domain, which contains two cysteine residues that
mediate homodimer formation via disulfide bonds (Schlegel et al. 1986; Horwitz et
al. 1988; Burkhardt et al. 1989; Surti et al. 1998). Although E6 is also involved in cell
transformation (section 1.2.4.4) mutational analysis of E5 showed that it is essential
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for cell transformation (DiMaio et al. 1986). It is capable of transforming a number of
different cell lines (Schiller et al. 1986; Bergman et al. 1988; Leptak et al. 1991). The
protein is localised largely to the membranes of the endoplasmic reticulum and Golgi
apparatus of transformed cells with its carboxy-terminus oriented intraluminally
(Burkhardt et al. 1989). It has been shown to bind and activate the P receptor for
platelet derived growth factor (PDGF P-R) (Petti et al. 1991; Petti and DiMaio 1992;
Goldstein et al. 1994), but it does not directly activate other receptors, including the
closely related PDGF a receptor or the epidermal growth factor (EGF) receptor
(Goldstein et al. 1994; Petti et al. 1994; DiMaio and Mattoon 2001). This is consistent
with the tissue tropism of the BPVs capable of infecting fibroblasts and other
mesenchymal cells that express abundant PDGF P receptor. On the basis of extensive
mutational analysis it has been proposed that BPVI-E5IPDGF P receptor complex
formation requires an electrostatic bond between a juxtamembrane lysine in the
PDGF P receptor and aspartic acid 33 of the BPV-l E5 protein and an hydrogen-bond
between a transmembrane threonine in the receptor and glutamine 17 of the BPV-l
E5 protein (DiMaio and Mattoon 2001). Moreover, mutational studies also indicate
that glutamine 17 and aspartic acid 33 are important in transformation (Meyer A.N. et
al. 1994; Sparkowski et al. 1996). The formation of the complex with PDGF P-R also
requires dimerization of the E5 protein (Nilson et al. 1995; Mattoon et al. 2001), and
glutamine 17 plays a role in stabilizing the E5 dimer which is oriented in an
antiparallel fashion to PDGF P-R (Kulke et al. 1992; Klein et al. 1999; DiMaio and
Mattoon 2001). After alanine scanning mutations analysis in the BPVI-E5 protein it
has been proposed that each E5 monomer had an independent binding site for the
PDGF P receptor, but the binding site was accessible only following E5 dimerisation
(Adduci et al. 1999). On the basis of mutational analysis, molecular modeling,
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analysis of the chimeric E5 proteins, and NMR studies (Surti et al. 1998; Klein et al.
1998; Klein et al. 1999; Mattoon et al. 2001) Di Maio and Mattoon (DiMaio and
Mattoon 2001) proposed that each PDGF P receptor molecule interacts with the
glutamine on one E5 monomer and the aspartic acid on the other. Thus, the E5 protein
has to dimerise in order to generate intact binding sites for the PDGF P receptor, a
model consistent with the finding that dimerisation-defective E5 mutants are also
defective for inducing receptor activation and transformation.
l-E5 can activate PI-3-K (phosphoinositide 3-Kinase) and c-src independently of
growth factor receptor activation (Suprynowicz et al. 2000; Suprynowicz et al. 2002).
The BPV-l E5 protein also binds to the 16 kDa transmembrane subunit c (also known
as ductin) of the vacuolar proton pump H+-ATPase (V-ATPase) (Goldstein et al.
1991; Finbow et al. 1991; Goldstein et al. 1992b). This pump is responsible for
controlling the pH of the Golgi apparatus and other intracellular organelles. 16K
consists predominantly of 4 transmembrane (TM) domains. The association between
the ATPase subunit and the E5 protein appears to be mediated largerly by
transmembrane interactions with the glutamic acid in position 143 of the 16K TM4
domain and the glutamine in position 17 within E5 as important contributors
(Goldstein et al. 1992a; Andresson et al. 1995). Acidification of the Golgi apparatus
is impaired in cells transformed by the E5 protein and it has been proposed that the E5
protein directly inhibits V-ATPase activity (Schapiro et al. 2000; Suprynowicz et al.
2000). Because many important growth regulatory proteins, including PDGF P
receptor, pass through the Golgi apparatus en route to their final destination in the
cell, the ability of the BPV E5 protein to perturb the pH of intracellular organelles
may influence the activity of these proteins and contribute to transformation (DiMaio
and Mattoon 2001).
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1.2.5.2 BPV -4 E5
The E5 (formerly E8) open reading frame of BPV -4 has been found where the E6
ORF would be expected to be, and encodes a 42 amino acids long hydrophobic
protein with homology to the BPV -1 E5 protein (Jackson et at. 1991). It is composed
of two domains: a very hydrophobic region, with an a-helix transmembrane span,
encompassing the first 30 residues of the protein, and a second region of mainly
hydrophilic amino acids comprising the C-terminal 12 residues. It is localised in the
endoplasmic reticulum, the Golgi apparatus and occasionally the plasma membrane
(Pennie et at. 1993). In vivo, it is found in the basal, suprabasal and in differentiated
cell layers of papillomas (Anderson et al. 1997; Araibi et al. 2004) and there are no
data to suggest that it binds to or activates growth factor receptors.
Domain swap analysis between the BPV -1 E5 and BPV -4 E5 proteins showed that the
C-terminal domain of 4-E5 is implicated in transformation and acts in a different way
from that of BPV -1 E5 (O'Brien et at. 1999). In fact, the two C-terminal sequences of
1-E5 and 4-E5 show poor homology. It is not known whether the 4-E5 protein binds
or not growth factor receptors. Growth factors activate a series of signal-transduction
cascades, among which activation of the mitogen-activated protein kinase (MAPK)
cascade, Ras-Raf-MEK-ERK, is the best characterized (Schaeffer et al. 1999). Most
studies indicate that these signals eventually control G 1 phase progression by
regulating cyclin Dl expression, cyc1in E and cyc1in A synthesis (Pages et at. 1993;
Weber et al. 1997; Balmanno et al. 1999). Unlike the l-E5 protein, 4-E5 upregulates
cyclin A and cyc1in A-associated kinases and a strong relationship exists between
cyc1in A promoter transactivation and cell growth and transformation (O'Brien and
Campo 1998; O'Brien et al. 2001). In recent work it has been found that 4-E5-
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mediated upregulation of cyclins is largerly independent of the MAPK cascade and is
probably also independent of growth factors (Zago et al. 2004).
Given the key role played by cyclin A-associated kinases in DNA replication, it is not
surprising that DNA tumour viruses encode protein(s) capable of activating cyclin A
transcription and inducing cyclin A-CDK activity (Ohkubo et al. 1994; Zerfass et al.
1995; Chang et al. 1997; Schulze et al. 1998). Recent data show that 4-E5 also acts to
bypass repression at the CCRE/CDE (cell cycle repressor element or cell cycle-
dependent element)(Grindlay et al. 2005). CCRE is one of the sites in the cyclin A
promoter which is crucially involved in repression of transcription in quiescent cells
and cells in early-G 1 and is occupied only when cyclin A transcription is repressed
(Blanchard 2000). E5 also transactivates the cyclin A promoter through the CCAA T
box element in a NF -Y-dependent manner. NF -Y belongs to a family of CCAAT box-
binding proteins involved in the control of the expression of many eukaryotic genes
and it is believed that E5 transactivates the cyclin A promoter through NF-Y
association with a p l l O CCAAT-box binding factor (pl l O CBF) (Grindlay et al.
2005).
The E5 protein of BPV -4 bind in vitro to the 16K protein causing loss of gap junction
intercellular communication in PalFs (Faccini et al. 1996).
The evidence of a similar mechanism for cell transformation brought about by I-E5
and 4-E5 comes from the fact that they both bind to 16K and inhibit gap junction
intercellular comunication (Faccini et al. 1996; Ashrafi et af. 2000). A number of
mutational studies on BPV -4 E5 (Ashrafi et al. 2000) and HPV -16 E5 (Rodriguez et
al. 2000; Adam et al. 2000) show that the ability of E5 proteins to bind 16K does not
correlate with their transforming activity. Binding to 16K may provide an export
mechanism for E5 transforming proteins to the Golgi and post Golgi compartments.
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Once in the Golgi when the V-A'TPase is first activated, E5 proteins may become
dissociated from the 16K and bind to other targets such as growth factor receptors
(Ashby et al. 2001).
1.2.5.3 HPV-16 E5
The HPV -16 E5 protein is 83 amino acids in length. Like the bovine papiIIomaviral 1-
E5 and 4-E5 proteins, the 16-E5 and the others HPV E5 proteins are highly
hydrophobic with conserved cysteines in the C-terminal domain (Bubb et al. 1988).
However, they possess an additional transmembrane domain and lack the active group
found at position 17 of BPV -1 E5 and BPV -4 E5 (Bubb et al. 1988). The E5 proteins
of HPVs show only a weak transforming activity. HPV-16 E5 does not transform cells
to the same extent as E6 and E7 but enhances the immortalization potential of E6 and
E7 (Stoppler et al. 1996) and in cooperation with E7 stimulates the proliferation of
human and mouse primary cells (Bouvard et al. 1994a; Valle and Banks 1995).
HPV -16 E5 has been shown to bind to a number of growth factor receptors (Hwang et
al. 1995) such as EGF-R and PDGF-R, like BPV-l E5, and also the colony
stimulating factor-I (CSF-l) (Nagata et al. 1993). However it seems that only the low
risk type HPV-6 E5 could interact with the PDGF-R (Conrad et al. 1994). Studies
monitoring the mitogenic response to EGF in E5-expressing human keratinocytes led
investigators to propose a synergistic interplay between E5 and EGF (Straight et al.
1993). In a recent work in K14E5 transgenic mice, in which the HPV-16 E5 gene was
directed in its expression by human keratin 14 promoter (hKI4) to the basal layer of
the epidermis, E5 alters the growth and differentiation of stratified epithelia and
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induces epithelial tumors at a high frequency via a pathway requiring functional EGF-
R (Genther Williams et al. 2005).
HPV -16 E5 also binds to 16 kDa ductin (Conrad et al. 1993) and this binding has
been shown not only to inhibit gap junction communication but also endosome
acidification and EGF-R degradation (Straight et al. 1995).
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1.3 IMMUNE EVASION BY VIRUSES
Generally pathogens have a short generation time and the host defence must be
proper, rapid and work at several levels. The first line of defence is represented by the
skin and epithelia that can keep out many intruders, but viruses often possess
specialised mechanism to overcome epithelial barriers. The next layer of defence is
the rapid production of specialised cells and molecules of the innate immune system
and these defences too can be penetrated. Finally, in many cases, lasting protection is
afforded through acquired immunity. However, the persistence and repeated
reactivation of many viruses must be enabled by specific evasion of adaptive
immunity.
1.3.1 EVASION OF ADAPTIVE IMMUNITY
The MHC I molecules, which are essential for presentation of foreign peptides to the
cytotoxic T lymphocytes (CTL), are targets of many pathogens, including viruses
(Ploegh 1998; Tortorella et al. 2000). CTL recognize virus-infected cells through the
specific interaction of their T-cell receptor with an MHC I molecule presenting a viral
peptide. The MHC I complex (described in detail in section 1.1.3) consists of an
heavy chain containing the peptide binding site and P2-microglobulin, which assemble
very rapidly in the lumen of the endoplasmic reticulum (ER). Peptides, generated by
the proteasome in the cytoplasm, are translocated by TAP (transporter associated with
antigen processing) into the ER where they assemble in ternary complexes and are
transported to the cell surface for presentation to CTL (York and Rock 1996). Once
on the cell surface, some MHC I molecules are endocytosed and either recycled back
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to the plasma membrane or retained intracellularly and degraded (Reid and Watts
1990; Abdel Motal et al. 1993) (the antigen processing and presentation is described
in detail in section 1.1.3.1). Hence, maintenance of steady-state levels of functional
MHC I complexes at the cell surface is achieved by a balance of several processes:
the synthesis and exocytic transport of newly synthesized MHC I molecules, the
recycling of endocytosed peptide-associated MHC I molecules, and the degradation of
denaturated MHC I molecules that have lost antigenic peptides (Zuniga et al. 1999).
Interference with the assembly and/or trafficking of the MHC I complex can
contribute to the persistence of a virus. Several viruses that induce chronic infections
encode proteins that target or modulate the host's immune system and have evolved
strategies for evading CTL-mediated immunity by interfering with the cell surface
display ofMHC I (Ploegh 1998; Tortorella et al. 2000; Johnson et al. 2001).
1.3.1.1 Interference with the generation of antigenic peptide
During an infection, viral gene products expressed in the cytosol may be targeted for
degradation and presented by MHC class I molecules to CTL that can act early to
eliminate the infected cells (Spriggs 1996). Thus it is not surprising that several
viruses have evolved a mechanism to evade the proteolysis and the subsequent
generation of antigenic peptides.
Epstein-Barr virus (EBV) is a member of the y-human herpesvirus family; it
maintains a life-long latent association with B lymphocytes and a permissive
association with stratified epithelium in the oropharynx (Greenspan et al. 1985; Yao
et al. 1989). The EBV nuclear antigen-l (EBNA-l) is produced early in the infected B
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cell and In general CTLs specific for EBNA-1 are generated during T-cell
development but fail to be activated during EBV infection suggesting that EBNA-1
peptides are not presented by class I molecules (Khanna et al. 1995). In fact EBNA-1
includes a unique glycine-alanine repeat (GAr) domain that inhibits the endogenous
presentation of CTL epitopes through the class I pathway by blocking proteasome-
dependent degradation of this antigen (Tellam et al. 2001).
Human cytomegalovirus (HCMV) is a large ~-herpesvirus coding for more than 200
potential proteins (Chee et al. 1990). Primary infections by HCMV are followed by
life-long infections that are asymptomatic in immunocompetent individuals, but lead
to severe, even life-threatening, disease if the immune system is compromised.
HCMV establishes latency in several somatic cell types, such as the monocytic and
endothelial cells, from which reactivation occurs (Chee et al. 1990; Soderberg-
Naucler et al. 1997; Fish et al. 1998). Ultimately, acute infections are controlled by
CD8T cell. In order to evade this cytotoxic Tvlymphocyte response HCMV contains
several genes in its genome dedicated to interfere with the MHC class I pathway. In
the immediate early phase of HCMV infection a CTL response is directed against
antigenic pepetides derived from a 72 kDa transcription factor. This CTL response is
abrogated when the 72 kDa protein is expressed together with a protein that shows
kinase activity, the matrix protein phosphoprotein 65 (pp65). The pp65 probably
phosphorylates the 72kDa protein and inhibits the generation of its derived antigenic
peptides. The phosphorylation might affect the 72kDa protein cleavage pattern or
result in its failure to be appropriately ubiquitin-conjugated (Gilbert et al. 1996).
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Human immunodeficiency virus (HIV) and influenza virus can modify antigenic
peptides through random mutations. An antigenic peptide derived from HIV can even
act as an antagonist peptide and thus prevent full activation of specific T cell
(Klenerman et al. 1994; Bertoletti et al. 1994).
It has been shown that also hepatitis B virus (HBV) isolates derived from two
chronically infected patients display variant epitopes that act as natural T-cell antigen
receptor (TCR) antagonists with the capacity to inhibit the CTL response to the wild-
type epitope (Bertoletti et al. 1994).
1.3.1.2 Interference with the antigenic peptide transport via the TAP
(transporter associated with antigen processing) complex
The a-herpesviruses, herpes simplex virus type 1 (HSV-l) and type-2 (HSV-2)
establish life-long infections with latent phases and recurrent acute infections leading
to typical lesions (Roizman and Sears 1996). During latency, HSV remains in
neurons which express very low levels of MHC class I molecules and do not seem to
express proteins and this condition might prevent immune detection. Upon
reactivation, however HSV replicates in MHC class l-containing epithelial cells, thus
exposing the virus to T-cell surveillance. The HSV genome contains approximately
100 ORFs the products of which are potential targets for the CD8T cells. To escape or
delay T-cell recognition, one of the immediate early proteins ofHSV, the infected-cell
protein 47 (ICP47), is dedicated to evasion of MHC class I antigen presentation.
ICP47 of HSV -1 and HSV -2 inhibits peptide transport by preventing peptide binding
by interacting with both TAP 1 and TAP2 on the cytosolic side of the ER (York et al.
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1994; Hill et al. 1995; Fruh et al. 1995). As consequence, empty major
histocompatibility complex class I molecules are retained in the endoplasmic
reticulum and recognition of HSV-infected cells by cytotoxic T lymphocytes is
abolished (Galocha et al. 1997).
The US6 gene of HCMV encodes for a 21 kDa type I membrane glycoprotein that
inhibits TAP function. This protein unlike ICP47, interacts with TAP complex on the
luminal side of the endoplasmic reticulum. The interaction ofUS6 with TAP does not
prevent peptide or ATP binding hence this interaction may prevent peptide transport
by occluding the exit pore of the TAP complex (Hengel et al. 1996; Hengel et al.
1997; Ahn et al. 1997; Lehner et al. 1997).
HPV 11 and HPV 6 cause recurrent respiratory papillomas, benign tumours of the
larynx and trachea (Gissmann et al. 1982). The E7 proteins encoded by these viruses
are believed to contributes to the apparent loss of TAP1 function found in papilloma
cells. If TAP1 is lacking or its function is abrogated there is a significant reduction in
cell surface MHC Imolecules bearing an antigenic peptide at the cell surface. It has
been shown that E7 binds TAP1 and can inhibit ATP-dependent peptide transport
resulting in poor presentation of viral antigen on HPV-infected cells (Vambutas et al.
2001).
1.3.1.3 Inhibition of MHe class I surface expression
The prototype for a viral protein interfering with MHC class I antigen presentation
was discovered in non-oncogenic adenoviruses: the E19 protein encoded in the E3
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region (Andersson et al. 1985; Burgert et al. 1985). This glycoprotein inhibits the
intracellular transport of MHC class I molecules by forming stable complex in the ER
(Cox et al. 1991). Such ER retention by E19 is attributed to a double lysine motif
within its cytoplasmic tail. This dilysine motif interacts with coat protein-I (COP-I),
involved in vescic1es retrieval between the ER and Golgi, and is a common ER
retention motif (Paabo et al. 1987; Jackson et al. 1990; Cosson and Letoumeur 1994).
E19 or a truncated version that lacks the ER retention signal can also bind to TAP,
independently of its association with MHC class I molecules and the TAP-associated
glycoprotein, tapasin (described in section 1.1.3.1). E19 may causes a decrease in
class UTAP association therefore delaying peptide loading of the MHC class I
molecules (Bennett et al. 1999).
HCMV in the immediate early phase of virus infection expresses US3, a 23 kDa
glycoprotein that retains class Imolecules in the ER (Ahn et al. 1996). US3 interacts
with peptide-loaded MHC class I molecules, but its mechanism of ER retention is not
clear. HCMV also encodes two early gene products, US2 and US11, that selectively
target class I heavy chains (HC) for degradation by the proteasome. In cells that
express US2 or US11, class I HC are dislocated from the ER through the translocon
(sec61p complex) and into the cytosol (Wiertz et al. 1996). It seems that class IHC
are ubiquitinated largely after extraction from the ER membrane. The mechanism of
degradation of class I HC by US2 and US11 is very similar to the degradation of
misfolded and abnormal proteins in the ER (Plemper et al. 1999). Given the different
mechanism of evasion shown by US3 and US2IUS11 HCMV has developed different
T-cell escape strategies at different times during the infectious cycle.
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The mouse cytomegalovirus (MCMV) gene m152 encodes a 40 kDa type I
glycoprotein expressed early during infection that retains class I molecules within the
ER-Golgi intermediate compartment, thus preventing surface expression of class I
molecules (Ziegler et al. 1997).
The MCMV gene m06 encodes a 48 kDa glycoprotein that forms a tight complex with
~2m-associatedMHC I class I molecules. After passing the Golgi, the complex enters
the endocytic route and reaches the lysosomes where both the viral protein and MHC
class I molecule undergo rapid proteolysis (Reusch et al. 1999). The m04 gene
encodes a 34 kDa glycoprotein (gp34) that interacts with class I molecules within the
ER and the complex is not retained but transported to the cell surface. Probably gp34
counteracts class I retention, perhaps to decrease susceptibility of infected cells to
recognition by natural killer cells (Kleijnen et al. 1997).
HIV expresses two proteins that downregulate the expression of surface MHC class I
molecules, Nef and Vpu (Piguet et al. 1999).
Vpu is an 81-residue oligomeric type l-anchored membrane protein that prevents the
cell surface expression of class I molecules acting on newly synthesised class I
molecules and inducing their destabilisation (Kerkau et at. 1997).
Nef is a 27-34 kDa multifunctional protein that has no apparent enzymatic activity
and is thought to function by acting as an adaptor protein (AP). Nef binds to the
cytoplasmic tail domain of class I HC (Harris and Neil 1994; Greenway et at. 1995;
Grzesiek et al. 1996; Rossi et al. 1996; Schaefer et al. 2000; Williams et at. 2002),
and contains a number of potential protein-protein interaction domains that are
required for MHC I downmodulation.
58
Chapter 1 INTRODUCTION
Nef localises to the plasma membrane and accelerates endocytosis of class I complex
in macrophages. The class l/Nef complex is then targeted to the lysosomes. Nef
targets the HLA-A and -B locus products, but not the -C and -E locus products for
lysosomal degradation (Le Gall et al. 1998; Cohen et al. 1999). This selective
downmodulation results from amino acid sequence variation in the Nef-binding
domain within the cytoplasmic tails of these molecules (Williams et al. 2002).
Nef disrupts MHC-I cell surface expression by a different mechanism from the one
used to downmodulate CD4. In HIV-infected lymphocytes and astrocytic cells, the
primary effect of Nef on MHC I is to disrupt its transport to the cell surface rather
than to promote its endocytosis (Swann et al. 200I;Kasper et al. 2003). It has been
found that Nef redirects MHC I from the trans-Golgi network (TGN) to lysosomes. In
this process the J.t 1 subunit of adaptor protein, AP-I, which is required for proper
sorting of lysosomal hydrolases from the TGN to lysososmes, is required for Nef to
disrupt MHC I trafficking. Nef stabilises an interaction between MHC Iand AP-l and
this interaction requires sequences from the N-terminal a helix of Nef and from the
MHC I cytoplasmic tail (Kasper et al. 2005; Williams et al. 2005).
Human T-cell leukemia virus type 1 (HTLV-1) is the etiologic agent of adult T-cell
leukemia/lymphoma (ATLL) (Poiesz et al. 1980; Hinuma et al. 1981; Yoshida et al.
1982), as well as the neurologic disorder tropical spastic paraparesislHTLV-1-
associated myelopathy (TSP-HAM) (Gessain et al. 1985; Rodgers-Johnson et al.
1985; Osame et al. 1986). HTLV-I induces a lifelong chronic infection, which may
result in ATLL in 1 to 5% of carriers 20 to 30 years after infection. The HTLV-l-
encoded protein, pI2', is a small hydrophobic protein that reside in the endoplasmic
reticulum and Golgi apparatus and can physically bind the free human major
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histocompatibility complex class I HC causmg its intracytoplasmic retention and
proteosomal degradation (Johnson et al. 2001).
1.3.2 EVASION OF INNATE IMMUNITY
1.3.2.1 Interferon and innate immune response
Interferons (lFNs) are the first cytokines to be molecularly characterized and have
been extensively studied in the context of host defence against viral infection. IFNs
regulate cellular antiviral, antitumour and immunological responses through IFN-
stimulated gene expression.
There are two types ofIFNs, type I IFNs (lFN-a and IFN-P) and type II IFN (IFN-y).
The IFNal P are produced by a variety of cells upon viral infection, while IFN-
y is not virus inducible and is produced by activated T lymphocytes and natural killer
cells (Lengyel 1982; Weissmann and Weber 1986; Pestka et al. 1987; Vilcek and Sen
1996). The IFNs c, P and IFNy-inducible gene promoters are characterised by the
presence of consensus elements known as IFN-stimulated response elements (ISRE)
and IFN-y activation sites (GAS), which mediate primary transcriptional induction in
response to IFN-cr/~ and IFN-y, respectively (Darnell et al. 1994).
Type I IFN production is stimulated early in the course of viral infection, and IFN
production is an important determinant of the course of the subsequent disease
(DeMaeyer 1988; Muller et al. 1994). IFNs act directly on the virally infected cell by
interfering with viral replication and by inhibiting cellular proliferation.
Immunomodulatory activities of IFNs also contribute to their antiviral roles. IFN-
60
Chapter 1 INTRODUCTION
yenhances the expression of cellular proteins such as MHC class I molecules that
contribute to immune-mediated lysis of virus-infected cells (DeMaeyer 1988).
The interferon regulatory factors (IRFs) constitute a family of transcription factors
that are believed to playa critical role in the regulated expression of the IFN-a and
IFN-P genes.
IRF-l in particular can activate transcription from the ISRE, which is present in the
promoters of gene activated by type I IFN and is itself IFN-y inducible. Some
members of the IRF family are involved in a variety of cellular growth control
mechanisms. Seven human members of the family have been characterized: IRF-l, -2,
-3, -4, -7, IFN consensus sequence binding protein (ICSBP) and interferon stimulated
gene factor 3 (ISGF3y).
IRF-l has been characterized as a transcriptional activator and an anti-oncogene
whose functional loss contributes to aberrant growth (Fujita et al. 1989; Harada et al.
1990; Reis et al. 1992; Harada et al. 1993).
IRF-3 is part of a virus activated transcription factor complex and its transcriptional
activity is increased in response to viral infection (Fujita et al. 1989; Schafer et at.
1998; Wathelet et al. 1998; Weaver et al. 1998).
The E6 protein encoded by HPV-16 can bind to IRF-3 and this interaction is specific
and results in a marked reduction of the IRF-3 transactivation function in vivo (Ronco
et al. 1998). The interaction of HPV -16 E6 with IRF-3 and the inhibition of its
transcriptional activity could contribute to the ability of the virus to disrupt the
cellular antiviral response.
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The E7 proteins encoded by HPV-11, HPV-16 and HPV-18 physically interact with
IRF-I and abrogate its transactivation function, probably through histone
deacetylation (Park et at. 2000; Urn et al. 2002).
The functional inactivation of IRF-l and IRF-3 by HPVs E7 and E6 proteins,
respectively, could play an important role in the escape of immune surveillance of
virus-infected cells. In fact this interaction could interfere with the transcriptional
activation of some genes, such as genes involved in antigen presentation (TAPI), and
possibly genes involved in the attraction of T lymphocytes to target cells (MCP-I) so
leading to HPVs immune evasion.
1.3.2.2 Viral evasion of natural killer cells
Natural killer (NK) cells are a central component of the innate immune system
(described in detail in sections 1.1.1 and 1.1,4) and are crucial in defence against
certain viruses.
NK cells are activated during a wide variety of viral infections by virus-induced type I
IFNs (Biron et al. 1999).
As described before in sections 1.3.1.1, 1.3.1.2 and 1.3.1.3, many pathogens have
effective means of avoiding the adaptive immune response. In eluding T cells,
however, these viruses might have increased their susceptibility to NK cell-mediated
defences. Many viruses have developed mechanism to evade the NK cell response.
These mechanisms go from expression of virally encoded MHC class I homologs and
selective modulation of MHC class I protein expression by viral proteins to virus-
mediated inhibition of activating receptor function and production of virally encoded
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cytokine-binding proteins or cytokine-receptor antagonists and, finally, direct viral
effects on NK cells.
A common feature of many viral infections is the virus-induced modulation of class I
expression. Viruses down-modulate class Imolecules that are efficient at presenting
viral peptides to CD8T cells, such as HLA-A and HLA-B, to evade CTL-mediated
destruction. In contrast, either HLA-C and HLA-E (described in section 1.1.4), the
dominant ligands for NK cell-inhibitory receptors, are spared from virus-induced
clearance from the cell surface, or their expression is specifically enhanced.
In HCMV infection at least four proteins, US2, US3, US6 and US11 act to deviate the
class Imolecules from their normal progression from the endoplasmic reticulum to
the cell surface (described in section 1.3.1.2, 1.3.1.3). But two dominant inhibitory
receptor ligands, HLA-C and HLA-E, are resistant to either US2- or US II-mediated
degradation, suggesting that virus-infected cells evade NK cell activity by sparing the
class Imolecules least effective at presenting viral peptides to CTL but most effective
at inhibiting NK cells (Schust et al. 1998; Lopez-Botet et al. 2001). HCMV actively
enhances the expression of HLA-E, the ligand for the inhibitory CD94-NKG2A
receptor complex (Tomasec et al. 2000; Ulbrecht et al. 2000). Cell surface expression
of HLA-E requires binding of a nanomer peptide derived from the signal sequence of
most HLA molecules (Braud et al. 1997). The HCMV UL40 protein possesses a
nanomer peptide homologous to HLA signal sequences and thus can enhance cell
surface expression ofHLA-E (Tomasec et al. 2000; Ulbrecht et al. 2000).
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MCMV possesses three genes, m04, m06 and m152, that selectively modulate class I
expression (described in section 1.3.1.3). m152 encodes for a 40kDa protein that
blocks transport of class I molecules from the ER to the Golgi (Ziegler et al. 1997;
Ziegler et al. 2000).
m04 encodes a 34kDa type I transmembrane glycoprotein which is expressed at the
cell surface in association with class I molecules. m04 it is believed to serve to oppose
the action of m152 by rescuing some class I molecules from ER retention, thus
protecting infected cells from NK cells which might otherwise be activated by the loss
of surface class I (Kleijnen et al. 1997; Kavanagh et al. 2001).
The ne! gene from HIV-l, HIV-2 and the SIV, encodes a 27kDa protein that is
expressed early after infection and selectively down-modulates the expression of
HLA-A and HLA-B, but not HLA-C or HLA-E (Le Gall et al. 1998; Cohen et al.
1999). Thus, HIV-infected target cells remain resistant to lysis by NK cells, and their
resistance depends on the failure of Nef to down-modulate HLA-C and HLA-E from
the cell surface. Nef acts by inducing the clathrin adaptor protein complex to
recognize a tyrosine-based sorting motif in the cytoplasmic tail of HLA-A and HLA-
B (Le Gall et al. 1998). The resistance of HLA-C to Nef-induced down-regulation is
due to locus-specific tyrosine-to-cysteine and aspartic-acid-to-asparagine substitutions
in the cytoplasmic tail (Le Gall et al. 1998; Cohen et al. 1999).
NK cells, in addition to receptors with inhibitory capabilities, have receptors whose
ligation can induce cytotoxicity, proliferation and cytokine production (Biassoni et al.
2001) (described in section 1.1.4).
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An effective viral evasion strategy would be to interfere with NK cell-activating
receptors. Also adhesion of the NK cell to the target cell is crucial for killing. Down-
regulation of adhesion molecules on target cells has also been linked with reduced NK
cell susceptibility.
In the case of human cytomegalovirus (HCMV) and Kaposi's sarcoma-associated
herpesvirus (KSHV), down-regulation of the lymphocyte function-associated antigen-
3 (LFA-3) and intercellular adhesion molecule-l (ICAM-l) molecules, respectively,
reduce the susceptibility of infected cells to NK cell killing (Fletcher et al. 1998;
Ishido et al. 2000).
Viruses may subvert NK cell responses through virus-encoded proteins that
counteract or modulate the interactions between cytokine or chemokine molecules and
their cognate receptors. Numerous poxviruses and herpesviruses encode homologues
of known cytokines and chemokines with agonistic or antagonistic function, or
secreted proteins or receptors that bind with high affinity to cytokines and chemokines
(Lalani et al. 2000).
Interference with anti-viral NK cell function could involve inhibition or antagonism
of cytokines such as IL-2, IL-I8, TNF-a, which participate in inducing NK cell IFN-
y production and cytotoxicity (Biron et al. 1999).
The binding and sequestration of IL-I8 from its cognate receptor has been suggested
to be involved in human papillomavirus-related pathogenesis. The oncoproteins HPV-
16 E6 and E7 inhibit IL-I8-induced IFN-y production in phytohemagglutinin (PHA)-
stimulated peripheral blood mononuclear cell (PBMC) and in an IL-I2-stimulated
immortalized NK cell line by specific and competitive binding to IL-I8 or IL-I8 a
chain receptor (IL-18Ra).(Lee et at. 2001; Cho et at. 2001). Down-modulation ofIL-
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I8-induced responses by HPV oncoproteins may contribute to viral pathogenesis or
carcinogenesis.
As discussed above, the selective pressure exerted by the immune system has led to
the evolution of a diverse array of strategies by different viruses. A great deal of
structural information is available on host targets, but for the viral proteins this
analysis is only now beginning.
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1.4 PROJECT AIMS
The papillomavirus E5 protein is localized in the endoplasmic reticulum (ER) and
Golgi apparatus (GA) of the host cells. PalF-E5 expressing cells are enlarged and
vacuolated and have a distorted Golgi apparatus (Ashrafi et al. 2000; Ashrafi et al.
2002). At least some of these characteristic are due to alkalinization of the Golgi
lumen (Marchetti et al. 2002), an effect mediated by the binding of BPV-1 and BPV-4
E5 proteins to the 16K ductinlsubunit c of the VO sector of the vacuolar H+-ATPase
(Goldstein et al. 1991; Faccini et al. 1996). Also, this binding has been deemed
responsible for the down-regulation of gap-junction communication (Faccini et al.
1996; Ashrafi et al. 2000). We asked whether all these effects would affect protein
traffic in E5-expressing cells. A very important protein complex the MHC I, which is
essential for presentation of foreign peptides to the cytotoxic T lymphocytes, is
transported from the ER through the Golgi apparatus before reaching the plasma
membrane. Many viruses have evolved strategies for evading CTL-mediate immunity
by interfering with the transport and cell surface display of MHC class I (Tortorella et
al. 2000). In E5-expressing cells the MHC class I expression is down-regulated
(Ashrafi et al. 2002). This thesis tried to further define the relationship between PV
E5 proteins, mainly BPV-4 E5 and MHC class I complex.
To this end the first aim was :
• To define whether E5 affects the transport of MHC class I molecules to the
cell surface evaluating surface and total MHC I expression in E5-expressing
cells
In PalF cells, BPV-4 E5 activates the transcriptional promoter of the cyclin A gene,
increases the cyclin A-cdk2 activity and interfere with protein degradation
67
Chapter 1 INTRODUCTION
(O'Brien et al. 1998; O'Brien et al. 1999; O'Brien et al. 200 I). In E5-expressing
cells there is less MHC I HC mRNA and protein (Ashrafi et al. 2002).
Therefore the second aim was :
• To analyse if the MHC I heavy chain (HC) is degraded in E5-expressing cells
• To measure if inhibition of transcription of MHC I HC and its degradation
can be alleviated by IFN treatment
• To evaluate ifE5 interacts physically with HC and which domain is involved
• To determine if this physical interaction with HC is common to other E5
protein such as BPV -1 E5 or HPV -16 E5
Virus infected cells lacking classical MHC I on their surface would be killed by NK
cells, unless non-classical MHC I molecules are present. Many viruses have evolved
strategies to selectively down-regulate classical but not non-classical MHC I.
The third aim was:
• To evaluate ifE5 interact with non-classical MHC I
The data presented in this thesis add a new step in the understanding of general
downregulation of MHC class I by E5 and point to a common pathway of
immunevasion by E5 proteins from different PV types.
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CHAPTER 2: MATERIALS AND METHODS
2.1 Materials
2.1.1 Antibodies
SUPPLIER ANTIBODY
Merck Biosciences Ltd Anti-Actin (Ab-I). Mouse monoclonal IgM
Nottingham, UK antibody (clone JLA20).
Amersham Pharmacia Biotech, Anti-mouse IgG horseradish peroxidase
Amersham, Bucks, UK linked whole antibody (raised in sheep)
Sigma Chemical Co., Ltd., Poole, Anti-mouse IgG (Fab specific)- FITC
Dorset, UK conjugated (raised in goat) specific for flow
cytometry
Sigma Chemical Co., Ltd., Poole, Anti-mouse IgG (whole molecule) -TRITC
Dorset, UK conjugated (raised in rabbit) specific for
immunofluorescence
Sigma Chemical Co., Ltd., Poole, Anti-mouse IgG (whole molecule)- FITC
Dorset, UK conjugated (raised in sheep) specific for
immunofluorescence
Cambridge Biosciences, Anti-mouse IgG-FITC conjugated (raised in
Cambridge, UK goat) AlexaFluor 488 specific for
immunofluorescence.
Sigma Chemical Co., Ltd., Poole, Anti-Rat IgG (whole molecule) peroxidase
Dorset, UK conjugate (raised in rabbit)
AbCam Ltd, 4A3, a mouse monoclonal antibody raised
Cambridge, UK against the 97kDa fragment ofGM130 a
member of the Golgin protein family
localised in the Golgi.
Cambridge Biosciences, BODIPY® TR Ceramide is a red-fluorescent
Cambridge, UK dye that is used to stain the Golgi apparatus.
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VMRD, Inc.
Pullman, WA 99163, U.S.A.
Covance
800 University Avenue
Berkeley, California
94710-2021
A kind gift from Dr. Stephen Man,
Cardiff University, Cardiff, U.K.
Vh Bio Ltd.
U.K.
A kind gift of Dr Jan Naessens
International Livestock Research
Institute Nairobi, Kenya
A kind gift of Dr Liz Glass
(IAH, Roslin, UK)
A kind gift of Dr Shirley Ellis
(IAH, Compton, UK)
Animal Health Trust
(Suffolk, UK)
A gift from Dr. M. Hibma, ICRF
Tumour Virus Group, University of
Cambridge
H58A, a mouse monoclonal antibody raised
against the equine MHC class I
HA.11, a mouse monoclonal antibody raised
against the twelve ammo acids peptide
C(YPYDVPDY A)SL. It recogmzes the
influenza hemagglutinin epitope in bracket.
HC 10, a mouse monoclonal antibody
specific for HLA-A,-B,-C class I heavy
chain.
H-2Ld, a mouse monoclonal antibody
specific for the mouse MHC class I.
IL-A165, a mouse monoclonal antibody that
recognizes the bovine transferrin receptor.
IL-A19, a mouse monoclonal antibody
raised against the bovine MHC class I
molecules (monomorphic determinant),
recogmzes p2-microglobulin-associated
MHC I heavy chain.
IL-A88, a mouse monoclonal antibody
raised against the bovine MHC class I
molecules (monomorphic determinant)
recognizes the MHC I free heavy chain.
MAC 291, a rat monoclonal antibody raised
against equine MHC class I
TVG261, a mouse monoclonal antibody
directed against amino acids 2-17 in the
amino terminus ofHPV-16 E2.
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2.1.2 Bacterial Hosts
SUPPLIER BACTERIAL HOSTS
Invitrogen Life Technologies, Ltd., E. coli DH5a competent cells
Paisley, UK
Stratagene California Building Hogehil XLI-Blue competent cells
Weg 15 Amsterdam, Netherlands
2.1.3 Buffers
TE 10mM Tris-HCI pH 8.0, ImM EDTA pH
8.0
10x TBE buffer 900mM Tris base, 900mM boric acid,
25mM EDTA, pH8.0
Phosphate buffered saline (PBS) I37mM NaCl, 44mM KCI, 1.4 mM
KHzP04, 8.5 mM NazHP04
Tris buffered saline (TBS) 40mM Tris HCI pH 7.6,
l.4MNaCI
Fixing Buffer 50% (w/v) Methanol, 40%(w/v) Glacial
Acetic Acid
lOx loading buffer 65% (w/v) Sucrose, 10mM Tris HCI pH8,
10mM EDTA pH8, 0.3% (w/v)
Bromophenol blue
SDS-P AGE Lysis buffer 100mM Tris-HCI (PH 6.8), 2% (w/v) SDS,
2% (w/v) glycerol
2x SDS gel loading buffer 4% (w/v) SDS, 0.2% (w/v) bromophenol
blue, 20% (v/v) glycerol and 100mM Tris,
pH6.8
RIPA buffer 50 mM Tris-HCI, pH 7.5, 50 mM NaCl, 1%
Nonidet® P40, 0,5% sodium deoxycholat,
0.1% SDS, protease inhibitors
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2.1.4 Cells
CELL TYPES DESCRIPTION GROWTH MEDIUM
PalF Primary embryonic bovine Dulbecco's Modified Eagles
fibroblasts and transformed Medium,
one described in sections 10% Foetal Calf Serum
2.2.2.1.2 and 2.2.2.1.3 4mM L-glutamine
100 IU penicillin
100)lg streptomycin
NIH 3T3 Mouse fibroblasts Dulbecco's Modified Eagles
Medium,
10% Foetal Calf Serum
4mM L-glutamine
100 IU penicillin
100)lg streptomycin
P815 Mouse mastocytoma cell RPMI 1640 Medium
line 10% Foetal Calf Serum
100 IU penicillin
100)lg streptomycin
2.1.4.1 Cell Culture Materials
SUPPLIER MATERIAL
Invitrogen Life Technologies, Ltd., Foetal Calf Serum
Paisley, UK
Invitrogen Life Technologies, Ltd., 10% Dulbecco s Modified Eagles Medium
Paisley, UK 200 mM glutamine
Geneticin. G418 sulphate
100 mM sodium pyruvate
Trypsin (Ix)
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2.1.5 Chemicals and Enzymes
Supplier- Amersham International pIc, Amersham, Bucks, UK
ECL Western detection agent
ECL Plus Western detection agent
Hyperfilm ECL
Redivue™ L-esS] methionine
AmplifyTM Fluorographic reagent
Supplier- BDH Chemicals Ltd., Poole, Dorset, UK
Calcium chloride
D-glucose
Glycerol
Supplier- Beta Lab., East Mosley, Surrey, UK
Yeast Extract
Supplier- Calbiochem, San Diego, U.S.A.
ALLN (Calpain Inhibitor I)
Bafilomycin Al
Concanamycin A (Folimycin)
LY 294002 [2-(4-Morpholinyl)-8-phenyl-4H-l-benzopyran-4-one]
Leupeptin hemisulfate
MG-l32 (Carbobenzoxt-L-Ieucyl-L-leucyl-L-leucinal)
NH4Cl
Supplier- Citifluor Ltd.UK
AFl Citifluor
Supplier- Difco laboratories, Detroit, Michigan, USA.
Bacto-Agar
Bactotryptone
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Supplier- Invitrogen Life Technologies, Ltd., Paisley, UK
All DNA restriction enzymes and appropriate buffer concentrates were obtained from
Invitrogen Life Technologies unless otherwise stated. The following reagents were
also obtained from Invitrogen:
Agarose (ultrapure electrophoresis grade)
LIPOFECT AMINE ™Reagent
LipofectAMINE PLUS™Reagent
Nitrocellulose membrane filter paper sandwich 0.45Jlm pore size
NuPAGE ®Novex®4-12% Bis-Tris Gel
Novex®4-12% Tris-Glycine Gel
lOx Novex® Tris-Glycine Running Buffer
20x NuPAGE ®MES SDS Running Buffer
20x NuPAGE ®MOPS SDS Running Buffer
20x NuPAGE ®Transfer Buffer
4x NuP AGE ®LDS Sample Buffer
2x Novex" Tris-Glycine SDS Sample Buffer
NuPAGE ®Sample Reducing Agent
NuP AGE ®Antioxidant buffer
T4 DNA ligase
Supplier- James Burrough Ltd., Witham, Essex, UK
Ethanol
Supplier- New England Biolabs
Alkaline phosphatase Calf Intestinal (CIP)
Bovine Serum Albumin
Supplier- Promega, Southampton, UK
TNT® Quick Coupled Transcription/Translation System
Canine Pancreatic Microsomal Membranes
Supplier- Sigma Chemical Co., Ltd., Poole, Dorset, UK
~-mercaptoethanol
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Bicinchoninic Acid solution
Bovine Serum Albumin
Bromophenol Blue
Coomassie Brilliant Blue R-250
Copper(II) sulphate (pentahydrate 4% (w/v) solution)
DEPC
Dithiothreitol (DTT)
Di-potassium hydrogen orthophosphate anhydrous
Ethylene diamine tetra acetate (EDT A) disodium salt
Dimethyl sulfoxide (DMSO)
Ethidium Bromide
Kanamycin
Kodak X-OMAT AR film
Leupeptin
Magnesium chloride
Magnesium sulphate
Monensin
Nonidet P-40 (NP40)
Phenol: Chloroform: Isoamyl Alcohol (25:24:1 (v/v))
Ponceau S solution
Potassium chloride
Potassium dihydrogen orthophosphate
Protein G-Sepharose suspension
Saponin
Sodium acetate
Sodium carbonate
Sodium dodecyl sulphate (SDS)
Sodium hydroxide
Tween-20 (Polyoxyethylene sorbitan nonolaurate)
Supplier- Roche Diagnostics GmbH, Germany
Protease Inhibitor Cocktail tablets
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Supplier Vector Laboratories Inc, UK
Vectashield
Supplier- VH Bio, Gateshead,UK
Performa" DTR Gel Filtration Cartridges
Supplier- VWR International, Leicestershire,UK
Acetic acid
Butan-l-ol
Chloroform
Hydrochloride acid
Methanol
Propan-2-o1
Sodium chloride
Tris Base
2.1.6 Equipment and Plasticware
SUPPLIER EQUIPMENT
Becton Dickinson Labware, Plymouth, Falcon 2059 polypropylene tubes
UK Falcon 2098 polypropylene tubes
Sterile Plastipak syringes
18 gauge sterile syringe needles
60, 100 mm tissue culture dishes
Greiner Sterile bijoux tubes
Sterile universal tubes
Cell scrapers
Filter tips
60 and 100mm bacteriological petri dishes
Sterile plastic universal containers
Coming BV, High Wycombe, Bucks, 25ml, l Oml 5ml pipettes
UK 24 well tissue culture plates
96 well tissue culture plates
Cryogenic vials
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VMR (MERCKlBDH) Sterile syringes
Needles
Saran wrap
Foil
Scientific Laboratory Supplies T25, 80, and 175 ern" tissue culture flasks
Sartorius Sterile 0.21lm filter
Sterile 0.451lm filter
Labco Cin Bins
Whatman International Ltd., Whatman 3MM filter paper
Maidstone, Kent, UK
2.1.7 Kits
SUPPLIER KIT
Perkin Elmer Cetus, Norwalk, USA. GeneAmp thinwalled reaction tubes
Applied Biosystems, Cheshire, UK BigDye™ Terminator v3.1 Cycle
Sequencing
BigDye ™5x Sequencing Buffer
HI-DI formamide
Taqman EZ RT-PCR kit
Promega Ltd., Chilworth Research TNT® Quick Coupled
Centre, Southampton, UK transcription/translation system
Canine Pancreatic Microsomal Membranes
Qiagen Ltd., Dorking, Surrey, UK QIA prep Spin plasmid miniprep kit
QIAquick gel extraction kit
QIAquick PCR purification kit
QIAGEN plasmid maxi kit
RNAeasy mini kit
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2.1.8 Molecular Weight Markers
SUPPLIER MARKER
Invitrogen Life Technologies, Ltd., See Blue ® Plus 2 Pre-Stained Protein
Paisley, UK Standard
Invitrogen Life Technologies, Ltd., ~X174 RF DNAlHae III Fragments
Paisley, UK IOObp DNA ladder
IKb DNA Ladder
2.1.9 Other Materials
SUPPLIER MATERIALS
Veterinary Pathology Central Services LB-Medium (Luria-Bertani Medium)
SOC
Sterile distilled water
Sterile glycerol
Sterile phosphate-buffered saline (PBS)
Merck Ltd., Poole, UK Silicone grease
Johnson and Johnson Medical Limited, PRESEPT* effervescent disinfectant
Berks, UK tablets.
Premier Beverages., Adbaston, Stafford, Marvel (Dried Skimmed milk)
UK
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2.1.10 Plasmids
The constructs described in this section were all generated by myself unless otherwise
stated. All constructs were verified by sequencing as described in section 2.2.3.1. For
a schematic representation refer to section 2.1.11. The constructs are listed in
alphabetical order.
pBluescript II SK (+) IS a 3.0Kb cloning vector obtained commercially from
Stratagene.
pBluescript-HLA-A2 (pBS-A2) contains the HLA-A2 gene cut out from pAL356-
A2 (kind gift of Dr Steve Mann) and inserted in the EcoRV/SpeI sites of pBluescript
II SK (+) under the control of the T7 promoter.
pBoLa-Luc was derived from pBoLa-19 (kind gift from Dr O. Russell), a plasmid
containing the promoter/enhancer, exon 1 and the 3'UTR of a cattle MHC class I
allele (Sawhney et al. 1995; Sawhney et al. 1996). The promoter sequences were
amplified by PCR using the forward primer
5' -GTTOAAGOCTCTCGAGGOCATCGOTCGAC-3' and the reverse primer
5' -TOCAAAGCTTCCTCTGOGTCTOGOAAGAAGC-3'. The resulting amplicon
of 1100 bp was digested with XhoIlHindIII and inserted between the XhoIlHindIII
sites of pOL3 (Promega) ahead of the luciferase gene sequence. (This construct was
made by Dr Robina Ullah, a former worker of this laboratory).
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pCI-neo16E5 contains the full length HPV-16 E5 open reading frame inserted in the
NhellXhol sites of the commercial cloning vector pCI-neo (Promega).This plasmid
was a kind gift of Prof. Angel Alonso.
pCMV-E2 expresses the full length E2 protein ofHPV-16 (nt 2725 to 3852) cloned
into the Xbal/Smal sites of the cytomegalovirus immediate-early promoter/enhancer-
based expression vector pCMV 4 and was a kind gift from Dr Lawrence Bank, ICGEB,
Trieste, Italy).
pcDNA3 is a 5.4 Kb cloning vector obtained commercially from Invitrogen. This
plasmid can be used as a' standard cloning vector, as a template for in vitro
transcription under the control of T7 or Sp6 promoters.
pcDNA3-N*01301 contain the Bos taurus cDNA for a MHC class I allele N*01301
(Formerly known as HD6 (Ellis et al. 1996) GenBank accession number:X80934)
inserted in the HindIIllEcoRI sites of the commercial cloning vector pcDNA3 (kind
gift of Dr Shirley Ellis).
pcDNA3-N*01301Stop339 is a construct that consists of a truncated form ofN*01301
in which a premature stop codon has been introduced at residue 339.
This mutant was generated by PCR using as template the pcDNA3-N*01301 with the
following primers:
Forward T7: 5' -CGAAA TTAAT ACGACTCACT ATAGGGAGACCCAAGC-3'
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N*OI301Stop: 5'- CTGTCATTGCTTGCAGCCTCGAGCTAGGTTGTAGGTCCGTC -3'
The reverse primer adds a point mutation resulting in a stop codon in position 339
(CAG in TAG) and an Xhol site (underlined) downstream the cloned sequence. The
resulting PCR product was then HindIIIIXhol digested and inserted in the
HindlIIlXhol sites of commercial vector pcDNA3.
peDNA3-N*00201 contain the Bos taurus cDNA for a MHC class I allele N*00201
(Formerly known as JSP.l (Pichowski et al. 1996) GenBank accession
number:X92870) inserted in the XbaIlEcoRI sites of the commercial cloning vector
pcDNA3 (kind gift of Dr Shirley Ellis). N*01301 and N*00201 are two different
alleles of class I loci.
peDNA3-B2 contains the equme cDNA for equme class I allele B2 (GenBank
accession number: X79891) inserted in the EcoRI site of a commercial cloning vector
pcDNA3 (kind gift of Dr Shirley Ellis).
pcDNA3-B4 contains the equme cDNA for equine class I allele B4 (GenBank
accession number:X79892) inserted in the EcoRI site of a commercial cloning vector
pcDNA3 (kind gift of Dr Shirley Ellis).
peDNA 3.1 (-) is a 5.4kb vector derived from pcDNA3 and designed for high-level
stable and transient expression in mammalian hosts also as a template for in vitro
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transcription under the control of a T7 promoter. Obtained commercially from
Invitrogen.
peDNA 3.1 (-)/HA4E5 is a construct that consists of the BPV-4 DNA fragment nt
332 to 460 encoding the E5 protein, tagged upstream with the HA peptide, (cut out
from pRFP-HAE5 177bp with BglIIlHindIII) inserted into the BamHIIHindIII sites of
pcDNA 3.1(-).
peDNA 3.1(-)HA-N17Y is a construct that consist of the N-terminus HA tagged
BPV -4 E5 protein containing a single amino acid substitution at residue 17 in which
an asparagine has been changed to tyrosine. This mutant was cut out from pZipneo
with BamHI and inserted in the BamHI site in pcDNA3.1(-).
peDNA 3.1(-)HA-N17A is a construct that consists of the N-terminus HA tagged
BPV -4 E5 protein containing a single amino acid substitution at residue 17 in which
an asparagine has been changed to alanine. This mutant was cut out from pZipneo
with BamHI and inserted in the BamHI site in pcDNA3.1(-).
peDNA 3.1(-)HA-4E5T is a construct that consists ofa truncated form ofN-terminus
HA tagged BPV-4 E5 protein in which a premature stop codon has been introduced at
residue 33.This mutant form was cut out from pZipneo with BamHI and inserted in
the BamHI restriction site in pcDNA3.1(-).
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pcDNA3.1(-)HA-IES (IES) is a construct that consists of the full length BPV-l E5
protein, tagged upstream with the HA peptide, cut out from pZipneo-HAIE5 with
BamHI and inserted into the BamHI of pcDNA 3.1(-).
pcDNA3.1(-)HA-IEST (lEST) is a construct that consists of a truncated form ofN-
terminus HA tagged BPV -1 E5 in which a premature stop codon has been introduced
at residue 32.
This mutant was generated by PCR using as template the pcDNA3.l(-)HAIE5 with
the following primers:
Forward BamHI: 5' -CCACCACACTGGACT AGTGGA TCCACT ATGTACCC-3'
RevHindIIIStop: 5'- GCACTCAAAATGATCAAGCTTCIAGTATACAAGAAAAAACAGC -3'
The forward primer maintains the BamHI restriction site (underlined) upstream of the
cloned sequence and the reverse primer adds a point mutation resulting in a stop
codon in position 32 (TGG in TAG) and an Hindlll site (underlined) downstream of
the cloned sequence. The resulting PCR product was then BamHIlHindIII digested
and inserted in the BamHIlHindUIsites ofpcDNA3.1(-).
pcDNA6-N*SOOOI-VS-His contain the Bos taurus eDNA for an MHC class I of
unknown function (Formerly known as HD59 (Ellis et al. 1996) or GeneX (Holmeset
et al. 2003) GenBank accession number:A Y188807) cloned into the Hindlll/Xhol
sites ofpcDNA6N5-His ABC (Invitrogen) (kind gift of Dr Shirley Ellis).
pcDNA6-N*01301-VS-His contain the Bos taurus eDNA for a MHC class I allele
(GenBank accession number:X80934) inserted in the Hindlll/Xhol sites of the
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commercial cloning vector pcDNA6N5-His ABC (Invitrogen) (kind gift of Dr
Shirley Ellis).
pDsRed-Nl is an eukaryotic expression plasmid for the Red Fluorescent Protein
(RFP). RFP expression is driven by the CMV immediate early promoter and the
multiple cloning site is between the RFP sequence and SV40 poly A site. It is
commercially available from Clontech.
pEGFP-Cl is an eukaryotic expression plasmid for the Green Fluorescent Protein
(GFP). GFP expression is driven by the CMV promoter and the multiple cloning site
is between the GFP sequence and SV40 poly A site. It is commercially available from
Clontech Lab. This plasmid was a kind gift from Dr M. Roberts (ICM, Glasgow).
pGEM®-llZf(+) is a 3.2Kb vector obtained commercially from Promega. This
plasmid can be used as a standard cloning vector, as a template for in vitro
transcription and for the production of ssDNA.
pGEM/HLA-Al contain the HLA-AI gene, cut out from pRSV5neoHLA-AI (kind
gift of Dr Steve Mann), and inserted in the SalI/BamHI sites of pGEM -llZf(+)
under the control of the T7 promoter.
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pGEMlHLA-B8 contains the HLA-B8 gene, cut out from pRSV5neoHLA-B8 (kind
gift of Dr Steve Mann), and inserted in the SalI/BamHI sites of pGEM -l1Zf(+)
under the control of the T7 promoter.
pGFP-MHC I expresses a fusion protein made up of the green fluorescent protein
(GFP) from pEGFP-Cl (Clontech) and the heavy chain of human MHC I B2705
inserted in the Hind III site of pRclRSV vector (Invitrogen) and was a kind gift from
Dr Simon Powis (University of Dundee, UK). In this construct the MHC I is tagged at
its C-terminus with the GFP.
pRFP-HA4E5 expresses a fusion protein made up of the red fluorescent protein
(DsRed) and the HA tagged BPV -4 E5 open reading frame inserted in BglII/HindIII
sites of pDsRed-NI vector (Clontech). (This construct was made by Emma
Tsirimonaki, a former worker of this laboratory).
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2.1.11 Schematic representation of constructs used in this thesis
For text description refer to section 2.1.10
The constructs are listed in alphabetical order
pBluescript-HLA-A2 (pBS-A2)
ampicillin loel'
. Kpn'
MCS
- Sac I
pBluescript II SK (+/-) Multiple Cloning Site Region
(sequence shown 598--826) Apo 1 Hinc 11
feeO 109 I A<c I
6_oH II T7 Promote, • Kpn I Oro II Xho I Sell
I I I I I I
TTGTAAAACGACGGCCAGTGAGCGCGCGTAATACGACTCACTATAGGGCGAATTGGGTACCGGGCCCCCCCTCGAGGTCGAC ...
M 13 -20 primer binding s~e T7 primer binding site KS primer binding site ...
HLA-A2
pAL356
4.60 Kb
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pBoLa-Luc
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pCI-neo16E5
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pCMV-E2
f1
on
pCMV4
4.9 kb
Ampr
Schematic representation
adapted from data by
Anderson et al., 1989
Del Vecchio et al., 1992
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pcDNA3-N*01301
pcDNA3-N*00201
pcDNA3
5.4 kb
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pcDNA3-N*01301Stop339
HindIII
1 339
HindIII XhoI
1 358
N*01301 HC
STOP XhoI
Smal
pcDNA3
5.4 kb Tth1111
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pcDNA3-B2
pcDNA3-B4
Smal
Pvul
pcDNA3
5.4 kb
8sml
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pcDNA3.1(-)HA4E5
peDNA 3.1 (-)
5427 bp
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pcDNA3.1( -)HA-4E5T
pcDNA3.1(-)HA-N17A
pcDNA3.1(-)HA-N17Y
1 17 33
peDNA 3.1 (-)
5427 bp
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pcDNA3.1(-)HA-IE5
peDNA 3.1 (-)
5427 bp
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pcDNA3.1(- )HA-IE5T
BamHI 1 32
-=B-=am=H"",,,"I,,---.~1
t ..STOP HindIIl
44
HindUI
peDNA 3.1 (-)
5427 bp
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pcDNA6-N*50001
, VS epitope
-
&
<:( 6xHis
pcDNA6N5-His
ABC
5.1 kb
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pcDNA6-N*01301- VS-His
VS epitope 6xHis
pcDNA6N5-His
ABC
5.1 kb
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pGEM-HLA-Al
pGEM-HLA-B8
HLA-Al
HLA-B8
i-!:~g}~~~tA:8~~Je2~
.-;iliidiij~i~
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pRFP-HA4E5
pGFP-MHC
pOsRed
4.1kb
pRc/RSV
5.2 kb
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2.1.12 Water
Distilled water for the preparation of buffer stocks was obtained from a Millipore
MilliRQ 15 system, and for protein, enzyme, RNA or recombinant DNA procedures
was further purified on a Millipore MilliQ System to 18Mnlcm.
2.2 Methods
2.2.1 Molecular biology
2.2.1.1 DNA Extraction
DNA samples were purified by extraction with phenol:chloroform in order to remove
contaminants, such as residual enzyme activities from a restriction reaction or
detergent which might otherwise interfere with subsequent cloning steps. In the first
round of extraction the DNA sample was mixed with an equal volume of
phenol:chloroform. The aqueous DNA and organic phase were mixed thoroughly by
vortexing, and then separated by centrifugation in a microcentrifuge at 14000 rpm for
5 minutes at room temperature. The upper aqueous phase was transferred in a clean
eppendorf tube, care was taken not to transfer any of the interphase to the tube, and
the extraction process repeated. The aqueous phase was then extracted with an equal
volume of chloroform (chloroform:isoamyl alcohol, 24:1 v/v) by vortexing and
centrifugation as described above. This was repeated to remove any traces of phenol
from the aqueous phase. The aqueous phase was transferred to a fresh eppendorf for
ethanol precipitation.
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Ethanol precipitation was used to concentrate DNA samples and also to remove solute
contaminants such as salt. The aqueous DNA solution was mixed with one-tenth
volume of 3M sodium acetate pH 5.2 and 2-2.5 volumes of ice-cold ethanol. The
sample was then mixed well by inversion several times and then stored at -20°C or,
alternatively, placed on dry ice for 15-30 minutes to facilitate DNA precipitation. The
precipitated DNA was collected by centrifugation in a microcentrifuge at 14000 rpm
for 15 minutes at 4°C. The supernatant was discarded,the pellet was washed with 70
% ethanol to remove any trace of salt and dried under vacuum before resuspension in
distilled water at an appropriate concentration. The DNA concentration was
determined as described below.
2.2.1.2 Quantification of Nucleic Acids
The concentration of nucleic acid in a solution was determined spectrophotometrically
in a WPA UVIIOI Biotech spectrophotometer. Samples were diluted in dH20 and
transferred to a quartz cuvette with a pathway of 1cm. The spectrophotometer was
initially calibrated using dH20 only as a blank. The optical density reading were
obtained at 260nm and 280nm; an O.D. reading of 1 at 260nm (A26o= 1) corresponds
approximately to a concentration of 50~g/ml of double stranded DNA, for
oligonucleotides an A260of 1 was taken to correspond to -35~g/ml, and for RNA an
AZ60of 1 was taken to correspond to 40~g/ml. The ratio between readings at 260nm
and 280nm (Az6o:Az8o)provided an estimate of the sample purity; a ratio of - 1.8
indicated that preparations contained essentially no protein or phenol contamination.
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2.2.1.3 Restriction Enzyme Digestion of DNA
Restriction digestions were carried out in small reaction volumes using enzymes and
their appropriate concentrated buffer solutions according to the manufacturer's
instructions. Plasmid DNA was incubated with 5-10 units enzyme/ug DNA in a
buffered solution ensuring that the total volume of enzyme added did not exceeded
one tenth of the final reaction volume. Small quantities of plasmid DNA «5~g) were
routinely digested in a 20~1 reaction volume as specified by the manufacturer for 1
hour at 37°C. Large digests were carried out in proportionally larger reaction
volumes. The digestion fragments were analysed by agarose gel electrophoresis as
described below.
2.2.1.4 Agarose Gel Electrophoresis
In general, 1% (w/v) agarose gels were used, but smaller fragments (100-400) were
separated on 2-4% gels. Low melting point agarose was used at a concentration of
1% (w/v) in order to isolate and purify required DNA restriction fragments. Gel
mixes containing the appropriate amount of agarose were dissolved in 1 x TBE buffer
by heating the solution in a glass conical flask in a microwave oven until all the
particles of agarose gel had dissolved. 0.5 ug/ml ethidium bromide was added to the
melted agarose when the agarose was hand hot then the gel was poured with the
addition of a comb with the required number and size of teeth placed immediately into
the gel to form the sample wells. The gel was submerged in 1 x TBE buffer. The
samples containing 1 x loading buffer were loaded in each well along with an
appropriate size marker (e.g. 100bp ladder, 1Kb ladder) into the first and/or last well
in the gel and run at 70-100 constant voltage usually until the samples' blue dye front
was 1-3 cm from the end of the gel. The separated DNA was visualised by
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illumination with short wave (312nm) UV light and photographed through a red filter
onto video print paper using an UVP gel documentation system.
2.2.1.5 Isolation and Purification of DNA Restriction Fragments from Agarose
Gels
The DNA fragment to be used for cloning was recovered from low melting point
agarose gels and visualised as described in section 2.2.1.4. The fragment was cut out
of the gel with a clean scalpel blade and the gel slice placed in an eppendorf tube.
Extraction of the DNA fragment from the agarose was achieved using a Qiagen
Qiaquick gel extraction kit following the manufacturer's instructions.
2.2.1.6 Ligation of DNA Fragments
Both vector DNA and the DNA fragment to be inserted into the vector were
separately digested with restriction enzymes and purified as described above and then
isolated by gel electrophoresis as described in section 2.2.1.4. The vector DNA was
dephosphorylated at its termini to prevent re-ligation. After the vector DNA had been
linearized by digestion, the reaction mixture was adjusted by adding
dephosphorylation buffer and 1 unit of Calf Intestinal Alkaline Phosphatase (CIP) was
added to the reaction mixture and incubated at 37°C for 1 hour. The reaction was
stopped by heating to 75°C for a further 15 minutes. All enzyme activity in the
reaction was finally stopped by heating to 90°C for a further 5 minutes.
The DNA fragment was purified using a Qiagen Qiaquick purification kit following
the manufacturer's instructions and then resuspended in appropriate volume of
distilled water and stored at -20°C. The DNA fragment was incubated with
dephosphorylated vector (lOOpg) at a ratio of 1:1; 1:3; 3:1 respectively in a reaction
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containing I x ligase buffer and I unit of T4 ligase at 16°Covernight always carrying
alongside a background control reaction containing the vector alone. Dilutions of this
reaction volume were used to transform competent bacterial cells (section 2.2.1.7).
2.2.1.7 Transformation of E. coli DH5a. or XLI-blue cells
Plasmids were propagated in commercially available E. coli DH5a or XLI-blue
competent cells supplied as frozen stocks (Invitrogen and Stratagene, respectively)
kept at -70°C until use. Bacteria were transformed following manufacturer's
instructions. Competent cells were thawed slowly on ice, and 20j..l1of aliquots put
into prechilled 1.5ml eppendorf tubes. 1-2 ng of the appropriate plasmid DNA was
added to each aliquot and mixed by gently moving the pipette tip trough the cells
while dispensing. The cells were then incubated on ice for 30 minutes before being
heat shocked for 45 seconds at 42°C. The tube was then immediately placed on ice
for 2 minutes. 180 j..llof room temperature SOC Media (2% Bactotryptone, 0.3%
Yeast Extract, 10mM NaCI, 2.5mM KCl, 20mM Mg2+ Stock (equimolar ratio of
MgCh.6H20 & MgS04.7H20) and 20mM Glucose) was then added to each
transformation reaction. The tube was then transferred to a shaking 37°C incubator
(approximately 225rpm) for 1 hour to allow expression of the antibiotic resistant
marker.
2.2.1.8 Glycerol Stocks
Host strains, and their derivatives containing useful plasmids, were stored as glycerol
stocks for future retrieval. 850 j..llof an overnight culture was mixed gently with 150
j..llsterile glycerol in a 1.5 ml Nunc Cryotubes and stored at -70°C. A sterile plastic
loop was used to retrieve an aliquot of cells as and when required.
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2.2.1.9 Small Scale Preparation of Plasmid DNA (Miniprep)
Small amounts of plasmid DNA were extracted from transformed bacterial colonies to
identify correct clones. Single colonies of bacteria carrying the required plasmid were
picked using a sterile yellow pipette tip and grown in S ml culture of L-Broth (1% w/v
Bactotryptone, O.S% w/v yeast extract, 1% w/v NaCI) containing antibiotic (10011g/ml
Ampicillin or SOllg/ml Kanamycin) at 37°C in a shaking incubator (22Srpm)
overnight. 10 separate colonies were generally picked for screening at anyone time.
Bacteria were pelleted from I.Sml of overnight culture by spinning in a
microcentrifuge (14000rpm) for 30 seconds at room temperature. DNA was prepared
using the QIA prep Spin plasmid miniprep kit following the manufacturer's
instructions.
2.2.1.10 Large Scale Preparation of Plasmid DNA (Maxiprep)
Bacteria containing the plasmid of interest were streaked onto an L-agar plate
containing the appropriate antibiotic and the plate inverted and incubated overnight at
37°C to allow colony formation. A single colony was picked, using a sterile yellow
tip, from this plate and used to inoculate a sterile universal tube containing S ml of L-
Broth medium and the appropriate antibiotic (i.e.: IOuug/ml Ampicillin) which was
then put in a shaking incubator at 22Srpm overnight at 37°C. This culture was then
added to SOOml of broth, containing l0011g/ml Ampicillin in a 1 litre glass conical
flask (to allow good aeration), then returned to the shaking incubator for 24 hours.
DNA was prepared using the QIA prep Spin plasmid maxiprep kit following the
manufacture's instructions.
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2.2.2 Cell Culture and Transfection
2.2.2.1 Cell Culture
All cell culture work was performed following strict aseptic techniques inside a
laminar flow hood (Class II Microbiological safety Cabins; Gelaire BSB4). Cells were
incubated in dry 37°C incubators containing 5% (v/v) C02 (Napco Model 5410
Genetic Research Instrumentation LTD).
2.2.2.1.2 Primary bovine fibroblasts (PaIF)
Primary bovine fibroblasts (PaIF) were isolated from the palate of bovine foetuses of
less than 5 months gestation obtained from the post-mortem room at the Glasgow
University Veterinary School, grown and used at passages 2-8 (Jaggar et al., 1990).
Cells were routinely cultured in DMEM containing 10% foetal calf serum, 37.5 ug/ml
penicillin, 50 ug/ml streptomycin and subcultured to maintain subconfluent
monolayers. Cells were expanded and stocks were made and frozen down in liquid
nitrogen for further experiments.
2.2.2.1.3 Stable transfection of PalF cells
PalF cells were transfected with a range of plasmids (see below) using a cationic lipid
(DOTAP, Boehringer Mannheim) and were selected in medium containing 500Jlg/ml
G418 for 21-28 days, and G418-resistant colonies were then picked and expanded. All
transfectants were routinely maintained in DMEM supplemented with 500Jlg/ml
G418 (Pennie et al., 1993; O'Brien et al., 1999; Ashrafi et al., 2002). The plasmids
used were:
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pZipneoHA4-ES, encoding 0418 resistance and carrying the BPV-4 ES ORF
containing a sequence encoding the 11 residue HA epitope of the influenza
virus, S' to the 4-ES sequence, has been reported previously (Faccini et al.,
1996; O'Brien et al., 1999). pZipneoHA4-ES served as the template for
mutant construction. 4-E5 mutants containing single amino acid substitutions
at residue 17 (N17A and NI7Y), a C-terminus truncated form of 4-E5 (4-
EST), in which a premature stop codon has been introduced at residue 33 and
a C-terminus truncated form of BPV-l E5 (I-EST) were produced by site-
direct mutagenesis as described in O'Brien et al., 1999.
pZipneoHAI-E5, encoding 0418 resistance and carrying the BPV-l ES ORF
containing a sequence encoding the 11 residue HA epitope of the influenza
virus, S' to the l-ES sequence, has been reported previously (Faccini et al.,
1996; O'Brien et al., 1999).
pZipneoE7, expressing the BPV-4 E7 ORF, has been described previously
(Pennie et al., 1993).
pT24, a pUCl3-derived plasmid containing the 6.6-kb activated human c-Ha-
ras oncogene, has been described previously (Pennie et al., 1993).
pJ4!l16-E6 was a gift from Dr. L. Crawford (Department of Pathology,
University of Cambridge). This plasmid construct is a pBR322 derivative
containing the HPV-16 E6 ORF and has been described previously (Pennie et
al., 1993).
In these cells, the combination of BPV-4 E7 (pZipneoE7), ES from BPV-4
(pZipneoHA4-E5) or BPV-I (pZipneoHAI-ES), and activated ras (pT24) induced cell
transformation but immortalization was conferred by HPV-16 E6 (pJ4!l16-E6)
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(Pennie et al., 1993), as the BPV-4 genome does not encode an E6 protein (Jackson et
al., 1991).
Normal cells were designated PalF or "parental"; cells transformed by HPV-16 E6,
BPV-4 E7 and activated ras were designated "no ES", cells transformed as above but
with the addition of either BPV-l or BPV-4 ES protein were designated "1-ES or 4-
ES", respectively. Cells were expanded and stocks were made and frozen down in
liquid nitrogen for further experiments.
2.2.2.2 Maintenance of cells in culture
Cells were fed twice weekly, old medium was aspirated from sub-confluent flasks and
fresh medium added. Replating was performed as follows: for T17Scm2 tissue culture
flask medium was aspirated off and the cells washed once with 10 ml phosphate-
buffered saline (PBS). The PBS was removed and 4 ml of 1x trypsin solution (in
Hanks Balanced Salt Solution (HBSS) w/o Ca and Mg wlEDTA 4NA [Ethylene
Diamine Tetra Acetic Acid Trisodium Salt]), which had been pre-warmed to 37°C,
was added to cells. Flasks were transferred to the 37°C incubator until the cells had
detached from the flasks. Complete medium was added and the cell suspension
transferred to a sterile universal tube. The cells were pelleted by centrifugation at
1000rpm for S minutes at room temperature. The pellet was then resuspended in fresh
growth medium and the cells reseeded at a 1:10 density.
2.2.2.3 Long Term Cell Storage
To freeze cell stocks for storage, confluent cultures were trypsinised, and pelleted as
described above (section 2.2.2.2). The pellet was then resuspended at a concentration
of approximately 106 cells/ml in growth medium containing 10% (v/v) DMSO. The
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DMSO in the medium acts as a cryoprotectant but all solution must be chilled, as
DMSO is toxic to cells at room temperature. Suspensions were divided into 1 ml
aliquots in 1-2 ml Nunc cryotubes and placed in a polystyrene box and frozen, well
insulated, at -70°C overnight to ensure a slow rate of cooling. The ampoules were
then transferred to a liquid nitrogen bank containing labelled storage rack until
required. Frozen stocks were recovered by removing the ampoules from liquid
nitrogen and placing them into a small, covered bucket of water at 37°C. Once
thawed, the cells were added to IOml of the appropriate pre-warmed growth medium,
centrifuged, resuspended in fresh growth medium and transferred to 175 cm2 flasks.
2.2.2.4 Transient Transfection for Immunofluorescence
Cells were seeded into 24-well plates containing covers lips at a density of 104
cells/well and grown overnight to approximately 80% confluence. Plasm ids (0.6 ug)
were transfected into cells using LIPOFECTAMINE and PLUS™ Reagent
(Invitrogen/Life Technologies, UK) according to the manufacturer's instructions.
Forty-eight hours after transfection, the cells were washed twice with PBS and then
fixed in fixing solution (l9ml PBS, 1ml 37% formaldehyde, OAg sucrose) for 10 min
at room temperature. Following a further three washes with PBS, the coverslips were
removed from the well and mounted in AFI (Citifluor, UK) and analysed either using
a Leica DMLB microscope or a Zeiss LSM 510 microscope.
2.2.5 Transient transfection and luciferase transcription assay
105 PalF cells were plated in each well of 6 well plates, in duplicate, with 5 ml of
DMEM, 10% FCS at 37°C in 5% CO2. Twenty four hours later, the cells were
transiently co-transfected with 1ug of pBoLa-Luc and 1ug of pZipneo or 1ug of pZip-
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4E5 (O'Brien et al. 1999), using the standard Lipofectamine Plus (Invitrogen, UK)
method. After 3 hr, cells were washed twice with 2 ml PBS and incubated in medium
for further 48 hr, with or without 250U/ml yIFN, before being harvested and lysed in
reporter lysis buffer. The lysates were either assayed for reporter enzyme activity
immediately or stored at -20°C.
Luciferase activity was determined using a luminometer with automatic injection
(Luminoskan Ascent-Thermo Labsystems). For each sample, 80111 of lysate and 80lll
of Luciferase assay buffer (Promega) were used. Luciferase activity was normalised
for protein content determined using the BCA assay (Sigma) (as described in section
2.2.4.2).
2.2.3 DNA and RNA analysis
2.2.3.1 Total RNA Extraction from Cell Lines
Cells were grown in a 175cm2 (TI75) flask to approximately 80% confluency. Total
RNA was then extracted by use of the RNAeasy Kit (Qiagen). The cells were washed
once with pre-warmed sterile PBS and trypsinised and counted. 1x 107 cells of all cell
lines were subjected to the RNA extraction method as per manufacturer's details. For
all RNA extractions the concentration of RNA was measured spectrophotometrically
as described in section 2.2.1.2. RNA samples were aliquoted and stored at -70°C.
2.2.3.1.1 Detection of MHC class I HC RNA by quantitative RT -PCR
Total RNA was extracted from Palf, no-E5 and PaIF-4E5 cells using the RNeasy Mini
kit (Qiagen, Sussex, UK), and residual DNA was removed by DNase I treatment
according to the manufacturer's guidelines (Invitrogen, UK).
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Real-time RT-PCR for MHC I heavy chain and bovine actin mRNA was carried out
using the Taqman EZ RT-PCR kit (Applied Biosystems, Foster City, CA, USA) with
gene-specific primers and FAM/TAMRA probe designed by primer express v1.7
software. 100 ng RNA was used per each reaction, done in triplicate. The primers,
spanning exons 2 and 3,were:
BovMHC_Taq_Forward 5'-TCCGGGCGAACCTGAAC-3' and
BovMHC_Taq_Reverse 5'-ACATCTCCTGGAAGGTGTGAGAC-3' and the probe
was 5'-CCGCACTCGGCTACTACAACCAGAGC-3'. Bovine actin primers were
BovACT_Taq_Forward 5'-CCTCACGGAACGTGGTTACAG-3' and
BovACT_Taq_Reverse 5'-TCTCCTTGATGTCACGCACAA-3' and the probe was
5'-TTACCACCACAGCCGAGCGGG-3'. RT-PCR was performed using an ABI
prism 7700 sequence detector. In each experiment, additional reactions with 10 ten-
fold serial dilutions of template DNA were performed with each set of primers and
probes on the same 96-well plates to generate standard curves. All samples were
amplified in triplicate. The relative amounts of MHC I heavy chain and bovine actin
mRNA were determined by using the standard curves.
2.2.3.1.2 Detection oCES RNA in PalF cells by RT-PCR
RNA was prepared (see 2.2.3.1) and used as template for reverse transcription and
PCR amplification by using the Perkin-Elmer Cetus RNA PCR kit. Primer sequences
are as follows: BPV-4 E5 forward 5'-CCA TAC GAT GTT CCA GAT TAC GCT -3'
and BPV-4 E5 reverse 5'-CCA TCC ATC TAA CCG AGT AAT AGT -3'
The reaction was carried out according to the manufacturers instructions, to the
following final concentrations: 5mM MgCh, IxPCR kit buffer II (500mM KCI,
100mM Tris-HCI), ImM of each of dATP, dGTP, dTTT, dCTP, 1 unit RNase
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inhibitor, 1ug RNA, 2.S units MuL V reverse transcriptase, O.IS IlM of BPV -4 ES
reverse primer and DEPC-treated water to a final volume of 20f.l1.All samples were
placed in the thermocycler and further incubated at 22°C for 10 minutes, 42°C for IS
minutes, 99°C for S minutes, and soaked at 4°C for S minutes. The above reaction
volume was increased to IOOf.l1by adding 2mM MgC}z, 1x kit PCR buffer II, O.IS f.lM
of BPV -4 ES forward primer and 2.S units of Taq Polymerase. Amplification
proceeded for 3S cycles of 94°C for 30 seconds, 60°C for 1 minute, 70°C for 4S
seconds and extension at 72°C for 10 minutes using the Perkin-Elmer Cetus 9600
thermocycler. S ul of each sample containing l x loading buffer was then analysed by
agarose gel electrophoresis to ensure correct amplification. (Ashrafi 1998).
2.2.3.1.3 Detection of BPV-4 E5 RNA by quantitative RT-PCR
RNA was extracted from PaIF-4ES and PaIF-NI7 A cells using RNAeasy mini Kit
(Qiagen, Sussex, UK) and residual DNA was inactivated using DNase I treatment
(Invitrogen). Q-RT-PCR for BPY-4 ES and bovine p-actin mRNA was carried out
using the Taqman EZ RT-PCR Kit (Applied Biosystems, Foster City, CA). Each
reaction was performed in triplicate using 100ng of RNA. Oligonucleotide primers,
designed using Primer Express (v 1.7, Perkin Elmer, Oak Brook, IL), were as follows:
BPV4 ES F5'-TGTCTTTGTGGCTTATCTATGTTTTGT-3';
BPY -4 ES R5'-CCGAGTAATAGTAGAAATTAACAGAAGGTACAC-3'; and
FAMI TAMRA probe 5'-CTTTTCTGGTGTGCTTTTAATTTTCTTGCACTGTTA-3'.
BovACT_Taq_Forward S'-CCTCACGGAACGTGGTTACAG-3' and
BovACT_Taq_Reverse S'-TCTCCTTGATGTCACGCACAA-3' and the probe was
S' -TTACCACCACAGCCGAGCGGG-3'.
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PCR reactions were performed using an AB! prism 7700 sequencer. Standard curves
were generated using lO-foldserial dilutions of each template DNA, which were used
for quantifying the relative levels of ES and ~-actin RNA.
2.2.3.2 DNA Sequencing
The sequence of all new plasmids was checked using Taq terminator sequencing on
an Applied Biosystems Prism 3100 Genetic Analyzer DNA sequencer. The region to
be sequenced first underwent PCR amplification. The sequencing reaction mix was
prepared by adding SOOngof template DNA (-6~1 of standard miniprep), 2~1 Sx
sequencing buffer, 3.2pmoles the appropriate primer, 4~1 of BigDye™ Terminator
Ready Reaction Premix (Applied Biosystems) made up with distilled H20 to a total
reaction volume of 20~1 in 200~1 thin walled eppendorf tubes. The samples were
placed in a MJ Research PTC-200 Peltier Thermal Cyeler and exposed to 2S cyeles of
96°C for IOseconds, SO°Cfor Sseconds and 60°C for 4 minutes. The PCR products
were purified using PERFORMA ® DTR Gel Filtration Cartridges. The columns were
first spun at 3000rpm for 2 minutes to remove buffer. The columns were then
transferred to sample collection tubes. The PCR sequencing reaction mix was then
loaded onto the centre of the gel column. The column was spun for 3000rpm for 2
minutes. The sample was then dried under vacuum for IS-20 minutes and then
resuspended in 20~1 Hi-Di formamide (99.S% formamide, 0.11% EDTA, 0.39%
water).
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Table 2.2 Sequencing primers
Primer Name Position Primer Nucleotide Sequence
T7 forward 5'-3' 864-882 5' -ATTAATACGACTCACTATAGGGA-3'
BGH reverse 5'-3' 1039-1021 5' -CTAGAAGGCACAGTCGAGGC-3'
SP6 reverse 5'-3' 1017-998 5' -ATTTAGGTGACACTATAGAA-3'
T3 reverse 5'-3' 806-787 5' -ATTAACCCTCACTAAAGGGG-3'
M13 reverse 5'-3' 826-807 5' -GGAAACAGCTATGACCATG-3'
2.2.4 Protein Analysis
2.2.4.1 Protein Preparations from Cells for Western Blot Analysis
Cells were lysed by aspirating the culture medium off, washing the cell monolayer
once with ice-cold PBS, the PBS was completely removed by aspiration.
200~1 SDS-Iysis buffer (100mM Tris-HCI pH6.8, 2% SDS, 2% glycerol and one
tablet protease inhibitor cocktail in 10ml final volume) was added to the
100mmlplates and cell debris was scraped off and transferred to microcentrifuge
tubes. The cells were further disrupted by repeated aspiration with a syringe. The cell
debris was pelleted at 14000 rpm and the supernatant transferred to a new
microcentrifuge tube.
2.2.4.2 Protein Concentration Assays
The BCAICuS04 Protein assay was used to spectrometrically determine the protein
concentration of dilute solutions following the manufacturer's instructions. Proteins
reduce alkaline Cu(II) to Cu(!) in a concentration-dependent manner. Bicinchoninic
acid is a highly specific chromogenic reagent for Cu(I), forming a purple complex
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with an absorbance maximum at 562nm. 10J..lIof protein solution was placed in
separate wells in 96 well plate. 200J..lI of developing solution (5ml BCA
(Biocinchoninic acid) solution plus 100J..lIof 4% (w/v) CuS04 (copper II sulphate
pentahydrate solution) was added to the protein samples and incubated at 37°C for 30
minutes.
The absorbance of each sample was read at 562nm using a WPA UV 110 1 Biotech
photometer plate reader. The absorbance reading was converted to concentration in
ug/ml for each sample using a standard curve generated from a series of control BSA
solutions of known concentration. The actual concentration of each protein sample
was calculated after multiplying by the relevant dilution factor.
2.2.4.3 SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE)
Protein samples were resolved according to the molecular weight usmg sodium
dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE). All Western blot
analysis was performed using NuPAGE™ pre cast gel system unless otherwise stated.
l Oug of each protein sample were electrophoresed on NuPAGE™ 4-12% Bis-Tris gel
(Invitrogen, UK) under denaturing conditions. Prior to loading, equivalent amount of
each protein sample (IOug) was mixed with 5J..lIof 4x SDS gel loading buffer
(Invitrogen, UK) and 2J..lIof2x reducing agent (Invitrogen, UK) made up to 20J..lIwith
dH20. Samples were then boiled for lOminutes at 70°C. The prepared protein samples
were then loaded into consecutive wells and lOJ..lISee Blue ® Plus 2 Pre-Stained
protein molecular weight marker (molecular weight range 3KD-250KD depending on
running buffer used) added to the first and/or last well on the gel. The gel was run by
electrophoresis at a constant voltage of 200V for 45minutes. The running buffer (Nu
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PAGE™ MES buffer, Invitrogen, UK) was used with 500).11antioxidant (Invitrogen,
UK) added to 200ml of the running buffer for the inner tank. Once the dye front was
near at the bottom of the gel, the gel was removed and used for western blot analysis.
2.2.4.4 Western Blotting
Separated protein samples were transferred to a nitrocellulose membrane using the
NuPAGE™ wet blotting tank. For this purpose the gel was removed from the
electrophoresis tank and transferred onto a nitrocellulose membrane (Invitrogen, UK).
Before transferring the membrane, the NuPAGE™ gel sandwich was pre-soaked with
transfer buffer with 500).11antioxidant added to 1L of transfer buffer (with 10% or
20% methanol depending on the number of gels being transferred). The gel sandwich
contains a pre-cut nitrocellulose membrane sandwiched between two filter papers.
The gel tank was set up as follows:-
1. The first sheet of filter paper, soaked in transfer buffer was placed neatly on
to the gel avoiding any air bubbles.
2. Then the nitrocellulose membrane was laid on the gel, and then a further
sheet of filter paper, all soaked in transfer buffer was added to the top.
3. The sandwich was rolled with a glass pipette to eliminate any air bubbles
4. The sandwich was placed into the transfer tank and run at 30V for
approximately 60 minutes, the time taken for the pre-stained marker proteins
to be completely transferred.
Once the transfer was completed, the membrane was blocked by shaking for a
minimum of 1 hour in 50 ml of block buffer (5% Marvel [dried milk] in TBS-0.5%
Tween) at room temperature. The nitrocellulose filter was washed in wash buffer
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(TBS- T) for 10 minutes. The filter was then placed in IOml blocking buffer
containing suitable primary antibody and incubated at room temperature for I hour (to
overnight depending on the antibody used) with gentle shaking. The primary antibody
solution was removed and the filter rinsed in blocking buffer then washed Ix 15
minutes and 2x 5minutes in IOOml volumes of fresh TBS- T. The filter was then
incubated in 20 ml blocking buffer containing a 112000 or 1/5000 dilution of the
applicable HRP-linked secondary antibody for 1 hour at room temperature with gentle
shaking. The filter was washed Ix for 15 minutes and 4x for 5 minutes with TBS-T
buffer. Excess surface liquid was removed from the filter by briefly blotting with a
piece of Whatman 3MM paper. The detection consisted of incubating the filter in an
equal volume of an Amersham Enhanced chemilluminescence (ECL) detection
reagents I and 2 for I minute at room temperature. The excess detection solution was
drained off the nitrocellulose filter and this was then wrapped in Saran wrap and
exposed to Amersham ECL film for 30 seconds and up to 30 minutes (depending on
the strength of the signal).
2.2.4.5 Western Blotting of IFN, inhibitors and monensin treated cells
PalF and E5-transformed cells were seeded in 24-well plate and treated or untreated
with 500 (or 250)U/ml ovine recombinant y -IFN for 48 h and treated with a panel of
lysosome and proteasome inhibitors :IIlM Bafilomycin AI, 50llM LY 294002, 40mM
NH4CI for 24 h, and ~IlM MG-132 and IOPIlM ALLN for 8 h at 37°C in 5% C02.
Ovine recombinant y-IFN and 2D6, a control supernatant from cells not expressing
IFN were a kind gifts of Dr G Entrican (Moredun Research Institute, Penicuik, UK).
For monensin treatment the cells were seeded in T75 flasks and were treated with 25
11M monensin for 30 min, 3 or 12 h.
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Cells were removed from 24-well plate or from the flasks by trypsinization, washed
with PBS, then lysed in lysis buffer: 100 mM Tris HCI, pH 7.5,2% SOS, 2% glycerol
in presence of protease inhibitors tablets and insoluble material was removed by
centrifugation at I4.000rpm. Ten ug of lysate were electrophoresed in 4 - 12%
NuPAGE gels, and proteins transferred to nitrocellulose membrane (Invitrogen) using
a blotting apparatus at 30V for 1 h. The membranes were blocked in 5%
milklTBS/Tween 20 (0.5%) at room temperature for 1 h before incubation with 1:100
dilution of mAb IL-A88 raised against the MHC I heavy chain, or 1:20.000 dilution of
mAb AB-I specific for actin. After repeated washing with TBS/Tween 20 (0.5%) the
membranes were incubated with 1:2000 dilution of anti-mouse Ig-HRP for mAB IL-
A88, and 1:5000 dilution of anti-mouse IgM-HRP for mAb AB-I, in 5%
milklTBS/Tween 20 (0.5%) for 1 h at room temperature. The membranes were
washed three times with TBS/Tween 20 (0.5%) and bound antibody was detected by
enhanced chemoluminescence staining (ECL).
2.2.4.6 Stripping Western Blot Membranes
If a western blot membrane was required for multiple analyses with different probe
antibodies then the initial primary and secondary antibodies were removed from the
membrane by stripping. The membrane post exposure to the Amersham ECL film was
washed for 10 minutes three times in PBS before being incubated for 30 min at 50°C
in Stripping Buffer (lOOmM 2-Mercaptoethanol, 2% SDS, 62.5mM Tris BCI pB 6.8).
The membrane was then washed with copious amounts of PBS until all traces of the
SDS were safely removed. The membrane was then blocked as described in 2.2.4.4
for the next probing primary antibody.
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2.2.4.7 In vitro Transcription Translation and Immunoprecipitation
In vitro transcription/translation reaction was performed using the TNT® T7 Quick
Coupled Transcription/Translation System (Promega, UK) in presence of Redivue L-
e5S] Methionine (Amersham Pharmacia Biotech, UK) following the manufacturer's
instructions. Briefly, 1 ug of plasmid DNA was mixed in a SOJlIreaction containing
TNT® mix (TNT® lysate with energy generating system, T7 RNA polymerase,
nucleotides, salts, recombinant RNasin® ribonuclease inhibitors) in presence of
canine microsomal membranes (CMM) (Promega, UK) at 30°C for I.S h.
Half of each transcription/translation reaction product was immunoprecipitated with
either 10 JlI rabbit antiserum Ab 274, raised against the C-terminus of the BPV -4 ES
protein (Anderson et al. 1997, Pennie et al. 1993; Araibi et al. 2004) or with 5 JlI of
mAb HA.Il (Cambridge Bioscience, UK) against the HA epitope tagging E5, or with
3 JlI mAb IL-A88 raised against the bovine MHC I HC; lO JlI mAb HClD specific for
human HLA-A,-B,-C class I heavy chain; 1:2 dilution MAC 291 raised against the
equine MHC class I (Animal Health Trust, Suffolk, UK); I: I 0 dilution H58A raised
against the equine MHC class I (VMRD Inc, USA).
The other half of each reaction was left without antibody as a negative control. For
co-immunoprecipitation experiments the individual transcription/translation products
were mixed in equivalent amounts and immunoprecipitated with double the amount of
either antibodies. For competition experiments, 10Jlg of a synthetic peptide
corresponding to the C-terminal 12 amino acid residues of ES (Anderson et al. 1997;
Araibi et al. 2004) or the transcribed/translated unlabelled product of the EST mutants
(BPV-I E5 or BPV-4 ES) were added to labelled N*01301 for an hour before the
addition of labelled E5 (either I-E5 or 4-ES) as above. After incubation overnight at
4°C, protein G-sepharose bead suspension (Sigma, UK) was added for I h at 4°C.
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Following two washes in a high salt buffer (SOmM Tris HCI pH 7.5, SOOmMNaCl,
1% NonidetP-40, O.OS%NaDoc) and one wash in a low salt buffer (SOmM Tris HCI
pH 7.S, 1% NonidetP-400, O.OS%NaDoc) the sepharose beads were resuspended in
20 JlI of SDS loading buffer, heated at 7SoC for 10 min, and then were
electrophoresed in 4-12% NuPAGE gels (Invitrogen) as described in section 2.2.4.3.
Gels were fixed with glacial acetic acid and methanol, incubated for IS min in
AmplifyTM Fluorographic reagent (Amersham, UK), dried and exposed for
autoradiography at -70°C overnight or exposed on a screen for quantification on a
Storm 840 apparatus using a ImageQuant vS.2 software.
2.2.4.8 In vivo co-immunoprecipitation
Control PalF cells and PaIF-4 E5 cells were treated with y-IFN and MG132 as
described in 2.2.4.5. Cells were lysed in RIPA buffer containing a cocktail of protease
inhibitors (Roche, UK). Protein lysate (100 ug) were immunoprecitated with 1:10
dilution of rabbit antiserum Ab 274. Immunoprecipitate (10 ug) were run in NuPAGE
gels, transferred onto nitrocellulose membranes and immunoblotted with 1:1000
dilution of mAb IL-A88. A parallel gel was stained with Coomassie blue. Briefly, the
gel was incubated in Coomassie staining solution (0.05%(w/v) Coomassie Brilliant
Blue R-250, 40% (v/v) ethanol, 10% (v/v) glacial acetic acid, 50% (v/v) water) for Ih
with gentle agitation and then the stained gel was incubated in destaining solution
(40% (v/v) ethanol, 10% (v/v) glacial acetic acid, 50% (v/v) water) until the
background became clear.
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2.2.5 FACS analysis
2.2.5.1 Detection of MHe class I and transferrin receptor by FACS
Cells were grown in a 175 cm2 flask to approximately 80% confluence. After removal
of the medium, the cells were washed once with PBS, then detached from the flask
with trypsin/EDTA and pelleted at 1000rpm at room temperature for 5 min. The cell
pellet was resuspended in DMEM, 10% FCS, for 1h at 37°C to allow surface antigens
to be re-expressed. The cells were washed and re-suspended in PBS, 1% BSA (PBS-
B) at 107 cells/ml. For the detection of surface MHC I, 100 III of cells were aliquoted
and incubated with an equal volume of anti-bovine MHC class I monomorphic mAb
IL-AI9 for PalF cells, and anti-mouse H-2Ld mAb (CL9011-A, Cedarlane
Laboratories) for NIH 3T3 cells, for 30 min at 4°C. For the detection of surface
transferrin receptor, cells were incubated with mAb IL-AI65 (Naessens and Davis
1996). The cells were washed three times in PBS-B, then gently resuspended in 100
III of PBS-B and incubated with an equal volume of a 1:200 dilution of anti-mouse
IgG-FITC (Sigma) at 4°C for 30 min in the dark. The cells were washed and
resuspended in 500 IIIPBS-B and analysed by flow cytometry. If the flow cytometry
analysis was not carried out immediately, the cells were resuspended in 500 III of 3%
paraformaldehyde (PFA) in PBS and kept at 4°C. For the detection of intracellular
MHC I, the cells were fixed in 3% PFA in PBS for 20 min at room temperature,
washed in PBS-B and permeabilized with 0.5% saponin in PBS-B for 30 min at room
temperature. Following a further wash in PBS-B, the permeabilized cells were stained
with mAb IL-AI9 as described above. Samples were examined in a Beckman Coulter
EPICS Elite analyser equipped with an ion argon laser with 15 mV of excitation at
488 nm. The data were analysed using Expo 2 software.
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2.2.6 Immunofluorescence
2.2.6.1 Visualization of Golgi apparatus by direct immunofluorescence
The Golgi apparatus was visualized by staining with BODIPY-TR-ceramide. Cells
were grown until 80% confluent in single well chamber slides. After removal of
medium cells were washed twice with serum free DMEM, 25 mM HEPES (DMEM-
H) and incubated in 200 J-LIof 5 J-LMBODIPY-TR-ceramide, which localizes to the
GA, in DMEM-H for 30 min at 4°C. Cells were then washed with PBS and incubated
in DMEM-H for 30 min at 37°C. After removal of the medium and washing with
PBS, cells were fixed with fresh 3% PFA for 20 min at room temperature and
mounted with Vectashield (Vector Laboratories Inc, UK).
2.2.6.2 Visualization of Golgi apparatus and endogenous Mile I by indirect
immunofluorescence
Cells were grown until 80% confluent in single well chamber slides. The cells were
washed twice with PBS and fixed with fresh 3% PFA in PBS for 20 min at room
temperature. After the PFA fixation, a second fixation was performed by dipping the
chamber slides in methanol for 4 min; then the cells were washed three times in PBS.
For GA detection, the cells were incubated with mAb 4A3 for 30 min at room
temperature, washed as above and incubated with Alexa-Fluor'TM 488 goat anti-
mouse IgG(H+L) conjugate (Molecular Probes, Europe BV) for 30 min at room
temperature. For the detection of endogenous surface MHC I, the cells were incubated
with mAb IL-A19 or mAb IL-A88 for 1 h at room temperature and washed three
times as above. The cells were then incubated with anti-mouse IgG-FITe (Sigma) at
RT for 1 h in the dark. Following three final washes with PBS, the slides were
mounted in Vectashield (Vector Laboratories Inc, UK). The images were collected
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with a LEICA DMLB fluorescence microscope equipped with a SenSys 1400 camera.
Data sets were processed using the QUIPS™ Smart Capture imaging software (Vysis,
UK).
2.2.6.3 Immunofluorescence of transient transfected cells
Round coverslips were first washed in distilled water, air-dried and put into a beaker
for autoclaving. The coverslips were placed in 24 well tissue culture plates and cells
seeded 1xl 05 cells per well. All transfections for immunofluorescence studies were
performed using LIPOFECTAMINE™ according to the manufacturer's instructions.
Twenty-four hours after transfection, the cells were washed twice with PBS and fixed
by 10 minute incubation at room temperature with a fixing solution (19ml PBS, 1ml
37% formaldehyde, O.4g sucrose) and washed three times with PBS.
For direct immunofluorescence the cells on coverslip were mounted in AFI Citifluor
and direct analysed using a Leica TCS SP2 confocal scanner (Leica-microsystems,
Heidelberg Germany) with a x63 oil immersion objective lens, NA 1.4. Data sets were
processed using the LSM 510 software.
For the indirect immunofluorescence the cells on coverslip were permeabilised by 10
minute incubation at room temperature with 1% NP40 in PBS containing 20% sucrose
and washed three times with 1% FCS in PBS and then incubated with the appropriate
antibody for 1 h at room temperature, washed in 1% FCSIPBS and then incubated
with an anti-mouse antibody conjugated either with Texas Red or with FITC (Sigma).
Following further washes in 1% FCSIPBS, coverslips were mounted in AFI Citifluor
and analysed as above.
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CHAPTER 3: The Bovine Papillomavirus type 4 E5 protein
retains MHC class I molecules in the Golgi apparatus
Background: E5 downregulation of MHC class I
BPV -4 ES is localized in the endomembrane compartment of the cell. The expression
of the protein in primary bovine cells leads to profound changes in cell morphology,
with extensive vacuolization (Ashrafi et al. 2000) affecting particularly the GA that
appears grossly distorted, swollen and fragmented, changes that do not occur in cells
that do not express ES.
Proper functioning of the Golgi apparatus is necessary for a number of cellular
processes including protein transport to the cell surface. MHC class I molecules are
synthesized in the ER, post-translationally modified in the ER and GA and
transported to the plasma membrane (Cresswell et al. 1999). This process appears to
be inhibited in cells expressing ES, which have very little, if any MHC I on their
surface, as assessed by FACS analysis, and very little amount of total (intracellular
plus surface) MHC I HC as assessed by immunoblotting (Ashrafi et al. 2002).
In this study Ashrafi et al, used two cell lines: primary embryonic bovine cells (paIF)
transformed by papillomavirus oncogenes, with or without ES from BPV -l or BPV-4
(see section 2.2.2.1.3), NIH 3T3 mouse fibroblasts transformed by BPV-4 ES (3T3 4-
ES) (Ashrafi et al., 2002). In addition, PalF cells acutely infected with a recombinant
retrovirus expressing ES were also examined (Ashrafi et al., 2002) ..
In contrast to non-transformed normal cells, or transformed cells expressing other
papillomavirus proteins, cells expressing ES do not express MHC I on their surface,
but retain it intracellularly, independently of the presence of other viral or cellular
oncogenes, or of whether the cells are long-term transformants or acutely infected. In
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these study lower levels of MHC I mRNA transcripts were also detected in the E5
transformed cells. It is resonable to assume that there is at least a degree of specificity
in the disturbance of protein traffic by E5 as the expression at the cell surface, and
presumably the transport of another membrane glycoprotein, the transferrin receptor,
is not affected. The conclusion from this study was that expression of E5 prevents
expression of MHC I to the cell surface and causes its retention within the cell
(Ashrafi et al. 2002).
3 PalF E5-expressing cells
Primary bovine fibroblasts (PaIF) were isolated and grown in cultured medium
(DMEM containing 10% serum) and used at passages 2-8 (Jaggar et al., 1990). Cells
were sub-cultured at appropriate intervals to maintain sub-confluent monolayers. PalF
cells were transfected using a lipofection transfection technique (DOTAP) with a
range of plasmid DNAs and were selected in medium containing 500l-lg/mlG418 (as
described in section 2.2.2.1.3 and in Pennie et al., 1993; O'Brien et al., 1999; Ashrafi
et al., 2002),
In these cells, the combination of BPV-4 E7, E5 from BPV-l or BPV-4, and activated
ras induced cell transformation but immortalization was conferred by HPV-16 E6
(Pennie et al., 1993), as the BPV-4 genome does not encode an E6 protein (Jackson et
al., 1991). Normal cells were designated PalF or "parental"; cells transformed by
HPV-16 E6, BPV-4 E7 and activated ras were designated "no E5", and cells
transformed as above but with the addition of either BPV-l E5 or BPV-4 E5 protein
were designated "1-E5 or 4-E5". Cells were expanded and stocks of either PaIF, no
E5 and 4-E5 cells were frozen down in liquid nitrogen for further experiments.
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3.1 Detection of E5 in PalF cells
Given the difficulty of protein detection due to the small SIze and highly
hydrophobicity of E5, its expression in PalF cells was firstly assessed by dot blot
analysis using a mouse monoclonal antibody raised against the HA epitope from the
influenza virus hemagglutinin tagged at the N-terminus of E5, described previously
(O'Brien et al., 1999). E5 expression in PalF cells was also assessed by RT-PCR of
E5 RNA (see section 2.2.3.l.2 from Ashrafi 1998) or by quantitative RT-PCR, as
described in this thesis (see section 2.2.3.1.3 and figure 4.2 C). Additionally, cells
used for either FACS analysis, immunofluorescence staining or western blots were
periodically checked for E5 expression either by RT-PCR or quantitative RT-PCR by
Miss Emma Tsirimonaki or Dr. Rubina Ullah (previous workers in this laboratory).
3.2 MHe I is retained in the GA in E5-transformed cells
Given the abnormal morphology of the ER and GA in E5-expressing PalF cells, and
given the importance of these structures in protein traffic, we investigated whether E5
expression would disrupt protein transport and in particular MHC I transport to the
cell surface. Parental PalF and transformed control (no E5) cells were incubated with
IL-AI9, a monoclonal antibody recognizing a monomorphic determinant of the
bovine MHC class I complex (Bensaid et al. 1989) and analysed by flow cytometry.
Both cell lines displayed MHC I on their surface as shown by the increase in relative
fluorescence intensity in the presence of mAb IL-A19 (Figure 3.2 A,C). In contrast,
there was no shift in fluorescence in the transformed cells expressing E5 (Figure 3.2
E,G) indicating that these cells do not present MHC I on their surface. To investigate
if this was due to a defect in MHC I transport to the cell surface, the cells were
permeabilized with saponin before staining to allow the penetration of the antibody
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inside the cells and therefore measuring the total MHC I content. The permeabilized
parental and transformed control cells exhibited a similar staining profile, not
different from that obtained for surface MHC I (Figure 3.2 B, D). In contrast, the
FACS profiles for the permeabilized E5 cells showed a positive staining for MHC I
(Figure 3.2 F, H), indicating that in these cells MHC I was retained intracellularly and
was not transported to the plasma membrane. However, the intensity of fluorescence
and the mean fluorescence of the E5 permeabilized cells were also noticeably reduced
when compared to the parental or transformed control cells (Figures 3.2 F, Hand 3.2
I), indicative of reduced levels of total MHC I in E5 cells. These data show that MHC
I is consistently absent from the cell surface in cells transformed by BPV-l E5 (l-E5)
or BPV-4 E5 (4-E5) (Ashrafi et at. 2002). To ascertain the intracellular localization of
MHC I in E5 cells, PaIF, no-E5 and l-E5 or 4-E5 cells were stained with either mAb
IL-AI9 or IL-A88 (Bensaid et al. 1989; Toye et al. 1990), which recognize P2-
microglobulin-associated MHC I heavy chain or free heavy chain, respectively. In
PalF and no-E5 cells, MHC I was detected on the cell surface and in a Golgi-like
structure (Figure 3.2 J). In contrast in both l-E5 and 4-E5 transformed cells, MHC I
was detected only in abnormal structures (Figure 3.2 J), reminiscent of the misshapen
GA in these cells (Ashrafi et al. 2002).
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Figure 3.2 MHC I is absent from the cell surface of E5-transformed cells
H
Relative fluorescence intensity
FACS profile of MHC I expression in parental and transformed PalF cells.
PalP cells (A,B), transformed control cells (no ES) (C,D), 4-ES transformed cells
(E,F) and l-ES transformed cells (G,H) were stained with mAb IL-A19 and analysed
by flow cytometry. The open histograms represent cells stained with PITC-conjugated
secondary antibody only. Surface MHC I (solid histogram) was measured in intact
cells (A,C,E,G) and total MHC I (solid histogram) was measured in saponin-
permeabilized cells (B,D,F,H).
(experiment done by Dr. Hossein Ashrafi and published in Ashrafi et al., 2002)
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Figure 3.2 MBC I is absent from the cell surface of E5-transformed cells
I) Representative mean fluorescence for surface and total MBC I in
transformed cells.
PaIF, no-E5 and l-E5 or 4-E5 cells were analysed for surface or total MHC I
expression by FACS. The mean fluorescence was calculated from the flow
cytometric analyses above (experiment done by Dr. Hossein Ashrafi).
J) Immunofluorescence detection of MBe I in PaiF, no-E5, l-E5 and 4-E5
cells. MHC I heavy chain was detected on the cell surface and in GA-like
structures in parental and control cells, but only in GA-like structures in E5 cells.
No fluorescence was detected in cells treated only with the secondary antibody.
The images were collected with a LEICA DMLB fluorescence microscope
equipped with a SenSys 1400 camera. Data sets were processed using the
QUIPS™ Smart Capture imaging software (Vysis, UK). Magnification 40x.
N=nucleus (experiment done by Dr. Hossein Ashrafi and representative figure
from data published in Marchetti et al. 2002).
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3.3 E5 and MIle I heavy chain colocalize in the Golgi apparatus
To define the intracellular structures in which MHC I was detected, PaIF, no-E5 and
4-E5 cells were transfected with a plasmid encoding a fusion of green fluorescent
protein (GFP) and the heavy chain of human MHC I B2705 (detail of construct in
chapter 2, sections 2.1.10 and 2.1.11), and stained with the Golgi marker BODIPY-
Texas Red-ceramide as described in Materials and Methods. In all cell lines, GFP-
MHC I heavy chain localized in the GA, which had the normal 'ring-like' appearance
in PalF and no-E5 cells, whereas it was swollen and distorted in 4-E5 cells (Figure 3.3
A). To investigate whether E5 and MHC I co-localize, the cell lines were co-
transfected with GFP-MHC I heavy chain and a plasmid encoding a fusion protein of
the fluorescent protein DsRed and BPV-4 E5 (RFP-E5 described in chapter 2,
sections 2.1.10 and 2.1.11). Like wild type E5 (Pennie et al. 1993), RFP-E5 localized
in the GA (Figure 3.3 B). In all cell lines, GFP-MHC I heavy chain co-localized with
RFP-E5 in the GA (Figure 3.3 B).
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Figure 3.3
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Figure 3.3 MHC I heavy chain and E5 co-localize in the GA
A) Cells stained with BODIPY-TR-Ceramide (red) to detect the GA and
transfected with GFP-MHC I heavy chain (green). GFP-MHC I heavy chain
localizes in the GA in all cell lines (experiment done by myself and figure
published in Marchetti et al., 2002).
B) Cells transfected with RFP-ES (red) or GFP-MHC I heavy chain (green). MHC
I heavy chain co-localizes with ES in the GA in all cell lines. The images were
collected with a LEICA DMLB fluorescence microscope equipped with a SenSys
1400 camera. Data sets were processed using the QUIPSTM Smart Capture imaging
software (Vysis, UK). The merge between BODIPY-TR and GFP-MHC lor GFP-
MHC I and RFP-ES fluorescent signals was achieved using the merge option in the
QUIPS™ imaging software (Vysis, UK). N= nucleus. Magnification 20x for PalF
cells in A,B and 40x for no-ES and 4-E5 cells in A,B (experiment done by myself
and figure published in Marchetti et al. 2002).
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3.3.1 Retention is specific
It was important to demonstrate that retention of MHC I in the GA was specific, and
not due, for instance, to the nature of the fusion proteins used in the study. Therefore,
the cells were transfected with a plasmid expressing the full length papillomavirus E2
protein (pCMV-E2 described in chapter 2, sections 2.1.10 and 2.1.11). The E2 protein
was detected by indirect immunofluorescence with a mouse monoclonal antibody
TVG261directed against amino acids 2-17 in the amino terminus of HPV-16 E2. As
expected (Ham et at. 1991), E2 localized in the nucleus in all cell lines, including 4-
E5 transformed cells (Figure 3.3.1 A), showing that E5 did not retain a predominantly
nuclear protein in the endomembrane compartment. Moreover, co-expression of E2
and GFP-MHC Iheavy chain, or E2 and RFP-E5 did not lead to co-localization: E2
was nuclear in all cases, and MHC I heavy chain and E5 were localized in the GA
(Figure 3.3.1 B).
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Figure 3.3.1 E2 localizes to the nucleus and does not co-localize with either
MHC I heavy chain or E5
A) Cells were transfected with E2 only, or B) co-transfected with E2 and GFP-
MHC I or E2 and RFP-E5. E2 was detected with mAb TVG216 and Texas Red-
conjugated secondary antibody in (A) and in the left panel of (B), and with a FITC-
conjugated secondary antibody in the right panel of (B). GFP-MHC I and RFP-E5
were visualized by direct immunofluorescence. The images were collected with a
Zeiss LSM 150 confocal microscope utilising a x63 oil immersion objective lens,
NA 1.4. Data sets were processed using the LSM 510 software. In B the figure that
shows the merge E2+E5 was enlarged for ease of visualization (experiment done
by myself and figures published in Marchetti et al. 2002).
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3.4 Prevention of GA acidification by the ionophore monensin prevents transport
of MHC I to cell surface
The monovalent ionophore monensin is widely used to investigate the function of the
GA and vesicular transport (Bachert et al. 2001; Halaban et al. 2002; Schoonderwoert
et al. 2002). Monensin disperses the proton gradient across the cell membranes and
impedes the proper acidification of Golgi cisternae by displacing and inhibiting the
H+-V-ATPase proton pump, leading to GA swelling and fragmentation and faulty
protein transport from the medial to the trans-Golgi (Tartakoff 1983; Boss et al. 1984;
Zhang et al. 1996; Chikuma et at. 2002). E5 complexes with 16kDa subunit c, a
component of the VOsector of the H+-V-ATPase (Goldstein et al. 1991; Conrad et al.
1993; Faccini et al. 1996; Ashrafi et al. 2002) and inhibits endomembrane
acidification (Straight et al. 1995; Schapiro et al. 2000). In view of the similarity
between the reported morphology of monensin-treated cells and E5 cells, and the
functional similarity between monensin and E5, we treated PalF and no-E5 cells with
monensin and analysed them for morphology, GA architecture and surface MHC I.
Indeed, monensin-treated PalF cells or no-E5 cells showed extensive vacuolization
and a grossly deformed GA (Figure 3.4 A, shown only for PalF cells). These results
indicate that the vacuolization and GA malformation in E5 cells are likely due to the
impeded acidification of the GA membranes brought about by the viral protein. Next
we investigated whether treatment with monensin resulted in a down-regulation of
surface MHC I in either PalF or no-E5 cells. Cells were treated with 25 uM monensin
for 30 min, 3 or 12 h, and analysed for surface or total MHC I by FACS analysis with
mAb IL-AI9 as described in materials and methods. Monensin treatment caused a
fourfold decrease in surface MBC I after 30 min in PalF cells and after 3 h in no-E5
cells (Figure 3.4 C). The levels of surface MBC I returned to those seen in non-treated
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cells after 12 h in both cell lines (data not shown) in agreement with the reported
ability of cells to recover from the effects of monensin treatment (Zhang et al. 1993).
We do not know why no-E5 cells down-regulated surface MHC I in response to
monensin less rapidly than PalF cells (3 h vs 30 min); the delay may be due to the
expression of the other oncoproteins present in no-E5 cells. The experiment was
repeated three times and the ratio between the mean fluorescence for total and surface
(TIS) MHC I was calculated. The TIS ratio confirmed that monensin treatment
reduces expression of surface MHC I after 30 min of treatment, the TIS ratio in PalF
cells was increased approximately four-fold, and in no-E5 cells the highest TIS ratio
was obtained after 3 h of treatment with an increase of approximately of two-fold
(Figure 3.4 C). The transport to the cell surface of another membrane glycoprotein,
the transferrin receptor, was not affected in E5 cells (Figure 3.5 A), and likewise there
were no differences in the levels of surface transferrin receptor between cells treated
and not treated with monensin (Figure 3.5 B) (Ashrafi et al. 2002). Monensin
treatment did not significantly affect the levels of total MBC I in PalF cells and
slightly decreased it in no-E5 cells, as judged by immunoblotting (Figure 3.4 B), and
therefore these data show that monensin inhibited the transport of MBC I to the cell
surface but not its expression. These results indicate that, following inhibition of GA
acidification by monensin, transport of MHC I to the cell surface is impeded, and
support the notion that E5 prevents MHC I transport through inhibition of GA
acidification.
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Figure 3.4 Monensin causes GA swelling and MHC I intracellular retention
A) Morphology and immunofluorescence of 4-E5 and PalF cells treated with
monensin
The morphology of 4-E5 cells and PalF cells treated with 25 JlMmonensin for 3 h
was assessed using phase contrast microscopy (top panels), and
immunofluorescence detection with mAb 4A3 to visualize the GA (bottom panels).
Monensin-treated cells are highly vacuolated and present a swollen GA, similar to
E5 cells, N=nucleus. Magnification 40x (experiment done by Dr. Hossein Ashrafi
and figure published in Marchetti et al., 2002)
B) Western blot analysis of monensin treated cells
PalF and no-E5 cells were treated with 25 JlM monensin for 3 h and 10 ug of
protein lysate were analysed by immunoblotting for MHC I expression. MHC I
heavy chain (MHC I HC) was detected with mAb IL-A88 (top panel) and actin, as
a loading control, with mAb AB-l (bottom panel). Monensin does not affect the
expression of MHC I heavy chain. The numbers on the right represent the
molecular weights marker in kilodalton (kDa) (experiment done by myself and
figure published in Marchetti et al. 2002)
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Figure 3.4 Monensin causes GA swelling and MHC I intracellular retention
C) FACS analysis of monensin treated cells
PalF and no-E5 cells were treated with 25 j.lMmonensin for 30 min or 3 h. Surface
and total MHC I expression was examined by FACS analysis using mAb IL-A19.
The mean fluorescence from one experiment is shown in the upper pane1. Surface
mean fluorescence decreased after 30 min treatment with monensin in PalF cells
and after 3 h treatment in no-E5 cells. The ratio between total mean fluorescence
and surface mean fluorescence (TIS) of PalF and no-E5 cells is shown in the
bottom panel. The bars represent the average ratio from three experiments (+1-
standard deviation). The TIS ratio increases approximately fourfold in PalF cells
after 30 min of monensin treatment, and approximately twofold in no-E5 cells after
3 h of treatment, indicating a decrease in surface MHC I (experiment done by
myself from data published in Marchetti et al. 2002).
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Figure 3.5 The transferrin receptor transport is neither affected by E5 or by
monensin
A) FACS analysis of the transferrin receptor
Surface (solid histogram) transferrin receptor expression m parental and
transformed PalF cells. Intact cells were stained with mAb IL-A165 and analysed
by flow cytometry. The open histogram represent cells stained with FITC-
conjugated secondary antibody only. The transport to the cell surface of the
transferrin receptor is not affected in E5 cells (experiment done by Dr.Hossein
Ashrafi and figure from data published in Ashrafi et al. 2002).
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Figure 3.5 The transferrin receptor transport is neither affected by E5 or by
monensin
B) FACS profile of transferrin receptor expression in monensin treated cells
PalF and no-E5 cells were untreated or treated with 25!J.MMonensin. Cells were
stained with mAb IL-AI65 and analysed by flow cytometry. The open histogram
represent cells stained with FITC-conjugated secondary antibody only. The solid
histogram represent either surface or total transferrin receptor expression.
There is no difference in the levels of surface transferrin receptor between cells
treated or not treated with monensin (experiment done by Dr. Hossein Ashrafi,
personal communication).
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CHAPTER 4: Effect of the Bovine Papillomavirus Type 4
E5 protein on the transport of MHC class I molecule
4.1 Signal transduction by inteferons (IFNs)
Type I (a,p) and type II (y) IFNs playa central role in the immune response. After
receptor binding by a-IFN or P-IFN, specific tyrosine kinases, Tyk2 together with
one or more additional tyrosine kinases, Janus-activated kinase (JAK)-I and JAK-2,
are phosphorylated. These activated tyrosine kinases activate the signal-transducing
proteins (Stark et al. 1998) and induce the formation of a complex of protein subunits
(interferon-stimulated gene factor [ISGF]-3a) consisting of STAT -I a or STAT-
P and STAT-2. The phosphorylated ISGF-3a complex is translocated to the nucleus
and forms (with the addition of a fourth subunit p48 or IRF-9), a DNA-binding
complex specific for the IFN-stimulated response element (lSRE). y-IFN receptor
activation results in a similar sequence of events, although the transcriptional
regulatory complex consists of a homodimer of STAT -I that binds to DNA elements
termed gamma activated sites (GAS) (figure 4.1).
Both p-interferon and y-interferon (P-IFN or y-IFN) increase the transcription activity
of the MHC I heavy chain gene by acting on the IFN-stimulated response element
(ISRE), a conserved cis-acting regulatory element present in the promoter of MHC
class I genes. The ISRE is a binding site for factors of the IFN-regulatory family
(IRF) that form a group of secondary transcription factors that regulate gene
transcription in a positive (IRF-I) or negative manner (lRF-2 and IFN consensus
binding protein, ICSBP) or act as helpers of proteinIDNA complex formation (p48
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also known as IRF-9). (reviewed in (Agrawal and Kishore 2000; Taniguchi et al.
2001) (summarised in figure 4.1).
Figure 4.1
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Figure 4.1 Pathway of signal transduction by IFNs
After binding to specific receptors, tyrosine kinases (JAK-l, JAK-2, Tyk2) are
activated. These tyrosine kinases phosphorylate inactive transcription factors
(STAT-la, STAT-l~, STAT-2), which form a transcriptional factor, interferon-
stimulated gene factor (ISGF)-3a or STAT-I a dimer. The phosphorylated ISGF-
3a complex is translocated to the nucleus and forms (with the addition of a fourth
subunit p48), a DNA-binding complex specific for the IFN-stimulated response
element (ISRE). The STAT-1a dimer is also translocated to the nucleus and binds
to DNA elements termed gamma activated sites (GAS). The interferon-stimulated
response element (ISRE) and the gamma activation site (GAS) have shared
nucleotides for all IFN-stimulated genes (ISG). IRF-l gene is induced via GAS
which is found within the IRF-1 promoter. IRF-1 then bind to ISRE, leading to the
activation of IFN-inducible genes (such as HLAlMHC genes). N= nucleotide; Y=
pyrimidine. (Picture from Cancer Medicine 2003 plus adaptation from data
published by (Gobin et al. 1999; Taniguchi et al. 2001).
4.2 Treatment of ES cells with interferon increases total but not surface MHe I
Previous work in this laboratory has shown that in E5 cells there is less MHC I heavy
chain mRNA and protein (Ashrafi et al. 2002). To assess if the biosynthetic pathway
of heavy chain is permanently inhibited by E5, PalF, no-E5 and E5 cells were treated
with either ~- or y-IFN or 2D6, a control supernatant from cells not expressing IFN.
Treatment with either IFN, but not with 2D6, increased production of the MHC I
heavy chain in all cell lines as assessed by quantitative RT-peR and immunoblotting
(Figure 4.2 A,B) and noticeably the treatment does not increase expression of 4-E5
(Figure 4.2 C). This shows that E5 cells are responsive to IFN and the biosynthetic
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pathway of MHC I heavy chain is not irreversibly inhibited by E5 but the production
of MHC I heavy chain is still lower than in no E5 cells.
To investigate whether the reduction in HC RNA was due to transcriptional repression
or to degradation of the RNA, pBoLa-Luc, containing the reporter gene for luciferase
under the transcriptional control of the promoter/enhancer of a bovine MHC class I
HC gene, was transiently introduced into PalF cells along with pZip4-E5 (O'Brien et
al. 1999) , a plasmid expressing BPV-4 E5. Expression of luciferase was less than
half the level than when pBoLa-Luc was cotransfected with an empty pZip vector
(Figure 4.2 D, white bars). This result indicates that the reduction in HC RNA in PalF
4-E5 cells is due to the E5-induced inhibition of the transcriptional promoter of the
HC gene. Additionally, y-IFN-treatment stimulated the expression of luciferase from
pBoLa-Luc by approximately 2-fold both in the presence or absence of 4-ES (Figure
4.2 D, grey bars). Even with y-IFN-treatment, in cells expressing 4-ES luciferase
expression did not achieve the levels observed in cells that did not express E5.
These results show that 4-E5 inhibits transcription of cattle class I HC genes, and that
IFN treatment rescues transcription, but without completely overcoming 4-ES-
induced repression.
The IFN-treated cells were also analysed by FACS to ascertain whether the increased
production of heavy chain led to a corresponding increase in surface MHC I.MHC I
surface expression increased only in PalF and no-E5 cells but not in E5 cells, or in
cells expressing the 4-E5 N17A mutant in which a substitution of the asparagine in
position 17 to alanine resulted in hypertransforming characteristics (described in
detail in section 5.2) (Figure 4.2 E), despite the increase in total MIIC I.These results
show that E5 inhibits the transport ofMHC I from the endomembrane compartment to
the cell surface.
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Figure 4.2 Treatment of E5 cells with interferon increases total but not
surface MHC I
A) IFNs treatment increase MHe I heavy chain transcription
Quantitative RT-PCR for MHC class I HC RNA was performed on RNA from no-
E5 cells, PaIF-4E5 cells and PalF cells expressing the hypertransforming 4-E5
mutant Nl7 A (PaIF-NI7 A), before (white bars) or after treatment with 500U/ml
P-IFN (grey bars) or 250U/ml y-IFN (black bars). The extent of amplification was
normalised to that of the actin RNA and is plotted as arbitrary units. The panel
shows the averages with standard deviations of at least three experiments. Both
P-IFN and y-IFN increased transcription of HC RNA in control and E5 cells.
(experiment done by Dr. Rubina Ullah a former worker in this laboratory from data
published in Marchetti et al., 2006).
B) IFNs treatment increase MHC I heavy chain expression in all cells.
Cells were treated for 48h with 500 U/ml of either P-IFN or y-IFN (lanes marked +),
or with 500 U/ml of the control supernatant 2DG (lanes marked -) and lOug of protein
lysates were analysed by immunoblotting. MHC I heavy chain (MHC I HC) was
detected with mAb IL-A88 (top panel) and actin, as loading control, with mAb AB-I
(bottom panel). The numbers on the right represent the molecular weights marker in
kilodalton (kDa) (experiment done by Dr. Hossein Ashrafi from data published in
Marchetti et al. 2002).
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Figure 4.2 Treatment of E5 cells with interferon increases total but not surface
MHCI
C) IFN treatment does not increase E5 mRNA
Quantitative RT-PCR for ES RNA was performed on RNA from PalF 4-ES cells and
PalF-N17A cells before (white bars) or after treatment with 2S0U/ml ~-rFN (grey
bars) or 2S0U/mi y-IFN (black bars). The extent of amplification was nonnalised to
that of the actin RNA and is plotted as arbitrary units. The panel shows the averages
of one experiment done in triplicate. (experiment done by Dr. Rubina Ullah a former
worker in this laboratory).
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D) BPV -4 E5 inhibits transcription from the BoLa promoter
BoLa promoter transcriptional activity in PalF parental cells transiently
cotransfected with pBoLa-Luc and pZipneo empty vector, or with pBoLa-Luc and
pZip-4E5 (O'Brien et al., 1999), either without (white bars) or with 250 D/ml 't:
IFN treatment (grey bars). Luciferase activity is plotted as arbitrary transcription
units, with the activity of pBoLa in PalF parental cells taken as 1. y-IFN increases
the transcriptional activity of pBoLa also in presence of E5. (experiment done by
Wendy Crawford a former student in this laboratory and picture from data
published in Marchetti et al., 2006).
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Figure 4.2 Treatment of ES cells with interferon increases total but not surface
MHCI
E) FACS profile of MHC I surface and total expression. MHC I is not
trasported to the cell surface in IFN-treated ES cells. Cells treated with P-IFN
(PaIF, 4-ES N17A) or y-IFN (no-ES, 4-ES) (solid histograms), or the control
supernatant 2DG (open histograms) were analysed for expression of total and
surface MHC I by FACS analysis with mAb IL-A19. IFN treatment increases both
total and surface MHC I in PalF and no-E5 cells, but only total MHC I in E5 cells
or cells expressing the hypertransforming mutant N17A. (experiment done by Dr.
Hossein Ashrafi from data published in Marchetti et a!., 2002).
4.3 Lysosome and proteasome inhibitors increase the stability of the heavy chain
in ES-expressing cells
MHC class I stability is regulated by proteasomes and lysosomes, which degrade mis-
located or mis-folded MHC class I molecules (Bartee et aI., 2004; Hewitt et aI., 2002;
Hughes et aI., 1997). The levels of HC protein are extremely low in PalF E5 cells, but
increase when transcription of the He gene is stimulated by IFN treatment, without
however reaching the levels of He in IFN-treated control cells (Figure 4.3). To
investigate further the cause of this reduction in He protein, the no-E5 and 4-E5 cell
lines were treated with inhibitors of lysosomes (bafilomycin or ammonium chloride)
or of proteasomes (MG132 or ALLN).
Ammonium chloride is a known lysosomotropic agent which enter the lysosome and
neutralize the H+ions (Poole et al. 1977); Bafilomycin is a macrolide antibiotic that
acts as a specific inhibitor of vacuolar-type H+-ATPase that playa pivotal role in
acidification and protein degradation in the lysosomes in vivo (Yoshimori et al. 1991);
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MG132 is a potent cell-permeable proteasome inhibitor that reduces the degradation
of ubiquitin-conjugated proteins by the 26S complex in mammalian cells (Rock et al.
1994) and ALLN (also known as MG101) is a potent cysteine protease and
proteasome inhibitor (Vinitsky et al. 1992).
Levels of MHC class Iwere assessed by immunoblotting. Treatment with inhibitors
increased the amounts of IIC in no-E5 cells but only marginally in 4-E5 cells (Figure
4.3, lanes with no IFN), probably because of the preceding block of HC gene
transcription. Given that the transcriptional block could be relieved by IFN, cells were
treated with both IFN and inhibitors. After the combined treatment, the level of HC
protein in 4-E5 cells was comparable with that of no-E5 cells (Figure 4.3). It is
reasonable to conclude that in E5 cells, as in control cells, the degradation of the HC
protein via the lysosomes and proteasomes can be abrogated by treatment with
inhibitors.
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Figure 4.3 Proteasome and lysosome inhibitors prevent degradation of MHC
class I He in control and E5 cells.
Cells were left untreated or treated with either 250U/ml y-IFN for 48 h, the
lysosome inhibitors Bafilomycin Al (l~M) or NH4CI (40mM) for 24 h, or the
proteosome inhibitors MG-I32 (5~M) or ALLN (10P~M) for 8 h. For combined
treatment with y-IFN and inhibitors, lysosome inhibitors were added for the last 24
h of y-IFN treatment, and proteosome inhibitors for the last 8 h. Protein lysates
were probed with mAb IL-A88 against HC, or with mAb AB-l against actin.
Combined y-IFN and inhibitors treatment increases levels of MHC class I HC in
both control and E5 cells. The experiment shown is representative of at least three
experiments giving essentially the same results. The numbers on the right represent
the molecular weights marker in kDa (experiment done by myself from data
published in Marchetti et al., 2006).
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4.4 Transport of MHC class I complex to the cell surface is irreversibly inhibited
by BPV-4 E5
To see whether the increase in MHC class I HC induced by treatment with IFN and
lysosome or proteasome inhibitors resulted in increased levels of MIIC class I
complex on the cell surface, flow cytometry analyses of the treated cells were
performed. Treatment with IFN+bafilomycin or IFN+MG 132 increased the amount of
surface MHC class I in no-ES cells by S-6 fold, but not in PalF 4-ES cells, where the
increase was so negligible that the shift in forward fluorescence could not even be
detected (Figure 4.4 A,B). These results show conclusively that the 4-ES protein
prevents the traffic of MHC class I complex to the cell surface in an irreversible
manner.
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Figure 4.4 MHC class I transport to the cell surface is irreversibly inhibited
by BPV-4 E5
Cells were treated with y-IFN + MG-I32 or y-IFN + Bafilomycin AI, as in Figure
4.3 and expression of surface MHC class I was analysed by flow cytometry with
mAb IL-AI9.
A) FACS profiles of control no-ES and 4-E5 cells with no treatment (white),
y-IFN +MG-132 (dark grey) and y-IFN + Bafilomycin Al (light grey).
B) The extent of surface MHC class I expression is plotted as Mean Forward
Fluorescence. In control cells, combined y-IFN and inhibitors treatment increases
surface MHC class I, whereas in 4-E5 cells surface MHC class I does not increase.
The experiment shown is representative of three experiments giving essentially
identical results (experiment done by myself from data published in Marchetti et
al.,2006).
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CHAPTER 5: Analysis of the effects of BPV-4 E5 wild type
protein and mutants on the inhibition of MHC I cell surface
transport: physical interaction between BPV-4 E5 and MHC
class I heavy chain
5.1 In vitro interaction between BPV-4 ES and classical Mile class I heavy chain
The retention of MHC class I in the Golgi apparatus is due at least in part to the
alkalinisation of the organelle (Marchetti et al. 2002), attributed to the binding of E5
to the 16k subunit c of the vacuolar H+ATPase (Goldstein et al. 1991). However, the
almost complete co-localisation of 4-E5 and the residual MHC class I in the Golgi
apparatus (Marchetti et al. 2002) would suggest additional mechanisms. To further
investigate this hypothesis, in vitro co-immunoprecipitation experiments were
performed. First, 4-E5 was cloned in a suitable plasmid for transcription translation
assay (pcDNA3.1(-», N*01301 eDNA, encoding the bovine HC N*01301 (formerly
known as HD6) was already cloned in a suitable plasmid (pcDNA3) under the control
of a T7 promoter (Ellis et al. 1996; Gaddum et al. 1996; Ellis et al., 1999) (details of
constructs in chapter 2, sections 2.1.10 and 2.1.11). The efficiency of translation was
assessed by in vitro transcription/translation assay (as described in Materials and
Methods section2.2.4.7) (fig. 5.1 A).
4-E5 and the bovine N*01301 HC were separately transcribed/translated in vitro in
the presence of 35S-methionine(Faccini et al. 1996) and then kept separately or mixed
together. The proteins were precipitated either with Ab 274 against the C-terminus of
E5 (Anderson et al. 1997; Araibi et al. 2004) or mAb IL-A88 against bovine HC.
There was no precipitate in the absence of antibody (Figure 5.1 D, lanes 3,5,7); the
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anti-E5 antibody precipitated 4-E5 but not N*01301 HC (Figure 5.1 B, lanes 3,2), and
mAb IL-A88 precipitated HC but not 4-E5 (Figure 5.1 D lanes 4,6). However, when
the two proteins were mixed together, they co-precipitated with either antibody
(Figure 5.1 B, lane 4 and 5.1 C, lane 3), indicating that 4-E5 and HC interact, at least
in vitro. This interaction is not an artefact as 4-E5 is precipitated by an antibody
against HC even when N*01301 HC is not labelled (Figure 5.1 C, lane 5).
To see whether the interaction between 4-E5 and HC was specific for a particular
MHC haplotype, the experiment was repeated with a different He, N*00201
(formerly known as JSP.1) (Pichowski et al. 1996). Also in this case, 4-E5 and
N*00201 He co-precipitated when incubated with mAb IL-A88 (Figure 5.1 D, lane
8), showing that interaction is not restricted to certain MHe alleles.
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Figure 5.1 BPV-4 E5 and MHC class I HC interact in vitro
A) Transcription/translation assay
lug of each plasmid encoding for the 4-E5 protein, the bovine N*01301 HC and the
luciferase control DNA was in vitro transcribed/translated in presence of 35S_
methionine. The produced proteins were run on a 4-12% NuPAGE gel and the dried
gel exposed on a screen and analysed on a Storm 840 apparatus. Luciferase was run
as an internal control in the transcription/translation reaction. The numbers on the left
represent the molecular weights marker in kilodalton (experiment done by myself).
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Figure 5.1 BPV4-E5 and MHC class I HC interact in vitro
In vitro co-immunoprecipitation.
For ease of description, 4-E5 wt will be referred to as E5; the red stars indicate the
interaction between E5 and either N*01301(B and C) or N*00201(D). The numbers
on the right represent the molecular weights marker in kilodalton.
B)35S-labelled in vitro transcribed/translated E5, and N*01301 HC were
immunoprecipitated with Ab 274, against the C-terminus of E5; the precipitated
proteins were run on a NuPAGE gel and the gel dried and exposed on a screen then
analysed on a Storm 840 apparatus. E5 and N*01301 HC interact physically.
C)35S-labelled in vitro transcribed/translated E5 and N*01301 HC were
immunoprecipitated with mAb IL-A88 against bovine MHC class I HC; the
precipitated proteins were processed as in A. E5 is precipitated by mAb IL-A88 even
when N*01301 is unlabelled (unIN*01301) (red star, lane 5). N*01301 HC and E5
interact physically. Note that lanes 1-4 and 5 were run in separate gels and aligned
with the other lanes for ease of comparison.
D)35S-labelled in vitro transcribed/translated E5 and N*00201 He were
immunoprecipitated with mAb IL-A88 against bovine MHC class I He and processed
as in A. N*00201 He and E5 interact physically. (experiments done by myself from
data published in Marchetti et al., 2006).
5.2 BPV-4 E5 mutants that do not transform cells do not down regulate MHC I
In a study of the cell transforming properties of E5 (O'Brien et al. 1999), this
laboratory established that mutation of the asparagine residue 17 of BPV -4 E5 to
tyrosine (N17Y) lead to loss of cell transformation and so did deletion of the C-
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terminus (E5T) of both BPV -4 and BPV -1 E5. On the contrary, mutation of Nl7 of
BPV -4 ES to alanine (N17 A) resulted in a hyper-transforming mutant. Further studies
established that the ability to down-regulate MHC class I expression co-segregated
with the ability to transform cells (Ashrafi et at. 2002; O'Brien and Campo 2003).
4-E5 mutants that did not transform did not down-regulate MHC class I as assessed
by flow cytometry (Figure 5.2 B) and both the total and cell surface levels of MHC
class I were similar to those of control cells. In contrast the hyper-transforming
mutant down-regulated surface MHC class I to the same extent as wild type 4-ES
(Figure S.2 B). Figure S.2 A is a schematic representation of 4-ES wild type protein
and its mutants. In table 5.3 the known characteristics of cells expressing 4-E5 or its
mutants are summarised (Faccini et al. 1996; Ashrafi et at. 2000; Ashrafi et al. 2002).
1 17 42
A MSL WLIYVLLLFWCAFNFLALLF AIIVYLLLISTITRLDGWD 4-E5 wild type
1 17 42
MSLWLIYVLLLFWCAFYFLALLF AIIVYLLLISTITRLDGWD 4-E5 N17Y
1 17 42
MSLWLIYVLLLFWCAF AFLALLF AIIVYLLLISTITRLDGWD 4-E5N17A
MSL WLIYVLLLFWCAFNFLALLF AIIVYLLLIStop
1 33
4-E5T
Figure 5.2 ES mutants that do not transform do not down-regulates MHC class I
A) Schematic representation of BPV -4 ES wild type protein and its mutants
The mutated amino acids are in red.
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Figure S.2 ES mutants that do not transform do not down-regulates MHC class I
B) Representative mean fluorescence of surface or total MHC I
Surface and total MHC I in transformed PalF cells expressing mutant forms of 4-ES
(N17Y, NI7A, 4-EST) and of l-ES (I-EST). The plus and minus signs above the
histogram refer to the degree of cell transformation (experiments done by Dr. Hossein
Ashrafi from data published in Ashrafi et al. 2002).
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5.3 Mutants and classical MHC class I heavy chain: BPV-4 E5 inhibits MHC
class I transport and binds to MHC heavy chain via its C-terminus.
To investigate whether the 4-E5 mutants were capable of interacting with HC, co-
immunoprecipitation experiments were performed as described above. Both NI7Y
and NI7 A were co-precipitated with HC by Ab 274 (Figure 5.3 A, lanes 6,8) and
mAb IL-A88 (Figure 5.3 B, lanes 5,7), while 4-E5T was not co-precipitated with
N*0130I HC by mAb IL-A88 (Figure 5.3 B, lane 9). 4-E5T lacks the C-terminal
domain and therefore could not be precipitated by Ab 274. As 4-E5 is tagged at its N-
terminus with the HA epitope, co-immunoprecipitation experiments with mAb HA.ll
raised against the HA epitope were performed. mAb HA.ll co-precipitated 4-E5 and
HC, although not as effectively as Ab 274, (Figure 5.3 C, lane 2) but did not co-
precipitate HC with 4-E5T (Figure 5.3 C, lane 3). These data indicate that the
interaction between 4-E5 and HC takes place via the C-terminus of 4-E5. To confirm
this, competition experiments with a well characterised peptide were performed. The
peptide sequence corresponded to the C-terminus of 4-E5, and its ability to compete
with 4-E5 had been validated in immunocyto- and immunohisto-staining experiment
(Pennie et al. 1993; Anderson et al. 1997; Araibi et al. 2004). The peptide did
successfully compete with 4-E5 in co-immunoprecipitation experiments (Figure 5.3
B, lane 11); its addition to the reaction prevented the interaction between 4-E5 and
N*01301, proving conclusively that the C-terminus of 4-E5 interacts with MHC class
IHC.
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Figure 5.3
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Figure 5.3 BPV ES and MHC class I HC interact via the C-terminus domain
er es,
For ease of description, 4-E5 wt will be referred to as E5 and 4-E5T as E5T. The
numbers on the right represent the molecular weights marker in kilodalton.
A) In vitro co-immunoprecipitation with Ab 274
35S-labelled in vitro transcribed/translated E5, N17Y or NI7A, and N*01301 HC were
immunoprecipitated with Ab 274, against the C-terminus of E5; the precipitate was
run in a PAGE gel and the gel exposed on a screen on a Storm 840 apparatus. Note
that lanes 1-3 and lanes 4-9 were run in separate gels and aligned together for ease of
comparison. The red stars indicate the interaction between N*O130 1 HC with either
E5 wt or its mutant forms NI 7Y or N 17A (experiment done by myself from data
published in Marchetti et al. 2006).
B) In vitro co-immunoprecipitation and competition with mAb IL-A88
35S-labelled in vitro transcribed/translated E5, NI7Y, N17A or E5T and N*01301 HC
were immunoprecipitated with mAb IL-A88 against bovine MHC class I HC and
processed as in A. E5, N17Y and N17A interact with HC (red stars), whereas E5T,
deleted in the C-terminus domain does not (red arrow lane 9). The C-terminus peptide
prevents E5 binding to N*01301 HC (red arrow lane 11). Note that lanes 1-4, 5-10
and 11 were run in a separate gel and aligned with the other lanes for ease of
comparison (experiment done by myself from data published in Marchetti et al.
2006).
C) In vitro co-immunoprecipitation with mAb HA.tt
35S-labeUed in vitro transcribed/translated E5 or E5T and HC were
immunoprecipitated with mAb HA.ll against the HA epitope tag of ES and EST and
processed as in A. Note that lanes 1-2 and 3-4 were run in a separate gel and aligned
with the other lanes for ease of comparison. The red stars indicate the interaction
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between N*01301 HC with ES wt. EST does not interacts with N*01301 HC (red
arrow lane 3) (experiment done by myself from data published in Marchetti et al.
2006).
5.4 In vivo interaction between BPV-4 E5 and MHC class I heavy chain
To confirm that 4-ES and HC interact also in cells, co-immunoprecipitation
experiments were performed in no-ES cells and in 4-ES cells. Both cell lines were
treated with IFN and MO 132 (as described in section 4.2 and 4.3) to bring the amount
of heavy chain in 4-ES cells to detectable levels. Protein lysates from both cell lines
were incubated with Ab 274 and the immunoprecipitates were run on a gel and
immunoblotted with mAb IL-A88. A band of the appropriate MW for HC
(approximately 4S kDa) was visible in a Comassie blue stained gel in the
immunoprecipitate from 4-ES cells, which was not visible in the immunoprecipitated
from no-ES cells (Figure S.4). This band reacted with mAb IL-A88 and corresponded
to bona fide HC detected by direct immunoblotting of protein lysates (Figure S.4).
Despite the combined IFN+MO 132 treatment, the HC band co-precipitated with 4-E5
is faint because the treatment does not increase expression of 4-ES (Figure 4.2 C) and
4-E5 is expressed at almost undetectable levels (O'Brien et al. 1999; O'Brien et al.
2001); therefore the amount of 4-E5 is limiting for the amount of bound HC.
However, the reactivity with mAb IL-A88 specific for bovine HC seen only in 4-ES-
expressing cells, the correspondence of the band with bona fide HC and the results
obtained in vitro, establish the identity of this band as MHC class I HC and confirm
that the interaction between 4-E5 and HC takes place also in cells.
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1 2 M 1 2 3 4
IP: Ab 274; IB: mAB IL-A88
Left panel: Comassie blue stained gel
Lanes: 1, co-IP from 4-ES cells
2, co- IP from no-ES cells
M, marker
Right panel: immunoblot
Lanes: 1, protein lysate from 4-ES cells
2, co- IP from 4-ES cells
3, protein lysate from no-ES cells
4, co- IP from no-ES cells
Figure 5.4 BPV-4 ES and MHC I HC interact in vivo
In vivo co-immunoprecipitation
No-E5 cells and 4-E5 cells were treated with y-IFN and MG132 as described in
materials and methods. Cells were lysed in RIPA buffer containing a cocktail of
protease inhibitors (Roche, Lewes, UK). 100f-lg of protein lysate were
immunoprecitated with Ab 274. l Ougof the immunoprecipitate were run in NuPAGE
gels, transferred to nitrocellulose membranes and immunoblotted with mAb IL-A88
as described in Materials and Methods. A parallel gel was stained with Comassie
blue. The red stars indicate the position of HC (experiment done by Mr Ed Doman a
worker in this laboratory from data published in Marchetti et al. 2006).
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Three conclusions can be reached from these experiments: one, binding of 4-E5 to HC
is necessary for down-regulation of MHC class I as shown by 4-E5T, but not
sufficient as shown by NI7Y; two, the nature of residue 17 is not important for the
interaction with HC, and three, the C-terminus of 4-E5 is responsible for the
interaction between 4-E5 and HC (Table 5.3).
Cell 16K GJIC MHCI MHCI MHCI
Cell type transformation interaction down down HC He
(in vitro) regulation regulation interaction interaction
(in vitro) (in vivo)
4-E5 wt + + + + + +
N17Y + + nd- - -
N17A ++ + + + + nd
4-E5T + nd- - - -
Table 5.3 Summary of characteristics of 4-E5 and its mutants
16K: 16K ductinlsubunitc, a component of the gap junction and of the VD sector of
the vacuolar H+-ATPase (Finbow et al. 1991; Goldstein et al. 1991; Conrad et al.
1993; Faccini et al. 1996). GJIC: gap junction intracellular communication. nd: not
done. The + and - represent the extent of expression of the characteristic.
5.5 In vitro transcription translation and immunoprecipitation of BPV-4 E5 and
putative non-classical MBe I heavy chain
While classical MHC molecules (HLA-AlB) are the main presenters of antigenic
peptides to cytotoxic T lymphocytes (CTL) cells, HLA-C and non-classical
HLAlMHC, such as HLA-E or -G, inhibit natural killer (NK) cell-mediated lysis by
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interacting with inhibitory NK receptors (Lee et al. 1998; Wang et al. 1998; Braud et
al. 1999b). Certain viral proteins, including HIV Nef and the US3IUL40 proteins of
CMV, have evolved to downregulate selectively HLA-A and -B, the main presenters
of peptides to CTLs, but not HLA-C or non-classical HLA-E (Ahn et al. 1996;
Tomasec et al. 2000; Furman et al. 2002) and are therefore capable of avoiding both
CTL and NK cell killing (Cohen et al. 1999). Human papillomavirus type 16 ES
(HPV-16 ES) selectively down regulates surface expression of HLA-A and HLA-B,
which present viral peptides to MHC class l-restricted cytotoxic T lymphocytes but
not the NK cell inhibitory ligands HLA-C and non-classical HLA-E (Ashrafi et al.
200S).
N*50001 (formerly known as GeneX or HDS9; (Ellis et al. 1996) appears to be a
bovine non-classical class I gene due to a number of characteristics: it is relatively
non-polymorphic, it is prone to alternative splicing, it has an early stop codon in the
cytoplasmic domain, producing a truncated C-terminus (19 amino acids shorter than
N*01301 HC), it has a number of unusual amino acid substitutions throughout, it has
a large deletion in the 3' UTR, and significant differences in the promoter region
compared to classical class I genes (Dr. Shirley Ellis personal communication)
(Figure S.SA).
While classical MHC I HC contains the C-terminus cytoplasmic tail, and is able to be
co-immunoprecipitated with the 4-ES protein (section S.l), the product of the bovine
non-classical class I gene N* 50001, lacks this domain.
To determine whether 4-ES selectively down-regulates classical MHC class I and
which HC domain is involved, co-immunoprecipitation experiments were performed.
The N*SOOOIHC was already cloned in the pcDNA6-V5-His vector under the control
of the T7 promoter (as described in chapter 2, sections 2.1.10 and 2.1.11). 4-ES and
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the N*50001 HC were transcribed/translated in vitro in the presence of 35S_
methionine and immunoprecipitated as described in Materials and Methods.
The proteins were precipitated with mAb IL-A88 against bovine He (this antibody is
known to work well with classical and non-classical HC; Shirley Ellis personal
communication) (Fig 5.5 s.c»
There was little or no precipitate in absence of antibody (Figure 5.5 D, lane 2); mAb
IL-AS8 precipitated N*50001 HC but not 4-E5 (figure 5.5 D, lane 3, 4). While 4-E5
was efficiently co-immunoprecipitated by mAb IL-AS8 with N*01301 HC that
contains the cytoplasmic tail (Figure 5.5 D, lane 5), 4-E5 was not co-
immunoprecipitated with N*50001 He that lacks this domain (Figure 5.5 D, lane 6).
To confirm this result, we performed competition experiments between N*01301 He
and 4-E5 with unlabelled N*50001 HC. The proteins were again precipitated with
mAb IL-AS8. N*50001 HC did not compete with 4-E5 in co-immunoprecipitation
experiments when 4-E5, N*01301 He and N*50001 HC were used together (Figure
5.5 Elane 2); the addition of N*50001 He to the reaction did not prevent the
interaction between 4-E5 and N*01301. It is resonable to conclude that the BPV-4 E5
and the non-classical MHe I He do not interact in vitro.
As described above, N*50001 lacks the C-terminus intra-cytoplasmic tail of classical
MHC class I HC and is 19 amino acids shorter than N*01301 (Figure 5.5 A). Given
the absence of interaction between E5 and N* 50001 we wondered whether the intra-
cytoplasmic domain of class I He was responsible for binding to E5. A C-terminus
truncation mutant of N*O130 1 He lacking the final 19 amino acid residues was made
(N*0130Istop339) and used in in vitro co-IP experiments with 4-E5. This mutant co-
precipitated with 4-E5 (figure 5.5 F lane 3) showing that the interaction between He
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and 4-ES does not involve the C-terminus intra-cytoplasmic domain of HC.
Furthermore, N*0130l HC bound ES whether tagged with VS-His at its C-terminus,
like N*SOOOI, or not (figure S.S F lanes 11 and 7), demonstrating that the C-terminus
epitope has no effect on the interaction.
It is not possible to analyze the expression or the function of N*50001 in bovine cells
(in vivo) because there is no specific antibody for its protein. To study the relationship
of BPV -4 ES with classical and non-classical MHC I, Araibi et aI., separately
expressed a classical, N*OI301, and a non-classical, N*50001, allele in the mouse
mastocytoma PSIS cells (Ellis et al., 1999) and subsequently introduced ES in these
cells (Araibi et al., 2006). The lack of in vitro interaction between ES and N*SOOOI
(see fig 5.5 D and E in this thesis) was corroborated by a "pull-down co-
immunoprecipitation" experiment between ES and N*SOOOI HC in the PSIS cells
expressing the two proteins (Araibi et al. 2006). Moreover, Araibi et al, showed that
BPV -4 ES does not retain the non-classical MHC class I in the Golgi, does not inhibit
its transport to the cell surface and does not affect the stability of N*SOOOI HC
(Araibi et al., 2006). Taken together, the results presented above lead to the firm
conclusion that ES does not interfere with the biosynthetic pathway of non-classical
N*SOOOIMHC class I.
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N*0130l
N*5000l
N*0130l
N*5000l
N*0130l
N*5000l
N*0130l
N*5000l
N*0130l
N*5000l
N*0130l
N*5000l
N*01301
N*5000l
Alpha 1
* 20 * 40 *~~~~~~~~~~~~~l~!~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Alpha 2
60 * 80 * 100 *~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~;~~~~~~~~~~~~~~~l~~~~~~!~
120 * 140 * 160 *
YGCDVGSDGRLRRGYEQYGYDGRDYLALNEDLRSWTAADTAAQISKRKMEAAGAAER
H .. G L N.HA K T W .. T .
Alpha 3
180 * 200 * 220~~~~~~~~~~~~~~~~~~~~~~~~~l~~~~~:~~~~~:~~~~~~~~~~~~~~~
* 240 * 260 * 280
ISLTWQRNGEDQTQDMELVETRPSGDGNFQKWAALVVPSGEEQRYTCRVQHEGLQEP
........................... T A .
Transmembrane domain Cytoplasmic domain
* 300 * 320 * 340
~~~~~~~;;I~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~:~I~~~~~~~~~AASN
*GDSAQSDVSLTVPK#
Figure 5.5 A) Alignment of the predicted amino acid sequences of N*01301
and N*50001
Dots indicate identity, # indicates stop codon. Divergent amino acids (bold) are
seen only in N*50001 (or other cattle non-classical class I alleles) and are not seen
in cattle classical class I alleles (www.ebi.ac.uk/ipdlmhc/bolW. The alignment was
achieved with DNAstar software using the Megalignment program.
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Lanes: 1, input N*0130I
2, N*01301-Ab
3, N*0130I +Ab
4, input N*5000I
5, N*5000I-Ab
6, N*5000I +Ab
38
IP: mAb ILA88 anti-bovine MHC I HC
c 3 kDa,---------, 491 2
MHCHC~
49
Lanes: 1, PalF
2, P8I5
3, P8I5-N*5000Iactin
~
WB: mAb IL-A88 anti-bovine MHC I HC
Figure 5.5 mAb IL-A88 which recognises all cattle classical class I genes also
recognises N*50001
B) In vitro immunoprecipitation
The plasmids pcDNA3 and pcDNA6 encoding N*OI30I (classical) and N*50001
(non-classical), respectively were transcribed/translated in presence of 35S-methionine
and the products were immunoprecipitated with mAb IL-A88 against bovine MHC
class I HC; the precipitates were run in a 4-12% NuPAGE gel and the dried gel
exposed on a screen and analysed on a Storm 840 apparatus. mAb IL-A88 recognise
N*5000I in immunoprecipitation (experiment done by myself).
C) Western blot analysis
Bovine PalF cells, mouse mastocytoma cells P8I5 (described in Materials and
Methods) or P8I5 cells expressing N*5000I (P8I5- N*5000I) (described by Ellis et
al. 1999) were harvested and IOug protein lysates were immunoblotted with mAb IL-
A88 against HC, or mAb AB-I against actin. mAb IL-A88 recognises HC from
bovine PalF cells and from mouse cells stably expressing bovine N*50001 (P815-
N*50001) and does not cross react with mouse HC (experiment done by myself).
The numbers on the right in B and C represent the molecular weights marker in
kilodalton.
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Figure 5.5
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Figure 5.5 BPV-4 E5 and non-classical MHC class I HC do not interact in vitro.
D) In vitro co-immunoprecipitation
35S-labelled in vitro transcribed/translated 4-E5, N*01301 HC and N*5000l HC were
immunoprecipitated with mAb IL-A88 against bovine MHC class I HC; the
precipitate was run in a 4-12% NuPAGE gel and the dried gel exposed on a screen
and analysed on a Storm 840 apparatus. 4-E5 interacts with classical N*01301 HC
(red star, lane 5) but does not interacts with non-classical N* 5000 1 HC (red arrow,
lane 6). Note that lanes 1-5 and 6-7 were run in a separate gels and aligned with the
other lanes for ease of comparison.
E) In vitro competition and co-immunoprecipitation
35S-labelled N*01301 He and 4-E5 and unlabelled N*5000l He were in vitro
transcribed/translated and immunoprecipitated with mAb IL-A88. The precipitate was
treated as in D. Non-classical N*5000l He fails to compete with classical N*01301
HC for binding to 4-E5 (red star, lane 2). The numbers on the right in D and E
represent the molecular weights marker in kilodalton (experiments done by myself
from data published in Araibi et al., 2006)
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mAb IL-A88: anti-bovine MHC I HC
Lanes: 1, input N* 01301 stOP339
2, N*01301stop339 +4-E5-Ab
3, N*01301stop339 +4-E5 +Ab
4, input 4-E5
5, input N*OI301
6, N*01301 +4-E5-Ab
7, N*OI301 +4-E5 +Ab
8, input 4-E5
9, input N*01301-V5-His
10, N*01301-V5-His+ 4-E5-Ab
11, N*0130I-V5-His+ 4-E5+Ab
12, input 4-E5
Figure 5.5 The intra-cytoplasmic domain of class I He is not responsible for
binding BPV -4 E5
F) In vitro co-immunoprecipitation
35S-labelled in vitro transcribed/translated 4-E5, N*0130I HC and N*0130Istop339
HC were immunoprecipitated with mAb IL-A88 against bovine MHC class I HC; the
precipitate was run in a 4-12% NuPAGE gel and the dried gel exposed on a screen
and analysed on a Storm 840 apparatus. The C-terminus truncated form
N*0130Istop339still interacts with 4-E5 (red star, lane 3) and N*01301 HC bound 4-
E5 whether tagged with V5-His at its C-terminus (red star, lane 11) or not (red star,
lane 7). The interaction between HC and 4-E5 does not involve the C-terminus
domain of HC. Note that lanes 1-8 and 9-12 were run in separate gels and aligned
with the other lanes for ease of comparison. The numbers on the right represent the
molecular weights marker in kilodalton (experiment done by myself).
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CHAPTER 6: PV E5 proteins interact in vitro with human
and equine major histocompatibility class I heavy chains:
common way to escape immunosurveillance ?
6.1 In vitro immunoprecipitation between classical HLA and HPV-16 E5
HPV-16 E5 also prevents the transport of classical MHC (HLA) class I complexes to
the cell surface and retains it in the Golgi apparatus (Ashrafi et al. 2005). It was
hypothesised that, like BPV-4 E5, HPV-16 E5 could retain HLA class I HC in the
Golgi apparatus by physically interacting with these molecules. To investigate if such
interaction exists, in vitro transcription/translation and co-immunoprecipitation
experiments were performed. First, different HLA haplotypes were cloned in
commercial cloning plasmids suitable for transcription/translation assay (generation
of constructs described in chapter 2, sections 2.1.10 and 2.1.11). The HPV-16 E5
protein was already tagged at its N-terminus with an HA epitope and cloned in a
plasmid (pCI-neo) under the control of the T7 promoter (details of construct in
chapter 2, section 2.1.10 and 2.1.11). Its efficiency of translation was assessed by in
vitro transcription/translation assay as described in Materials and Methods (Fig. 6.1
A). HPV-16 E5 and the human HLA HCs were separately transcribed/translated in
vitro in the presence of 35S-methionine and then kept separately or mixed together.
The proteins were precipitated either with mAb HC10, specific for the human HLA
class I HC or mAb HA.l1 raised against the HA epitope. The mAb Hel0 precipitated
HLA-Al, A2 and B8 HCs but not 16-E5 (Figure 6.1 B, lanes 3,11,19,5,13,21 upper
panel), and the mAb HA.11 precipitated 16-E5 but little or no HCs (Figure 6.1 B,
lanes 5,13,21,3,11,19 bottom panel). However, when the two proteins were mixed
together, they co-precipitated with either antibody (Figure 6.1 B, lanes 7,15,23 upper
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and bottom panel), indicating that 16-E5 and the HCs from different haplotypes
interact, at least in vitro (Ashrafi et al. 2006b). These results shown that the
interaction is not restricted to certain HLA alleles.
A
N*01301 Al A2 B8
kDa
49
.as..
28
Figure 6.1 HPV-16 ES and classical HLA class I He interact in vitro
A) Transcription/translation assay
N*01301, HLA-Al, HLA-A2 and HLA-B8 were in vitro transcribed/translated in
presence of 35S-methionine. The produced proteins were run on a 4-12% NuPAGE
gel and the dried gel exposed on a screen and analysed on a Storm 840 apparatus.
The bovine N*01301 HC was run alongside the human Hes as a control of
transcription/translation reaction and as a comparison for the molecular weight of the
resultant proteins. The numbers on the left represent the molecular weights marker in
kilodalton (experiment done by myself).
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Figure 6.1 HPV-16 E5 and classical HLA class I He interact in vitro
B) In vitro co-immunoprecipitation
35S-labelled in vitro transcribed/translated l6-E5, AI, A2 and B8 were
immunoprecipitated with mAb HClO specific for the human HLA class I heavy chain
(upper gels) or mAb HA.ll raised against the HA epitope (bottom gels). The
precipitates were run on a 4-12% NuPAGE gel as above. The red stars indicate the
interaction between 16-E5 and either HLA-Al (lane 7), HLA-A2 (lane 15) or HLA-B8
(lane 23). Note that lanes 1-8, 9-16 and 17-24 were run in separate gels and aligned
with the other lanes for ease of comparison. The numbers on the right represent the
molecular weights marker in kilodalton (experiment done by myself).
kDa
-49
-38
-28
_17
-14
-6
181
Chapter 6 RESULTS
6.2 BPV and equine sarcoids
The equine sarcoid, a locally aggressive, fibroblastic skin tumour, is the most
common dermatological neoplasm reported in horses. Although the disease is not
metastatic, the lesions rarely regress and if left untreated can become aggressive.
Despite the strict species-specificity of PVs, it has been shown that BPV-1 and less
frequently BPV -2 are associated with the pathogenesis of sarcoid disease (Lancaster
et al. 1977; Gorman 1985; Nasir and Reid 1999; Martens et al. 2001). However,
there are numerous differences between BPV -lor BPV -2 infection in cattle and in
horses. Infection in cattle results in benign cutaneous fibropapillomas, productive for
infectious progeny virus. Bovine papillomas regress in response to an appropriate
effector immune response. Although the precise mechanisms are not clear, a cell
mediated immune response is the major contributor to the regression of papillomas
(Okabayashi et al. 1991; Coleman et al. 1994; Knowles et al. 1996). In contrast,
BPV -lor BPV -2 infection in horses results in sarcoids, non permissive for virus
production (Gorman 1985), locally aggressive and non-regressing (Ragland 1970).
Although equine sarcoids are not permissive for virus production, the BPV -lor BPV-
2 major transforming protein, E5, is expressed in over 75% of sarcoids (Nasir and
Reid 1999; Carr et at. 2001 b; Chambers et al. 2003b). It is still not known how E5
contributes to sarcoid pathogenesis. One hypothesis could be that expression of E5 in
sarcoids is sufficient to downregulate the equine leucocyte antigen (ELAlMHC),
likely resulting in immunevasion as it has been hypothesized for BPV -4 E5 and
bovine classical MHC class I and HPV -16 E5 and classical HLA.
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6.2.1 In vitro immunoprecipitation between ELA He and BPV-l E5
To investigate the possibility of an interaction between the ELA HC and the BPV-l
E5 in vitro immunoprecipitation were performed. We received plasmids encoding two
classical ELA HC: EqB2 and EqB4 (kind gift of Dr. Shirley Ellis). The full length
BPV-1 E5 protein was cloned in a plasmid suitable for transcription translation assay
(as described in chapter 2, section 2.1.10 and 2.1.11). The efficiency of translation
was assessed by in vitro transcription/translation assay (Fig. 6.2.1 A and Blane I).
BPV-I E5 and the ELA HCs were separately transcribed/translated in vitro in the
presence of 35S-methionine and then kept separately or mixed together. The proteins
were precipitated with either mAb MAC291 or mAb H58A, specific for the equine
class I HC. To assess the reactivity of the two available mAb MAC291 and mAb
H58A a preliminary immunoprecipitation was preformed. The two mAb showed
different reactivities with mAb MAC291 reacting better with the EqB2 class I HC and
the mAb H58A with EqB4 class I HC (figure 6.2.1 C). Taking account of this result,
mAb MAC291 and mAb H58A were chosen to immunoprecipitate EqB2 HC and
EqB4 HC, respectively.
The mAb MAC 291 immunoprecipitate EqB2 HC but not l-E5wt (figure 6.2.1 D
lanes 3,4 upper gel) and mAb H58A immunoprecipitate EqB4 but not I-E5wt (figure
6.2.1 D lanes 3,4 bottom gel). However, when the two proteins were mixed together,
they co-precipitated with the appropriate antibody (figure 6.2.1 D lanes 6 upper and
bottom gels) indicating that BPV-1 E5wt interacts with equine class I HC at least in
vitro, and this interaction can take place with two different equine alleles.
To further investigate if this in vitro interaction occurs via the C-terminus of the BPV-
lE5 protein as shown for the BPV-4 E5 (section 5.3), a truncated form of BPV-l E5
with a stop codon in position 32 (I-E5T) was generated by PCR and cloned in a
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suitable plasmid for in vitro tanscriptionltranslation (construct details in chapter 2,
sections 2.1.10 and 2.1.11). The efficiency of translation of I-E5T was assessed by in
vitro transcriptionltranslation assay (Fig. 6.2.1 Blane 2). Then, co-
immunoprecipitations between the truncated I-E5T which lacks the C-terminus
domain and the equine HCs (B2, B4) were performed. The I-E5wt was co-
precipitated with HC by mAb MAC29I or mAb H58A (figure 6.2.1 D, lane 6 upper
and bottom gels), while I-E5T was not co-precipitated either with EqB2 HC or EqB4
HC (figure 6.2.1 E, lanes 5 and 9).
To confirm this result, competition experiments between EqB2 HC or EqB4 HC and
I-E5 with either unlabelled l-E5T or unlabelled l-E5 were performed. As expected,
the full length unlabelled l-E5 competed with itself preventing the interaction of
labelled E5 with both EqB2He and EqB4 He (Figure 6.2.1 F lanes 2 and 5), whereas
the unlabelled I-E5T protein did not compete with I-E5 (Figure 6.2.1 G lanes 2 and
5) and the addition of I-E5T to the reaction did not prevent the interaction between 1-
E5 and EqB2 HC or EqB4 He.
These data indicate, conclusively, that the interaction between l-E5 and equine HCs
takes place via the C-terminus of l-E5, as shown for 4-E5.
These results show a common behaviour between the E5 proteins of BPY-1 and BPY-
4 at least in vitro.
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6, inputB4
7, B4-mAbH58A
8, B4+mAbH58A
9, B4-mAbMAC291
10, B4+mAbMAC291
Figure 6.2.1 Equine HC transcription/translation assay and control
immunoprecipitation
Equine leucocyte antigen EqB2 (B2) HC, EqB4 (B4) HC (A), BPV-1E5wt (1-E5) and
BPV-1E5T (1-E5T) (B) were in vitro transcribed/translated in presence of 35S_
methionine. The produced proteins were run on a 4-12% NuPAGE gel and the dried
gel exposed on a screen and analysed on a Storm 840 apparatus to assess the
efficiency of translation. (C) Equine HC control immunoprecipitation 35S-labeUed
in vitro transcribed/translated EqB2 HC and EqB4 HC were immunoprecipitated with
mAb MAC291 and mAb H58A specific for the equine class I heavy chain. The
precipitated were run on a 4-12% NuPAGE gel and treated as above. The mAb
MAC291 reacts better with EqB2 (red circle, lane 5 underlined in figure text) and
mAb H58A reacts better with EqB4 (red circle, lane 8 underlined in figure text). The
numbers on the left represent the molecular weights marker in kilodalton
(experiments done by myself).
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28 5, B4+1-E5-Ab
6, B4+ 1-E5+Ab
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1-E5 *• 6
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Figure 6.2.1 In vitro co-immunoprecipitation between equine HCs and BPV-IE5
D) 35S-labelled in vitro transcribed/translated EqB2 (B2), EqB4 (B4) and BPV -lE5wt
(I-E5) were immunoprecipitated with mAb MAC291 (upper gel) and mAb H58A
(bottom gel) specific for the equine class Iheavy chain. The precipitates were run on a
4-12% NuPAGE gel and the dried gel exposed on a screen and analysed on a Storm
840 apparatus. The red stars indicate the interaction between l-E5 wt and either B2
(lane 6, upper gel) or B4 (lane 6 bottom gel). Note that lanes 1-3, 4-5 of the bottom
picture were run in separate gels and aligned with the other lanes for ease of
comparison. The numbers on the right represent the molecular weights marker in
kilodalton (experiments done by myself).
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49
* HC* ~38
28
17
14
I-E5T
~
6
Lanes: 1, l-E5T+MAC291
2,I-E5T+H58A
3, input l-E5T
4,I-E5T+B2-MAC291
5,I-EST+B2+MAC291
6, input B2
7, input I-EST
8, l-E5T+B4-H58A
9,I-E5T+B4+H58A
10, input B4
Figure 6.2.1 In vitro co-immunoprecipitation between equine HCs and BPV-
lEST
E) 35S-labelled in vitro transcribed/translated EqB2 (B2), EqB4 (B4) and BPV-IE5T
(I-EST) were immunoprecipitated with mAb MAC291 or mAb H58A specific for the
equine class Iheavy chain. The precipitates were run on a 4-12% NuPAGE gel and the
dried gel exposed on a screen and analysed on a Storm 840 apparatus. I-EST does not
interact (red arrows) either with B2 (red star, lane 5) or B4 (red star, lane 9).
Note that lanes 1-7 and 8-10 were run in separate gels and aligned with the other lanes
for ease of comparison. The numbers on the left represent the molecular weights
marker in kilodalton (experiment done by myself).
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Figure 6.2.1 The BPV-1 ES protein compete with itself in co-mmunoprecipitation
experiment
F) 35S-labelled in vitro transcribed/translated EqB2 (B2),EqB4 (B4), BPV-IE5wt (1-
E5) and unlabelled l-E5 (unll-E5) were immunoprecipitated with mAb MAC291 or
mAb H58A specific for the equine class I heavy chain. The unlabelled l-E5 protein
prevent its interaction with the equine HCs (red arrows, lanes 2 and 5). The
precipitated were run on a 4-12% NuPAGE gel and the dried gel exposed on a screen
and analysed on a Storm 840 apparatus. The numbers on the left represent the
molecular weights marker in kilodalton (experiment done by myself).
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Figure 6.2.1 The BPV-l EST protein does not compete with BPV-l ES in co-
immunoprecipitation experiment
G) 35S-labelled in vitro transcribed/translated EqB2 (B2), EqB4 (B4), BPV-IE5wt (1-
E5) and unlabelled I-E5T (unll-E5T) were immunoprecipitated with mAb MAC29I
or mAb R58A specific for the equine class Iheavy chain. The I-E5T protein did not
prevent the interaction between I-E5 and the equine RCs (red arrows, lanes 2 and 5).
The precipitated were run on a 4-12% NuPAGE gel and the dried gel exposed on a
screen and analysed on a Storm 840 apparatus. Note that lanes 1-3 and 4-6 were run in
separate gels and aligned with the other lanes for ease of comparison. The numbers on
the left represent the molecular weights marker in kilodalton (experiment done by
myself).
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CHAPTER 7: DISCUSSION
7.1 Introduction
During viral infection or malignant transformation, a spectrum of peptides derived
intracellularly from viral or transformation-associated antigens is bound to MHC I
molecules in the endoplasmic reticulum (ER). Following transport from the ER
through the Golgi apparatus (GA) to the cell surface, the MHC class I/peptide
complexes are presented to virus-specific cytotoxic T lymphocytes (CTL), signalling
virus infection and enabling killing of the infected or tumour cell.
MHC I molecules therefore playa crucial role in immune recognition and clearance
of these types of cell. Viruses need to escape immunosurveillance by the host to
establish infection and to generate new infectious progeny.
The importance of MHC class I molecules in virus clearance has been demonstrated
by the identification of many mechanisms of interference with the MHC class I
pathway evolved by viruses, starting with prevention of peptide processing, as in the
case of EBV, HCMV and HIV (Klenerman et al. 1994; Bertoletti et al. 1994; Gilbert
et al. 1996; Tellam et al. 2001) followed by interference with antigenic peptide
transport via TAP complex, as in the case ofHSV, HCMV, HPV-6 and HPV-ll (Ahn
et al. 1997; Lehner et al. 1997; Galocha et al. 1997; Vambutas et al. 2001) and finally
inhibition of MHC class I surface expression, as in the case of Ad, HCMV, MCMV,
HIV and HTLV-l (Bennett et al. 1999; Johnson et al. 2001; Kasper et al. 2005;
Williams et al. 2005; Piguet 2005). In each of these strategies, the outcome is the
failure by the infected cell to present viral peptide antigens to effector T cells and
hence avoidance of detection and destruction by the host immune system.
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Papillomaviruses are poorly immunogenic. Even in immunocompetent hosts, whether
animals or humans, PV persist for a significant period of time, usually spanning
several months, before activation of the host immune system. This lack of recognition
suggests the host immune system is unaware of, or disabled by, PV infection.
The ability of the virus to persist has been attributed to the nature of the virus life
cycle, which may prevent the immune cells having access to the viral proteins. In fact
these proteins are expressed in the suprabasallayers of the epithelium, i.e. in cells not
readily exposed to the immune system, and moreover are produced in very low
amounts, often below the threshold required for the activation of immune cells, thus
leading to tolerance (Tindle 2002).
Together with E6 and E7, E5 is a transforming protein of PV. While E6 and E7 are
the main oncoproteins of mucosal human papillomavirus (HPVs) (Munger et al. 2001;
Mantovani et al. 2001), E5 is the major oncoprotein of bovine papillomaviruses
(BPVs), particularly ofBPV-l (DiMaio and Mattoon 2001). The E5 protein is a small
hydrophobic peptide (from 83 amino acid residues in HPV-16 to 42 residues in BPV-
4). Data suggest that BPV E5 is a type II membrane protein with a high hydrophobic
a-helical trans-membrane domain and an hydrophilic C-terminus domain oriented
inside the Golgi lumen (Surti et al. 1998) whereas HPV-16 E5 is composed of three
hydrophobic domains that are capable of spanning a membrane three times (Bubb et
al. 1988) or may exist in a l3-hairpin conformation, in which the N- and C- terminus
domains exist within the membrane, connected by a loop the central portion of which
is exposed on the cytoplasmic or luminal surface, but its orientation in membranes is
still unknown (Alonso et al. 2002). It is expressed during the early stages of infection
in the deep layers of the infected epithelium and its expression is extinguished as the
lesion progresses (Burnett et al. 1992; Anderson et al. 1997; Chang et al. 2001).
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In agreement with its hydrophobic nature, E5 is localized in the endomembrane
compartments of the endoplasmic reticulum and Golgi apparatus of the host cell
(Burkhardt et al. 1989; Pennie et al. 1993). Although there are evidence that in
organotypic raft culture E5 can support cell cycle progression and activate late viral
functions upon epithelial differentiation (Fehnnann and Laimins 2003), its function in
vivo is not known but in vitro cell transformation is brought about by the activation of
several kinases, from growth factor receptors to cyclins-cdks (Morgan and Campo
2000).
E5 interacts physically with the cellular protein 16k ductinlsubunit c, a component of
the gap junction and of the VO sector of the vacuolar H+-ATPase (Goldstein et al.
1991; Conrad et al. 1993; Finbow et al. 1995; Faccini et al. 1996). This physical
interaction has been deemed responsible for the down-regulation of gap junction
communication (Oelze et al. 1995; Faccini et al. 1996; Ashrafi et al. 2000) and for the
lack of acidification of endosomes and GA (Straight et al. 1995; Schapiro et al. 2000).
The inhibition of acidification of the endomembrane components has been attributed
to a malfunction of the H+-ATPase (Briggs et al. 2001), although lack of acidification
of late endosomes or inhibition of the vacuolar proton pump are not always observed
(Thomsen et al. 2000; Ashby et al. 2001).
Previous data from this laboratory have shown that transformed bovine cells
expressing BPV-1 E5 or BPV-4 E5 are highly vacuolated and have an enlarged and
often disrupted GA (Ashrafi et al. 2000; Ashrafi et al. 2002), and this morphology has
been attributed to the interaction of E5 and 16k subunit c. In these cells, E5 proteins,
including E5 from HPV-16, cause down-regulation of the major histocompatibility
class I (MHC I) complex (Ashrafi et al. 2002; O'Brien and Campo 2002). Moreover,
the down-regulation of MHC I by BPV E5 takes place not only in cultured cells but
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crucially also in vivo in BPV-4-induced papillomas (Araibi et al. 2004) and this may
contribute to PV escape from immunosurveillance and aid the establishment of viral
infection.
The work described in this thesis extended the analysis of the functions of BPV -4 E5
and its mutants on the downregulation of MHC class I molecules in PalF cells and
investigated E5 behaviour in relation to: transcription of the MHC I HC, degradation
of MHC I HC protein and MHC I complex transport. This work addressed for the first
time the question of whether the BPV E5 proteins downregulate MHC I through
physical interaction with the complex and describes that this interaction is mediated
by the C-terminus domain ofE5 at least in BPV.
Moreover, other lines of evidence support the hypothesis that BPV -4 E5, as described
for HPV -16 E5 (Ashrafi et al. 2005) is able to downregulates classical but not non-
classical MHCIHLA potentially allowing the virus to evade CTL and NK killing
(Araibi et al. 2006).
7.2 BPV-4 E5 irreversibly inhibits the transport of MHC class I molecules to the
cell surface
The BPV oncoprotein E5 downregulates surface expression of MHC I, which may
affect the recognition and killing of PV -infected cells by CTL (Ashrafi et al. 2002;
O'Brien and Campo 2002). E5 interferes with several steps of the MHC I pathway,
including transcription of MHC I heavy chain mRNA, expression of MHC I heavy
chain protein, and transport of MHC I complex to the plasma membrane (Ashrafi et
al.2002).
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7.2.1 Golgi apparatus retention
Both endogenous MHC Ior exogenous (transfected) GFP-MHC I heavy chain fusion
protein are retained in the swollen and misshapen GA characteristic of E5-expressing
cells and co-localize with the E5 protein in the GA (figures 3.2 J and 3.3 A and B).
The detection of endogenous MHC I in the GA with mAb IL-AI9, which does not
recognize free MHC I heavy chain, indicates that the heavy chain is complexed with
~2-microglobulin. This suggests that the arrest of MHC I transport occurs following
MHC class I complex formation in the ER and is due instead to a fault in cellular
transport across the Golgi compartments. Indeed, treatment of control cells with the
ionophore monensin resulted in the acquisition of a phenotype remarkably similar to
that of E5 cells, with many vacuoles and a distorted GA, with a concordant rapid and
marked down-regulation of surface MHC I (figure 3.4 A, B and C). Monensin is a
well-characterized inhibitor of GA acidification, which hinders cellular transport of
newly synthesized proteins, particularly interfering with transfer across Golgi
compartments and compromising secretion from the medial to the trans-Golgi
(Tartakoff 1983). Taking into account the similar functional effect of monensin and
E5, these data suggest that E5 causes GA malformation and retention of the MHC I
complex in the GA at least in part by increasing GA pH.
However, the impeded transport of the MHC I complex in E5 cells is not part of a
generalized disturbance of intracellular traffic as the transport of the transferrin
receptor is not affected by E5 expression (Ashrafi et af. 2002) nor by treatment with
monensin (figure 3.5 A and B). Like E5, the HTLV-l pli, another small
hydrophobic viral protein, binds to the 16k subunit c component of the H+- V-ATPase
(Franchini et af. 1993). p12' can also bind MHC I causing its intracytoplasmic
retention and degradation (Johnson et af. 200 I). Moreover, it has been shown that
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improperly processed MHe I molecules accumulate and are degraded in an expanded
Golgi intermediate compartment (Raposo et al. 1995). In E5-expressing cells the
interaction of E5 with 16k subunit c may lead to improper processing of MHC I that
then accumulates in the GA, an hypothesis that is consistent with the cellular
localization of the MHC class I complex in the E5 cells.
7.2.2 BPV-4 E5 reversibly inhibits transcription of the MHC class I He gene.
In PalF 4-E5 cells, the levels of He RNA are barely detectable (Ashrafi et al. 2002),
and by quantitative RT-Pf'R we estimate that the amount of HC RNA in these cells is
between 1- and 3-fold less than in control cells (Figure 4.2 A, white bars). The
reduction ofHC RNA is due to a transcriptional inhibition of the HC gene (Marchetti
et al. 2006).
In order to determine if the MHC I biosynthetic pathway was rendered irretrievably
malfunctional by E5, PalF control and E5-expressing cells were treated with type I
and II IFNs which are potent inducers of MHC I expression (Agrawal and Kishore
2000). All of the cell lines tested, including the 4-E5 cells, responded to IFN
treatment by increasing the level of MHC I heavy chain to approximately the same
extent, although the effect was more marked with y-IFN than with P-IFN (figure 4.2
A and B).
The downregulation of the heavy chain gene promoter is supported by two
observations: E5 downregulates a BoLa HC gene promoter/enhancer (Figure 4.2 D
and (Marchetti et al. 2006) and treatment with either P- or y-IFN, both of which
increase HC gene transcription (Agrawal and Kishore 2000), leads to accumulation of
HC RNA also in PalF 4-E5 cells, and to increased activity of the BoLa He
promoter/enhancer (Figure 4.2 A, grey and black bars; 4.2 D and Marchetti et al.
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2006). However, even in the presence of IFN, the levels of HC RNA in PalF 4-E5
cells are still approximately 2- to 3-fold lower than in control cells. This suggests that
E5 expression causes a transcription inhibitor to bind to the BoLa promoter/enhancer,
and that this putative inhibitor exerts its action even when IFN-induced transcription
activators promote transcription. This hypothesis however requires confirmation and
other explanations are possible. BPY E5 is not present in the nucleus (Burkhardt et al.
1989; Pennie et al. 1993; Zago et al. 2004) and its effect on transcription is therefore
not direct. Rather, BPY E5 interferes with several signal transduction pathways
(O'Brien et al. 2001; DiMaio and Mattoon 2001; Zago et al. 2004; Grindlay et al.
2005), and it is therefore likely that inhibition of the BoLa promoter/enhancer is
achieved by interference with one or more of these pathways. It has already been
shown that BPY-4 E5 affects the expression of cyclin A by acting indirectly on the
transcriptional promoter of the cyclin A gene (O'Brien et al. 1999; Grindlay et al.
2005). BPY-4 E5 inhibition of the BoLa promoter/enhancer is another example of E5
interference with transcription regulation.
7.2.3 E5 induces the degradation of MHC class I HC
MHC class I half-life is regulated by degradation in the proteasomes and lysosomes
(Bartee et al. 2004) and several viral proteins contribute to the destruction of MHC
class I by favouring HC ubiquitination, or by inducing peptide mis-folding or
complex mis-location (Hughes et al. 1997; Hewitt et af. 2002; Bartee et al. 2004). In
PalF 4-E5 cells, levels of HC are much lower than in control cells (Ashrafi et al.
2002). Treatment with either proteasome or lysosome inhibitors in presence of y-IFN
rescues HC to levels comparable to those of control cells (Figure 4.3). In 4-E5
expressing cells the stability of HC is drastically reduced and the virtual absence of
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HC in PalF 4-E5 cells is in agreement with the retention of MHC class I in the GA by
E5 and with the degradation of mis-folded, mis-located or improperly processed MHC
class I by both proteasomes and lysosomes. BPY E5 interacts with 16k subunit c of
the VO sector of the V -ATPase (Goldstein et al. 1991; Faccini et at. 1996) and this
interaction results in alkalinization of the GA (Schapiro et al. 2000), which in turn we
have argued is in part responsible for retention of MHC class I in the GA (Marchetti
et al. 2002). The Y-ATPase pump is ubiquitous in the endomembrane compartments,
including the lysosomes, so it would have been expected that its inhibition by E5
would not have lead to He degradation, or that lysosome inhibitors would have no
effect on He degradation. This apparent discrepancy may be due to different reasons.
First, E5 resides mainly in the GA and may inhibit the pump only in this organelle,
similar to HPY-16 E5, which alters endosomal pH but not GA pH (Disbrow et al.
2005); second, E5 may disable the pump only transiently (Ashby et al. 2001), and
third, E5 interference with the pump is not complete and stronger inhibition is needed
for blocking protein degradation in the lysosomes.
7.2.4 BPV-4 E5 irreversibly blocks transport ofMHC class I to the cell surface
The arguments discussed above point to the fact that both E5-induced transcriptional
inhibition of the He gene and degradation of He peptide can be overcome. However,
the transport of MHC class I from the endomembranes to the cell surface is
irreversibly compromised by E5. Although after treatment with IFN and
proteasome/lysosome inhibitors, the amount of HC in PalF 4-E5 cells is similar to that
of control cells, surprisingly the increase in surface MHe class I is negligible (Figure
4.4). This suggested additional mechanisms for retention ofMHe Iin the GA.
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7.3 BPV-4 E5 interacts physically with He
BPV-l E5 interacts physically with the receptor for PDGF (Petti et al. 1994) and both
BPV-l E5 and BPV-4 E5 interact with 16k subunit c (Goldstein et al. 1991; Faccini et
al. 1996). Given the established interaction between E5 and membrane proteins, we
hypothesized that BPV-4 E5 interacts also with MHC class I HC. Indeed, this is the
case and the two proteins coprecipitate not only in vitro (Figures 5.1 B,C and D) but
also in vivo (Figure 5.4 A). This interaction is not an artefact as E5 is precipitated by
an antibody against HC even when HC is not labelled (Figure 5.1 C, lane 5). E5 and
HC interact in PalF-4 E5 cells as shown by the co-immunoprecipitation of HC with an
antibody against E5 only in PaIF-4 E5 cells and not in control cells (Figure 5.4 A,
lanes land 2). The reason for the low levels of the HC coprecipitated with 4-E5
resides is the fact that, although the levels of HC can be boosted many fold by the
combined treatment of IFN and proteasome/lysosomes inhibitors, expression of E5 is
not affected (Figure 4.2 C); E5 is present at barely detectable levels (O'Brien et al.
1999) and is therefore rate-limiting for complex formation with HC. The interaction
between E5 and HC reflects a genuine relationship between the two proteins as there
is agreement between interaction in vivo and in vitro and a good correlation between
interaction in vitro and downregulation of MHC class I in vivo. Furthermore,
interaction takes place also between HPV-16 E5 and HLA-A in human keratinocytes
(Ashrafi et al. 2006b) and HPV-83 E5 and HLA-A2 in vitro (Ashrafi et al. 2006a),
suggesting that the physical relationship between E5 proteins and HCs is a common
mechanism to downregulate surface MHC/HLA class I.We do not know the MHC
class I phenotype of the PalF cells but, as the in vitro co-immunoprecipitation
experiments have been done with two different class I alleles, encoded at different
loci, and E5 downregulates MHC class Iin papillomas from calves of different breeds
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(Araibi et al. 2004), it is reasonable to conclude that BPV-4 E5 can interact with and
downregulate most, if not all classical class IHCs. This is indeed the case for HPV-16
E5 (Ashrafi et al. 2006b).
7.3.1 The interaction between BPV-4 E5 and HC is mediated by the C-terminus
domain of 4-E5
4-E5T which is a C-terminus deletion mutant of BPV-4 E5 does not inhibit the
expression ofMHC class I or its transport to the cell surface (Ashrafi et al. 2002). The
lack of downregulation is due to lack of interaction with HC. 4-E5T does not interact
with HC (Figure 5.3 Blane 9 and C lane 3) and the interaction between 4-E5 and HC
is prevented by a peptide corresponding to the C-terminus of 4-E5 (Figure 5.3 Blane
11). The C-terminus tail of 4-E5 is clearly critical to the function of the protein: 4-
E5T is not transforming (O'Brien et al. 1999), does not induce the typical
morphological changes brought about by 4-E5, and does not distort the GA (Ashrafi
et al. 2000). The ability to bind MHC class IHC has to be added to the functions of 4-
E5 C-terminus. However, the physical interaction between 4-E5 and HC appears to be
necessary but not sufficient for downregulation of MHC class I as the 4-E5 mutant
N17Y binds HC but does not inhibit MHC class I expression (Figures 5.3 A lane 6
and Blane 5 and 5.2 B). This situation is reminiscent of the fact that interaction
between BPV-1 E5 or BPV-4 E5 and 16k subunit c is not sufficient for cell
transformation (Ashrafi et al. 2000; Ashby et al. 2001) and points to a complex
interaction of E5 proteins with cellular mechanisms/pathways. Nevertheless, we
confirm here previous observations from this laboratory that only transformation-
competent E5 proteins are capable of inhibition of MHC class I transport. It is
interesting that BPV-4 E5 can potentially interact with more than one membrane
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protein simultaneously. E5 interacts with 16k subunit c through the transmembrane
residue 17 (glutamine in BPY-l ES, asparagine in BPY-4 ES) (Goldstein et at.
1992b), and could therefore interact with HC through its C-terminus at the same time.
BPY-1 ES interacts with the PDGP receptor through glutamine 17 and the
juxtamembrane aspartate 33 (Petti et al. 1997; Klein et al. 1998) in a multiprotein
complex that can include 16k ductin (Goldstein et al. 1992a; Lai et al. 2000). Residue
33 is not present in either l-E5T or 4-EST (O'Brien et al. 1999), and we cannot rule
out that it plays a role in the interaction with He. However, although we have not
investigated any interaction between BPY-4 ES and PDGP receptor, cell
transformation by BPY-4 ES does not appear to depend on signalling from growth
factor receptors (Zago et al. 200S), and it is therefore unlikely that receptor binding
would compete with HC binding.
7.4 BPV-4 E5 and putative non-classical class I : possible evasion of NK killing
of infected cells
As described before many pathogens have effective means of avoiding the adaptive
immune response and a common feature of many viral infections is the virus-induced
modulation of class I expression. However there are several examples of
discrimination between classical and non-classical class I targeting by viruses. While
classical class I expression is most often down-regulated by viral interference at one
or more points in the pathway between transcription and cell surface expression,
expression of non-classical class I genes usually remains undisturbed (Cohen et al.
1999; Tomasec et al. 2000; Wang et al. 2002). It has been proposed that this enables
the virus-infected cell to evade cytotoxic T cell responses while at the same time
sending inhibitory signals to NK cells via expression of one or more non-classical
class I genes. This relates to engagement of inhibitory NK receptors by non-classical
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class I molecules, for example CD94INKG2 molecules by HLA-E, KIR2DL4 by
HLA-G (Hofmeister et al. 2003; Borrego et al. 2005).
In vitro and in vivo immunoprecipitation experiments have shown that BPV-4 E5
binds to bovine class I HC and allowed to map the HC-interacting domain of E5 to its
C-terminus end (paragraph 5.3 and (Marchetti et al. 2006). Recent data from this
laboratory have also shown that HPV-16 E5 down-regulates classical HLA I (MHC
class I) but not non-classical HLA-E (Ashrafi et at. 2005). To determine whether
BPV-4 E5, like HPV-16 E5, is incapable of down-regulating certain non-classical
MHC genes, we used a recently described gene in the bovine MHC class I cluster,
N*50001 (Di Palma et al. 2002). N*50001 and other eight putative non-classical class
I sequences (N*50001-N*50501, see http://www.ebi.ac.uk/ipd/mhclbol~ have been
recently identified in cattle cDNAs, and most of them have not yet been functionally
characterized.
N*50001 (GenBank accession: AY188807) was first identified in 1995 when it was
termed HD59 (Ellis et al. 1996) and subsequently was mapped to a region of the cattle
MHC containing several classical class I genes (Di Palma et al. 2002). N*50001
encodes a HC with a truncated cytoplasmic domain (8 rather than 28 amino acids),
and in this sense resembles human HLA-G (Geraghty et al. 1987) (Figure 5.5A).
Immunoprecipitation experiments showed lack of interaction between 4-E5 and
N*50001 and this prompted the question of whether the intra-cytoplasmic domain of
class I HC was responsible for binding to 4-E5.
The C-terminus truncation mutant of N*O1301 HC lacking the final 19 amino acid
residues still interacts with 4-E5 (figure 5.5 F lane 3). Furthermore, N*01301 HC
bound 4-E5 whether tagged with V5-His at its C-terminus, like N*50001, or not
(figure 5.5 F lanes II and 7), demonstrating that the C-terminus epitope has no effect
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on the interaction. These results lead to the conclusion that 4-E5 does not interact with
the non-classical N*50001 MHC class I, in marked contrast to its inhibitory effect on
classical MHC class I.
Moreover BPV-4 E5 does not affect either the stability ofN*50001 heavy chain or the
transport ofN*50001 MHC I complex to the cell surface (Araibi et al. 2006). A major
difference between classical N*01301 and non-classical N*50001 He is the
truncation of the intra-cytoplasmic domain in the latter, but the interaction with 4-E5
does not take place via this domain. This finding contrasts with the binding of HIV
Nef to the intra-cytoplasmic domain of HLA-A and with the observation that the
inability of Nef to bind some non-classical HLA resides in amino acid differences in
the intra-cytoplasmic domain of HLA-E and the absence of the domain in HLA-G
(Williams et al. 2002; Pizzato et at. 2004). There are several aminoacid differences
throughout the extracellular domains between classical N*01301 and non-classical
N*50001 He (Figure 5.5A), but which one of these differences is responsible for the
differential interaction with 4-E5 remains to be established.
Downregulation of classical MHe class I and lack of downregulation of non-classical
MHC class I by BPV-4 E5 suggest that, like other viruses, BPV is potentially capable
of evading CTL and NK killing of infected cells.
7.5 PV E5-MHC I HC interaction: a common mechanism that leads to
immunoevasion ?
Despite the failure to isolate papillomavirus from equine sarcoids, there is now a large
body of evidence strongly supporting the hypothesis that BPV is the etiological agent
of equine sarcoids. Both BPV-1 and BPV-2 have been detected in sarcoid tumours,
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with BPV-1 the predominant type (Trenfield et al. 1985; Angelos et al. 1991; Lory et
al. 1993; Bloch et al. 1994; Reid et al. 1994).
Several studies have evaluated BPV gene expression in equine sarcoids demonstrating
the presence of BPV-l DNA, BPV specific RNA and the presence of the major BPV
transforming protein E5 (Nasir and Reid 1999; Carr et al. 2001a; Carr et al. 2001b;
Chambers et al. 2003a). These studies clearly provide evidence that the viral genes
are expressed and that therefore the presence of the viral DNA is not accidental.
The role of the immune response in determining the outcome of PV infections is well
established. In most cases, regression of PV lesions occurs following activation of the
host immune response. However, several immune evasion mechanisms that may
contribute to persistence and progression of PV-associated disease have also been
described in this thesis and in (O'Brien and Campo 2002).
Sarcoid are non-regressing, in contrast to many other lesions caused by PV infection,
suggesting that expression of the BPV proteins in equine cells may evoke similar
immune evasion mechanisms. Results from this thesis show that 4-E5, the major
oncoprotein of BPV-4, retains MHC class I molecules within the Golgi apparatus and
prevents transport ofMHC class I complex to the cell surface both in vitro and in vivo
(figure 3.2, 5.1, 5.2, 5.4 and Marchetti et al. 2002; Ashrafi et al. 2002; Araibi et al.
2004; Marchetti et al. 2006). Moreover this impaired transport of MHC class I
complex is due to the physical interaction of the MHC I HC with the C-terminus of
the 4-E5 protein (figure 5.3 and Marchetti et al. 2006). We asked whether this type of
interaction could occur between BPV-1 E5 and the equine leukocyte antigen HC.
Immunoprecipitation experiments shown that 1-E5 was able to interact in vitro with
equine HC whereas the truncated form l-E5T that lacks the C-terminus domain was
not (figures 6.2.1 D and E). In fact, like the C-terminus deletion mutant of 4-E5 (4-
203
Chapter 7 DISCUSSION
EST), I-EST is transformation disabled (O'Brien et al. 1999), and it has been shown
that the down regulation of surface MHC I and cell transformation co-segregate
(paragraph S.2 and (Ashrafi et al. 2002; O'Brien PM and MS Campo 2003).
Moreover, the addition of I-E5T in competition experiments did not prevent the
interaction between l-ES and EqB2 HC or EqB4 HC (Figure 6.2.1 G) whereas the full
length l-E5 did compete with itself (Figure 6.2.1 F) indicating, conclusively, that the
interaction between l-ES and equine HCs takes place via the C-terminus of l-ES.
There are several amino acidic similarities throughout the C-terminus domains of
BPV-l ES and BPV-4 E5, but which one of these aminoacid is responsible for the
interaction with class I HC remains to be established.
Moreover, also HPV-16 E5 is able to interact in vitro with HLA-AI, -A2, -B8 and in
vivo with HLA-A3 and the down-regulation of surface HLA I and interaction with HC
are mediated by the first hydrophobic domain of HPV-16 ES (Ashrafi et al. 2006b).
7.6 Role of BPV-4 E5 in papillomavirus pathogenesis
During BPV infection, despite the presence of numerous papillomas actively
producing virus, early or late viral antigens are not recognised by the host immune
system for a significant period of time (Chandrachud et al., 1994, 1995; McGarvie et
al., 1995). This suggests that the host immune system is unaware of, or disabled by,
BPV infection. Failure of inducing anti-viral immune responses during papillomavirus
infection is believed to be due in part to the nature of the virus life cycle, which may
prevent the immune cells having access to the viral proteins (Tindle 2002). As
described in this thesis, BPV-4 ES downregulates classical MHC class I at more the
one level in PalF cells. However, in PalF cells, ES was co-expressed with E6, E7 and
activated ras (Pennie et al., 1993), leaving open the possibility, albeit remote, that the
204
Chapter 7 DISCUSSION
downregulation of MHC class I was due to a functional interaction between the viral
and cellular oncoproteins. This is likely not the case as Araibi et al., have shown that,
in mouse mastocytoma P8I5 cells, E5 alone profoundly inhibits expression of both
surface and total classical MHC class I in the absence of other viral or cellular
oncoproteins (Araibi et al., 2006).
It maybe argued that the results presented in this thesis are limited to the in vitro
system. Araibi et al., investigated the relationship between the expression of BPV-4
E5 and MHC class I in naturally occurring papillomas. In this study, E5 was detected
exclusively in the cytoplasm of epidermal cells, from the basal and parabasallayers to
the spinous and squamous layers. Cells that expressed E5 did not express MHC class I
and cells that expressed BPV-4 E7, but no E5, still had detectable MHC I (Araibi et
al., 2004). The conclusion from this study was that although cooperation between
BPV-4 E5 and E7 is necessary to achieve full transformation, downregulation of
MHC I is only induced in the presence of E5, and E7 is not responsible for
downregulation of MHC I.
The detection of E5 in cells from the basal to the squamous layers are in agreement
with previous studies (Anderson et aI., 1997; Burnett et aI., 1992) and confirms the
hypothesis of the function of E5 protein in natural infection; expression of E5 protein
in the basal layer support its role in immune evasion by downregulation of MHC I in
those cells that are accessible to immune surveillance. Expression of E5 protein in
differentiated layers supports its role in viral replication and packaging of the viral
genome (Fehrmann et al., 2003). In addition, expression of E5 protein in the
intermediate layers supports its role in the maintenance of the transformed state of
papillomas.
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7.7 Conclusions
It has been shown that BPV-4 E5-induced retention of MHC class I in the GA is
linked to cell transformation (Ashrafi et al. 2002; O'Brien and Campo 2003) and is
due to the alkalinization of the GA (Marchetti et al. 2002). Results in this thesis
suggest that direct binding between E5 and HC contributes to (but is not sufficient
for) the inhibition of MHC class I transport to the cell surface. The expression of E5 is
much lower than that of HC, but this stoichiometric imbalance is offset by E5-induced
transcriptional inhibition of the HC gene and degradation of the HC peptide.
However, E5 prevents traffic of the MHC class I complex even when the amount of
HC is greatly increased by drug treatment, therefore, for E5 to exert any effect on HC,
the binding must be dynamic. One possible model could be the following: E5 retains
newly assembled MHC class I complex in the GA by preventing GA acidification and
by physically interacting with HC; the mis-located complex is shunted to lysosomes
for degradation, and E5 is free to interact with new MHC class I and re-start the
process (Figure 7.6). While aspects of this model need confirming, the absence of
MHC class I in the E5-expressing cells of naturally occurring BPV-4 induced
papillomas supports our suggestion that E5 plays an important role in the
establishment and persistence of viral infection by allowing the infected cells to
escape host immunosurveillance (Araibi et al. 2004).
Other viral proteins, such as HIV Nef (Williams et al. 2002) and HCMV US2 and
US8 (Chevalier et al. 2002 ; Tirabassi et al. 2002), to name but a few, bind HC and
downregulate surface MHC class I, and E5 now joins this large number. It is
interesting to point out the parallels between E5 and Nef. Nef binds both Vma13, a
component of the V1 sector of the vacuolar ATPase, facilitating the internalization of
surface receptors (including MHC class I), and MHC class I HC, disrupting MHC
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class Itraffic (Williams et al. 200S; Lu et al. 1998). Furthermore, as for E5, the same
domain of Nef necessary for disruption of MHC class I traffic, mediates the binding
to the HC (Williams et al. 2005).
BPV-4 E5 interacts with two different alleles of classical MHC class IHC (N*OI301
and N*00201) in vitro and the interaction has been confirmed in vivo in PalF cells,
BPV-l E5 interacts with two different equine classical class IHC (EqB2 and EqB4)
in vitro, the HPV-I6 E5 interacts with classical HLA-A3 in HaCaT cells, and AI, A2
and B8 in vitro (Ashrafi et al. 2006b) and HPV-83 ES interacts with HLA-A2
(Ashrafi et al. 2006a). These results show that all the ES proteins tested, independent
of the PV type, are able to interact with different classical class Ialleles.
These observation add a new step in the general downregulation of MHC class I by
ES proteins and point to a common pathway of immunevasion by E5s from different
PV types.
This similarity is intriguing and supports the hypothesis that the carcinogenicity of
papillomavirus types reflects viral evolution with carcinogenic PV types (HPV-16,
BPV-l, BPV-4) coding for an ES protein, whereas most low-risk types either lack a
definable homologous ES ORF and/or a translation start codon for ES (Schiffman et
al. 200S). Moreover, in a study on mucosal HPVs Bravo and Alonso have shown that
ES-like proteins can be classified into four groups according to their chemical
characteristic and evolutionary relationships. This classification matches the
epidemiological characteristics of the mucosal HPVs and their differential association
with cancer development (Bravo et al. 2004; Clifford et al. 2003; Munoz et al. 2003).
Like HPV-16 ES, BPV-4 E5 is incapable of down-regulating certain non-classical
MHC genes (Ashrafi et al. 2005, paragraph S.S and Araibi et al. 2006). These results
suggest that BPV-4 ES could potentially provide a mechanism for the escape of the
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infected cells from not only CTL but also NK killing as it has been shown for other
viral proteins like HIV Nef and HCMV UL40 (Cohen et al. 1999; Tomasec et al.
2000; Ulbrecht et al. 2000).
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Figure 7.6 Possible model ofMHe class I trafficking in BPV E5-expressing cells
(B) compared with the normal MHC class I trafficking pathway (A). After the
assembly and peptide loading in the ER (discussed in detail in section 1.1.3.1 and fig.
1.4), MHC I molecules transit through the Golgi apparatus before reaching the cell
surface for presentation to CTL cells. (B) In BPV E5-expressing cells E5 retains
newly assebled MHC class I complex in the Golgi apparatus (GA) by preventing GA
acidification and by physically interacting with HC; the mis-located complex is
directed to lysosomes for degradation and E5 is free to interact with new MHC class I
and re-start the process.(Picture adapted from Van Kaer .Tissue Antigens 2002). HC,
heavy chain; CNX, calnexin; ~2m, ~2-microglobulin; CRT,calreticulin; Tpsn,
tapasin; 2, LMP2; 7,LMP7; M, MCL-I.
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7.S Future work
It has been shown that the BPV-4 ES C-terminus domain is involved in the interaction
with the MHC I heavy chain (HC). Further studies are needed to establish which
amino acid(s) within the C-terminus domain is/are essential for this type of
interaction.
Further analysis on which domain of MHC I heavy chain is involved in this
interaction are required. It has been shown that the HC C-terminus domain is not
involved but further mutation analysis of heavy chain will identify which amino
acid(s) is/are responsible for the interaction.
Lack of surface MHC I and the presence of non-classical MHC I in infected cells
expressing ES would allow evasion of cytotoxic T lymphocyte and NK killing and
thus establishment of viral infection. CTL and NK killing assays on ES-expressing
cells would clarify this point.
Bovine papillomavirus has been used as model system in which to study the
interaction of a papillomavirus with its natural host and with environmental cofactors
(Jarrett et al. 1978; Campo et al. 1994b) and has been important in the recognition of
the oncogenic nature of the virus and the development of anti-viral vaccine (Campo
1997). Comparative pathology studies between BPV and HPV-induced diseases have
contributed to the understanding of HPV-induced cancer in humans. Moreover the
latest insights in BPV ES, E2 (Zhao et al. 2000; Abroi et al. 2004) and E7
(Narechania et al. 2004) functions show that BPV can still lead the way and
contribute significantly to our understanding of virus biology.
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Down-regulation of MHC class I by bovine papillomavirus E5 oncoproteins
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The papilloma virus E5 protein is localized in the
endoplasmic reticulum (ER) and Golgi apparatus (GA)
of the host cell. Transformed bovine fibroblasts expres-
sing bovine papilloma virus (BPV) E5 are highly
vacuolated and have a much enlarged, distorted and
fragmented GA. Major histocompatibility complex class
I (MHC I) is processed and transported to the cell
surface through the GA. Given the cellular localization
of E5 in the GA and the morphologically abnormal GA,
we investigated the expression of MHC I in cells
transformed by E5 from BPV-l and BPV-4. Two cell
lines were used: bovine cells that also express E6, E7 and
activated ras, and NIH3T3 cells that express only E5. In
addition, PalF cells acutely infected with a recombinant
retrovirus expressing E5 were also examined. In contrast
to non-transformed normal cells, or transformed cells
expressing other papillomavirus proteins, cells expressing
E5 do not express MHC I on their surface, but retain it
intracellularly, independently of the presence of other
viral or cellular oncogenes, or of whether the cells are
long-term transformants or acutely infected. We con-
clude that expression of E5 prevents expression of MHC
I to the cell surface and causes its retention within the
cell. In addition, lower amounts of total MHC I heavy
chain and of heavy chain RNA are detected in E5-
transformed cells than in control cells. As surface
expression of another glycosylated membrane protein,
the transferrin receptor, is not affected, it appears that
E5 targets MHC I with at least a degree of specificity.
In papilloma virus lesions this effect would have important
implications for antigen presentation by, and immuno-
surveillance of, vitally infected cells.
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Introduction
Papilloma virus is an oncogenic virus which infects
mucosal and cutaneous epithelia where it induces
benign hyperproliferative lesions. In the great majority
of cases, papilloma virus infections are usually cleared,
after a variable period of time, usually several months,
by a cell mediated immune response directed against
viral antigens (Frazer and Tindle, 1996). Occasionally
however, the lesions do not regress and can progress to
cancer. Persistent viral infection is required for
neoplastic progression and failure of virus clearance
is attributed to a poor immunological response.
The papilloma virus genome encodes three proteins,
E5, E6 and E7, capable of inducing unscheduled
proliferation of keratinocytes. All three proteins can
transform cells in vitro, although their contribution to
cell transformation appears to vary in different virus
types. While E6 and E7 are the main oncoproteins of
mucosal HPVs (Kubbutat and Vousden, 1996; Kunhe
and Banks, 1999), E5 is the major oncoprotein of
BPYs, particularly of BPY-I. The E5 protein, and the
closely related E8 protein of subgroup B bovine
papillomaviruses (BPY), therein collectively designated
E5 (Morgan and Campo, 2000), is a small hydrophobic
peptide (from 83 amino acid residues in human
papillomavirus type 16 [HPV-16] to 42 residues in
BPY-4) which is expressed in the deep layers of the
infected epithelium (Anderson et al., 1997; Burnett et
al., 1992; Chang et al., 2001). While E6 and E7 are
present throughout the course of the disease and their
functions are necessary for the maintenance of a
transformed state, expression of E5 takes place early
in infection, and is often, but not always (Chang et al.,
2001), extinguished in frank cancers. In genital lesions
induced by mucosal HPV, the expression of E5 is
extinguished as the lesion progresses to malignancy,
due to the frequent occurrence of the integration of the
viral genome into the host chromosome at the E2/E5
open reading frame (ORF); in the lesions induced by
BPY the mechanisms that silence the expression of E5
from an intact episomal genome are not known.
E5 is localized in the endomembrane compartments of
the endoplasmic reticulum (ER) and Golgi apparatus
(GA) of the host cell (Burkhardt et al., 1989; Pennie et
al., 1993). BPY-4 E5 induces anchorage independence
(Pennie et al., 1993), allows cell growth in low scrum,
prevents contact inhibition (Ashrafi et al., 2000; O'Brien
et al., 1999) and down-regulates gap junction commu-
nication (Ashrafi et al., 2000; Faccini et al., 1996). The
ability of the E5 expressing cells to grow independent of
sUbstrate and in low serum is accompanied and likely due
to activation of cyelin A-cdk2 (O'Brien and Campo,
1998), while the down-regulation of gap junction
communication, observed also in cells expressing HPV-
16 E5 (Oelze et al., 1995), is accompanied by binding of
£5 to the 16 k ductinfsubunit c, a component of the gap
jUnction and of the VO sector of the vacuolar H +-
ATPase (Finbow et al., 1991; Goldstein et al., 1991;
Conrad et al., 1993; Faccini et al., 1996). This physical
interaction has been deemed responsible also for the lack
of acidification of endosomes and GA (Schapiro et al.,
2000; Straight et al., 1995), which has been attributed to
a malfunction of the H+ -ATPase (Briggs et al., 2001),
although inhibition of the vacuolar proton pump is not
always observed (Ashby et al., 200 I). Cellular transfor-
rnation by E5 is also accompanied by the activation of
growth factor receptors (Martin et al., 1989; Petti et al.,
1991; Leechanachai et al., 1992; Straight et al., 1993) and
other kinases (Gu and Matlashewski, 1995; Crusius et
al., 1999; Suprynowicz et al., 2000). It is reasonable to
aSSume that the various aspects of cell transformation by
Such a small protein may all derive from its very location
in the endomembrane compartment, particularly the
GA, with the putative consequent disruption of exocytic
and endocytic cellular traffic, including transport of the
MHC I complex.
Recognition and elimination of virally infected cells
by T-Iymphocytes require presentation of viral peptides
by the MHC elass I complex. Peptides are loaded onto
the MHC I heavy chain in the ER, where f32-
rnicroglobulin and chaperones, such as TAP, associate
with the complex. MHC I is glycosylated as the
Complex is transported from the ER through the GA
to the plasma membrane for recognition by T-cells
(Cresswell et al., 1999). Deglucosylation in the GA is
necessary for the dissociation of MHC I from both
calreticulin and TAP peptide transport molecules (Van
Leeuwen and Kearse, 1996). In addition, the assembly
of the MHC I complex with peptide is pH dependent
(Reich et al., 1997). Therefore, given the cellular
lOcation of E5 in cell membranes and the attendant
inhibition of membrane compartment acidification, we
investigated whether MHC I would be properly
transported to the cell surface. We report that in E5-
expressing cells MHC I is down-regulated and retained
intracellularly, thus adding yet another function to the
Pleiotropic action of this protein.
Results
Iv!orphology of Golgi apparatus in PalF cells
As reported previously (Ashrafi et al., 2000), the E5-
expressing transformed PalF cells were very enlarged
and highly vacuolated (Figure la). Vacuole formation
takes place only in the presence of the full transform-
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ing forms of E5. The vacuoles are compartmentalized,
with vacuoles communicating within but not between
compartments as shown by the distribution of the
fluorescent dye lucifer yellow injected into single cells
(Ashrafi et al., 2000).
E5 inhibits acidification of the endomembrane
compartments, and it is known that the inhibition of
acidification of endomembrane compartments by
ionophores leads to fragmentation of the Golgi
apparatus. Therefore, to investigate the origin of the
vacuoles in E5 cells, we visualized the GA by
immunofluorescence. Monoclonal antibody (mAb)
4A3 is raised against GM 130, an integral component
protein of Golgi membranes (Barr et al., 1998). When
PalF cells or transformed control cells were incubated
with mAb 4A3 the GA showed a normal morphology
(Figure 1b). In the E5-expressing cells, the GA showed
a disrupted architecture and numerous vacuoles had
reacted with the antibody (Figure Ic). Often only
vacuoles were stained (Figure Ic, left panel). Similar
A
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Figure 1 Golgi apparatus morphology in parental and trans-
formed PalF cells. Cells were stained with mAb 4A3. (a) Phase
contrast field of highly vacuolated 4-E5 expressing cells. (b)
Examples of transformed control cells (no E5); (c) Examples of
4- E5 transformed cells. (G) Golgi apparatus (indicated by an
arrow in one of the b panels); N: nucleus. Magnification: x 10 in
(a); x 40 in all the other panels
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Figure 2 FACS profiles of MHC I expression in parental and transformed PalF cells. PalF cells (a,b), transformed control cells
(c,d), 4-E5 transformed cells (e.f) and l-E5 transformed cells (g,h) were stained with mAb lL-AI9 and analysed by flow cytometry.
Surface MHC I was measured in intact cells (a.c.e.g) and total MHC I was measured in saponin-permeabilized cells (b,d,f,h)
c
results were obtained when the GA was stained with
fluorescent BODIPY-ceramide, which localizes to the
Golgi membranes, or when it was visualized by
electronmicroscopy (data not shown). These results
suggest that at least some of the vacuoles in E5 cells
are derived from the fragmentation of the Golgi
G
D
Oncogene
H
Relative fluorescence intensity
cisternae. The fragmentation of the GA in E5 cells
does not appear to be a consequence of long-term
culturing as in approximately one-third of PalF cells
acutely infected with a recombinant retrovirus expres-
sing BPV-4 E5 (see below) the GA was enlarged, when
compared with cells infected with the control rctro-
virus, although not as distorted as in long-term E5
transformants (data not shown).
Morphology of Golgi apparatus in NIIl3T3 cells
To ascertain the state of the GA in cells other than
PalF cells, we investigated the morphology of the GA
in NIH3T3 cells expressing BPV-4 E5 using mAb 4A3.
Despite the alkaline pH of the GA in the 3T3 E5 cells
(R Schlegel and S Campo, unpublished observations),
there were no obvious structural abnormalities between
the GA in control NIH3T3 and that detected in the E5
cells (data not shown). This suggests that the abnormal
GA morphology observed in PalF cells expressing E5
may be cell type dependent.
MHe class I on the cell surface
Given the abnormal morphology of the ER and GA in
E5-expressing PalF cells, and given the importance of
these structures in protein traffic, we investigated
whether E5 expression would disrupt protein transport
and in particular MHC I transport to the cell surface.
Parental PalF and transformed control cells were
incubated with IL-A 19, a monoclonal antibody
recognizing a monomorphic determinant of the bovine
MHC class I complex (Bensaid et al., 1989) and
analysed by flow cytometry. Both cell lines displayed
MHC I on their surface as shown by the increase in
relative fluorescence intensity in the presence of mAb
IL-A 19 (Figure 2a,c). In contrast, there was no shift in
fluorescence in the transformed cells expressing E5
(Figure 2e,g) indicating that these cells do not present
MHC I on their surface. To investigate if this was due
to a defect in MHC I transport to the cell surface, the
cells were permeabilized with saponin before staining
to allow the penetration of the antibody inside the cells
and therefore measuring the total MHC I content. The
permeabilized parental and transformed control cells
exhibited a similar staining profile, not different from
that obtained for surface MHC I (Figure 2b,d). In
contrast, the FACS profiles for the permeabilized E5
cells showed a positive staining for MHC I (Figure
2f,h), indicating that in these cells MHC I was retained
intracellularly and was not transported to the plasma
membrane. However, the intensity of fluorescence and
the mean fluorescence of the E5 permeabilized cells
were also noticeably reduced when compared to the
parental or transformed control cells (Figures 2f.h and
7a), indicative of reduced levels of total MHC I in E5
cells.
Levels of total M HC class I
The FACS analyses above suggested a reduced level
not only of surface but also of total MHC I in E5
transformed cells. To confirm this observation, the
amount of total MHC I in the eontrol and transformed
cell lines was investigated by immunoblotting using
mAb IL-A88, specific for a monomorphic determinant
on the bovine MHC I heavy chain (Toye et al., 1990).
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While the MHC I heavy chain was easily detectable in
PalF and control cells, little MBC I could be detected
in the l-E5 or 4-E5 cells when high amounts of protein
were used (Figure 3a), confirming that E5 down-
regulates expression of MHC I. The difference in
sensitivity of detection of total MHC I in E5-expressing
cells by FACS or immunoblotting is likely to be due to
the different affinities of IL-A 19 and IL-A88 antibodies
for the bovine MHC I antigen (data not shown).
Levels of MHC class I transcripts
The noticeable reduction in the levels of MHC I heavy
chain could be due to protein degradation, transcrip-
tion inhibition, rapid RNA degradation or combina-
tions thereof. To ascertain this point, we analysed the
level of transcripts encoding the heavy chain of the
MHC I complex by semi-quantitative RT -PCR, using
generic oligonucleotide primers that amplify a 733
base-pair (bp) fragment from all classical bovine MHC
class I genes and a 533 bp fragment from the
corresponding mRNA (Sawhney et al., 1995). As a
control we amplified actin eDNA using primers specific
for bovine actin (Sibbet et al., 2000). Amplifications
were carried out for progressively increasing numbers
of cycles. While the 273 bp fragment of actin RNA was
amplified from both non transformed PalF and l-E5
transformed cells with similar kinetics (visible on gel
after 20 cycles, Figure 3b), the amplification kinetics of
MHC I heavy chain RNA were different in PalF and
E5-transformed cells. In PalF cells, the expected 533 bp
fragment was visible after 20 cycles; in contrast in both
l-E5 and 4-E5 transformed cells the amplicon could
not be detected until 25 cycles and in lower amounts
(Figure 3b). A 733 bp fragment was not detected either
in the test reactions or in the control reactions (with no
RNA), confirming that the amplification did not
involve genomic DNA. This result shows that the
observed down-regulation of MHC I heavy chain
protein is not due solely to protein degradation but
also to transcription inhibition or RNA degradation.
M lIC I on the cell surface in transformed N IIJ3T3 cells
The transformed PalF cells analysed above express a
variety of oncogenes and it could be argued that down-
regulation of MHC I is due to the interaction of E5
with the E6, E7 or ras oncoproteins. Therefore NIH
3T3 cells expressing only BPV E5 were also analysed
for the expression of MHC I. Control 3T3 cells
expressed similar levels of surface and total MHC I
(Figures 4a.b and 7b). However, 3T3 4-E5 cells. like
the transformed E5 PalF cells, did not express MHC I
on the surface but retained it intracellularly (Figures
4c,d and 7b). These results show that inhibition of
MHC I transport is due to the expression of the E5
protein per se and not to its interaction with other
oncoproteins.
However in contrast to the transformed PalF cells,
the E5-transformed 3T3 cells did not show any
noticeable reduction in total MHC I. The reduction
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Figure 3 (a) Western blot analysis of MHC I heavy chain expression in protein lysates from parental and transformed PalF cells.
Top panel, MHC I heavy chain detected with mAb IL-A88. Bottom panel, actin detected with mAb AB-I. Amount of protein
loaded is indicated. Lanes 1,5,9: parental PalF, lanes 2,6,10: l-E5 transformed cells; lanes 3,7,11: control transformed cells; lanes
4,8,12: 4-E5 transformed cells. The secondary antibody was used at a dilution of I: 5000 in lanes 1-8 and I: 2000 in lanes 9-12.
The arrows on the right point to the 46 kDa marker and the bold arrows on the left to the MHC I heavy chain (he) and actin. (b)
Semi-quantitative RT-PCR analysis of MHC I heavy chain RNA in parental and transformed PalF cells. Amplicons were
generated in increasing cycles of amplification from 10 to 30, as indicated. Left panels, actin RNA from PalF and I-E5 cells. Right
panels, MHC I Heavy chain RNA from PalF and E5 transformed cells. Lane c: amplification reactions with no RNA; M: the 500
and 600 bp bands of the DNA ladder marker
of total MHC I in PalF cells may be due therefore to
the combined effects of the viral oncoproteins and/or
activated ras, the enlargement and fragmentation of the
GA, and to transcriptional down-regulation.
MHC J on the cell surface in PalF cells acutely infected
with recombinant retroviruses
The PalF and 3T3 transformed cell lines above are
established lines and their long-term culture may have
affected the down-regulation of surface MHC I. Hence,
PalF cells acutely infected with the recombinant 4-E5
retrovirus were analysed for MHC I expression. Again,
these cells showed a marked reduction in surface MHC
I (Figure 5c) and a less pronounced reduction in total
MHC I (Figure 5d), remarkably similar to that
observed in the established transformed cells (Figure
7a). This reduction was not observed in PalF cells
infected with the control retrovirus (Figure 5a,b),
confirming that E5 is indeed the cause of the inhibition
of MHC I expression.
Transferrin receptor
To ascertain whether the down-regulation of surface
MHC I by E5 was specific or due to a generalized
disturbance in exo- or endocytic protein transport, we
Oncogene
analysed cell surface presentation of another membrane
glycoprotein, the transferrin receptor. There was no
difference between the total or cell surface amount of
transferrin receptor in parental PaIF, control or E5
cells (Figure 6 and data not shown). Therefore
synthesis and maturation of glycoproteins is not
generally affected in E5 transformed cells, indicating
at least a degree of specificity for the E5 down-
regulation of MHC I.
Down-regulation of surface MHC I and cell
transformation co-segregate
A panel of PalF cell lines expressing mutant forms of
the E5 protein (Ashrafi et al., 2000) was analysed for
down-regulation of surface MHC I. The E5 mutants
used here were an hyper-transforming form of BPV-4
E5 in which an asparagine residue at position 17 has
been substituted with alanine (N17 A); two mutant E5
forms that have completely lost their transformation
ability, N17Y, in which residue 17 has been substituted
with tyrosine, and the C-terminal truncation mutant
E5T, which has no hydrophilic tail, and BPV-I E5T, a
similar C-terminal truncation mutant. Only the hyper-
transforming mutant of 4-E5 was capable of inhibiting
MHC I transport to the cell surface (Figure 7c). There
was no difference between total and surface MHC I in
Surface
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Figure 4 FACS analysis ofMHC I expression in NIH 3T3 and NIH 3T3 E5 cells. NIH 3T3 cells carrying empty vector (a.b), or expressing
4-E5 (c.d) were stained with mAb CL90I I-A and analysed by flow cytometry. Surface MHC I was measured in intact cells (left panels a,e)
and total MHC I was measured in saponin-permeabilized cells (right panels b.d]
cells expressing transformation defective ES mutants,
although a slight decrease in surface MHC I was
observed in cells expressing BPV-l EST (Figure 7c).
Discussion
various steps of the MHC I pathway, from prevention
of peptide processing to formation of non functional
MHC I complexes (see Yewdell and Bennink, 1999 for
review). In each of these strategies, the outcome is the
failure by the infected cell to present viral peptide
antigens to cells of the immune system.
Papilloma viruses are poorly immunogenic. The
prolonged absence of an immune response even in
immunocompetent hosts has been attributed to a
variety of causes (reviewed by Frazer et al., 1999).
The viral proteins are expressed in the suprabasal
layers of the epithelium, i.e. in cells not readily exposed
to the immune system, and moreover are produced in
very low amounts, often below the threshold required
for the activation of immune cells, thus leading to
tolerance. We report here a possible new mechanism of
immune evasion of papilloma virus: the down-regula-
tion of MBC I by the early E5 oncoprotein.
BPV E5 is localized in the endomembrane
compartment of the cell. Expression of the protein
in primary bovine cells leads to profound changes in
cell morphology, with extensive vacuolization (Ashrafi
During viral infection or malignant transformation, a
spectrum of peptides derived intracellularly from viral
or transformation-associated antigens is bound to
MHC I molecules and displayed on the surface of
the infected or tumour cell. These class I/peptide
complexes are recognised by specific cytotoxic T
lymphocytes (CTL), which kill the infected or malig-
nant cells. MHC I molecules therefore play a crucial
role in immune recognition and clearance of these
types of cell.
Viruses need to escape immunosurveillance by the
host to establish infection and to generate new
infectious progeny. It is well known that viruses have
developed a number of different mechanisms to avoid
immune recognition by CTL by interfering with
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Figure 5 FACS analysis of MHC I expression in PalF cells acutely infected with E5-recombinant retrovirus. PalF cells infected with empty
retrovirus (a.b) or the 4-E5 retrovirus (c.d) were stained with mAb IL-AI9 and analysed by flow cytometry. Surface MHC I was measured in
intact cells (left panels a,c) and total MHC I was measured in saponin-permeabilized cells (right panels b.d)
et al., 2000); the GA is particularly affected being
grossly distorted, swollen and fragmented. Trans-
formed cells that do not express E5 do not present
any apparent GA malformation, so we conclude that
it is the presence of the small hydrophobic E5
protein in the GA itself that induces these changes.
This conclusion is supported by the swelling of the
GA in cells acutely infected with an E5-expressing
recombinant retrovirus, a result that also suggests
that GA alterations do not depend on the interaction
of E5 with the other oncoproteins present in long-
term transformants. Interestingly, mutant forms of E5
which have lost or maintain only residual transforma-
tion ability do not cause noticeable changes in cell
morphology or vacuolisation (Ashrafi et al., 2000).
However, gross disruption of the GA does not occur
in NIH3T3 cells that express only E5, despite their
impaired GA acidification (R Schlegel and S Campo,
unpublished observation), so perhaps the morpholo-
gical alteration of the GA observed in primary
bovine cells, the virus natural host, is cell type-
dependent.
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Proper functioning of the Golgi apparatus is
necessary for a number of cellular processes including
protein transport to the cell surface. MHC I is
synthesized in the ER, post-translationally modified
in the GA and transported to the plasma membrane
(Cresswell et al., 1999). This process appears to be
inhibited in cells expressing E5, which have very little.
if any, MHe I on their surface. Down-regulation of
surface MHe I takes place both when E5 is expressed
with other viral transforming proteins or alone, in
long-term transformants or in acutely infected cells,
and whether or not the GA has undergone distortion
and fragmentation. Therefore, the down-regulation of
surface MBC I is due solely to E5 and does not require
either other papillomavirus proteins or activated Ras.
Moreover, MBe I down-regulation is not confined to
BPV E5 proteins, as preliminary experiments show that
NIH 3T3 cells expressing either HPV-6 or HPV-16 E5
have lower levels of surface MIIC I, as do PalF cells
acutely infected with a retrovirus expressing HPV-16
E5 (data not shown). Therefore, inhibition of surface
Mile I expression appears to be a common character-
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Figure 6 FACS analysis of surface transferrin receptor expression in parental and transformed PalF cells. Intact cells were stained with
mAb IL-A165 and analysed by flow cytometry. The mean fluorescence (rnf) values for the individual cell lines. calculated from the flow
cytometric analyses. are inside the respective panels
IStiC of both HPV and BPV E5 oncoproteins. In
addition, there is at least a degree of specificity in the
disturbance of protein traffic by E5 as the expression at
the cell surface, and presumably the transport, of the
transferrin receptor, another membrane glycoprotein, is
not affected.
The absence of MHC I on the cell surface appears to
be due in part to intracellular retention as MHC I is
detected once the cells are permeabilized. There is
however, less total MHC I in PalF cells that express E5
than in control cells. We also detected lower levels of
MHC I mRNA transcripts in the E5 cells. It is not
possible at this stage to ascertain the contribution of
transcription inhibition and of protein degradation to
the overall down-regulation of MHC I, but it would
appear that the reduced levels of MHC I heavy chain
protein cannot be solely due to lack of RNA, and it is
likely that both processes play a part. However,
inhibition of transcription is directly due to E5
expression: the presence of approximately equal
amounts of MHC I in parental cells and transformed
control cells (expressing E7) argues against transcrip-
tional down-regulation of the heavy chain gene by E7,
as recently suggested (Georgopoulos et al., 2000).
Moreover, expression of MHC I in HPV-positive
cervical carcinomas, expressing E7 but not E5, has
also been shown to be post-transcriptionally controlled
(Cromme et al., 1993).
The reason why the level of total MHC I remains
unaltered in E5-expressing NIH3T3 cells remains to be
investigated, but it may be linked to the unaltered
morphology of the GA in these cells. MHC I may be
degraded more rapidly in the grossly distorted GA
compartment of PalF cells. This hypothesis is
supported by the finding that improperly processed
MBe I molecules accumulate and are degraded in
an expanded ER-Golgi intermediate compartment
(Raposo et al., 1995).
We have not yet determined the mechanism of how
E5 expression results in transcriptional inhibition and
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Figure 7 Representative mean fluorescence for surface or total
MHC I in transformed cells. The mean fluorescence was
calculated from the flow cytometric analyses above. (a) Surface
and total MHC I mean fluorescence in control (PaIF. no E5).
transformed cells expressing BPV-4 E5 (4-E5) or BPV-I E5 (1-
E5). PalF cells acutely infected with empty retrovirus (v-control)
or retrovirus expressing 4-E5 (v-4-E5). (b) Surface and total MHC
mean fluorescence in NIH 3T3 cells carrying empty vector (3T3)
or expressing BPV-4 E5 (4-E5). (c) Surface and total MHC I in
transformed PalF cells expressing mutant forms of 4-E5 (N 17Y,
NI7A, 4-E5T) and of I-E5 (I-EST). The plus and minus signs
above the histogram refer to the degree of cell transformation (for
more details concerning the cell lines expressing mutant E5
proteins see Ashrafi et al .• 2000)
loss of surface MHC I.We have shown previously that
expression of E5 leads to changes in transcriptional
control (O'Brien and Campo, 1998; O'Brien et al.,
1999), although the mechanisms used by this mem-
brane-localized protein to signal to the transcription
machinery in the nucleus are not known. The MHC I
transport pathway may be blocked in the journey of
the peptide/Ml-IC complex to the cell surface, or the
MHC complex could be rapidly internalized once it has
reached the cell surface. The recognition of MHC I by
mAb IL-AI9, which detects MHC I heavy chain
Oncogene
complexed with P-2 microglobulin (Bensaid et al.,
1989), suggests that the block is a relatively late event
in the genesis and transport of MHC I. Therefore, we
would expect that inhibition of TAP function (Cromme
et al., 1994; Keating et al., 1995) which is responsible
for loss of MHC I in pre-malignant and malignant
cervical disease (Bontkes et al., 1998; Brady et al.,
2000), and in HPV-associated laryngeal papillomas
(Vambutas et al., 2000), is unlikely to play a role in E5-
induced MHC I loss. This is more likely to be a feature
of malignancy as observed for other malignant
tumours (Seliger et al., 1997). However, this point
remains to be investigated experimentally. Interest-
ingly, HPV-16 E5 has been shown recently to inhibit
endocytic trafficking (Thomsen et al., 2000), a finding
supporting the blocking of MHC I following complex
assembly.
There have been other examples of viral proteins
with similar functions to E5 interfering with MHC I. It
has been shown that HIV-l Nef binds Vma l J, one of
the components of the hydrophilic VI sector of the V-
ATPase (Lu et al., 1998) and causes the accumulation
of endocytosed MHC I in the trans-Golgi (Greenberg
et al., 1998). Another small hydrophobic protein,
HTL V-1 p 121, which, like E5, binds to V-ATPase
subunit c (Franchini et al., 1993), causes the
intracytoplasmic retention and degradation of MHC I
(Johnson et al., 200 I). It thus appears that interference
with either sector of the proton pump prevents MHC I
localization to the cell surface, either in the exocytic or
the endocytic pathway.
We observed that mutant forms of E5 defective for
transformation are not capable of down-regulating
either surface or total MHC I. Therefore, inhibition of
MHC I in primary cells appears to be associated with
full transformation, including malformation of Golgi
structures. It is tempting to speculate whether the
transport or the post-translational modification of
cellular proteins involved in cell transformation are
similarly affected. Cell surface receptors and adhesion
molecules are post-translationally modified and trans-
ported to the plasma membrane through the GA (Bellis
et al., 1999; Rudd et al., 1999); small GTPases of the
ras family are either stably or transiently targeted to
and post-translationally modified in the endomem-
branes (Apolloni et al., 2000; Choy et al., 1999;
Erickson et al., 1996; Noguchi et al., 1998). Aberrant
glycosylation of glycoproteins by Golgi enzymes often
accompanies malignant transformation (Dennis et al.,
1999). Interference with any or all of the proper
processing of these proteins could lead to cell
transformation and explain the pleiotropic action of
E5.
In conclusion, the down-regulation of cell surface
MHC I by E5 may direetly affect immune recognition
and clearance of virally-infected cells. E5 protein is
produced early in the infection process, in the virally-
infected basal keratinocytes in the deep layers of the
papilloma. Loss of MHC I expression in these cells
would lead to a loss of immune recognition by c1ass-I
restricted effector cells, which could contribute to viral
persistence and the subsequent development of
malignancy.
Materials and methods
Cell lines
Primary embryonic bovine cells (PaIF) transformed by
papillomavirus oncogenes, with or without ES from BPY-l
or BPY-4 (l-ES or 4-ES respectively), or their mutant forms,
have been described before (O'Brien et al., 1999). In these
cells, the combination of BPY-4 E7, ES from either BPY-l or
BPY -4, and activated ras induces cell transformation but
immortalization is conferred by HPY-16 E6 (Pennie et al.,
1993), as the BPY -4 genome does not encode an E6 protein
(Jackson et al., 1991). Briefly, normal parental cells are
designated PalF or 'parental'; cells transformed by E6, E7
and activated ras are designated 'no ES' and referred to in
the text as 'control', and cells transformed as above but with
the addition of either ES protein are designated 'E5'. NIH
3T3 mouse fibroblasts transformed by BPY-4 ES (3T3 4-ES)
have also been previously described (O'Brien and Campo,
1998). Control NIH3T3 cells containing the empty expression
vector are designated '3T3'. All cell lines were grown in
Dulbecco modified Eagles medium (DMEM) (Life Technol-
ogies, UK) containing 10% foetal calf serum (FCS) at 37°C
in 5% CO2,
Construction of recombinant amphotropic retroviruses
The E5 ORF of BPY-4 was amplified by PCR and cloned
into the BamHI - Hindi II site of the retroviral vector
pLZRSpBMNZ (Pear et al., 1993). The BPY-4 ES ORF
has at its 5' end a 39 bp sequence encoding the HA epitope
(O'Brien et al., 1999). The construct was propagated in the
Max Efficiency STBL2 bacterial strain (Life Technologies).
Transformations were carried out according to the manufac-
turer's guidelines and the plasmid was prepared according to
the Plasmid Maxi Kit (Qiagen) protocol.
The plasmid was transfected into the packaging cell line
Phoenix A (Mann et al., 1983) using the Dotap" Liposomal
method (Boehringer Manheim). Briefly 3-S x 106 cells were
seeded into medium flasks in DMEM/IO% FCS and
incubated for 24 h at 37°C in S% CO2, The cells were then
transfected with 10 Jig of plasmid DNA in OPTIMEM
reduced serum medium (Life Technologies) and incubated
at 37°C for 12 h. After replacing the medium, the cells were
incubated for a further 12 h followed by 48 h at 33°C. The
supernatant containing the packaged retrovirus was collected
and centrifuged to eliminate cell debris. The supernatant was
either used directly to infect the target cells or aliquoted and
snap frozen for later use.
Infection of PalF cells with recomhinant retroviruses
PalF cells (2 x 105) were seeded into a 2S cm2 culture flask
and incubated at 37°C. Before infection, the medium was
removed and cells were overlaid with equal volumes of viral
supernatant and 2 x Infection Mix (10 Jlg/ml polybrene in
DMEM, 10% FCS), in a total volume of 1.5 ml. The flasks
were centrifuged at 500 g for 45 min, then incubated at 33"C
for 6 h, when fresh DMEM, 10% FCS, was added to a final
volume of 5 ml. Forty-eight hours or 5 days post infection
the cells were harvested for investigation of GA morphology
or flow cytometry analysis.
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Visualization of Golgi apparatus
The GA was visualized by immunofluorescent detection using
monoclonal antibody (mAb) 4A3 raised against GM 130, an
integral GA protein (Barr et al., 1998). Cells were grown until
80% confluence in single well chamber slides. After removal
of medium, the cells were washed twice with PBS and fixed
with fresh 3% PFA in PBS for 20 min at room temperature.
After the PFA fixation, a second fixation was performed by
dipping the chamber slides in - 20"C methanol for 4 min.
The cells were washed three times in PBS, then incubated
with mAb 4A3 for 30 min at room temperature and washed
as above. The cells were then incubated with AlexaFluor™
488 goat anti-mouse IgG(H + L) conjugate (Molecular
Probes) (I: 1500 dilution) for 30 min at room temperature.
Following a final wash with PBS, the slides were mounted in
PBS and analysed under a fluorescence microscope.
Detection of M HC class I alit! transferring receptor by FA CS
Cells were grown in a 175 cm2 flask to approximately 80%
confluence. After removal of the medium, the cells were
washed once with PBS, then detached from the flask with
trypsin/EDT A and pelleted at 200 g at room temperature for
S min. The cell pellet was resuspended in DMEM, 10% FCS,
for I h at 37"C to allow surface antigens to be re-expressed.
The cells were washed and re-suspended in PBS, 1% BSA
(PBS-B) at 107 cells/rnl, For the detection of surface MHC I,
100 Jll of cells were aliquoted and incubated with an equal
volume of anti-bovine MHC class I monomorphic mAb (Il-
A 19; Bensaid et al., 1989) for PalF cells, and anti-mouse H-
2ld mAb (Cl9011-A, Cedarlane laboratories) for NIH 3T3
cells, for 30 min at 4"C. For the detection of surface
transferrin receptor, cells were incubated with mAb Il-
Al65 (Naessens and Davis, 1996). The cells were washed
three times in PBS-B, then gently resuspended in 100 III of
PBS-B and incubated with an equal volume of a I: 200
dilution of anti-mouse IgG-FITC (Sigma) at 4"C for 30 min
in the dark. The cells were washed and resuspended in 500 III
PBS-B and analysed by flow cytometry. If the flow cytometry
analysis was not carried out immediately, the cells were
resuspended in 500 III of 3% PFA in PBS and kept at 4·C.
For the detection of intracellular MHC I, the cells were
fixed in 3% PFA in PBS for 20 min at room temperature,
washed in PBS-B and permeabilized with 0.5% saponin in
PBS-B for 30 min at room temperature. Following a further
wash in PBS-B, the permeabilized cells were stained with
mAb Il-A 19 as described above. Samples were examined in a
Beckman Coulter EPICS Elite analyser equipped with an ion
argon laser with 15 mY of excitation at 488 nm. The data
were analysed using Expo 2 software.
Detection of MHC I by Western blots
Cells were removed from the flasks by trypsinization, washed
with PBS, then lysed by sonication in lysis buffer (100 mM
Tris HCI, pH 7.S, 2% SDS, 20% glycerol) and insoluble
material was removed by centrifugation at 20 000 g. Two, 5
and 10 ug of lysate were electrophoresed in 4 - 12%
NuPAGE gels (Invitrogen), and proteins transferred to
nitrocellulose membrane (Invitrogen) using a sernidry blotting
apparatus at 20 v/ISO A for I h. The membranes were
blocked in 5% milk/TBS/Tween 20 (0.05%) at room
temperature for I h before incubation with mAb Il-A88
which recognizes MHC I heavy chain (Toye et al., 1990) or
mAb AB-l (Calbiochem) specific for bovine actin. After
repeated washing with TBS/Tween 20 (0.05%) the mern-
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branes were incubated with anti-mouse Ig-HRP (Amersham
Pharmacia Biotech) for mAB IL-A88, and anti-mouse IgM-
HRP (Oncogene Calbiochem-Novabiochem International) for
mAb AB-I, in 5% milk/TBS/Tween 20 (0.05%) for I h at
room temperature. The membranes were washed three times
with TBS/Tween 20 (0.05%) and bound antibody was
detected by enhanced chemoluminescence staining (ECL)
(Amersham Pharmacia Biotech).
Detection of M HC I heavy chain transcripts by RT - PCR
RNA was extracted from normal parental PalF cells and
transformed cells expressing either I-E5 or 4-E5 using the
'RNeasyl\ Mini kit' (Qiagen) according to the manufacturer's
guidelines. Reverse transcription and amplification was
carried out in one step using the 'Superscript One-Step
RT - PCR' kit (Life Technologies). The MHC I-generic
primers BoLaex2F (5'-GGC TCC CAC TC(G/C) (A/C)TG
AGG TAT TTC) and BoLaex3R (5'-TCT CCA GGT ATC
TGC GGA GCC) were designed to amplify exons 2 and 3 of
all classical MHC I heavy chain sequences generating a
product of 533 base pairs (bp) from RNA and a 733 bp
product from DNA (Sawhney et al., 1995). As a positive
control, bovine actin primers were used which generate a
273 bp fragment (Sibbet et al., 2000).
The RT - PCR reactions were carried out in 50 III total
volume, MHC I primers were used at a final concentration of
0.2 11M, bovine actin primers at 0.5 11M and RNA was
adjusted to I ug. A semi-quantitative approach was used
where reactions underwent the same RT-cycle (45°C for
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The bovine papilloma virus oncoprotein E5 retains MH C class I molecules
in the Golgi apparatus and prevents their transport to the cell surface
Barbara Marchetti', GHossein Ashrafi', Emmanouella Tsirimonaki', Philippa M O'Brien' and
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During papillomavirus infection, the E5 protein localizes
in the cell Golgi apparatus and other endomembrane
compartments. Cells transformed by E5 do not express
major histocompatibility class I complex (:\1HC I) on
the cell surface, while cells transformed by the other
transforming proteins E6 and E7 do. In addition, the
total amount of both MHC I protein and mRNA is
reduced in E5-transformed cells. Here we show that
expression of bovine papillomavirus E5 causes the
retention of MHC I in the Golgi apparatus, thus
preventing its transport to the cell surface. We ascribe
this effect to a failure of acidification of the Golgi
apparatus, as similar effects are observed in control cells
treated with the ionophore monensin. Treatment of E5-
transformed cells with either p- or (,-interferon increases
the synthesis of MHC I, showing that inhibition of
MHC I expression by E5 is not irreversible. However,
even after interferon treatment, MHC I, although
increased in quantity, is not transported to the cell
surface. E5 therefore affects MHC I at several levels,
but prevention of MHC I transport to the cell surface
appears to be the dominant effect. Lack of surface MHC
I would have profound consequences for presentation of
viral peptides to the immune system.
Oncogene (2002) 21, 7808 - 78 I6. doi: 10. I038/sj.onc.
1205885
Keywords: papillomavirus; E5; MHC class I; immune
evasion; Golgi apparatus
Introduction
PapiIIomaviruses (PV) are small DNA tumour viruses
which infect mucosal and cutaneous epithelia where
they induce benign hyperproliferative lesions. In most
cases, papilloma virus infections are cleared after
several months by a cell mediated immune response
directed against viral antigens (Frazer and Tindle,
1996). Occasionally, however, the lesions do not
regress; failure of virus clearance is attributed to a
poor immunological response and persistent viral
infection poses a greater risk of neoplastic progression.
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Together with E6 and E7, E5 is a transforming
protein of PV. While E6 and E7 are the main
oncoproteins of mucosal human papilloma virus
(HPVs) (Mantovani and Banks, 2001; Munger et al.,
200 I), E5 is the major oncoprotein of bovine
papillomaviruses (BPVs), particularly of BPV-I
(DiMaio and Mattoon, 2001). The E5 protein is a
small hydrophobic peptide (from 83 amino acid
residues in HPV-16 to 42 residues in BPV-4), and
recent data suggests that it is a type II membrane
protein with one «-hclical trans-membrane span in
BPV E5 and up to three trans-membrane spans in HPV
E5 (Surti et al., 1998). It is expressed during the early
stages of infection in the deep layers of the infected
epithelium and its expression is extinguished as the
lesion progresses (Burnett et al., 1992; Anderson et al.,
1997; Chang et al., 200 I).
In agreement with its hydrophobic nature, E5 is
localized in the endomembrane compartments of the
endoplasmic reticulum (ER) and Golgi apparatus (GA)
of the host cell (Burkhardt et al., 1989; Pennie et al.,
1993). The function of E5 in vivo is not known, but in
vitro cell transformation is brought about by the
activation of several kinases, from growth factor
receptors to cyclins-cdks (Morgan and Campo, 2000).
E5 interacts physically with the cellular protein 16k
ductin/subunit c, a component of the gap junction and
of the VO sector of the vacuolar H + -ATPase (Gold-
stein et al., 1991; Conrad et al., 1993; Finbow et al.,
1995; Faccini et al., 1996). This physical interaction has
been deemed responsible for the down-regulation of
gap junction communication (Oelze et al., 1995;
Faccini et al., 1996; Ashrafi et al., 2000) and for the
lack of acidification of endosomes and GA (Straight et
al., 1995; Schapiro et al., 2000). The inhibition of
acidification of the endomembrane components has
been attributed to a malfunction of the II + -ATPase
(Briggs et al., 2001), although lack of acidification of
late endosomes or inhibition of the vacuolar proton
pump are not always observed (Thomsen et al., 2000;
Ashby et al., 2001).
We have recently shown that transformed cells
expressing BPV-1 or BPV-4 E5 are highly vacuolated
(Ashrafi et al., 2000) and have an enlarged and often
disrupted GA (Ashrafi et al., 2002). and have
attributed this morphology to the interaction of E5
and 16k subunit c. In these cells, E5 proteins, including
E5 from IIPV-16, cause down-regulation of the major
histocompatibility class I (MHC I) complex (Ashrafi et
al., 2002; O'Brien and Campo, 2002), and this may
contribute to PV escape from immunosurveillance and
aid the establishment of viral infection.
Here we extend our observations on MHC I down-
regulation in BPV E5-transformed cells and report that
E5 causes the retention of MHC I in the GA and
prevents its export to the plasma membrane. The lack
of surface expression of MHC I is observed even when
the levels of MHC I heavy chain are increased by
interferon treatment of E5 cells. The interference of E5
with MHC I transport is likely due to the lack of
acidification of the GA in E5 cells, as similar effects are
observed in non-transformed and non-E5 transformed
control cells treated with the ionophore monensin.
Results
MHC I is retained in the CA in E5-transformed cells
MHC I is consistently absent from the cell surface in
cells transformed by BPV-I E5 (I-E5) or BPV-4 E5 (4-
E5), as assessed by FACS analysis (Figure la) (Ashrafi
et al., 2002). To ascertain the intracellular localization
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of MHC I in E5 cells, primary bovine cells (PaIF),
PalF cells transformed by E6 and E7 (designated no-
E5) and by the addition of E5 (designated E5 cells)
were stained with either mAb IL-A 19 or IL-A88
(Bensaid et al., 1989; Toye et al., 1990), which
recognize f32-microglobulin-associated MHC I heavy
chain or free heavy chain, respectively. In PalF and no-
E5 cells, MHC I was detected on the cell surface and in
a Golgi-like structure (Figure Ib). In contrast in both
l-E5 and 4-E5 transformed cells, MHC I was detected
only in abnormal structures (Figure Ib), reminiscent of
the misshapen GA in these cells (Ashrafi et al., 2002).
Similar results were obtained with either antibody
(data not shown).
E5 and M HC I heavy chain co-localize in the CA
To define the intracellular structures in which MHC I
was detected, PalF, no-E5 and 4-E5 cells were
transfected with a plasmid encoding a fusion of green
fluorescent protein (GFP) and MHC I heavy chain,
and stained with the Golgi marker BODIPY-TR-
ceramide. In all cell lines, GFP-MHC I heavy chain
localized in the GA, which had the normal 'ring-like'
B
Figure 1 MHC class I is absent from the cell surface of E5-transformed cells. (a) FACS profiles of MHC I surface expression in
parental (palF) cells, transformed control cells (no-ES), and cells transformed by BPV-l E5 (l-ES), BPV-4 ES (4-ES) or the 4-ES
hypertransforming mutant Nl7A (Ashrafi et al., 2000). Cells were stained with mAb IL-AI9. The open histograms represent cells
stained with FlTC-conjugated secondary antibody only. Control cell lines express surface MHC I (solid histograms), whereas ES-
transformed cells do not as indicated by the almost complete overlap of the two histograms. (b) Immunofluorescence detection of
MHC I in PaIF, no-ES, l-E5 and 4-E5 cells. MHC I heavy chain was detected on the cell surface and in GA-like structures in
parental and control cells, but only in GA-like structures in E5 cells. No fluorescence was detected in cells reacted only with the
secondary antibody (data not shown). N = nucleus
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appearance in PalF and no-E5 cells, whereas it was
swollen and distorted in 4-E5 cells (Figure 2a).
To investigate whether E5 and MHC I co-localize,
the cell lines were co-transfected with GFP-MHC I
heavy chain and a plasmid encoding a fusion protein of
the fluorescent protein DsRed and BPV-4 E5 (RFP-
E5). Like wild type E5 (Pennie et al., 1993), RFP-E5
localized in the GA (Figure 2b), whereas DsRed on its
own was distributed uniformly in the nucleus and
cytoplasm (data not shown). In all cell lines, GFP-
MHC I heavy chain co-localized with RFP-E5 in the
GA (Figure 2b).
Retention of MHC I in the CA by E5 is specific
It was important to demonstrate that retention of
MHC I in the GA was specific, and not due, for
instance, to the nature of the fusion proteins used in
the study. Therefore, the cells were transfected with a
plasmid expressing the papillomavirus E2 protein. As
expected (Ham et al., 1991), E2 localized in the nucleus
in all cell lines, including 4-E5 transformed cells
(Figure 3a), showing that E5 did not retain a
predominantly nuclear protein in the endomembrane
compartment. Moreover, co-expression of E2 and
GFP-MHC I heavy chain, or E2 and RFP-E5 did
not lead to co-localization: E2 was nuclear in all cases,
and MHC I heavy chain and E5 were localized in the
GA (Figure 3b).
Prevention of CA acidification by the ionophore rnonensin
prevents transport of MHC I to the cell surface
The monovalent ionophore monensin is widely used to
investigate the function of the GA and vesicular
transport (see Barchet et al., 200 I; Halaban et al.,
2002; Schoonderwoert et al., 2002). Monensin
A
disperses the proton gradient across the cell
membranes and impedes the proper acidification of
Golgi cisternae by displacing and inhibiting the H + -
V-ATPase proton pump, leading to GA swelling and
fragmentation and faulty protein transport from the
medial to the trans-Golgi (Tartakoff, 1983; Boss et al.,
1984; Zhang et al., 1996; Chikuma et al., 2002). E5
complexes with 16k subunit c, a component of the VO
sector of the H+ -V-ATPase (Goldstein et al., 1991;
Conrad et al., 1993; Faccini et al., 1996; Ashrafi et al.,
2000) and inhibits endomembrane acidification
(Straight et al., 1995; Schapiro et al., 2000). In view
of the similarity between the reported morphology of
monensin-treated cells and E5 cells, and the functional
similarity between monensin and E5, we treated PalF
and no-E5 cells with monensin and analysed them for
morphology, GA architecture and surface MHC I.
Indeed, monensin-treated PalF cells or no-E5 cells
showed extensive vacuolization and a grossly
deformed GA (Figure 4a, shown only for PalF cells).
These results indicate that the vacuolization and GA
malformation in E5 cells are likely due to the impeded
acidification of the GA membranes brought about by
the viral protein.
Next we investigated whether treatment with
monensin resulted in a down-regulation of surface
MHC I in either PalF or no-E5 cells. Cells were treated
with 25 f..lM monensin for 30 min, 3 or 12 h, and
analysed for surface or total MHC I by FACS.
Monensin treatment caused a fourfold decrease in
surface MHC I after 30 min in PalF cells and after 3 h
in no-E5 cells (Figure 4b). The levels of surface MHC I
returned to those seen in non-treated cells after 12 h in
both cell lines (data not shown) in agreement with the
reported ability of cells to recover from the effects of
monensin treatment (Zhang et al., 1993). We do not
know why no-E5 cells down-regulated surface MHC I
B
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Figure 2 MHC I heavy chain and E5 co-localize in the GA. (a) Cells stained with BODIPY-TR-Ceramide (red) to detect the GA
and transfeeted with GFP-MHC I heavy chain (green). GFP-MHC 1 heavy chain localizes in the GA in all cell lines. (b) Cells trans-
fected with RFP-E5 (red) or GFP-MHC I heavy chain (green). MHC I heavy chain co-localizes with E5 in the GA in all cell lines
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Figure 3 E2 localizes to the nucleus and does not co-localize with either MHC I heavy chain or E5. (a) Cells were transfected with
E2 only, or (b) co-transfected with E2 and GFP-MHC lor E2 and RFP-E5. E2 was detected with mAb TVG216 and Texas Red-
conjugated secondary antibody in (a) and in the left panel of (b), and with a FITC-conjugated secondary antibody in the right panel
of (b). GFP-MHC I and RFP-E5 were visualized directly
in response to monensin less rapidly than PalF cells
(3 h vs 30 min); the delay may be due to the expression
of the other oncoproteins present in no-E5 cells. The
experiment was repeated three times and the ratio
between the mean fluorescence for total and surface (T!
S) MHC I was calculated. The TIS ratio confirmed that
monensin treatment reduces expression of surface
MHC I: after 30 min of monensin treatment, the TIS
ratio in PalF cells was increased approximately four-
fold, and in no- E5 cells the highest TIS ratio was
obtained after 3 h of treatment (Figure 4b). The
transport to the cell surface of another membrane
glycoprotein, the transferrin receptor, was not affected
in E5 cells (Ashrafi et al., 2002), and likewise there
were no differences in the levels of surface transferrin
receptor between cells treated and not treated with
monensin (data not shown).
Monensin treatment did not significantly affect the
levels of total MHC I in PalF cells and slightly
decreased it in no-E5 cells, as judged by immunoblot-
ting (Figure 4c), and therefore we conclude that
monensin inhibited the transport of MHC I to the cell
surface but not its expression. These results indicate
that, following inhibition of GA acidification by
monensin, transport of MHC I to the cell surface is
impeded, and support the notion that E5 prevents
MHC I transport through inhibition of GA acidifica-
tion.
Treatment of E5 cells with interferon increases total but
not surface MHC J
Both ,8-interferon and y-interferon (,8-IFN or ')1- IFN)
increase the transcription activity of the MHC I
heavy chain gene promoter (Agrawal and Kishore,
2000) leading to higher expression levels of heavy
chain. We have previously shown that in ES cells
there is less MHC I heavy chain mRNA and protein
(Ashrafi et al., 2002). To see if the biosynthetic
pathway of heavy chain is permanently inhibited by
ES, we treated PaIF, no-ES and ES cells with either
{3- or y-IFN or the control supernatant 20G.
Treatment with either IFN, but not with 20G,
noticeably increased production of the MHC I heavy
chain to approximately the same extent in all cell
lines as assessed by immunoblotting (Figure 5a). This
shows that E5 cells are responsive to IFN and the
biosynthetic pathway of MHC I heavy chain is not
irreversibly inhibited by E5. The IFN-treated cells
were also analysed by FACS to ascertain whether the
increased production of heavy chain led to a
corresponding increase in surface MHC I. MHC I
surface expression increased only in PalF and no-E5
cells but not in E5 cells, or in cells expressing the
hypertransforming 4-ES Nl7A mutant (Figure Sb),
despite the increase in total MHC I. These results
unequivocally show that E5 inhibits the transport of
Oncogene
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Figure 4 Monensin causes GA swelling and MHC I intracellular retention. (a) Morphology of 4-E5 cells and PalF cells treated
with 25 liM monensin for 3 h using phase contrast microscopy (top panels), and immunofluorescence with mAb 4A3 to visualize
the GA (bottom panels). Monensin-treated cells are highly vacuolated and present a swollen GA, similar to E5 cells, N = nucleus.
(b) PalF and no-ES cells were treated with 25 liM monensin for 30 min or 3 h. Surface and total MHC I expression was examined by
FACS analysis using mAb lL-AI9. The mean fluorescence from a representative experiment is shown in the upper panel. Surface
mean fluorescence decreases after 30 min treatment with monensin in PalF cells and after 3 h treatment in no-ES cells. The ratio
between total mean fluorescence and surface mean fluorescence (TIS) of PalF and no-E5 cells is shown in the bottom panel.
The bars represent the average ratio from three experiments (+ 1- standard deviation). The TIS ratio increases approximately four-
fold in PalF cells after 30 min of monensin treatment, and approximately twofold in no-E5 cells after 3 h of treatment, indicating a
decrease in surface MHC 1. (c) PalF and no-E5 cells were treated with 25 liM monensin for 3 hand 10 lig of protein lysate were
analysed by immunoblotting for MHC I expression. MHC I heavy chain (MHC I he) was detected with mAb IL-A88 (top panel)
and actin, as a loading control, with mAb AB-l (bottom panel). Monensin does nOI affect the expression of MHC I heavy chain
MHC I from the endomembrane compartment to the
cell surface.
Discussion
MHC class I molecules playa crucial role in immune
recognition and clearance of virus infected cells. The
proteolytic degradation of viral proteins generates a
spectrum of peptides that are transported into the ER
and loaded onto the MHC class I complex, which
consists of the MHC I heavy chain and {32-micro-
globulin. Following transport from the ER through the
GA to the cell surface, the MHC class Ijpeptide
complexes are presented to virus-specific cytotoxic T
lymphocytes (CTL), signalling virus infection and
enabling killing of the infected cell. The importance
of MHC class I molecules in virus clearance has been
demonstrated by the identification of many mechan-
isms of interference with the MHC class I pathway
evolved by viruses, from prevention of peptide
processing to formation of non-functional MHC I
complexes (Yewdell and Bennink, 1999). In each of
these strategies, the outcome is the failure by the
infected cell to present viral peptide antigens to effector
Oncogene
T cells and hence avoidance of detection and
destruction by the host immune system.
PV are poorly immunogenic. Even in immunocom-
petent hosts, whether animals or humans, PV persist
for a significant period of time, usually spanning
several months, before activation of the host immune
system. This lack of recognition, in spite of the
expression of abundant viral protein, suggests the host
immune system is unaware of, or disabled by, PV
infection. The ability of the virus to persist has been
attributed to the nature of the virus life cycle, which
may prevent the immune cells having access to the viral
proteins (Tindle, 2002). Although undoubtedly a factor
in immune evasion, there is now increasing evidence
that PV encode proteins that can directly subvert the
host immune response, resulting in a delay in, or
prevention of, resolution of infection (O'Brien and
Campo, 2002). We have recently shown that the PV
oncoprotein E5 can down-regulate the surface expres-
sion of MHC I, which may affect the recognition and
killing of PV -infected cells by CTL (Ashrafi et al.,
2002; O'Brien and Campo, 2002). E5 appears to
interfere with several steps of the MHC I pathway,
including transcription of MHC I heavy chain mRNA,
expression of MHC I heavy chain protein, and
A
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Figure S (a) {3-IFN and y-IFN increase MHC I heavy chain expression in all cells (a). Cells were treated for 48 h with 500 U/ml of
either {3-IFN or y-IFN (lanes marked +), or with 500 Ujml of the control supernatant 206 (lanes marked -), and MHC I was
analysed by immunoblotting as described in Figure 4. (b) MHC I is not transported to the cell surface in IFN-treated E5 cells. Cells
treated with {3-IFN (PalF, 4-E5 NI7A) or y-IFN (no-ES, 4-ES) (solid histograms), or the control supernatant 206 (open histograms)
were analysed for expression of total and surface MHC I by FACS analysis with mAb IL-A 19. IFN treatment increases both total
and surface MHC I in PalF and no-ES cells, but only total MHC I in E5 cells or cells expressing the hypertransforming mutant
Nl7A
transport of MHC I complex to the plasma membrane
(Ashrafi et al., 2002). Here we have focused our
attention on the faulty transport of MHC I to the cell
surface.
In order to determine if the MHC I biosynthetic
pathway was rendered irretrievably malfunctional by
E5, we treated the cells with type I and II IFNs which
are potent inducers of MHC I expression (Agrawal and
Kishore, 2000). All of the cell lines tested, including the
E5 cells, responded to IFN treatment by increasing the
level of MHC I heavy chain to approximately the same
extent, although the effect was more marked with y-
IFN than with p-IFN. Thus, although E5 reduces the
levels of both mRNA and protein, transcription and
translation of the MHC I heavy chain can be recovered
showing that the effects of E5 on MHC I expression
are not irreversible. What is clearly irreversibly
impaired in E5 cells is the transport of MHC I to the
cell periphery, as despite the marked increase in MHC
I heavy chain, no MHC I is found on the surface of the
IFN-treated E5 cells. E5 therefore retains MHC I
intracellularly.
Both endogenous MHC I or exogenous (transfected)
GFP-MHC I heavy chain fusion protein are retained in
the swollen and misshapen GA characteristic of ES-
expressing cells and indeed co-localized with the E5
protein in the GA. The detection of endogenous MHC
I in the GA with mAb IL-AI9, which does not
recognize free MHC I heavy chain, indicates that the
heavy chain is complexed with p2-microglobulin. This
suggests that the arrest of MHC I transport occurs
following MHC class I complex formation in the ER
and is instead a fault in cellular transport across the
Golgi compartments. Indeed, treatment of control cells
with the ionophore monensin resulted in the acquisi-
tion of a phenotype remarkably similar to that of E5
cells, with many vacuoles and a distorted GA, with a
concordant rapid and marked down-regulation of
surface MHC I. Monensin is a well-characterized
inhibitor of GA acidification, which hinders cellular
transport of newly synthesized proteins, particularly
interfering with transfer across Golgi compartments
and compromising secretion from the medial to the
trans-Golgi (Tartakoff, 1983). Taking into account the
similar functional effect of monensin and E5, we
suggest that ES causes GA malformation and retention
of the MHC I complex in the GA by increasing GA
pH.
However, the impeded transport of the MHC I
complex in E5 cells is not part of a generalized
disturbance of intracellular traffic as we have hown
that the transport of the transferrin receptor is not
affected by E5 expression (Ashrafi et al., 2002) nor by
treatment with monensin. How then does E5 prevent
Oncogene
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MHC I from exiting the GA and reaching the plasma
membrane?
Like E5, the HTL V-I pI z', another small hydro-
phobic viral protein, binds to the 16k subunit c
component of the H+ -V-ATPase (Franchini et al.,
1993). pl Z' can also bind MHC I causing its
intracytoplasmic retention and degradation (Johnson
et al., 2001). However, we feel that a physical
interaction between E5 and MHC I is an unlikely
cause of MHC I retention in the GA. E5 is expressed
at a very low level in transformed cells (O'Brien et al.,
1999), and although IFN treatment markedly increases
the expression of MHC I heavy chain, it has no effect
on E5 expression (R Ullah et al., unpublished
observations). Hence a one-to-one interaction between
E5 and MHC I heavy chain is stochiometrically
incompatible.
A more likely explanation may be that E5-induced
acidification of the GA causes the incorrect glycosyla-
tion of the MHC I heavy chain. This hypothesis is
supported by the observation that monensin disrupts
the processing of N- and a-linked carbohydrates on
glycoproteins and this disruption inhibits the intracel-
lular transport of a variety of proteins (Anderson and
Pathak, 1985). Moreover, it has recently been reported
that 16k subunit c suppresses the tumour-related
glycosylation of cell surface receptors, and that this
effect is independent of V-ATPase function (Skinner
and Wildeman, 2001). Therefore, it is possible that the
interaction of E5 with 16k subunit c may lead to
improper glycosylation and processing of MHC I.
Improperly processed MHC I molecules accumulate
and are degraded in an expanded Golgi intermediate
compartment (Raposo et al., 1995), which is consistent
with the cellular localization of the MHC class I
complex in the E5 cells. In addition, degradation would
account for the reduced amounts of MHC I heavy
chain observed in E5 cells. It remains to be seen if
inhibition of the E5-16k subunit c interaction can
revert, at least partially, the transformed phenotype of
E5 cells and restore surface MHC I expression.
Materials and methods
eel/lines
Primary embryonic bovine cells (PaIF) transformed by PV E6
and E7 oncogenes, with or without BPV-I or BPV-4 ES (I-ES
or 4-ES respectively), have been described previously
(Ashrafi, 1998; O'Brien et al., 1999). In these cells, the
combination of BPV-4 E7, ES from either BPV-I or BPV-4,
and activated ras induces cell transformation but immorta-
lization is conferred by HPV-16 E6 (Pennie et al., 1993). as
the BPV-4 genome does not encode an E6 protein (Jackson et
al .• 1991). Briefly. normal parental cells are designated PalF;
cells transformed by E6, E7 and activated ras are designated
'no-ES' and cells transformed as above but with the addition
of either ES protein are designated 'ES'. The cell lines were
grown in Dulbecco's modified Eagles medium (DMEM)
(InVitrogen/Life Technologies, UK) containing 10% foetal
calf serum (FCS) at 37"C in 5% CO2• unless specified to the
contrary.
O~togene
Treatment of cells with monensin
PalF and no-E5 cells were treated with 25 /.1M monensin
(Sigma, UK) for 30 min, 3 or 12 h. The morphology of the
GA and surface MHC I were determined as described below.
Treatment of cells with interferon
One million PaIF, no-E5 and E5-transformed cells were
seeded in lOOmm diameter tissue culture dishes. The
following day, the medium was replaced with fresh medium
with or without 500 U/ml fJ-IFN (Sigma) or recombinant
ovine y-IFN (Graham et al .• 1995). 2D6, a supernatant from
cells not expressing IFN, was used as control. After 48 h, the
cells were harvested for detection of M HC I by irnmunoblot-
ting or FACS analysis (see below). Ovine recombinant y-IFN
and 2D6 were a kind gift of Dr G Entrican (Moredun
Research Institute, Penicuik, UK).
Plasm ids
pGFP-MHC I expresses a fusion protein made up of the
green fluorescent protein (EGFP) and the heavy chain of
human MHC I B2705 and was a kind gift from Dr Simon
Powis (University of Dundee, UK). pRFP-E5 expresses a
fusion protein of the fluorescent protein DsRed and BPV-4
E5. It was constructed by inserting the BPV-4 E5 open
reading frame tagged with the sequence for the HA epitope
(O'Brien et al., 1999) into the BgnI and HilllnlI sites of
pDsRed-CI (ClonTech, UK). pCMVE2 expresses the E2
protein of HPV-16 and was a kind gift from Dr Lawrence
Bank (ICGEB, Trieste, Italy).
Antibodies
Monoclonal antibody (mAb) 4A3 is raised against GM 130.
an integral GA protein (Barr et al., 1998) and was a kind gift
of Dr Martin Lowe (University of Manchester, UK). MAbs
IL-AI9 and IL-A88 are raised against monomorphic
determinant of bovine MHC I (Bensaid et al., 1989; Toye
et al., 1990), which recognize fJ2-microglobulin-associated
MHC I heavy chain or free heavy chain, respectively. They
are kind gifts of Dr Liz Glass (IAH, Roslin, UK) and Dr
Shirley Ellis (IAH. Compton, UK), respectively. TVG261
recognizes the E2 protein of HPV-16 and was a kind gift of
Dr Merilyn Hibma (University of Otago. New Zealand).
DNA transfection
Cells were aliquoted into 24-well plates containing coverslips
at 104 cells/well and grown overnight to approximately 80%
c~nfluence. Plasmids (0.6ljg) were transfccted into cells using
LipofecteMtNf PLUST Reagent (Invitrogen/Life Tech-
nologies, UK) according to the manufacturer's instructions.
Forty-eight hours after transfection, the cells were washed
twice with PBS and then fixed in 1.85% formaldehyde
(Sigma) diluted in PBS containing 2% sucrose (Schwarz/
Mann, USA) for 10 min at room temperature. Following a
further three washes with PBS, the coverslips were removed
from the well and mounted in AFI (Citifluor, UK).
Visualization of GFP and RFP plasmids
Cells expressing fluorescent GFP-MHC I and RFP-E5 were
visualized either using a Leica DMLB microscope or a Zeiss
LSM 510 microscope.
Detection of E2
Cells were transfected with pCMVE2 and fixed 24 h after
transfection as described above. Following washes in PBS,
the cells were permeabilized in 0.5% NP40/PBS/10% sucrose
for 10 min at room temperature and then washed three times
with 1% FCS/PBS. The coverslips were incubated in mAb
TVG261 for I h at room temperature, washed in 1% FCS/
PBS and then incubated with an anti-mouse antibody
conjugated either with Texas Red or with FITC (Sigma).
Following further washes in 1% FCS/PBS, coverslips were
mounted in AFI and analysed as above.
Visualization of Golgi apparatus
The GA was visualized by staining with BODIPY-TR-
ceramide. Cells were grown until 80% confluent in single
well chamber slides. After removal of medium cells were
washed twice with serum free DMEM, 25 mM HEPES
(DMEM-H) and incubated in 200 III of 5 liM BODIPY-TR-
cerarnide, which localizes to the GA, in DMEM-H for
30 min at 4°C. Cells were then washed with DMEM-H for
30 min at 37°C. After removal of the medium and washing
with PBS, cells were fixed with fresh 3% paraformaldehyde
(PFA) for 20 min at room temperature and mounted with
Vectashield (Vector Laboratories Inc, UK).
Cytoimmunofluorescent detection of Golgi apparatus and
MHCI
The cells were washed twice with PBS and fixed with fresh
3% PFA in PBS for 20 min at room temperature. After the
PFA fixation, a second fixation was performed by dipping the
chamber slides in -20"C methanol for 4 min; then the cells
were washed three times in PBS. For GA detection, the cells
were incubated with mAb 4A3 for 30 min at room
temperature, washed as above and incubated with Alexa-
FluorTM 488 goat anti-mouse IgG(H + L) conjugate
(Molecular Probes, Europe BV) for 30 min at room
temperature. For the detection of endogenous surface MHC
I, the cells were incubated with mAb IL-AI9 or mAb IL-A88
for I h at room temperature and washed three times as
above. The cells were then incubated with anti-mouse IgG-
FITC (Sigma) at 4°C for I h in the dark. Following three
final washes with PBS, the slides were mounted in PBS and
analysed under the fluorescence microscope.
Detection of MHC class I by FACS
Cells were grown in a 175 cm2 flask to approximately 80%
confluence. After removal of the medium, the cells were
washed once with PBS, then detached from the flask with
trypsin/EDT A and pelleted at 200 g for 5 min at room
temperature. The cell pellet was resuspended in DMEM, 10%
FCS, for I h at 37°C to allow surface antigens to be re-
expressed. The cells were washed and re-suspended in PBS-
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Biotech).
Acknowledgements
We thank Dr Robina Ullah for her measurements of MHC
I heavy chain and E5 mRNA in IFN-treated cells. We are
indebted to Drs Shirley Ellis, Gary Entrican, Liz Glass,
Martin Lowe, Stuart Ford and Simon Powis for their kind
gifts of reagents. We thank Dr Simon Powis for his critical
reading of the manuscript. This work was supported by the
Medical Research Council, the Association for Interna-
tional Cancer Research and Cancer Research UK (formerly
Cancer Research Campaign). MS Campo is a Fellow of
Cancer Research UK.
Ashrafi GH. (1998). Mutational analysis of the transforming
protein E8 (E5) of bovine papillornavirus Type 4. PhD
Thesis. Glasgow University, UK.
Ashrafi GH, Pitts JD, Faccini A, McLean P, O'Brien V,
Finbow ME and Campo MS. (2000). J. Gen. Virol., 81,
689-694.
Oncoeene
E5 retention of MHC class I in Golgi apparatus
B Marchetti et al
7816
Ashrafi GH, Tsirimonaki E, Marchetti B, O'Brien PM,
Sibbet GJ, Andrew L and Campo MS. (2002). Oncogene,
21,248-259.
Barr FA, Nakamura N and Warren G. (1998). EMBO J., 17,
3258 - 3268.
Bachert C, Lee TH and Linstedt AD. (2001). Mol. Bioi. Cell.
12, 3152 - 3160.
Bensaid A, Kausha1 A, Machugh ND, Shapiro SZ and Teale
AJ. (1989). Anim. Genet .. 20, 241-255.
Boss WF, Morre' DJ and Mollenhauer HH. (1984). Eur. J.
Cell Bioi., 34, 1- 8.
Briggs MW, Adam JL and McCance DJ. (2001). Virology.
280, 169-175.
Burkhardt A, Willingham M, Gay C, Jeang KT and Schlegel
R. (1989). Virology, 170,334-339.
Burnett S, Jareborg N and DiMaio D. (1992). Proc. Natl.
Acad. Sci. USA. 89, 5665-5669.
Chang JL, Tsao YP, Liu DW, Huang SJ, Lee WH and Chen
SL. (2001). J. Biomed. sa., 8, 206-213.
Chikuma T, Inomata Y, Tsuchida K, Hojo Hand Kato T.
(2002). Neurosci. Lett., 326, 89 - 92.
Conrad M, Bubb VJ and Schlegel R. (1993). J. Virol., 67,
6170-6178.
DiMaio D and Mattoon D. (2001). Oncogene, 20, 7866-
7873.
Faccini AM, Cairney M, Ashrafi GH, Finbow ME, Campo
MS and Pitts JD. (1996). J. Virol., 70, 9041- 9045.
Finbow ME, Harrison M and Jones P. (1995). Bioessays, 17,
247-255.
Franchini G, Mulloy JC, Koralnik 11, Lo Monico A,
Sparkowski JJ, Andresson T, Goldstein DJ and Schlegel
R. (1993). J. Viral .. 67, 7701-7704.
Frazer JH and Tindle RW. (1996). Papilloma virus Reviews
Lacey C (ed). Leeds, UK: Leeds University Press, pp. 151 -
164.
Goldstein DJ, Finbow ME, Andresson T, McLean P, Smith
K, Bubb V and Schlegel R. (1991). Nature, 352, 347-349.
Graham SP, Jones GE, MacLean M, Livingstone M and
Entrican G. (1995). J. Compo Pathol., 112, 185-195.
Ha1aban R, Patton RS, Cheng E, Svedine S, Trombetta ES,
Wahl ML, Ariyan S and Hebert DN. (2002). J. BioI.
Chem., 277, 14821-14828.
Ham J, Dostatni N, Gauthier JM and Yaniv M. (1991).
Trends Biochem. Sci., 16,440-444.
Jackson ME, Pennie WD, McCaffery RE, Smith KT,
Grindlay GJ and Campo MS. (1991). Mol. Carcinog., 4,
382-387.
Oncogene
Johnson JM, Nicot C, Fullen J, Ciminale V, Casareto L,
Mulloy JC, Jacobson S and Franchini G. (2001). J. Virol.,
75, 6086 - 6094.
Mantovani F and Banks L. (2001). Oncogene, 20, 7874-
7887.
Morgan 1M and Campo MS. (2000). Papillomavirus Report,
11,127-132.
Munger K, Basile JR, Duensing S, Eichten A, Gonzalez SL,
Grace M and Zacny VL. (200 I). Oncogene, 20,7888 -7898.
O'Brien PM and Campo MS. (2002). Virus Res.: Virus escape
from immunosurveillance. Campo MS (ed.) Shannon,
Ireland: Elsevier Science.
O'Brien V, Ashraf GH, Grindlay GJ, Anderson Rand
Campo MS. (1999). Virology., 255, 385-394.
Oelze I, Kartenbeck J, Crusius K and Alonso A. (1995). J.
Virol., 69, 4489 - 4494.
Pennie WD, Grindlay GJ, Cairney M and Campo MS.
(1993). Virology, 193,614-620.
Raposo G, Martien van San ten H, Leijendekker R, Geuze
HJ and Ploegh HL. (1995). J. Cell Bioi., 131, 1403-1419.
Schapiro F, Sparkowski J, Adduci A, Suprynowicz F,
Schlegel Rand Grinstein S. (2000). J. Cell Bioi., 148,
305 - 315.
Schoonderwoert VT, Jansen EJ and Martens GJ. (2002). Eur,
J. Biochem., 269,1844-1853.
Skinner MA and Wildeman AG. (2001). J. Bioi. Chem., 276,
48451 - 48457.
Straight SW, Herman B and McCance DJ. (1995). J. Viro/.,
69, 3185 - 3192.
Surti T, Klein 0, Aschheim K, DiMaio D and Smith SO.
(1998). Proteins. 33, 601-612.
Tartakoff AM. (1983). Cell. 32,1026-1028.
Thomsen P, van Deurs B, Norrild B and Kayser L. (2000).
Oncogene, 19, 6023 - 6032.
Tindle RW. (2002). Nat. Rev. Cancer. 2, 59-65.
Toye PG, MacH ugh ND, Bensaid AM, Alberti S, Teale AJ
and Morrison WI. (1990). Immunology, 70, 20-26.
Yewdell JW and Bennink JR. (1999). Ann. Rev. Cell Dev.
Biol., 15, 579 - 606.
Zhang GF, Driouich A and Staehelin LA. (1993). J. Cell Sci..
104,819-831.
Zhang GF, Driouich A and Staehelin LA. (1996). Eur, J. Cell
Bioi., 71, 332-340.
Appendix (c)
Journal of General Virology (2004), 85, 2809-2814 001 10.1099/vir.0.80 128-0
Short
Communication
Downregulation of major histocompatibility
complex class I in bovine papillomas
E. H. Araibi, B. Marchetti, G. H. Ashrafi and M. S. Campo
Correspondence
M. S.Campo
s.campo@vetgla.ac.uk
Institute of Comparative Medicine, Division of Pathological Sciences, University of Glasgow,
Garscube Estate, Glasgow G61 10H, UK
Bovine papillomavirus (BPV) induces papillomas in cattle; in the great majority of cases, these
regress due to the host immune response, but they can persist and progress to malignancy. Even in
the absence of malignant transformation, BPV infection persists for a significant period of time
before activation of the host immune system, suggesting that the host immune system is unaware of,
or disabled by, BPV. E5 is the major oncoprotein of BPV, which, in addition to its transforming
properties, downregulates the expression and transport to the cell surface of major histocompatibility
complex class I (MHC I). Here, it is shown that co-expression of MHC I and E5 in papillomas
caused by BPV-4 infection is mutually exclusive, in agreement with the inhibition of surface MHC I
expression by E5 that is observed in vitro. The inhibition of MHC expression in E5-expressing
papilloma cells could explain the long period that is required for activation of the immune response
and has implications for the progression of papillomas to the malignant stage; absence of
peptide presentation by MHC I to cytotoxic T lymphocytes would allow the infected cells to
evade the host cellular immune response and allow the lesions to persist.
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Papillomaviruses are oncogenic viruses that induce benign
proliferative lesions of epithelia, called papillomas or warts.
Papillomavirus infections are usually eliminated by a cell-
mediated immune response, which is directed against viral
antigens (O'Brien & Campo, 2002). However, in a minority
of cases, mucosal lesions do not regress and can progress to
cancer. High-risk human papillomavirus types 16 and 18
(HPV-16 and -18) are the main causative factors in the
development of cancer of the cervix uteri (zur Hausen,
2002). Bovine papillomavirus type 1 and 2 (BPV-l and -2)
and BPV-4 are respectively involved in carcinogenesis of the
urinary bladder and the alimentary tract in cattle; BPV-1 is
also involved in cancer of the penis (Campo, 1997,2002). In
all cases, cancer is preceded by, and derives from, pre-
existing papillomas.
Papillomas that are induced by BPV develop through four
well-defined stages, from stage 1 or plaque, the first clinical
manifestation of infection, to stage 4, when the papilloma
starts to regress (Jarrett, 1985). From infection to regression,
papilloma development often takes longer than 12 months.
In the case of BPV-4-induced papillomas, regression is
accompanied by infiltration of immune cells, primarily
CD4 + T lymphocytes in the adjacent dermis, as well as
CDS + T lymphocytes infiltrating the keratinocytes (Knowles
et al., 1996). Persistence, spread and progression of papil-
lomas to cancer occur mainly in animals that graze on
bracken fern (Pteridium spp.) (Campo et al., 1994). These
animals are immunocompromised by immunosuppres-
sants, such as sesquiterpenes, that are present in the plant.
However, papillomas can also spread and persist in cattle
that are not exposed to bracken fern (Tsirimonaki et al.,
2003). Even in the absence of malignant transformation,
BPV infection can persist for a significant period of time
before activation of the host immune system. Lymphocytes
from infected animals do not recognize early or late viral
antigens until late in infection, despite the presence of
numerous papillomas actively producing virus (Chandrachud
et al., 1994, 1995; McGarvie et al., 1995; Kirnbauer et al.,
1996). This lack of recognition suggests that the host
immune system is unaware of, or disabled by, BPV infection.
It is now known that papillomaviruses can subvert the
immune response indirectly, as virus replication is confined
to the epithelial cells above the basal membrane and there-
fore occurs in a site that is recognized poorly by immune
cells (Frazer et al., 1999). In addition, papillomaviruses
appear to interfere directly with host antiviral immune
mechanisms, including the interferon response and major
histocompatibility complex class I (MHC I) antigen pre-
sentation to cytotoxic T lymphocytes (O'Brien & Campo,
2002; Tindle, 2002).
We have shown recently that expression of the E5 oncopro-
tein of BPV-l, BPV-4 and HPV-16 has a profound effect
on the synthesis and transport of MHC I in cultured cells
and, therefore, can potentially contribute to the ability of
the virus to evade immune recognition (Ashraf et al., 2002,
2004; Marchetti et al., 2002; O'Brien & Campo, 2002).
To ascertain whether the downregulation of MHC I that
is observed in cultured cells takes place in tumours, we
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investigated the expression of BPV-4 E5 and MHC I m
clinical samples of BPV-4 papillomas.
Papillomas from the palate, rumen and oesophagus, as well
as samples of normal palate, tongue and buccal mucosa,
were collected post-mortem from animals that were referred
to the University of Glasgow Veterinary School. Tissue
samples were fixed and stored in 10% formaldehyde in PBS
at pH 7·5 and embedded in paraffin wax for histological
processing. Serial sections (1' 5 urn) were cut and placed on
microscopic slides that had been treated with VECTABOND
(Vector). After deparaffinization in Histo-clear (National
Diagnostics), sections were rehydrated in graded ethanol
and incubated in 0·5% H202/methanol for 20 min to
quench endogenous peroxidase. Sections were subjected to
antigen-retrieval treatment with 0·01 M sodium citrate
buffer (pH 6) in a pressure cooker for 75 s at 103'4 kPa,
blocked with 1% normal unlabelled swine serum (Scottish
Antibody Production Unit) in TBS containing 0'1 % Tween
20 for 30 min at room temperature and then incubated for
1·5 h at room temperature with primary antibodies for
detection ofE5, E7,MHC I heavy chain and the proliferation
marker Ki67, as detailed below. The sections were then
incubated with biotin-labelled secondary antibody (Dako)
and streptavidin-biotin complex (Dako) for 45 min, follow-
ing the manufacturer's instructions. Immunoreactivity was
visualized with diaminobenzene (Sigma). Sections were
counterstained with Gill's haematoxylin, dehydrated, cleared
in Histo-clear and mounted permanently with DPX mountant
under a coverslip prior to microscopic examination. A total
of seven papillomas was analysed, with at least three sections
and three different section fields examined per papilloma; all
papillomas were classified as stage 2/3, i.e. mature papil-
lomas producing virus, and presented the typical features of
BPV-4 infection (Jarrett, 1985), including an irregular basal
layer (Fig. la and b), fronds of transformed cells terminat-
ing in keratinized tips (Fig. 2d) and koilocytes, cells with
highly enlarged cytoplasm that are typical of papillomavirus
infection (Fig. 2d, black arrow). In contrast, the normal
bovine alimentary mucosal epithelium had a typical archi-
tecture, composed of a regular basal cell layer and supra-
basal, spinous and squamous layers (Fig. Id).
BPV-4 E5 was detected with each of two rabbit antisera,
274 and 275, that were raised against a synthetic peptide
representing the 12 C-terminal amino acids of the protein,
conjugated to keyhole limpet haemocyanin (Anderson et al.,
1997). Similar results were obtained with both anti-E5
2 3
Fig. 1. Expression of E5 in BPV-4-induced papillomas. Representative papilloma sections stained with anti-E5 antiserum 274
(1 : 2000). (a) Papilloma 1803, showing E5 expression in basal and suprabasal layers. (b) Papilloma 386, showing E5
expression in suprabasal layers. (c) Serial section of papilloma 386 incubated with secondary antibody only. (d) Normal buccal
mucosa, showing no expression of E5. (e) Autoradiograph of in vitro-labelled [35S]E5. Lane 1, input E5 protein; lane 2, E5
immunoprecipitated with antiserum 274; lane 3, E5 immunoprecipitated with antiserum 274 pre-absorbed with an E5
C-terminal peptide. (f) Serial section of papilloma 386 incubated with pre-absorbed antiserum, showing loss of reactivity.
Magnification, x 40 (a); x 20 (b, c and I); x 10 (d).
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Fig. 2. Expression of MHC I in BPV-4-induced papillomas. Representative papilloma sections stained with anti-MHC I heavy
chain mAb IL-A88 (1 : 200). (a) Section of normal buccal mucosa, showing MHC I expression throughout most of the
thickness of the epithelium. (b) As (a) but at higher magnification, showing staining of MHC I on the cell surface. (c) Serial
section of papilloma 386 stained with mAb IL-A88, showing lack of reactivity. (d) Section of papilloma 1804 stained with
antiserum 274, showing E5 expression in the suprabasal, transit and lower spinous layers (boxed area 1) and in differentiated
keratinocytes (black arrow). Boxed area 2 shows transit and lower spinous layers without E5 expression. (e) Serial section of
papilloma 1804 stained with mAb IL-A88, showing MHC I expression in cells lacking E5 (boxed area 2) and lack of MHC I
expression in cells expressing E5 (boxed area 1). Magnification, x 10 (a, d and e) and x 20 (b and c).
antisera; only results that were obtained with antiserum 274
are shown. In agreement with previous results by us and
others (Burnett et al., 1992; Anderson et al., 1997), E5 was
detected exclusively in the cytoplasm of epidermal cells,
from the basal and parabasal layers to the spinous and
squamous layers (Figs la and b, and 2d). Expression was,
however, discontinuous, as reported previously (Anderson
et al., 1997); no papilloma was stained in all cell layers. To
verify the specificity of the immunostaining of E5, several
controls were carried out. There was no staining with pre-
immune serum (data not shown) or when only secondary
antibody was used (Fig. l c), and the E5 antiserum did not
react with normal mucosa (Fig. Id). Furthermore, when the
E5 antiserum was pre-absorbed with the antigen peptide by
using 3 ~g peptide (ml antiserum) -1, pre-absorption elimi-
nated reactivity, both in immunoprecipitation of in vitro-
translated E5 labelled with [S35]methionine (Fig. l e) and in
immunostaining experiments (Fig. If). E5 expression in the
differentiated layers of the papillomas was often accompanied
by expression of the proliferation antigen Ki67 (Fig. 3g),
detected by mAb MIB-I (Dako). Expression of Ki67 con-
firmed the transformed nature of these cells: in normal epi-
thelia, cells cease to proliferate once they leave the basal layer.
To analyse expression ofMHC I in papillomas, we incubated
sample sections with mAb IL-A88, which detects the heavy
chain of bovine MHC I (Toye et al., 1990). In normal
epithelium, there was strong staining of the capillaries and
stromal cells; the epithelium was stained throughout most of
its thickness (Fig. 2a) and staining on the surface of the cells
was particularly clear in cells of the basal and supra basal
layers (Fig. 2b). There was no staining without primary
antibody (data not shown). In sections of papillomas, MHC
I could be detected in stroma and capillaries (Fig. 3e) and on
the surface of some epithelial cells, as in normal tissue, but
not in cells expressing E5 (Figs 2d and e, and 3a and b),
independent of whether the cells were in the deeper layers
(Fig. 3a and b), the suprabasal, transit and lower spinous
layers (Fig. 2d and e, boxed area 1) or the more superficial
layers (Figs 2d and e, and 3d and e). These results suggested
that expression of E5 is incompatible with expression
ofMHC I.
The E7 proteins of HPV-I6 and -11 have been implicated,
respectively, in the downregulation of MHC I either
through inhibition of the transcriptional promoter of the
MHC I heavy chain (Georgopoulos et al., 2000) or indirectly
through inhibition of TAP, the transporter associated with
peptide (Vambutas et al., 2001). To ensure that the absence
of MHC I in bovine papillomas was due to E5 and not to E7,
we stained papilloma sections with rabbit antisera 11547 and
11823, which were raised against a fJ-galactosidase-E7
fusion protein (Anderson et al., 1997). Similar results were
obtained with both antisera; only results that were obtained
with antiserum 11547 are shown. E5 and E7 are co-expressed
in the same cells (Anderson et al., 1997) and, accordingly, in
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this study, cells that expressed either E5 or E7 alone were
seldom detected. Nevertheless, in cells that expressed E5 and
did not express E7, or expressed it at levels below detection,
there was little or no MHC I (Fig. 3a-c). Conversely, cells
that expressed E7, but not E5, still had detectable MHC I
(Fig. 3d-f and h-j). Thus, it appears that expression ofE7 is
not responsible for downregulation of MHC I.
Although the lack of MHC I in the uppermost layers of
the papillomas (Figs 2e and 3e) was consistent with the
differentiated state of the cells, its absence in the basal
(Fig. 3b) and the immediate suprabasal (transit and lower
spinous) (Fig. 2e, boxed area 1) layers could not be
attributed to cell differentiation, as MHC I was present in
these areas of normal mucosa (Fig. 2a). Furthermore, MHC
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Fig. 3. Expression of E5, E7, MHC I and Ki67 in BPV-4-induced papillomas. Representative papilloma sections stained with
anti-E5 antiserum 274 (1 : 2000; a, d and h), anti-bovine MHC I heavy chain mAb IL-A88 (1 : 200; b, e and i) anti-E7
antiserum 11547 (1 : 250; c, f and j) or with anti-Ki67 mAb MIB-1 (1 : 200; g). (a) Papilloma 1803, showing expression of E5
in the basal layers. (b) Serial section of papilloma 1803, showing lack of expression of MHC I in cells expressing E5. (c) Serial
section of papilloma 1803, showing lack of expression of E7 in the basal layers. (d) Papilloma 1810, showing E5 expression in
differentiated keratinocytes, but not in basal cells. (e) Serial section of papilloma 1810, showing expression of MHC I in basal
cells. (f) Serial section of papilloma 1810, showing expression of E7 in basal cells and co-expression with E5 in differentiated
keratinocytes. The boxed area in (d) and the corresponding areas in (e) and (f) are shown at higher magnification in (h-j),
respectively. (g) Serial section of papilloma 1810, showing expression of Ki67 in basal cells and in E5-expressing
differentiated keratinocytes. Magnification, x 40 (a-c, h-j); x 20 (d-g).
I was absent in similar areas of papillomas where £5 was not
expressed (Fig. 2d and e, boxed area 2).
We conclude that £5 inhibits the expression of MHC I in
BPV-induced papillomas, corroborating and validating our
observations on downregulation of MHC I by £5 in vitro.
HPV-16 and other high-risk HPV types induce cervical
intraepithelial neoplasia (CIN), the precursor lesion of
cervical cancer (zur Hausen, 2002). MHC I downregulation
has been observed in CIN, but £5 expression was not
investigated (Bontkes et al., 1998). Given that HPV-16 £5
down regulates MHC I (Ashrafi et al., 2004) and that HPV-
16 £5 can be found in CIN samples (Chang et al., 2001), it
can be speculated that £5 is also responsible for MHC I
downregulation in CIN.
It remains to be seen whether the £5-induced down-
regulation of MHC I leads to evasion of the host immune
response, thus allowing the virus to establish infection and
allowing the infection to persist.
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E5 Protein of Human Papillomavirus Type 16 Selectively Downregulates Surface HLA
Class I
G. "ossein Ashrafi, Mohammad R. Haghshenas, Barbara Marchetti, Philippa M. O'Brien and M. Saveria Campo"
Institute of Comparative Medicine, Department of Pathological Sciences. Glasgow University, Glasgow, Scotland, United Kingdom
Papillomaviruses have evolved mechanisms that result in escape
from host immune surveillance. The E5 protein is expressed early
in papillomavirus infection in the deep layers of the infected
epithelium. It is localized to the Golgi apparatus (GA) and endo-
plasmic reticulum. The E5 protein of bovine papillomavirus (BPV)
impairs the synthesis and stability of major histocompatibility
(MHC) class I complexes and prevents their transport to the cell
surface due to retention in the GA. Here we show that human
papillomavirus type 16 (HPV-16) E5 also causes the retention of
MHC (HLA) class I complexes in the GA and impedes their
transport to the cell surface, which is rescued by treatment with
interferon. Unlike BPV E5, HPV-16 E5 does not affect the synthe-
sis of HLA class I heavy chains or the expression of the transporter
associated with antigen processing TAP. These results show that
downregulation of surface MHC class I molecules is common to
both BPV and HPV E5 proteins. Moreover, we determined that
HPV-16 E5 downregulates surface expression of HLA-A and
HLA-B, which present viral peptides to MHC class I-restricted
cytotoxic T lymphocytes (CTLs), but not the natural killer (NK)
cell inhibitory ligands HLA-C and HLA-E. Selective downregula-
tion of cell surface HLA class I molecules may allow the virus to
establish infection by avoiding immune clearance of virus-infected
cells by both CTLs and NK cells.
Key words: human papillomaviruses; E5 oncoprotein; HLA class I;
HLA-NB; HLA-CIE
Papillomaviruses (PVs) are small DNA tumor viruses that infect
the epithelia of humans and animals. causing benign hyperprolif-
erative lesions. In most cases. PV infections are cleared after
several months following activation of the host immune system
against viral antigen. I However. occasionally the lesions do not
regress and can progress to cancer. Certain PVs are more com-
monly associated with malignancy. including the human PV
(HPV) types 16 and 18, high-risk viruses for the development of
cervical cancer in women.s and bovine PV (BPV) type 4. associ-
ated with carcinomas of the alimentary canal in cattle.' Persistent
viral infection is required for neoplastic progression and failure of
virus clearance is attributed to a poor immunologic response.
The PV genome encodes 3 transforming proteins. E5, E6 and
E7. E5 is a small hydrophobic protein ranging in size from 42
amino acid residues in BPV-4 to 83 amino acid residues in HPV-
16. E6 and E7 are the main transforming proteins of HPV.4.S E5 is
the major transforming protein of BPV and plays a lesser role in
transformation by HPV.6 While E6 and E7 are expressed through-
out the course of the disease and are necessary for the maintenance
of a transformed phenotype. E5 is expressed during the early
stages of infection and its expression is often. but not always.
extinguished as the lesion progresses toward malignancy.s These
characteristics point to a role of E5 in establishment of PV infec-
tion and the initiation of cell transformation.
The E5 protein is localized in the Golgi apparatus (GA). endo-
plasmic reticulum and occasionally the plasma membrane of the
host cell. Its localization in the endomembrane compart-
ments. where it interacts with the vacuolar ATPase 16k ductinl
subunit c,1-9 is deemed responsible for the lack of acidification of
the GA and endolysosomes and the consequent impaired functions
of these organelles.t'''!
We have shown that one of the outcomes of BPV E5 expression
in primary cells is the retention of major histocompatibility (MHC)
class I complexes in the GA and the inhibition of their transport to
the cell surface.12•I] Furthermore. BPV E5 inhibits both transcrip-
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tion of the MHC class I heavy chain gene and affects the stability
of the heavy chain protein.P In this study. we show that HPV -16
E5 also prevents the transport of MHC (HLA) class I complexes to
the cell surface due to retention in the GA. Moreover. we show that
HPV-16 E5 selectively downregulates HLA-A and HLA-B mole-
cules on the cell surface but does not affect the transport of HLA-C
and HLA-E. These studies identify a potential novel mechanism by
which PV-infected cells may avoid clearance by cytotoxic T
lymphocytes (CTLs) and natural killer (NK) cells. aiding in the
establishment and persistence of PV infection.
Material and methods
HPV-16 E5 expression constructs
The E5 ORF was cloned into 3 expression plasmids: pcDNA3
(Invitrogen. Glasgow. U.K.). under the transcriptional control of
the universal cytomegalovirus (CMV) immediate early promoter
(pc-16E5); pL2. under control of the Epstein-Barr virus (EBV)
ED-L2 promoter. active only in epithelial cells':' (pL2-16E5); and
the retrovirus expression plasmid pLZRSpBMLZ (Clontech, Palo
Alto. CA). Amphotropic retrovirus expressing HPV-16 E5 (RT-
16E5) was generated by transient transfection of the packaging cell
line Phoenix IS as previously described.P
Establishment of HPV E5-expressing cell lines
The immortalized human keratinocyte HaCaT cell line was
grown in Dulbecco's modified eagle medium (DMEM) without
CaCl2 (Invitrogen). supplemented with I mM sodium pyruvate,
2 mM glutamine and 10% fetal calf serum (FCS) at 37°C in 5%
CO2, Primary bovine PalF cells'? and NIH 3T3 cell lines were
grown in DMEM. 10% FCS at 37°C in 5% CO2,
HaCaT cells were stably transfected with 4 JLgof pcDNA. pL2.
pc-16E5. or pL2-16E5 per I X 106 cells using Lipofectamine Plus
(Invitrogen) according to the manufacturer's instructions. Follow-
ing transfection, the cells were selected in DMEM containing
500 u.g/rnl G4l8 (Invitrogen) for 21 days. After this time. G418-
resistant colonies were marked. individually picked and expanded
into clonal cell lines for analysis. The retrovirus RT-16E5. or its
empty counterpart (generated using wild-type pLZRSpBMLZ
plasmid). was used to infect primary PalF cells as described'? and
the cells were analyzed 2 days later.
NIH3T3 cells expressing HPV -6b E5 or HPV -16 E5 under the
control of the mouse moloney leukemia virus (MMLV) LTR in
pZip-neo were a kind gift from Dr. Show-Li Chen (National
Defense Medical Center. Taipei, Taiwan) and Professor Richard
Schlegel (Georgetown University. Washington. DC). respectively.
Quantitative RT-PCR
Total RNA was isolated from HaCaT cells using the RNcasy
Mini Kit (Qiagen, Crawley. U.K.). and residual DNA was removed
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by DNase I treatment (Invitrogen). Real-time RT-PCR for HPV -16
E5 and l3-actin mRNA was carried out using the Taqman EZ
RT-PCR kit (Applied Biosystems, Foster City, CA). Each reaction
was performed in triplicate using 100 ng of RNA. Oligonucleotide
primers, designed using Primer Express (v 1.7, Perkin-Elmer, Oak
Brook, IL), were as fullows: 16E5wt F 5'-TGACAAATCTTG-
ATACTGCATCCA-3'; 16E5wt R 5'-CTGCTGTTATCCACA-
ATAGTAATACCAATA-3'; and a FAMrrAMRA probe 5'-AAC-
ATTACTGGCGTGCTTTTTGCTTTGCT -3'. Primers and probe
sequences for l3-actin quantitation were purchased from Applied
Biosystems. PCR reactions were performed using an ABI Prism
7700 Sequencer. Standard curves were generated using ID-fold
serial dilutions of each template DNA, which were used to quan-
titate the relative levels of E5 and l3-actin mRNA. E5 mRNA
levels were normalized according to the l3-actin controls.
FACS analysis of MHC class I expression
HaCaT. PalF and NIH3T3 cells were grown in T175 ern" flasks
until subconfluent. After removal of the medium, the cells were
washed once with PBS. then detached from the flask with trypsin!
EDTA and pelleted at 200g for 5 min at room temperature (RT).
The cell pellet was resuspended in DMEM, 10% FCS. and incu-
bated for I hr at 37°C to allow surface antigens to be reexpressed.
The cells were then washed and resuspended in PBS/I % bovine
serum albumin (BSA; PBS-B) at a concentration of 107 cells/m!.
For the detection of surface MHC class Imolecules. 100 IJ.Iof cells
were aliquoted and incubated for 1 hr at 4°C with an equal volume
of monoclonal antibody (mAb) as follows: pan antihuman MHC
class I W6/32 (I:100; Serotec, Oxford. UK), antibovine MHC
class I IL-AI9 (1:1.000),16 antimouse H-2Ld CL9011-A (1:50;
Cedarlane Laboratories, Newcastle, UK). or anti-HLA-CIE DT9
(I :50; a kind gift from Dr. Veronique Braud, Centre National de la
Recherche Scientifique. Sophia Antipolis, France) for 30 min at
4°C. Following 3 washes in PBS-B, cells were incubated with
1:100 dilution of antimouse IgG-FITC (Sigma, SI. Louis. MO) fur
30 min at 4°C in the dark. The cells were then washed as above,
resuspended in 500 IJ.IPBS-B and analyzed by flow cytometry. If
the flow cytometry analysis was not performed immediately. the
cells were resuspended in 500 IJ.Iof 3% paraformaldehyde in PBS
and kept at 4°C. A mouse monoclonal antibody against HPV-16
E2 (TVG261; a kind gift of Dr. M. Hibma) was used as negative
control (I :50).
For the detection of intracellular MHC class I. the cells were
first permeabilized with 0.5% saponin in PBS-B for 30 min at RT.
Following a wash in PBS-B, the cells were then incubated with
primary antibody as described above. All samples were examined
in a Beckman Coulter EPICS Elite analyzer equipped with an ion
argon laser with 15 mV of excitation at 488 nm. Data were
analyzed using Expo 2 software.
Immunofluorescence detection of MHC class I and GA
In all experiments, HaCaT cells (I X 104) were aliquoted into
24-well plates containing coverslips and grown overnight. After
removal of the medium. cells were washed twice with PBS and
fixed in 1.85% formaldhehyde in PBS containing 2% sucrose for
10 min at RT. After fixatiun, cells were washed twice and incu-
bated in permeabilizing solution (0.5% NP-40. 10% sucrose in
PBS) for 10 min at RT and then washed as above.
For detection of MHC class I, the fixed and permeabilized cells
were incubated with I :50 dilution of W6/32 antibody for 1 hr at
RT. Following 2 further washes, the cells were incubated with
I :500 dilution of antimouse IgG-FITC (Sigma) for 1 hr at 4°C in
the dark. For visualization of the GA, the cells were incubated with
mAb 4A3 (1:200) recognizing golgin GMl30, an integral GA
protein.!" for 1 hr at RT. Following 2 washes as above, the cells
were incubated with 1:1,000 dilution of anti mouse IgG-TRITC
(Sigma) for 1 hr at 4°C in the dark.
To analyze the localization of MHC class I in E5-expressing
cells, control HaCaT cells (pcDNA and pL2) and E5-expressing
cells (pc-16E5 and pL2-16E5) were incubated with mAb 4A3,
washed as described above, then incubated with anti mouse IgG-
TRITC (l: 1,000) and FITC-conjugated W6/32 (I:10; Sigma).
In all cases, the cells were washed 3 times after incubation with
secondary antibody. and the coverslips were mounted onto slides
using Citifluor. Images were captured using a Leica TCS SP2 true
confocal scanner microscope (Leica Microsystems, Heidelberg,
Germany) and a wavelength of 488 nm (MHC class I) or 543 nm
(GA). The merge between the FITC and TRITC fluorescent signals
was achieved using the Leica TCS SP2 accompanying software.
Immunoblotting detection of MHC class I and TAP
HaCaT cells were removed from the flasks by trypsinization,
washed with PBS, then lysed by sonication in lysis buffer
(lOO mM Tris HCI, pH 7.5, 2% SOS, 20% glycerol) and insoluble
material was removed by centrifugation at 20,000g for 10 min at
4°C; 10 IJ.g of lysate were electrophoresed in 4-12% NuPAGE
gels (Invitrogen), and proteins were transferred to nitrocellulose
membrane using a semidry blotting apparatus at 20 V/I50 A for
1 hr. The membranes were blocked in 5% milk in Tris-buffered
saline (TBS) containing 0.05% Tween 20 (TBST) for 1 hr at RT.
For detection of MHC class I, the membranes were incubated
with the following mAb: HCIO, specific for HLA class I heavy
chain (I :50; a kind gift from Dr. Stephen Man, Cardiff University,
Cardiff, U.K.), MEM-E/02 specific for human HLA-E (1:50; Se-
rotec), or AB-I (1:20,000; Oncogene Research Products. Notting-
ham. UK) specific for actin. For detection of the transporter
associated with antigen processing TAP, the membranes were
incubated in 1:1.000 dilution of rabbit anti-TAP-I antibody
(Chemicon, Hampshire, UK). After repeated washing with TBST,
the membranes were incubated with either I :20,000 dilution of
antimouse Ig-HRP (Amcrsham Pharmacia Biotech, Bucks, UK)
for HCIO and MEM-E/02. 1:5,000 dilution of antimouse IgM-
HRP (Oncogene Calbiochcm-Novabiochern, Nottingham, UK) for
AB-I, or 1:5,000 dilution antirabbit IgG-HRP (Sigma) in 5%
milkrrBST for I hr at RT. The membranes were washed 3 times
with TBST and bound antibody was detected by enhanced che-
moluminescence (ECL; Arnersham Pharmacia Biotech).
Treatment of cells with interferon
One million parental HaCaT cells, control cells expressing
pcONA3 or pL2 and cells expressing HPV-I6 E5 were seeded in
TI75 cm2 tissue culture flasks. The following day, the medium
was replaced with fresh medium with or without 500 Ulml IFN-13
(Sigma). After 48 hr, the cells were harvested for detection of
MHC class Iby immunofluorescence or flow cytometry analysis as
described above.
Results
Detection of £5 expression in cell lines
As E5 is expressed at very low levels in cells and there are no
reliable antibodies against the protein, it is very difficult to detect
its expression by imrnunoblotting.!" Therefore, we confirmed in-
stead that the E5 ORF was being transcribed using quantitative
RT-PCR. Ten clones from each HaCaT cell transfection with
pcONA, pL2, pc-16E5, or pL2-l6E5 were picked and expanded
into cell lines for analysis. RNA was isolated and the relative level
of E5 mRNA expression was determined by comparison to l3-actin
mRNA. The results of 6 clones expressing HPV -16 E5 (3 as
pc-16E5 and 3 as pL2-16E5) are shown in Figure I.Although low
(4 orders of magnitude less than that of l3-actin). all of the cell lines
expressed E5 mRNA. The amount of E5 mRNA was comparable
among each cell line. ranging from approximately 0.01 to 0.02 pg
per 100 ng of RNA. The levels of E5 mRNA in HaCaT keratin-
ocytes are approximately lOO-fold lower than those in WI2 cells
(derived from cervical intraepithelial neoplasia), I" which express
E5 from the resident multicopy episomal HPV -16 genome (data
not shown). This observation therefore excludes the possibility that
any effect seen in HaCaT cells is due to E5 overexpression.
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FIGURE 1-Expression of E5 RNA in transfected cell lines. HaCaT
cells were transtected with pcDNA3 (pcDNA), pcDNA3 expressing
the HPY-16 E5 ORF (pc-16E5), pL2, or pL2 expressing the E5 ORF
(pL2-l6E5). Quantitative RT-PCR was used to determine the relative
amount of HPY-16 E5 and [3-actinmRNA in 3 of each cell line. The
results of 6 representative cell lines are shown. Relative RNA values
are expressed as the mean of 3 independent experiments :t standard
deviation.
Downregulation of surface HLA class / in cells expressing
HPVE5
Given that BPY E5 can inhibit transport of MHC class I mol-
ecules to the cell surface,12.13we investigated whether HPV-16 E5
could likewise downregulate surface HLA class I. Using FACS
analysis, we determined the levels of HLA class I in HaCaT cell
lines expressing HPV -I6 E5 under the control of the CMY pro-
moter (pc- 16E5) or expressing E5 under the control of the epithe-
lial-specific EBY promoter (pL2-l6E5). HaCaT cells harboring
empty plasmids expressed similar levels of HLA class I as parental
HaCaT cells, with approximately twice as much total (surface plus
intracellular) HLA class I than surface alone (Fig. 2a). In contrast,
all of the pc-16E5 and pL2-16E5 HaCaT cell lines analyzed had
reduced levels of surface HLA class I, approximately half that of
the control or parental cells, whereas the level of total HLA class
I remained constant (Fig. 2a). This effect was highly reproducible
and specific as no signal above background (secondary antibody
only) was detected when an anti-HPV-16 E2 antibody was used
(Fig. 2e). Furthermore, we showed a marked reduction of surface
MHC class I in NIH 3T3 mouse fibroblasts expressing HPY-6 E5
or HPY - I6 E5 under the MML Y LTR and in primary bovine PalF
cells acutely infected with recombinant retrovirus expressing
HPV-16 E5 (RV-16E5; Fig. 2b). These results show that down-
regulation of MHC class I is stimulated by E5 proteins encoded by
both BPY and HPY, including low- (HPY-6) and high-risk (HPY-
16) viruses. Moreover, stimulation of MHC class I downregulation
in primary cells (pal F) shows that this effect is not due to the
immortalized phenotype of the HaCaT keratinocytes.
HLA class / is retained in GA in E5-expressing epithelial cells
To ascertain the intracellular localization of HLA class I, E5-
expressing HaCaT cell lines, parental and control cell lines were
costained with the antibodies W6/32 (pan MHC class I) and 4A3
(antigolgin). In the control cells, HLA class I was expressed both
on the cell surface and in the GA (Fig. 3a). Identical staining
patterns were observed in parental HaCaT cells (data not shown).
In contrast, in HPV-16 E5-expressing cells, HLA class I was
detected almost exclusively in the GA (Fig. 3b). These results
show that HPV -16 E5 prevents the HLA class I complex from
reaching the cell surface and retains it in the GA.
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FIGURE 2 - HPV E5 downregulates surface HLA class I. (a)
Parental HaCaT cells (3 lines), cells harboring empty vectors
(pcDNA3, 3 lines; pL2, 4 lines) or expressing HPV-16 E5 (pc-
l6E5, 4 lines; pL2-16E5, 3 lines) were analyzed for expression of
total and surface HLA class I by FACS with mAb W6/32. The
average mean fluorescence for each expression vector was calcu-
lated from the flow cytometric analyses. A background of 0.4 (the
reading of cells stained with no primary antibody and only second-
ary antibody) was subtracted in all cases. Standard deviation (z ) is
shown. (b) FACS analysis of surface and total MHC class I in NIH
3T3 cells carrying empty vector (pZip), expressing HPY-6b E5
(pZ-6E5) or HPY-16 E5 (pZ-16E5), and in PalF cells carrying
empty retrovirus (empty RV) or expressing HPV-16 E5 (RV -16E5).
One cell line of each was analyzed. (c) FACS analysis with an
unrelated antibody (anti HPV -16 E2) showing no reaction above
background.
Expression of HLA class / heavy chain is not inhibited by
HPV-/6 £5
The results above suggested that, in contrast to BPV E5,
HPV -16 E5 did not have any effect on the overall levels of the
HLA class I heavy chain. To confirm this observation, we deter-
mined the relative levels of HLA class I in the control and
E5-expressing HaCaT cell lines using mAb HCIO, specific for the
human HLA class I heavy chain.>' Although the levels of HLA
class I heavy chain were slightly lower in the pL2 and pL2-l6E5
cell lines than in the pcDNA and pc-16E5 cell lines, there were no
significant differences between the cells expressing HPV -16 E5
and their respective control cells (Fig. 4), con tinning that HPV -16
E5 does not downregulate expression of the HLA class I heavy
chain.
E5 has no effect on TAP expression
Transport of class I complexes to the cell surface is prevented
if the transporter associated with antigen processing (TAP) is
malfunctioning.r! Therefore, it was important to establish
whether E5 was affecting HLA class I transport by inhibiting
TAP expression, as reported for HPV-I I E7.22 TAP-I protein
was investigated in control and E5-expressing HaCaT cell lines
by immunoblotting. There appeared to be a lower level of
TAP-l in the pL2 cells but there was no significant reduction of
TAP-I in cells expressing E5 (Fig. 4), indicating that down-
regulation of surface HLA class I is not due to an ability of E5
to downregulate TAP-I. An effect on the functionality of TAP
cannot be ruled out, however.
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FIGURE 3 - HLA class I is retained in the Golgi apparatus in HPV-16 E5-expressing cells. HaCaT cells carrying empty vectors or expressing
E5 (at least 3 lines of each) were stained with mAb W6/32 (antJ-HLA class I) and mAb 4A3 (antigolgin GM 130) and analyzed using confocal
microscopy. N, nucleus. Representative cells are shown. (a) Control HaCaT cells carrying either pcDNA or pL2 empty vector. (b) HeCaT cells
expressing HPV-16 E5 in either pcDNA (pc-16E5) or pL2 (pL2-16ES).
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FIGURE 4 - HPV- J 6 E5 does not inhibit expression of HLA heavy
chain (he) or TAP. Equal amounts (10 I1g) of protein lysates from one
line each of HaCaT cells carrying empty vectors (pcDNA, pL2) or
expressing HPV-16 E5 (pc-16ES, pL2-16E5) were analyzed by irn-
munoblotting with mAb HClO (anti-he), anti-TAP-l antiserum, or
mAb AB-l (antiactin).
Treatment of £5 cells with interferon rescues HLA class J traffic
to cell surface
Interferon-B (IFN-f3) increases transcription from the MHC
class I heavy chain gene promoters" leading to higher expression
of heavy chain. To determine if increased synthesis of heavy chain
led to an increase in transport of HLA class I complexes to the cell
surface, we treated HaCaT parental, control and E5-expressing
cells with IFN-f3 and analyzed HLA class I expression and local-
ization by FACS and immunofluorescence. Treatment with IFN-J3
increased the total amount of HLA class I approximately 2-fold in
all of the cell lines tested (Fig. Sa compared with Fig. 2a). More-
over, we found an approximately 2-fold increase in surface HLA
class I in the parental and control cells and an approximately 4-fold
increase in the E5-expressing cells (Fig. Sa compared with
Fig. 2a). This resulted in all of the cell lines, including those
expressing HPV-16 E5, as having similar levels of surface HLA
class L IFN-J3 treatment did not affect expression of E5 (data not
shown) and therefore the observed increase in HLA class I levels
cannot be attributed to changes in E5 expression. Unlike in BPV
E5-expressing cells.P IFN -13 treatment appeared to overcome the
block exerted by E5 on HLA class I transport. To confirm this
observation, HaCaT cells carrying empty vector or expressing
HPV-16 E5, untreated or treated with IFN, were incubated with
mAb W6/32 and analyzed for HLA class I localization. In the
untreated E5-expressing cells, HLA class I was mostly detected in
the GA as before (Fig. 5b). In contrast, HLA class I was detected
on the surface of E5-expressing cells treated with IFN. These
experiments show that HPV -16 ES-expressing cells are responsive
to IFN and that the E5-induced HLA class I transport inhibition is
reversible by IFN.
HLA-CI£ expression is not inhibited by HPV-J6 £5
While MHC class I molecules HLA-A and -8 are the main
presenters of antigenic peptides to CTLs, HLA-C and nonclassical
MHC molecules, such as HLA-E, inhibit NK cell-mediated lysis
by interacting with inhibitory NK receptors.24-26 To determine
whether HPV-16 E5 could selectively downregulate HLA class I
molecules, we determined the levels of HLA-C/E in parental,
control and E5-expressing HaCaT cell lines. Cells were stained
with mAb DT9 that recognizes both HLA-C and -E and were
analyzed by flow cytometry for surface and total HLA-C/E. Al-
though the shift in forward fluorescence was small (Fig. 6a and b),
in agreement with the observation that human fibroblasts have
little HLA-E,27 it was consistently higher than background (sec-
o~dary antibody only; Fig. 6b) and higher than the readings ob-
tamed With an unrelated antibody (Fig. 2c). Importantly, there
were no significant differences between the control and E5-ex-
pressing cells (Fig. 6a).
In addition, we determined the cellular localization of HLA-C/E
in the E5-expressing cells by immunofluorescence using mAb
DT9. There were no differences between the staining patterns of
H~A-C/E in the control cells and in the E5-expressing cells
(Fig.fie); therefore, we conclude that expression of ES does not
lead to any appreciable decrease in surface HLA-C/E, in agree-
ment with the FACS data.
Finally, we determined the levels of total HLA-E by immune-
blotting with mAb MEM-E/02, specific for HLA-E. Similarly, we
did not detect any significant differences between HLA-E levels in
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the control cells and the E5-expressing cells (Fig. 6d). The ease of
HLA-CIE detection by immunofluorescence and immunoblotting
compared with flow cytometry is likely attributable to the different
affinities of the 2 antibodies for HLA (mAb DT9 and MEM-E/02)
and to the greater sensitivity of mAb DT9 in immunofluorescence.
These results confirm that HPV-16 E5 downregulates the surface
expression of the classical HLA class I molecules HLA-A and -B,
but not HLA-C or -E. We are unable to discriminate between
HLA-C and HLA-E as mAb DT9 recognizes both molecules, and
mAb MEM-E/02, specific for HLA-E, does not function in flow
cytometry or immunofluorescence.
Discussion
Progression from acute HPV infection to malignancy requires
persistence of virus, which in tum appears to depend on several
FIGURE 5 - TFN treatment res-
cues transport of HLA class I to
the cell surface. (a) Parental Ha-
CaT cells (3 lines), cells carrying
empty vectors (pcDNA and pL2, 3
lines each), or cells expressing
HPV-16 E5 (pc-16E5, pL2-IE5, 3
lines each) were treated with
500 Vlml TFN-I}for 48 hr and an-
alyzed for expression of total and
surface HLA class I by FACS
analysis with mAb W6/32. The av-
erage mean fluorescence for each
expression vector was calculated
from the flow cytometric analyzes.
A background of 0.4 (the reading
of cells stained with no primary
antibody and only secondary anti-
body) was subtracted in all cases.
Standard deviation (±) is shown.
(b) Immunofluorescence detection
of HLA class I with MAb W6/32
in at least 3 cell lines carrying
empty vector (pcDNA) or express-
ing HPV-16 E5 (pc-16E5), un-
treated or treated with IFN-I} as in
(a). N, nucleus. Representative
lines are shown.
factors, including the genetic background of the host,28.29environ-
mental cofactors''? and the ability of the virus to avoid immune
clearance." The immune system plays a decisive role in determin-
ing the clinical outcome of HPV disease, as demonstrated by the
increased persistence and enhanced neoplastic progression of HPV
infections in hosts with cell-mediated immune deficiencies.v-P
However, even in immunocompetent individuals, HPVs persist for
a significant period of time before activation of the host immune
system. This lack of recognition suggests the host immune system
is unaware of, or disabled by, HPV infection. HPVs can subvert
the immune response indirectly via the nature of the virus life
cycle>' and by direct interference with the host antiviral immune
mechanisms, including the IFN response and MHC class I antigen
presentation to CTLsI.35
MHC class I (HLA class I in humans) plays a pivotal role in the
eradication of virally infected and transformed cells. The impor-
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FIGURE 6 - HPV-16 E5 does not downregulate HLA-CIE. (a) FACS analysis of surface and total HLA-CIE with mAb DT9 in parental HaCaT
cells (3 cell lines), cells carrying empty vectors (pcDNA and pL2, 3 lines for each vector) or expressing HPV-16 E5 (3 lines of pc-16E5 and
4 of pL2-l6E5). The average mean fluorescence for each expression vector was calculated from the flow cytometric analyses (example in b).
A background of 0.4 (the reading of cells stained with no primary antibody and only secondary antibody) was subtracted in all cases. Standard
deviation (:':) is shown. (b) Representative FACS profiles of pc-16E5 and pL2-16E5 cells (one line of each). Dotted line and open histogram:
forward fluorescence with secondary antibody only; solid histogram: forward fluorescence with primary and secondary antibody. (c) Immuno-
fluorescence detection of HLA-CIE with mAb DT9 in 2 lines each of cells carrying empty vector (pL2) or expressing HPV-16 E5 (pL2-16E5).
N, nucleus. (d) Detection of HLA-E heavy chain by immunoblotting. Protein Iysates from 3 lines each of parental HaCaT cells, cells carrying
empty vector (pcDNA3 or pL2) or expressing E5 (pc-16E5 or pL2-16E5) were analyzed by immunoblotting with mAb MEM-E/02 (anti-HLA-E)
or mAb AB-I (antiactin). Representative lines are shown.
tance of MHC class I in virus clearance is highlighted by the
acquisition of numerous mechanisms of interference with the
MHC class I pathway by many viruses.w Independently of the
molecular nature of these mechanisms, the outcome is failure of
the infected cells to present viral peptides to effector CTLs effec-
tively, resulting in avoidance of detection and destruction.
We have recently shown that both BPV-4 and BPV-l interfere
with the MHC class I pathway through the retention of MHC
class I complexes in the GA by the oncoprotein E5.,,12,13Here we
show that these properties are not a peculiarity of BPV E5 but are
shared by E5 proteins of mucosal HPV, including E5 encoded by
the low-risk HPV type 6, the etiologic agent of genital warts and
HPV-16, the papillomavirus most frequently associated with cer-
vical carcinoma. Since our initial observations were published, it
has also been reported that HPV2a E5 can inhibit HLA class I
transport to the cell surface."? Therefore, downregulation of sur-
face MHC class I appears to be a property of many, if not all,
papillomavirus E5 proteins.
We found that HPV-16 E5 promotes the retention of HLA
class I in the GA, a salient characteristic of cells expressing BPV-4
E5. It is established that E5 proteins bind 16k subunit c, a com-
ponent of the Vo sector of the H+ V-ATPase,7-9 and that a possible
outcome of this interaction is the inhibition of acidification of the
GA and endosomes.rv-' ' The retention of MHC class I in the GA
by BPV-4 E5 is due at least in part to the impeded acidification of
the organelle, as retention in the GA and downregulation of surface
MHC class I are also caused by monensin, an inhibitor of V-
ATPase and GA acidification.P The same mechanism may under-
pin the retention of HLA class I in the GA by HPV-16 E5.
However, given the selective downregulation of HLA types by
HPV-16 E5, the lack of GA acidification cannot be the whole
explanation and other mechanisms must come into play. These
points are currently under investigation,
Despite the similarities, there are also differences between the
extent to which BPV-4 E5 and HPV-16 E5 interfere with the MHC
class I pathway. BPV-4 E5 downregulates transcription of the
MHC class I heavy chain gene, promotes degradation of the
translated polypeptide and blocks the transport of the MHC class I
complex to the cell surface.12,13 In contrast, HPV-16 E5 does not
inhibit expression of the heavy chain, but reduces the transport of
HLA class I to the cell surface without completely abolishing it.
Furthermore, contrary to what we observed with BPV E5,13 inhi-
bition of HLA class I transport by HPV-16 E5 is reversible by IFN
treatment. The reason for this latter difference is not known but it
can be speculated that the increased production of HLA class I
heavy chain by IFN is sufficient to overcome the inhibitory effect
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mediated by the low levels of HPV-16 E5. In contrast. as BPV E5
also inhibits transcription and promotes degradation of the MHC
class I heavy chain.'? IFN treatment is insufficient to restore MHC
class I expression to normal levels. These data are also consistent
with our hypothesis that there is a correlation between protein
oncogenicity and immune evasion.P As discussed earlier. BPV E5
is a more effective transforming protein than HPV -16 E56 and
therefore would be predicted to have a greater effect on MHC
class I downregulation (and other immune evasion mechanisms)
than HPV-16 E5. In contrast. in oncogenic HPV infections. the 2
major transforming proteins E6 and E7 would complement the
inhibitory effect of the lesser transforming protein E5 on the MHC
class I pathway. HPV -16 E7 can repress the MHC class I heavy
chain gene promoter.?" thus likely replacing the inhibitory action
of BPV on the same promoter. and in addition can bind directly to
TAP. thus further contributing to the downregulation of HLA class
1.21 Furthermore. both HPV E6 and E7 can inhibit the type I IFN
pathway. thus preventing the IFN-mediated release of E5-induced
blockage in HLA class I trafficking.40-42
Although an efficient mechanism to avoid CTL-mediated im-
mune clearance. the total absence of surface MHC class I renders
cells more susceptible to NK cell attack. Human NK cells express
multiple receptors that interact with HLA class I molecules. in-
cluding killer cell immunoglobulin-like receptors (KIRs) that pre-
dominantly recognize classical HLA class I. including HLA-C.
and the C type lectin superfamily of receptors that specifically
interact with the nonclassical class I molecule HLA-E.24-26 Rec-
ognition of the class I molecules by their inhibitory receptors
inhibits NK-mediated cell lysis. which would occur in the absence
of HLA-CIE. Accordingly. certain viral proteins. including HIV
Nef and the US3IUL40 proteins of CMV. have evolved to down-
regulate selectively HLA-A and -B. the main presenters of pep-
tides to CTLs. but not HLA-C or _E.27.43.44and are therefore
capable of avoiding both CTL and NK cell killing.e" We show here
for the first time that papillomaviruses, in particular HPV-16. may
also employ a similar immune evasion strategy via expression of
E5. Our experiments show that neither synthesis nor transport to
the cell surface of HLA-CIE is affected by E5 expression. leading
to the conclusion that E5 selectively inhibits surface expression of
HLA-A and HLA-B. NK cells of patients with HPV-induced
anogenital lesions are incapable of specific killing HPV-16-in-
fected cells.46 although the mechanism by which this occurs is as
yet unknown. Moreover. concordant with loss of MHC class I
molecules that present viral peptides, there is a very low frequency
I. O'Brien PM. Campo MS. Evasion of host immunity directed by
papillomavirus-encodedproteins. Virus Res 2002;1-2: !O3-18.
2. zur Hausen H. Papillomaviruses and cancer: from basic studies to
clinical application. Nat Rev Cancer 2002;2:342-50.
3. Campo MS. Animal models of papillomavirus pathogenesis. Virus
Res 2002;89:249-61.
4. Mantovani F. Banks L. The human papillomavirus E6 protein and
its contribution to malignant progression. Oncogene 2001;
20:7874-87.
5. MungerK, Basile JR, Duensing S. Eichten A, Gonzalez SL, Grace M.
Zacny VL. Biological activities and molecular targets of the human
papillomavirus E7 oncoprotein. Oncogene 2001;20:7888-98.
6. Venuti A. Campo MS. The E5 protem of papillornaviruses. In: Me-
Cance DJ, ed. Progress in medical virology: papillomaviruses.
Elsevier. Amsterdam. The Netherlands. 2002. 141-62.
7. Goldstein DJ. Finbow ME, Andresson T, McLean p. Smith K,
Bubb V. Schlegel R. Bovine papillomavirus E5 oncoprotein binds
to the 16K component of vacuolar H(+)-ATPases. Nature 1991;
352:347-9.
8. Faccini AM, Cairney M, Ashraf GH. Finbow ME, Campo MS. Pitts
JD. The bovine papillomavirus type 4 E8 protein binds to ductin and
causes loss of gap junctional intercellular communication in primary
fibroblasts. J Virol 1996;70:9041-5.
9. Conrad M, Bubb VJ. Schlegel R. The human papillomavirus type
6 and 16 E5 proteins are membrane-associated proteins which
associate with the l6-kilodalton pore-forming protein. J Virol
1993;67:6170-8.
of HPV-specific HLA-A-restricted CTLs in patients infected with
HPV -16. an order of magnitude lower than those found in other
viral infections. including influenza A and EBV.47 It is not yet
known whether these observations are the consequence of E5
expression; however. experiments to establish the functional out-
come of ES expression on CTL and NK cell recognition of HPV-
transfected cells are in progress.
Regardless. our results support the hypothesis that E5 plays a
major role in immune evasion by HPV. To this end. it is interesting
to note that HPV -16 E5 has also been reported to inhibit both Fas
ligand- and tumor necrosis factor-related apoptosis-inducing li-
gand (TRAIL)-mediated apoptosis in HaCaT cells'S and. consis-
tent with its role in the alkalinization of endosomes, prevents the
endosomal breakdown of the invariant chain.?" a chaperone im-
portant in the maturation of HLA class Il, leading to inhibition of
expression of surface HLA class n.·9 Therefore. E5 can disrupt
several critical components of the cell-mediated immune response
to viruses. which may contribute to the establishment and persis-
tence of HPV infection.
It remains to be seen if E5 expression causes HLA class I
downregulation also in vivo. This appears to be the case in bovine
papillomas (data not shown). HLA class I downregulation has been
observed in CINSO and in cervical carcinomas." However. the
downregulation of HLA class I in cervical carcinomas. which often
do not express E5, is common to other cancer types and therefore
unlikely to be due to E5. No correlation was made between HLA
class I downregulation and E5 expression in ClN, and this point
warrants further investigation.
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Abstract
Bovine papillomaviruses (BPVs) are oncogenic viruses. In cattle, BPV-I/2 is associated with urinary bladder cancer and BPV-4 with upper
or tract cancer. BPV ES is a small hydrophobic protein localised in the endoplasmic reticulum (ER) and Golgi apparatus (GA). ES is the major
transforming protein of BPVs. capable of inducing cell transformation in cultured mouse fibroblasts and. in cooperation with E7, in primary
bovine cells. ES-induced cell transformation is accompanied by activation of several cellular protein kinases, including growth factor receptors,
and alkalinisation of endosomes and GA. We have reported that BPV ES causes swelling and fragmentation of the GA and extensive vacuolisation
of the cytoplasm. We now show that ES from both BPV-I and BPV-4 disturbs the actin cytoskeleton and focal adhesions in transformed bovine
cells, where these morphological and behavioural characteristics are accompanied by hyperphosphorylation of the cellular phosphotyrosine kinase
c-src. Both BPV-I and BPV-4 ES increase the motility of transformed mouse cells, but only BPV-I E5 causes transformed mouse cells to penetrate
a matrigel matrix. BPV-I transformed mouse cells, but not BPV-4 transformed mouse cells, have hyperhpsphorylated c-src.
© 2005 Elsevier B.V. All rights reserved.
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1. Introduction
Papillomaviruses (PYs) are oncogenic viruses, which induce
benign hyperproliferative lesions of the cutaneous and mucous
epithelia. PY infections are usually eradicated by a cell-mediated
immune response directed against viral antigens. Occasionally,
however, in a small but sizeable minority of cases the viral
lesions do not regress and progress to cancer. High risk human
papillomaviruses type 16 and 18 (HPY-16 and -18) are the main
causative factor in the development of cancer of the cervix uteri
(zur Hausen, 2002). Bovine papillomavirus type I and 2 (BPV-l,
BPV-2) and BPV-4 are, respectively, involved in carcinogene-
sis of the urinary bladder and of the alimentary tract in cattle
(Campo, 1997). BPV-l also induces penile papillomas that can
progress to cancer (Jarrett, 1985).
• Corresponding author. Tel.: +44 1413302876; fax: +44 141 3305602.
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The BPV-l genome encodes three transforming proteins, E5,
E6 and E7, whereas BPV-4 does not possess an E6 gene (Jackson
et al., 1991). For both viruses E5 plays a major role in cell
transformation (Pennie et al., 1993; Venuti and Campo, 2002).
ES is a small hydrophobic peptide of 44 amino acid residues
in BPY-l and 42 residues in BPV-4, localised in the endomem-
brane compartments of the endoplasmic reticulum (ER) and
Golgi apparatus (GA) of the host cell. In warts and papillomas
E5 is expressed in the cytoplasm of the basal and suprabasal
layers and of the spinous and squamous layers. Expression is,
however, discontinuous (Burnett et al., 1992; Anderson et al.,
1997; Araibi et al., 2004).
Despite its small size, BPV E5 has wide pleiotropic effects. It
induces growth in low serum and in suspension, prevents contact
inhibition, down-regulates gap junction communication (GJIC)
(for reviews, see DiMaio and Mattoon, 2001, and Venuti and
Campo, 2002, and references therein), induces swelling and
fragmentation of the GA and vacuolisation of the cytoplasm
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(Ashrafi et al., 2002) and inhibits the expression ofMHC class I
on the cell surface (Ashrafi et al., 2002; Marchetti et al., 2002).
BPV-I E5 interacts with, and activates, the PDGF receptor and
several other kinases, including c-src; both BPV-l and BPV-4
E5 bind 16k ductinlsubunit c, a component of the gap junction
and of the VO sector of the vacuolar H+-ATPase, and prevent
the acidification of the GA. Both the down-regulation of GJIC
and the alkalinisation of the endomembrane compartments are
ascribed to the interaction with 16k ductinlsubunit c and a mal-
function of the V-ATPase, but the latter is not always observed
(Venuti and Campo. 2002).
In addition to the previously described functions, here we
now show that BPV-l and BPV-4 E5 disturb the actin cytoskele-
ton and focal adhesions in transformed bovine cells, and
increase the motility of transformed mouse cells. However,
only BPV-I E5 confers invasiveness to transformed mouse
cells.
2. Materials and methods
2.1. PalF cell lines
PalF are parental primary bovine foetal palate cells, PaIF-
control cells are partially transformed by BPV-4 E7, HPV-16
E6 and activated ras; PaIF-IE5 and PaIF-4E5 express either
the E5 protein of BPV-I (IE5) or BPV-4 (4E5), respectively,
in addition to the other oncogenes. They have been described
before (Ashrafi et al., 2000; Ashrafi et al., 2002). Please note
that 4E5 was previously called 4E8. When the two BPV E5 pro-
teins present the same characteristics they will be referred to as
E5, otherwise their provenance will be specified.
2.2. NIH 3T3 lines
3T3-pZip cells are NIH 3T3 cells harbouring empty pZip-
neo plasmid vector. 3T3-1E5 and 3T3-4E5 cells are NIH 3T3
cells transformed by BPV-l E5 and BPV-4 ES, respectively, and
have been described before (Ashrafi et al., 2002; O'Brien and
Campo, 1998). All cell lines were grown in Dulbecco modified
Eagles medium (DMEM) (Life Technologies, UK), 10% fetal
calf serum (FCS) at 37 QCin S% C02.
2.3. Cytoimmunofluorescence
Cells were grown on glass coverslips (l04 cells/coverslip),
washed twice with PBS, fixed by 10-min incubation at room
temperature with 3% paraformaldehyde and washed three times
with PBS. They were permeabilised by 20-min incubation at
room temperature with O.S% Triton X-lOO (Sigma, UK) in
PBS-I % FCS and washed three times with PBS-l % FCS.
Cells were stained with FITC- or TRITC-phalloidin (Sigma)
to visualise actin fibres, or reacted with monoclonal anti-
body V9131 (11400; Sigma) or monoclonal antibody PXC-
10 (1/400; Sigma) to visualise vinculin or paxillin, respec-
tively, and FITC-conjugated anti-mouse secondary antibody
(11200; Sigma). After washes with 1% FCS in PBS, cover-
slips were mounted in AFl. Fluorescence was analysed using
a Leica DMLB microscope or a Leica TCS SP2 confocal
microscope.
2.4. Immunoblotting
Cells were removed from the flasks by trypsinization, washed
with PBS, and then lysed in lysis buffer (100 mM Tris-HC1,
pH 7.S, 2% SDS, 20% glycerol) containing protease inhibitors
(Roche Diagnostic Ltd.). Insoluble material was removed by
centrifugation at 20,000 x g. Ten micrograms of lysate were
electrophoresed in 4-12% NuPAGE gels (Invitrogen), and pro-
teins transferred to nitrocellulose membrane (Invitrogen) using
a semidry blotting apparatus at 20V/1S0A for I h. The mem-
branes were blocked for 1h in 5% milklTBSlTween 20 (0.05%)
at room temperature before a 2 h incubation with anti-actin
AB-I (1110,000; Merck Bioscience, UK), anti-vinculin V913I
(1/2000) and anti-paxillin PXC-IO (1/2000) antibodies (from
Sigma). An antibody to GAPDH (112000; Abeam Ltd, UK) was
used to control for the amount of protein. For detection of c-src
protein, membranes were probed with anti-total c-src poly clonal
antibody SC-I8 (1 :200; Santa Cruz Biotechnology Inc.), oranti-
phopshporylated (active) c-src polyclonal antibody c-src(p4l6)
(1:1000; kind gift of M. Frame). After repeated washing with
TBS/Tween 20 (0.05%) the membranes were incubated with
either anti-mouse (for actin, vinculin, paxillin and GAPDH) or
anti-rabbit (for c-src) Ig-HRP (1/2000; Amcrsharn Pharrnacia
Biotech, UK) in S% milkITBSlTween 20 (0.05%) for I h at
room temperature. The membranes were washed three times
with TBSlTween 20 (0.05%) and bound antibody was detected
by enhanced chemiluminescence staining (ECL) (Amersham
Pharmacia Biotech).
2.5. Motility assay
Cells were grown in DMEM, IO%FCS until confluent. A
scratch was made in the cell monolayer with a microlance 3
needle and the cell were photographed in a phase-contrast micro-
scope at 0, 2, 4, 6 and 8 h after scratching. The scratch width in
the cell monolayer at 0 time was arbitrarily assigned a value of
1 and the width of each scratch at various time points was mea-
sured and expressed as a fraction of 1.At least five measurements
per cell line were taken.
2.6. Invasion assays
The ability of cells to invade was measured indirectly by
anchorage independence assays and by matrigel invasion. The
former assays were carried out as described by Pennie et al.,
1993. Briefly, cells (lOs) were added to 15ml of 1% Metho-
eel in DMEM, 30% FCS, plated in duplicate in bacterial Petri
dishes and left at 37 cC for 12 days before being scored and pho-
tographed. At least three assays were performed for cell line.
Inverse invasion assays were carried out as previously
described (Hennigan et al., 1994) with exceptions that reduced
growth factor mat rigel (BD Biosciences) was used. Single cells
were seeded at 2 x 104 per Transwell and DMEM above the
matrigel contained 10% FCS. Cells were stained with calcein
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3.2. £5 disturbs focal adhesions in PalF cellsAM (Scott et al., 2004). Confocal microscopy and quantitation
was largely as previously described (Hennigan et al., 1994), with
exceptions that a positive pixel is defined as one with an inten-
sity value greater than operator-defined background and that
optical sections were scanned at 3 u.rn intervals. Only cells in
the 9 urn section or above were considered invasive for quan-
titation purposes. A compound image of these sections was
quantified (Hennigan et al., 1994) then normalised to the value
obtained from the corresponding 0 urn section as a "loading"
control. Overall results were determined from three separate
assays performed with duplicate samples in each, with the
exception of 3T3-4E5 cells, which were only included in two
assays. Up to 6 separate serial sections were quantified for each
sample.
3. Results
3.1. £5 disturbs and collapses the actin cytoskeleton in
PalF cells
PaIF-IE5 and PaIF-4E5 cells have a very disturbed morphol-
ogy: they are highly vacuolated and have a swollen, misshapen
and often fragmented GA (see Fig. 4 of Faccini et al., 1996,
Fig. I of Ashrafi et al., 2000 and Fig. I of Ashrafi et al., 2002).
To see if E5 expression affected other cell structures, we
stained the PalF cell lines for actin fibres with FITC- or TRITC-
phalloidin which stains the cytoskeleton. Analysis of the cells
revealed that cells expressing E5 had long pseudopods, lamel-
lipods and pronounced ruffles and a profoundly disturbed actin
cytoskeleton, with shortened actin fibres that did not appear to
reach the cell membrane (Fig. lA). The shortening of the actin
fibres was not observed in PalF cells expressing 4N 17S and
4E5T, non-transforming mutants of BPV-4 E5, whereas it was
present in cells expressing 4N 17A, a hyper-transforming mutant
of the protein (Fig. lA). These differences in cell morphology
were not due to differences in expression of the various E5 pro-
teins as both wild type E5 and its mutants were expressed at
comparable levels (O'Brien et al., 1999). This confirmed that the
abnormal morphology of the actin cytoskeleton in E5-expressing
cells was due to the transforming action ofE5. Furthermore, no
obvious abnormalities were observed in the parental non trans-
formed cells or in the transformed PalF-control cells (Fig. lA;
Table I).
Table I
Characteristics of bovine and murine cells expressing BPV E5
The fibres of the actin cytoskeleton connect with focal adhe-
sions (FA), structures that allow interaction between cells and
substrate (Geiger et al., 200 I). Vinculin and paxillin are both
component of FA (Geiger et al., 200 I). To determine whether
FA were also affected by E5, cells were stained with anti-
bodies against vinculin or paxillin. In the parental PalF and
PalF-control cells, vinculin was clearly located in FA at the
periphery of the cell (Fig. IB). In the PaIF-I E5 and PaIF-4E5
cells vinculin was detected in internal structures, while small
chain-like structures similar to focal complexes (Geiger et al.,
2001) were sometimes observed at the cell periphery (Fig. IB
and inset; Table I). Growing PaIF-E5 cells on fibronectin, which,
being a ligand for integrins, induces formation of FA, did not
lead to the appearance of FA on the cell surface (data not
shown). FA, therefore, appeared disturbed in PaIF-E5 cells.
When PalF eells were co-stained for actin and vinculin, vin-
culin was found at the end of the shortened actin fibres in E5
cells (Fig. IC), indicating that the interaction between vinculin
and actin fibres was maintained but not on the cell surface.
In PalF cells expressing non transforming mutants of BPV-
4 E5, the FA resembled those of parental and control cells,
whereas in PalF cells expressing the hyper-transforming mutant
they resembled those of PaIF-E5 cells (Fig. IC). Similar results
were obtained with paxillin, another component of FA (data not
shown).
3.3. £5 does not induce degradation of actin or FA
components
To see if the disruption of the actin fibres and the disassem-
bly of the FA were due to E5-induced degradation of actin,
vinculin or paxillin, as observed for the heavy chain of the
major histocompatibility complex (MHC) class I (Ashrafi et
al., 2002; Marchetti et al., 2002), cell Iysates from the PalF
cell lines were analysed for these proteins. No noticeable differ-
ences were seen between control cells and E5-expressing cells
(Fig. 2). Moreover, the pattern of actin fibres and of FA did
not change when E5-expressing cells were incubated with the
proteasome inhibitor MG-132 or the calpain inhibitors I and
II (calpain degrades FA proteins) (data not shown), confirming
that the observed interference with these structures is not due to
protein degradation.
PalF control ceJls PalF-IE5
Disturbed cytoskeleton
Mis-located vinculin/paxillin
Anchorage independence
Motility
Invasion
pY-c-src
No
No
No
Ndb
No"
No
Yes
Yes
Yes
nd"
nd"
Yes
PaIF-4E5 3T3 control cells 3T3·IES 3T3-4ES
Yes No Yes Yes
Yes No No No
Yes No Yes' Yes'
nd" No Yes Yes
nd" No Yes No
Yes No Yes No
• Data from O'Brien and Campo, 1998.
b Could not be determined because of monolayer lifting.
C Could not be determined because of cell death in matrigel.
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Fig. I. Morphological changes in cells expressing BPV-l or BPV-4 E5 proteins. (A) PaIF-E5 cells and PaIF-4E5NI7A cells have shortened actin fibres and large
lamellipodia protrusions. Parental PalF cells, control cells and cells expressing non-transforming mutants of BPV-4 E5 have a well organised cytoskeleton. 3T3-E5
cells have a collapsed actin cytoskeleton, while control 3T3Zip cells have a well organised cytoskeleton. Cells were stained with FITC-phalloidin (green) or TRITC-
phalloidin (red) and analysed using a Leica DMLB microscope. TRITe-phalloidin was used to permit double fluorescence analysis (see panel C). The white line
in the 4E5NI7A panel delineate the outer margin of the cell. The large size of the PaIF-IE5, PaIF-4E5 and PaIF-4E5NI7A cells precludes the imaging ora larger
field without loss of resolution, but all PalF E5 cells present a morphology similar to the one shown here for single cells. Magnification 400x. (B) PalF-E5 and
PalF -4E5N 17A cells do not have focal adhesions on their surface. Cells were stained with mAb V9131 (11400) to visualise vinculin, and FITC-conjugated anti-mouse
secondary antibody (1/200). Cells were analysed using a Leica DMLB microscope. The boxed areas in the IE5 and 4E5 panels are enlarged in the panels below to
show the absence of focal adhesions on the cell surface and the presence of focal complex-like structures. An equivalent area is enlarged for PaIF-4E5N 17A cells.
Magnification 400 x . (C) PaIF-E5 cells have vinculin at the tip of the short actin fibres. Cells were stained for vinculin as in (B), and with TRlTC-phalloidin to
visualise actin fibres as in (A). Cells were analysed in a Leica TCS SP2 confocal microscope and images merged using the accompanying software. Magnification
400 x . The images of IE5 and 4E5 cells are at higher magnification (800 x) to show the interaction between vincul in and actin at the tip of the shortened actin fibres.
Likewise, the images of 4E5N 17S and 4E5T are at higher magnification (800x) to show the presence of vinculin at the cell periphery. The white lines in the IE5
and 4E5 panels delineate the outer margin of the cells. For cell nomenclature, see Section 2.
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Fig. I. (Continued).
3.4. £S enables PalF cells to grow independently of
substrate
Adhesion to substrate is controlled by FA and disruption of
FA promotes cell growth independent of substrate (Carragher
and Frame, 2004). We have already reported that both PalF and
NIH 3T3 cells expressing BPV E5 are capable of anchorage-
independent growth (O'Brien et al., 1999; O'Brien and Campo,
1998). We confirm that this is indeed the case: PaIF-l E5, PaIF-
4E5 and PaIF-4N 17A cells grew in methocel, whereas neither
'" '"'"-l IJJg ":tu, t.i.. t.i..-a c ~ -a~ 0u ~
vinculin 97kD
paxillin 64kD
46kDactin
Fig. 2. Actin and focal adhesion components in PaIF-E5 cells. E5 does not
induce the degradation of actin, vinculin or paxillin. Membranes with proteins
from PalF cells were probed with anti-actin mAb AB-I (1/20,000), anti-vinculin
mAb V9131 (1/2000) and anti-paxillin mAb PXC-IO (1/2000) and then anti-
mouse 19-HRP (1/2000). Bound antibody was detected by enhanced chemilu-
minescence staining.
parental PaIF, control or PaIF-4E5T cells were capable of doing
so (Fig. 3; Table 1). The disruption of FA brought about by E5
is likely to contribute to the ability of the cells to grow in an
anchorage independent fashion.
3.S. NIH 3T3 cells expressing BPV £5 are more motile
The cytoskeleton and the FA regulate cell shape and cell
motility (Geiger et al., 2001). Given the profusion of pseu-
dopods, lamellipods and membrane ruffies and the absence of
FA in PaIF-IE5 and PaIF-4E5 cells, we sought to analyse their
motility in the scratch wound assay. However, the assay could not
be performed with the PalF cell lines because the cell monolay-
ers would lift and float instead of scratching (Table I). Therefore,
we decided to analyse NIH 3T3 cells transformed by BPV E5
(O'Brien and Campo, 1998; O'Brien et al., 2001). Firstwe anal-
ysed the status of the actin cytoskeleton of these cells, as we did
for the PalF cell lines. Following staining with FITC-phalloidin,
the actin cytoskeleton was normally organised in 3T3-pZip cells,
but was collapsed in the 3T3-E5 cells, with actin located corti-
cally and long pseudopodes (Fig. 1A; Table 1). The morphology
of the 3T3-E5 cells was however less disturbed that that ofPalF-
E5 cells. Despite the collapse of the actin cytoskeleton, as in
the PalF cells, there were no differences in the levels of actin
between control and E5 cells (data not shown), and no disrup-
tion of FA was observed in the 3T3-E5 cells with either the
paxillin or the vinculin antibody (data not shown; Table 1). In
the scratch assay, the 3T3-E5 cells repopulated and closed the
wound faster than control cells (Fig. 4A and B; Table 1), indi-
cating that BPV E5 can increase cell motility, at least in NIH
3T3 cells. Increase motility however appears to be independent
of the status of FA in NIH 3T3 cells.
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Fig. 3. PalF-E5 ceJls and PalF-4ESNI7A cells, but not PalF-4EST or control ceJls, grow in Methocel. CeJls were grown in 1% Methocel in DMEM, 30% FCS and
photographed after 12 days of growth (x40). At least three assays were performed for ceJlline. Numbers in the panels indicate the average % (±S.D.) of total cell
seeded into each plate on day 0 (105).
3.6. NIH 3T3-1 E5 cells are more invasive
Next we wished to analyse whether, in addition to increased
motility, E5 transformed cells would also be more invasive. To
this end we employed the three-dimensional matrigel invasion
assay (Hennigan et al., 1994, Scott et al., 2004). Both control and
PaIF-E5 cells died in the matrigel and, therefore, their invasion
ability could not be assessed (Table 1). Thus, as for the motility
assay, we performed the test on the NIH 3T3 cells. Parental3T3-
pZip cells did not invade the matrigel, whereas 3T3-l E5 cells
were capable of invasion and were detected at least 9 urn from
the filter (Fig. 5). Surprisingly, however, 3T3-4E5 cells were
not capable of invading and were not detected beyond the upper
surface of the filter (Fig. 5; Table I). The inability of3T3-4E5
cells to invade the matrigel was not due to poor E5 expression,
as E5 was expressed at detectable levels (O'Brien et al., 2001),
or to death as the cells were detected on the filter (Fig. 5).
3.7. c-src is hyperphosphorylated in E5-expressing cells
The cellular protein c-src is a tyrosine kinase that modu-
lates the actin cytoskeleton and cell adhesions (Frame et al.,
2002). Activation of the catalytic activity of c-src through phos-
phorylation initiates a signal transduction cascade that induces
adhesion turnover, actin re-modelling, cell migration and inva-
sion (Frame, 2002, 2004; Frame and Brunton, 2002). Given
the ability of PalF E5 cells to grow in suspension and the
disrupted state of their cytoskeleton and FA, and the greater
motility of 3T3-1 E5 and 3T3-4E5 cells and invasion prop-
erties of the 3T3-IE5 cells, we examined the phosphoryla-
tion status of c-src in these cells. We found that c-src was
more highly phosphorylated in transformed PalF-l E5 and PaIF-
4E5 cells and in 3T3-IE5 cells than in the parental or con-
trol cells (Fig. 6A and B; Table I). On the contrary, c-src
was hypophosphorylated in 3T3-4E5 cells which were inca-
pable of invasion. Thus, a precise correlation between c-src
activation and cell morphology and behaviour could not be
established.
Cytoskeletal rearrangements and cell motility can be con-
trolled by the small GTPase family members (Nobes and Hall,
1999). We analysed levels of RhoA, Rae and Cdc42 in both
PalF and 3T3 E5-expressing cells but did not find any difference
with control cells (data not shown). We were unable to detect
activated Rho GTPases in our cellular samples by using spe-
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Fig.4. 3T3·E5 cells are more motile. (A) Cell mono layers were scratched (wounded) and the scratch width at 0 time was arbitrarily assigned a value of I and the
width of each scratch at various time points was measured and expressed as a fraction of 1 At least five measurements per cell line were taken. (B) examples of
wound healing of3T3·pZip, 3T3·1 E5 and 3T3-4E5 cells. The black vertical lines indicate the maximum width of the wound. Images were taken at 0 and 6 h.
cific pull-down assays, and therefore, the activation status of the
small GTPases remains to be elucidated.
Table 1 shows a summary of the characteristics of PalF and
3T3 cells.
4. Discussion
We describe here further characteristics of morphological cell
transformation brought about by the E5 oncoproteins from one
cutaneous (BPY-I) and one mucosal BPY (BPY-4) in two dif-
ferent cell systems, primary bovine PalF cells (the natural host
of BPY) and established murine NIH 3T3 cells. While PalF
cells need several viral (E5, E6 and E7) and cellular (activated
ras) oncoproteins to achieve transformation (Pennie et ai., 1993;
O'Brien et ai., 1999), mouse NIH 3T3 cells can be easily trans-
formed by a variety of agents, including BPY E5 (Schiller et ai.,
1986; O'Brien and Campo, 1998). Despite these differences, the
use of the two different cell systems has provided information
that could not be obtained in one system alone.
4.1. £5 and PalF cell morphology
Expression of either BPY-4 or BPY-l E5 brings about pro-
found modifications in the actin cytoskeleton, with "shortened"
actin fibres, without any noticeable reduction in the overall
amount of actin. These cytoskeletal rearrangements are accom-
panied by increased formation of lamellipodia, membrane ruf-
fles and filopodia.
Both E5 proteins induce also the relocation, but not degra-
dation, of vinculin and paxillin (both components of FA) at the
end of the shortened actin fibres. This destabilisation of FA, in
addition to E5-induced up-regulation of cyclin A (O'Brien et ai.,
1999), is likely to underlie the ability of E5-transformcd cells
to grow independently of anchorage to the substrate (O'Brien et
ai., 1999; Ashrafi et al., 2000).
The cytoskeleton and FA are not the only cell structures
affected by E5 in PalF cells. The Golgi apparatus (GA) is
enlarged and often fragmented, and the cytoplasm is highly vac-
uolated (Faccini et al., 1996; Ashrafi et al., 2000 2002). We
have attributed these modifications of the endomembrane com-
partments to their alkalinisation brought about by a malfunction
of the H+ Y-ATPase due to the interaction between ES and 16k
subunit c, as similar changes in the GA and cytoplasm are caused
in control cells by the ionophore monensin, which inhibits the
proton pump (Marchetti et ai., 2002). However, treatment of
PalF control cells with monensin did not cause changes in FA,
and the changes in actin fibres were dissimilar to those observed
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Fig. 5. 3T3-1 E5 cells are invasive. (A) Confocal microscope images of calcein-stained cells in the invasion assay. The upper row shows cells on the underside of the
filter and the lower row shows the corresponding compound images of transverse sections (Section 4 and above), showing cells that have invaded greater than 9 urn
into the matrigel. (B) Quantitation of invading cells. The units for the y-axis are percent positive pixels after normalization for loading (see Section 2 for details).
in E5 cells (data not shown). We, therefore, conclude that the
rearrangement of the actin cytoskeleton and the destabilisation
of the FA are caused by E5 through a different pathway(s) than
the targeting of the proton pump.
PalF cells transformed by the complete BPV-4 genome and
activated ras also have a distorted shape with enlarged cytoplasm
and vacuoles (Jaggar et al., 1990). Although not experimentally
proven, it is reasonable to assume that these changes are due, at
least in part, to the E5 protein.
4.2. £5, cell motility and invasiveness in NIH 3T3 cells
BPV E5 induces anchorage independence in PalF cells as
described earlier (Pennie et al., 1993; O'Brien et al., 1999) and
confirmed here. Despite their ability to grow when deprived of
substrate, the PalF -E5 cells were not capable of surviving in the
matrigel and thus their invasion ability could not be assessed.
The reason for the failure of the PalF E5 cells to survive in the
matrigel may reside in their inability to stay alive in the absence
of contact with surrounding cells. Likewise, we could not estab-
lish the effects of E5 on motility in PalF cells because of the
lifting of the monolayer when scratched. Given the impossibility
to assess the motility and invasiveness ofPalF cells, we decided
to investigate these properties in NIH 3T3 cell tran formed by
either BPV-l or BPV-4 E5 (O'Brien and Campo, 1998; 0'Brien
et al., 200 1). The analysis of these transformed cells proved fruit-
ful and in addition revealed differences between BPV-! E5 and
BPV-4 E5. While both 3T3-! E5 cells and 3T3-4E5 cells had a
disturbed actin cytoskeleton and showed enhanced motility, only
3T3-1E5 cells proved invasive, suggesting a greater transforma-
tion potential ofBPV-! E5 than BPV-4 E5 in NIH 3T3 cells.
4.3. Activation of c-src
The cellular tyrosine kinase c-src modulates the actin
cytoskeleton and cell adhesions (Frame, 2002). Pho phoryla-
tion of c-src activates a signal transduction cascade that induces
adhesion turnover, actin re-modelling, cell migration and inva-
sion (Frame, 2002, Frame and Brunton, 2002). BPV-! E5 acti-
vates c-src in NIH 3T3 cells (Suprynowicz et al., 2002) and, in
agreement with these observations, we found that c-src i hyper-
phosphorylated (activated) in PalF-IE5 and PaIF-4E5 cells and
in 3T3-1 E5 cells. The activation of c-src may be due to the
ES-induced alkalinisation of the GA (Schapiro et al., 2000), as
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Fig.6. C-src is hyperphosphorylated in E5-expressing cells. CA)PalF cells. Top panel, membranes with cell proteins were probed with anti-ph phorylated (active)
c-src polyclonal antibody c-src(p416) (I: 1000) or anti-total c-src polyclonal antibody SC-lS Cl:200), and then anti-rabbit Ig-HRP (112000). Bound antibody was
detected by enhanced chemiluminescence staining. Bottom panel, the western blots were scanned in a MagicScan and quantified using the Image Quant 5.3 oftware
(Molecular Dynamics). The ratio of phosphorylated c-src over total c-src is shown. The experiment was repeated two times with essentially identical re ult . (B)
NIH 3T3 cells. Top panel, membranes with cell proteins were probed as in (A) top panel, and the western blots were scanned and quanttfied a in (A) bottom panel.
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speculated by Suprynowicz et al. (2002) and may contribute to
the transformed status of the cells observed here. However, c-
src is not hyperphosphorylated in 3T3-4E5 cells, highlighting
another difference between SPV-l E5 and SPV-4 E5. As there
is not a clear-cut correlation between c-src activation and cell
morphology and behaviour, the precise consequence of c-src
activation cannot be unequivocally established. The reason why
SPV-4 E5 induces phosphorylation of c-src in PalF cells but
not in NIH 3T3 cells is not known. It is to be noted however
that SPV-4 E5 is not alone in exhibiting cell-specific effects: the
oncoprotein v-fos easily transforms rodent fibroblasts but not
human cells, although it makes the latter invasive (Scott et al.,
2004, and references therein).
4.4. Cell morphology and viral proteins
It is interesting that the Nef protein of HIV, with which E5
shares the ability to bind components of the H+ V-ATPase and
to down-regulate surface MHC class I (Kasper and Collins,
2003; Lu et al., 1998), also induces rearrangements of the actin
cytoskeleton and the formation of lamellipodia and filopodia
(Fackler et al., 1999). Expression of SV40 small t in epithe-
lial cells brings about similar morphological and structural
changes (Nunbhakdi-Craig et al., 2003), including the forma-
tion of numerous giant cells, as in our PalF system (Ashrafi
et al., 2000; Faccini et al., 1996). The changes in cell shape
and cytoskeleton observed in these three different viral pro-
tein systems resemble those associated with activation of small
GTPases, particularly Rae (Nobes and Hall, 1999). Indeed this
is the case for Nef(Fackleret al., 1999), and both Rae and Cdc42
are over-expressed in small t-expressing cells (Nunbhakdi-Craig
et al., 2003). Like Nunbhakdi-Craig et al. (2003), we could not
detect activation of the small GTPases, but, unlike those authors,
did not find any change in their level of expression (data not
shown) and are, therefore, unable to conclude that E5 activates
them.
4.5. Conclusions
As shown here and as reported before, SPV E5 has a global
effect on the morphology and behaviour of PalF cells: cells are
vacuolated with a distended and fractured Golgi apparatus, have
a rearranged actin cytoskeleton and disassembled focal adhe-
sions, grow in low serum and independently of substrate, and
protein traffic to the cell periphery is disturbed. Furthermore E5
affects several signal transduction pathways and cell cycle reg-
ulators. The small size ofE5 suggests that these multiple effects
are due to a critical interaction(s) between E5 and a crucial cel-
lular partner(s).
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ORIGINAL ARTICLE
The E5 protein of BPV-4 interacts with the heavy chain of MHC class I
and irreversibly retains the MHC complex in the Golgi apparatus
B Marchetti', GH Ashrafi', ES Dornan', EH Araibi', SA Ellis
2 and MS Campo'
IDivision of Pathulugical Sciences, Institute of Comparative Medicine, University of Glasgow, Glasqow, UK and 'Tmmunoloqy (/111/
Pathology Division, Institute for Animal Health, Compton, Berks, UK
BPV -4 E5 inhibits transcription of the bovine MHe class
I heavy chain (HC) gene, increases degradation of He
and downregulates surface expression of MHC class I by
retaining the complex in the Golgi apparatus (GA). Here
we report that transcription inhibition can be alleviated by
interferon treatment and the degradation of HC can be
reversed by treatment with inhibitors of proteasomes and
Iysosomes. However, the inhibition of transport of MHe
class I to the cell surface is irreversible. We show that E5
is capable of physically interacting with HC. Together
with the inhibition of the vacuolar ATPase (due to the
interaction between E5 and 16k subunit c), the interaction
between E5 and HC is likely to be responsible for
retention of MIIC class I in the GA. C-terminus deletion
mutants of E5 are incapable of either downregulating
surface MHC class I or interacting with HC, establishing
that the C-terminus domain of E5 is important in the
inhibition of MHC class I.
Oncogene (2006) 25,2254-2263. doi: 1O.1038/sj.onc.1209245;
published online 14 November 2005
Keywords: BPV-4; E5; MHC class I; heavy chain;
interaction; immunoevasion
Introduction
MHC class I presents antigenic peptides, including viral
pep tides, to cytotoxic T lymphocytes (CTL), effector
cells capable of recognizing and destroying transformed
or infected cells. M HC class I is therefore a central
player of the adaptive immune response. Numerous
viruses have developed the ability of downregulating
MHC class I (Piguet, 2005) either through direct
interaction between viral proteins and MHC class I, as
in the case of HIV and HCMV (Chevalier et al., 2002;
Furman et al., 2002; Tirabassi and Ploegh, 2002;
Williams et al., 2002; Kasper and Collins, 2003), or
indirectly, as in the case of Adenovirus (Ad) 12 (Piguet,
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2005). Similarly, the E5 oncoprotein of both BPV-l and
BPV-4 inhibits the transport of MHC class I to the cell
surface and retains the complex in the Golgi apparatus
(GA) (Ashrafi et al., 2002; Marchetti et al., 2(02). BPV-4
E5-induced downregulation of MHC class I takes place
not only in cultured cells but crucially also in naturally
occurring papillomas (Araibi et al., 2004). We have
argued that the downregulation of MHC class I is an
important step in the establishment and persistence of
papilloma virus infections and neoplastic progression of
premalignant lesions to squamous carcinoma (Ashrafi
et al., 2005). While both BPV and HPV E5 proteins
retain MHC class I in the GA, only BPV E5 induces a
general downregulation of MIIC' class I expression
(Ashrafi et al., 2002; Marchetti et al., 2002). Here we
show that BPV-4 E5-induced transcriptional inhibition
of the MHC class I heavy chain (HC) gene and
degradation of the HC peptide can be alleviated by
treatment with interferon (IFN) or proteasomc and
lysosome inhibitors respectively, but that MHC cl"1SSI
transport to the cell surface is irreversibly compromised,
probably due to a physical interaction between E5
and HC.
Results
The downregulation of MHe class I by BPV E5 takes
place at several levels: transcription of the IIC.
degradation of the HC and transport of the MHC
complex to the cell surface (Ashraf et al., ~002;
Marchetti et al., 2002).
Transcription of the HC of the AI IIC class I complex ill
Ei-expressing cells increases with IFN treatment
In PaIF-4E5 cells, including cells expressing N 17A. a
hypertransforming mutant of BPV-4 E5 (4E5), the levels
of the HC RNA are drastically reduced compared to
control cells (Figure l a, white bars). To investigate
whether the reduction in HC RNA was due to
transcriptional repression or to increased degradation
of the RNA, pBoLa-Luc, containing the reporter gene
for luciferase under the transcriptional control of the
promoter/enhancer of a bovine M HC class I He gene.
was transiently introduced into PalF cells along with
pZip-4E5, a plasmid expressing BPV-4 E5. Expression
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Figure 1 BPV·4 £5 inhibits transcription from the BoLa
promoter. Quantitative RT-peR for MHe class I He RNA was
performed on RNA from PalF control cells and PalF·4ES cells (a),
before (white bars) or after treatment with 500UJml PIFN (grey
bars) or 250U/mll'IFN (black bars). The extent of amplification
was normalized to that of the actin RNA and is plotted as arbitrary
units. The panel shows the averages with standard deviations of at
least three experiments. Both PIFN and l'IFN increased transcrip-
tion of He RNA in control and E5 cells. (b) BoLa promoter
transcriptional activity in PalF parental cells transiently cotrans-
fected with pBoLa·Luc and pZipneo empty vector, or with pBol.a-
Luc and pZip-4E5, either without (white bars) or with 250U/ml
l'IFN treatment (grey bars). Luciferase activity is plotted as
arbitrary transcription units, with the activity of pBoLa in PalF
parental cells taken as 1. The values are the average of three almost
identical measurements. l'IFN increases the transcriptional activity
of pBoLa also in the presence of ES.
of luciferase was less than half the level than when
pBoLa-Luc was cotransfected with an empty pZip
vector (Figure 1b, white bars). This result indicates that
the reduction in HC RNA in PaIF-4ES cells is due to the
ES-induced inhibition of the transcriptional promoter of
the HC gene, similar to the repression of class I
transcription by Adl2 EIA (Piguet, 200S).
The transcription of genes encoding MHC HCs is
stimulated by both class 1 and class 2 IFNs (Agrawal
and Kishore, 2000). The bovine HC promoter used in
these experiments contains responsive elements for both
PIFN and yIFN (data not shown). Treatment of the
PalF control and PalF-4ES cell lines with either PIFN or
yIFN lead to a noticeable increase of HC RNA: between
BPV·4 E5 and MHC class 1
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2- and 3-fold in control cells, and between Sand 10 fold
in the PaIF-4ES cells (Figure la, grey and black bars).
Similar increases in transcription of the HC gene upon
IFN treatment were observed in parental PalF cells
(data not shown). However, despite the IFN-induced
increase in HC gene transcription, the levels of HC
RNA in the PaIF-4ES cells were 2- to 3-fold lower than
in the control cells. Additionally, yIFN-treatment
stimulated the expression of luciferase from pBoLa-
Luc by approximately 2-fold both in the presence or
absence of 4ES (Figure 1b, grey bars). Even with yIFN·
treatment, in cells expressing 4ES luciferase expression
did not achieve the levels observed in cells that did not
express ES (Figure Ib). Treatment with IFN did not
increase transcription of the 4ES gene (data not shown).
We conclude from these results that 4ES inhibits
transcription of cattle class I HC genes, and that IFN
treatment rescues transcription, but without completely
overcoming 4ES-induced repression.
Lysosome and proteasome inhibitors increase the stability
of the HC in Ei-expressing cells
MHC class I stability is regulated by proteasomes and
lysosomes, which degrade mis-located or mis-folded
MHC class I molecules (Hughes et al., 1997; Hewitt
et al., 2002; Bartee et ai., 2004). The levels ofHC protein
are extremely low in PaIF-4ES cells, but increase when
transcription of the HC gene is stimulated by IFN
treatment, without however reaching the levels of HC in
IFN-treated control cells (Figure 2). To investigate
further the cause of this reduction in HC protein, the
control and 4ES cell lines were treated with inhibitors of
lysosomes (bafilomycin or ammonium chloride) or of
proteasomes (MG132 or ALLN). Levels ofMHC class I
were assessed by immunoblotting. Treatment increased
the amounts of HC in control PalF cells but only
marginally in PaIF-4ES cells (Figure 2, lanes with no
IFN), probably because of the preceding block of HC
gene transcription. Given that the transcriptional block
could be relieved by IFN, we treated cells with both IFN
and inhibitors. After the combined treatment, the level
of HC protein in PaIF-4ES cells was comparable with
that of control PalF cells (Figure 2). We conclude
therefore that in 4ES cells, as in control cells, the
degradation of the HC protein via the lysosomes and
proteasomes can be abrogated by treatment with
inhibitors.
Transport of MHC class I complex to the cell surface is
irreversibly inhibited by £5
To see whether the increase in MHC class I HC induced
by treatment with IFN and lysosome or proteasome
inhibitors resulted in increased levels of MHC class I
complex on the cell surface, we performed flow
cytometry analyses on the treated cells. Treatment with
IFN + bafilomycin or IFN +MG 132 increased the
amount of surface MHC class I in control cells by
S- to 6-fold, but not in PaIF-4ES cells, where the increase
was so negligible that the shift in forward fluorescence
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Figure 2 Protcasome and lysosome inhibitors prevent degradation
of MHC class! HC in PalF control and PaIF-4E5 cells. Cells were
left untreated or treated with either 250 U/ml y!FN for 48 h, the
lysosome inhibitors Bafilomycin Al (111M) or H4Ci (40mM) for
24h, or the proteosome inhibitors MG-132 (SliM) or ALLN
(IOOIlM) for 8 h. For combined treatment with y!FN and
inhibitors, lyso orne inhibitors were added for thc last 24 h of
ylFN treatment, and proteosome inhibitors for the last 8 h. Protein
lysates were probed with mAb IL-A88 against HC, or with mAb
AB-l against actin. Combined yIF and inhibitors treatment
increases levels of MHC class I HC in both control and E5 cells.
The experiment shown is representative of at least three experi-
ments giving essentially the same results.
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Figure 3 MHC class I transport to the cell surface is irreversibly
inhibited by BPV-4 E5. Celis were treated with ylFN + MG-132 or
yIF + Bafilomycin A I, as in Figure 2, and expression of surface
MHC class] was analysed by flov cytornetry with mAb lL-AI9.
(a) FACS profiles of control and 4£5 cells with no treatment
(white), ylF +MG-132 (dark grey) and yIFN +Bafilomycin Al
(light grey). (b) The extent of surface MHC class I expression is
plotted as mean forward fluorescence. In control cells, combined
y[FN and inhibitors treatment increases surface MHC class l,
whereas in E5 celis, surface MHC clas I does not increase. The
experiment shown is repre entative of three experiments giving
essentially identical result.
could not even be detected (Figure 3). We conclude that
the 4E5 protein prevents the traffic of MHC class I
complex to the cell surface in an irreversible manner.
Oncogene
E5 and He protein interact physically
We have shown that the retention of MHC class I in the
GA is due at least in part to the alkalinization of
the organelle (Marchetti et al., 2002), attributed to
the binding of E5 to the 16k subunit c of the vacuolar
H+ ATPase (Goldstein et al., 1991). However, the
almost complete colocalization of 4E5 and the residual
MHC class I in the GA (Marchetti et al., 2002) would
suggest an interaction between 4E5 and the complex. To
investigate if any such interaction exists, we performed
coimmunoprecipitation experiments both in vitro and in
vivo. 4E5 and the bovine HD6 HC (Ellis et al., 1996;
Gaddum et al., 1996) were separately transcribed/
translated in vitro in the presence of 35S-labelled
methionine (Faccini et al., 1996) and then kept
separately or mixed together. The proteins were
precipitated either with Ab 274 against the C-terminus
of BPV-4 E5 (Anderson et al., 1997; Araibi et al., 2004)
or mAb IL-A88 against bovine HC. There was no
precipitate in the absence of antibody (Figure 4c,
lanes 3, 5, 7); the anti-ES antibody precipitated E5
but not HD6 HC (Figure 4a, lanes I, 5), and the mAb
IL-A88 precipitated HC but not E5 (Figure 4c lanes 4,
6). However, when the two proteins were mixed
together, they coprecipitated with either antibody
(Figure 4a, lane 2 and 4e, lane 3), indicating that E5
and HC interact.
To see whether the interaction between E5 and HC
was specific for a particular MHC haplotype, we
repeated the experiment with a different HC, JSP.1
(Pichowski et al., 1996). Also in this case, E5 and JSP.I,
HC coprecipitated when incubated with mAb rL-A88
(Figure 4c, lane 8), showing that interaction is not
restricted to certain MHC alleles.
To confirm that E5 and HC interact also in cells,
coimmunoprecipitation experiments were performed in
PalF control cells and in PaIF-4E5 cells. Both cell lines
were treated with IFN and MG132 as described above
to bring the amount of HC in PaIF-4E5 cells to
detectable levels. Protein Iysates from both cell lines
were incubated with Ab 274 and the immunoprecipitates
were run on gel and immunoblotted with mAb lL-A88.
A band of the appropriate MW for He (approximately
45 kDa) was visible in a Comassie blue stained gel in the
immunoprecipitate from PaIF-4E5 cells, which was not
visible in the immunoprecipitated from control cells
(Figure 4d). This band reacted with mAb IL-A88 and
corresponded to bona fide HC detected by direct
immunoblotting of protein Iysates (Figure 4d). Despite
the combined IFN + bafilomycin treatment, the HC
band coprecipitated with E5 is faint because the
treatment does not increase expression of E5 (data not
shown) and E5 is expressed at almost undetectable levels
(O'Brien et al., 1999,2001); therefore, the amount of E5
is limiting for the amount of bound HC. However, the
reactivity with mAB IL-A88 specific for bovine HC only
in E5-expressing cells, the correspondence of the band
with bona fide HC and the results obtained in vitro,
establish the identity of this band as MHC class r HC
and confirm that the interaction between E5 and HC
takes place also in cells.
£5 inhibits MHe class I transport and binds to MHe He
via its Caerminus
In a study of the cell transforming properties of BPY-4
E5 (O'Brien et al., 1999), we established that mutation
of the asparagine residue 17 to tyrosine (N 17Y) lead
to loss of cell transformation and so did deletion of the
C-terminus (E5T) of the protein. On the contrary,
mutation of NI7 of BPY-4 E5 to alanine (NI7A)
resulted in a hyper-transforming mutant. The ability to
downregulate MHC class I expression cosegregated with
the ability to transform cells (Ashrafi et al., 2002;
O'Brien and Campo, 2003). BPY E5 mutants that did
not transform did not downregulated MHC class I as
assessed by flow cytometry (Figure 5a) and by immuno-
fluorescence (Figure Sb), and both the total and cell
surface levels of MHC class I were similar to those of
control cells. In contrast, the hyper-transforming
mutant of BPY-4 E5 downregulated surface MHC class
I to the same extent as wild-type E5 (Figure 5a). To
investigate whether the BPY-4 E5 mutant~ were capabl.e
of interacting with HC we performed coimmunopreci-
pitation experiments in vitro as above. Both NI7Y and
NI7A were coprecipitated with HC by Ab 274
(Figure 4a, lanes 6, 8) and mAb I~-~88 (Fi~ure 4e,
lanes 5, 7), while E5T was not coprecipitated with HD6
HC by mAb IL-A88 (Figure 4e, lane 9). E5T lacks the
C-terminal domain and therefore could not be pre-
cipitated by Ab 274. As E5 is tagged a~ its N-termi~H~s
with the HA epitope, we performed connmunoprecipi-
tation experiments with mAb HA.II raised against the
HA epitope. mAb HA.II coprecipitate~ E5 and HC,
although not as effectively as Ab 274, (Figure 4b, lanes
1,2) but did not coprecipitate HC with E5T ~Figure ~b,
lanes 3, 4). These data indicate that the mteracuon
between E5 and HC takes place via the C-terminus of
E5. To confirm this, we performed competition experi-
ments with a well-characterized peptide corresponding
to the C-terminus of E5, the ability of which to compete
with E5 had been validated in immunocyto- and
immunohisto-staining experiment (Pennie et al., 1993;
Anderson et al., 1997; Araibi et al., 2004). The peptide
did successfully compete with E5 in coimmunoprccipita-
tion experiments (Figure 4e, lane II); its addition to the
reaction prevented the interaction be~ween E5 a~d HD6,
proving conclusively that the C-termmus of E5 mteracts
with MHC class I He.
Three conclusions can be reached from these experi-
ments: one, binding of E5 to HC is necessary for
downregulation of MHC class I as shown by E5T, but
not sufficient as shown by NI7Y;. two, t~e n~ture of
residue 17 is not important for the mteraction with HC;
and three, the C-terminus of E5 is responsible for the
interaction between E5 and HC.
Discussion
The E5 oncoprotein of BPY-4 has a profound effect on
MHC class I expression and transport. E5 disruption of
the normal metabolism of MHC class I takes place at
BPV·4 E5 and MHC class I
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several levels: transcription, protein degradation and
complex transport.
Inhibition of transcription of the MHe class I He gene by
BPV-4 £5 can he alleviated by IFN treatment
In PalF-4E5 cells, the levels of HC RNA are barely
detectable (Ashrafi et al., 2002), and by quantitative
RT-PCR we estimate that the amount of HC RNA in
these cells is between 10- and 30-fold less than in control
cells (Figure la, white bars). The reduction ofHC RNA
is due to a transcriptional inhibition of the HC gene.
This conclusion is supported by two observations:
E5 downregulates a BoLa HC gene promoter/enhancer
(Figure Ib, white bars) and treatment with eithe~ fl. or
I'IFN, both of which increase HC gene transcr.lptlOn
(Agrawal and Kishore, 2000), leads to accum~latlOn of
HC RNA also in PaIF-4E5 cells, and to mcreased
activity of the BoLa HC promoter/enhancer (Figure I,
grey and black bars). However, even in the presence ?f
IFN, the levels of HC RNA in PaIF-4E5 cells are stlll
approximately 2- to 3-fold lower than in control. c~lls.
This suggests that E5 expression causes a transcnption
inhibitor to bind to the BoLa promoter/enhancer, and
that this putative inhibitor exerts its action even when
IFN-induced transcription activators promote tran-
scription. This hypothesis however requires confirma-
tion and other explanations are possible. BPY E5 is not
present in the nucleus (Burkhardt et al., 1989; Pennie
et al., 1993; Zago et al., 2004) and its effect on
transcription is therefore not direct. Rather, BPY E5
interferes with several signal transduction pathways
(DiMaio and Mattoon, 2001; O'Brien et al., 2001; Zago
et al., 2004; Grindlay et al., 2005), and it is therefore
likely that inhibition of the BoLa promoter/enhancer is
achieved by interference with one or more of these
pathways. We have already shown that BPY-4 E5
affects the expression of cyclin A by acting indirectly on
the transcriptional promoter of the cyclin A gene
(O'Brien et al., 1999; Grindlay et al., 2005) and BPY -.4
E5 inhibition of the BoLa promoter/enhancer IS
another example of E5 interference with transcription
regulation.
Degradation ofM lie class I lie can be inhibited in PalF
cells
MHC class I half-life is regulated by degradation in the
proteasomes and lysosomes (Bartee et al., 200~) and
several viral proteins contribute to the destruction of
MHC class I by favouring HC ubiquitination, or by
inducing peptide mis-folding or complex mis-location
(Hughes et al., 1997; Hewitt et al., 2002; Bartee et al.,
2004). In PalF-4E5 cells, treatment with either protea-
some or lysosome inhibitors rescues HC to levels
comparable to those of control cells (~igure 2}. In
4E5-expressing cells the half-life of HC IS drastically
reduced (data not shown) and the virtual absence of HC
in PalF-4E5 cells is in agreement with the retention of
MHC class I in the GA by E5 and with the degradation
of mis-folded, mis-located or improperly processed
MHC class I by both proteasomes and lysosomes.
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BPV E5 interacts with 16k subunit c of the VO sector
of the V-ATPase (Goldstein et al., 1991; Faccini et al.,
1996) and this interaction results in alkalization of the
GA (Schapiro et al., 2000), which in turn we have
argued is in part responsible for retention of MHe class
I in the GA (Marchetti et al., 2002). The V-ATPase
pump is ubiquitous in the en do membrane compart-
ments, including the lysosomes, so it would have been
a
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(Ashby et al., 2001), and third, E5 interference with the
pump is not complete and stronger inhibition is needed
for blocking protein degradation in the Iysosomes.
BPV-4 £5 irreversibly blocks transport of MHC class I to
the cell surface
The arguments discussed above point to the fact that
both ES-induced transcriptional inhibition of the He
a
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0
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Figure 5 C-terminus deletion mutants of BPY ES do not
downregulate surface MHC class l. (a) The expression of MHC
class I in control cells, and in cells expressing wild type or mutant
ES was assessed by flow cytometry analysis with mAb IL-AI9. The
extent of MHC class I expression is plotted as mean forward
fluorescence. (b) Surface localization of MHC class I in parental
PalF cells and in cells expressing BPY-4 EST. MHC class I was
detected with mAb IL-A88 and FITC-conjugated secondary
antibody (green) and the Golgi apparatus with BODIPY-TR-
ceramide (red) in a Leica TCS SP2 confocal scanner microscope.
The merge between the FITC and Texas Red fluorescent signals
was achieved using the Leica TCS SP2 accompanying software.
The nontransforming ES mutants Nl7Y and EST fail to down-
regulate surface MHC class l.
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gene and degradation of He peptide can be overcome.
However, the transport of MHe clas T from . the
endomembranes to the cell surface is irrevers! bly
compromised by ES. Although after treatment ""ith
IFN and proteasomejlysosome inhibitors, the amOt.lllt
of He in PaIF-4ES cells is similar to that of control cell ,
the increase in surface MHe class I i negligible
(Figure 3). The alkalinization of the GA by ES is III
part responsible for the intracellular retention of JI,.1lie
class I, as it is also observed in cells treated with the
ionophore monensin, which di perse the proton gra-
dient of the GA (Marchetti et al., 2002). However. we
found it surprising that treatment with ly 0 orne
inhibitors resulted in a large increase in surface rv{J-Ie
class I in control cells but not in PalF-4ES cell
(Figure 3), and hypothesized that an additiOnal
reason(s) would be responsible for the inhibition of
MHe class I traffic in PaIF-4ES cell .
BPV-4 £5 interacts physically witli HC
BPY -1 ES interacts physically with the receptor for
PDGF (Petti and DiMaio, 1994) and both BPY -1 and
BPV-4 ES interact with 16k subunit c (Gold tein et al.,
1991; Faccini et al., 1996). Given the established
interaction between ES and membrane proteins, we
hypothesized that BPV-4 ES interacts al 0 with JVlH
class I He. Indeed, this is the case and the two protei~
coprecipitate in vitro and in vivo (Figure 4). --rhl
interaction is not an artefact, as ES is precipitated by
an antibody against He even when He i not labelled
(not shown), and EST, a C-terminal truncated version of
ES, does not interact with He (Figure 4). ES and H
interact also in PaIF-4ES cells as shown by the
coimmunopreeipitation of He with an antibody again t
ES only in PaIF-4ES cells and not in control cells- The
reason for the low levels of the He coprecipitated with
4ES resides in the fact that, although the level of He
can be boosted many folds by the combined treatment
of IFN and proteasomejlysosome inhibitor, e pre-
sion of E5 is not affected; ES is pre ent at barely
detectable levels (O'Brien et al., 1999) and is therefore
rate-limiting for complex formation with HC. The
interaction between E5 and He reflect a genuine
relationship between the two proteins a there is
agreement between interaction in vivo and in vitro and
a good correlation between interaction in vitro and
downregulation of MHe class I in vivo. Furthermore,
Figure 4 BPV-4 E5 and MHC class I HC interact via the C-terminus domain of Es. (a) "S-Iabelled ill vilro transcribed/translated E5,
Nl7Yor 17A, and HD6 HC were immunoprecipitated with Ab 274, against the C-terminus of ES; the precipitate was run in a
NuPAGE gel and the dried gel exposed on a screen on a Storm 840 apparatus. Note that lane 1-3 and lanes 4-9 were run in separate
gels and aligned together for ease of comparison. (b) "S-labelled ill vitro transcribed/translated E5 or EST and HC were
immunoprecipitated with mAb HA.ll against the HA epitope tag of £S and EST and processed as in (a). E5T does not interact with
HD6 HC. (c) "S-Iabelled in vitro transcribed/translated E5 and JSP.l HC were immunoprecipitated with mAb fL- 88 again t bovine
MHC class I HC and processed as in (a). ES and JSP.l HC interact physically. (d) Coimmunoprecipitation of E5 and HC in PalF-4E5
cells. Left panel: Comassie blue stained gel of protein immunoprecipitates with Ab 274 from PaIF-4ES and PalF control cells. Right
panel: immunoblot with mAb IL-A88 of Ab 274-immunoprecipitates from PaIF-4ES and control cells. A band corresponding to I-I
and reacting with IL-A88 is visible only in the immunoprecipitated from PaIF-4E5 cells. (c) "S-Iabelled ill vitro transcribcd/translat d
E5, N17Y, Nl7A or EST and HD6 HC were immunoprecipitated with mAb lL-A88 against bovine MHC class 1 HC and proces ed as
in (a). £5, Nl7Y and Nl7A interact with HC, whereas EST, deleted in the C-terminus domain, does not. The C-terminus peptide
prevents ES binding to HD6 HC. Note that lanes 5-10 were run in a separate gel and aligned with the other lanes for ease of
comparison.
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HLA-A in human keratinocytes (Ashrafi et al., in
preparation), suggesting that the physical relation-
ship between E5 proteins and HCs is a common
mechanism to downregulate surface MHCjHLA
class I. We do not know the MHC class I phenotype
of the PalF cells but, as the in vitro coprecipitation
experiments have been done with two different class I
alleles, encoded at different loci, and E5 downregu-
lates MHC class I in papillomas from calves of
different breeds (Araibi et al., 2004), it is reasonable to
conclude that BPV -4 E5 can interact with and down-
regulate most, if not all classical class I HCs, This is
indeed the case for HPV·16 E5 (Ashrafi et al., in
preparation).
The interaction between BPV·4 E5 and He is
mediated by the Cvterminus domain of E5. The
conclusion is based on the three observations that E5T
does not inhibit the expression of MHe class I or its
transport to the cell surface (Ashrafi et al., 2002), that
E5T does not interact with He and that the interaction
between E5 and He is prevented by a peptide
corresponding to the Csterminus of E5 (Figure 4). The
Csterminus tail of E5 is clearly critical to the function of
the protein: E5T is not transforming (O'Brien et al.,
1999), does not induce the typical morphological
changes brought about by E5, and does not distort the
GA (Ashrafi et al., 2000). The ability to bind MHC class
I HC has to be added to the functions of E5 Cvterminus.
However, the physical interaction between 4E5 and He
appears to be necessary but not sufficient for down-
regulation of MHC class I as the E5 mutant N17Y binds
He but does not inhibit MHe class I expression
(Figures 4 and 5). This situation is reminiscent of the
fact that interaction between E5 and 16k subunit c is not
sufficient for cell transformation (Ashrafi et al., 2000;
Ashby et al., 2001) and points to a complex interaction
of E5 with cellular mechanisms/pathways. Nevertheless,
we confirm here our previous observation that only
transformation-competent E5 proteins are capable of
inhibition of MHC class I.
It is interesting that BPV E5 can potentially interact
with more than one membrane protein simultaneously.
E5 interacts with 16k subunit c through the transmem-
brane residue 17 (glutamine in BPV -I E5, asparagine in
BPV-4) (Goldstein et al., 1992b), and could therefore
interact with He through its Cvterminus at the same
time. BPV·1 E5 interacts with the PDGF receptor
through glutamine 17 and the juxtamembrane aspartate
33 (Petti et al., 1997; Klein et al., 1998, 1999) in a
multiprotein complex that can include 16k ductin
(Goldstein et al., 1992a; Lai et al., 2000). Residue 33 is
not present in either I·E5T or 4·E5T (O'Brien et al.,
1999), and we cannot rule out that it plays a role in the
interaction with He. However, although we have not
investigated any interaction between BPV-4 E5 and
PDGF receptor, cell transformation by BPV-4 E5 does
not appear to depend on signalling from growth factor
receptors (Zago et al., 2004; Grindlay et al., 2005), and it
is therefore unlikely that receptor binding would
compete with HC binding.
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Other viral proteins, such as IIIV Nef (Williams et al.•
2002) and HeMV US2 and US8 (Chevalier et (1/., 2002;
Tirabassi and Ploegh, 2002), to name but a few, bind
He and downregulate surface MHC class I, and E5 now
joins this large number. It is interesting to point out the
parallels between E5 and Ncr. Nef binds both Vma 13, a
component of the VI sector of the vacuolar ATPase,
facilitating the internalization of surface receptors
(including MHe class I), and MHe class I He,
disrupting MHC class I traffic (Lu et a/., 1998; Williams
et a/., 2002). Furthermore, as for E5. the same domain
of Nef necessary for disruption of MHe class I traffic,
mediates the binding to the He (Williams et al .• 2005).
Thus, although papillomavirus and IIIV are very
different viruses, each encodes a protein with similar
functions.
Conclusions
We have demonstrated that BPV-4 E5-induced retention
of MHe class I in the GA is linked to cell transforrna-
tion (Ashrafi et a/., 2002; O'Brien and Campo. 2003) and
is due to the alkalinization of the GA (Marchetti et (1/.,
2002). Here we suggest that direct binding between E5
and He contributes to (but is not sufficient for) the
inhibition of MHC class I transport to the cell surface.
The expression of E5 is much lower than that of 1IC, but
this stoichiometric imbalance is offset by E5-induced
transcriptional inhibition of the He gene and degrada-
tion of the HC peptide. However, E5 prevents traffic of
the MHe class I complex even when the amount of He
is greatly increased by drug treatment, therefore. for E5
to exert any effect on HC. the binding must be dynamic.
We propose the following hypothesis. consistent with
our results: E5 retains newly assembled MHC class I
complex in the GA by preventing GA acidification and
by physically interacting with He; the mis-located
complex is shunted to Iysosomes for degradation, and
E5 is free to interact with new MHC class I and re-start
the process. While aspects of this hypothesis need
confirming, the absence of MHC class I in the
E5-expressing cells of naturally occurring BPV-4 in-
duced papillomas supports our suggestion that E5 plays
an important role in the establishment and persistence of
viral infection by allowing the infect cells to escape host
immunosurveillance (Araibi et al., 2004).
Materials and methods
Cells
The bovine foetal PalF cells and their transformed derivatives
have been described before (Pennie et al., }993). Briet1y,they
are as follows: 'parental' PalF cells are normal foetal primary
cells; 'control' cells are cells transformed by BPY·4 E7, HPY·
16 E6 and activated ras; PaIF·lE5 or Pall:-4E5 are 'control'
cells additionally expressing either BPY·l E5 or BPY·4 E5,
respectively. The latter cells are referred to as PalF E5 cells
when a particular description applies to both PalF·l E5 and
PaIF-4E5. PaIF·NI7Y and -NI7A express a nontransforming
and a hypertransforming mutant of BPY·4 E5, respectively
(O'Brien et al .• 1999). All the clones analysed within each type:
exhibit the same characteristics (Pennie et al., 1993; O·Brien
et al., 1999; Ashrafi et al., 2002; Marchetti et al., 2002). Cells
were grown in DMEM, 10% foetal calf serum (FCS) at 3TC
in 5% CO2 as previously described (Ashrafi et al., 2002).
Plasm ids
pcDNA3.l(-)/HA4E5 contains the BPV-4 E5 ORF (nt 332-
460) tagged at the 5'end with the sequence for the HA epitope
inserted into the Bam HI/ HindIII sites of pcDNA3.1 (-)
(Invitrogen, UK). pcDNA 3.1(- )/4E5T contains the HA-
tagged BPV-4 E5 ORF in which a premature stop codon has
been introduced to terminate the protein at residue 32 (O'Brien
et al., 1999). pcDNA3-HD6 and pcDNA-1SP.I contain cDNA
for 2 Bos taurus MHC class I HC alleles, HD6 and lSP.1
(GenBank Accession Numbers X80934 and X92870, respec-
tively) (Ellis et al., 1996; Pichowski et al., 1996) inserted in the
HindIII/EcoRI sites of pcDNA3 (Invitrogen, UK). Both
pcDNA 3.1(-) and pcDNA3 contain the cloned gene of
interest under the control of the T7 promoter for in vitro
transcription/translation experiments (see below).
pBoLa-Luc was derived from pBoLa-19, a plasmid contain-
ing the promoter/enhancer, exon I and the 3'UTR of another
cattle MHC class I allele (Sawhney et al., 1995, 1996). The
promoter sequences were amplified by PCR using the forward
primer 5'GTTGAAGGCTCTCGAGGGCATCGGTCGAC3'
and the reverse primer 5'TGCAAAGCTTCCTCTGGGT
CTGGGAAGAAGC3'. The resulting amplicon of 1100 base
pairs was digested with XhoI and HindIII and inserted between
the XhoI and HindIII sites of pGL3 ahead of the luciferase
gene sequences. pBoLa-19 was a kind gift from Dr G Russell.
Treatment of cells with IFN
106 parental, control and PalF-4E5 were seeded in tissue
culture flasks. The following day, the medium was replaced
with fresh medium with or without 500 Ujrnl PIFN (Sigma,
UK) or 250 Ujrnl recombinant ovine ylFN (Graham et al.,
1995) for 48h. Ovine recombinant ylFN was a kind gift of
Dr G Entrican (Moredun Research Institute, Penicuik, UK).
Treatment of cells with lysosome and proteosome inhibitors
Cells were treated either with the lysosome inhibitors
Bafilomycin Al (111M) (Calbiochem, UK) or NH4CI (40mM)
(Calbiochern, UK) for 24 h, or with the proteosome inhibitors
MG-132 (5IlM) (Calbiochem, UK) or ALLN (IOOIlM)
(Merck Biosciences, UK) for 8 h. For combined yIFN and
inhibitors treatment, lysosome inhibitors were added for the
last 24 h of yIFN treatment, and proteosome inhibitors for the
last 8 h of ylFN treatment. The cells were then harvested for
detection of MHC class I by immunoblotting or flow
cytometry analysis.
Transient transfection and luciferase transcription assays
105 PalF cells were plated in each well of six-well plates, in
duplicate, with 5 ml of DMEM, 10% FCS at 37°C in 5% CO2.
After 24 h, the cells were transiently cotransfected with I Ilg of
pBoLa-Luc and I Ilg of pZipneoor I Ilg o~ pZip-4E5 (~'Brien
et al., 1999), using the standard Lipofectamine Plus (Invitrogen,
UK) method. After 3 h, cells were washed twice. with 2 ml PBS
and incubated in medium for further 48 h, WIth or WIthout
250U/ml yIFN, before being harvested and lysed in reporter
lysis buffer. The lysates were either assayed for reporter
enzyme activity immediately or stored at -20°e. Luciferase
activity was determined as described previously (O'Brien et al.,
1999) and activity was normalized for protein content
determined using the BCA assay (Pierce Chemical Co.).
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Detection of Mile class [lie RNA by quantitative RT-peR
Total RNA was extracted from parental, control and Pulf-
4E5 cells using the RNeasy Mini kit (Qiagen, Sussex, CK). and
residual DNA was removed by DNase I treatment according
to the manufacturer's guidelines (Invitrogen, UK).
Real-time RT-PCR for MHC I HC and bovine actin
mRNA was carried out using the Taqman EZ RT-PCR kit
(Applied Biosystems, Foster City, CA, USA) with gene-
specific primers and FAM/T AM RA probe designed by primer
express vl ,7 software. In total, 100 ng RNA was used per each
reaction, carried out in triplicate. The primers, spanning exons
2 and 3, were BovMHC_Taq_Forward 5'-TCCGGGCG
AACCTGAAC-3' and BovMHC Taq Reverse 5'-ACATCT
CCTGGAAGGTGTGAGAC-3' -;lI1d -the probe was 5'-
CCGCACTCGGCTACTACAACCAGAGC-3'. Bovine actin
primers were BovACT_Taq_Forward 5'-CCTCACGGAA
CGTGGTTACAG-3' and BovACT_Taq_Reverse 5'-TCTCC
TTGATGTCACGCACAA-3' and the probe was 5' -TT ACCA
CCACAGCCGAGCGGG-3'. RT-PCR was performed using
an ABI prism 7700 sequence detector. In each experiment.
additional reactions with 10 ID-fold serial dilutions of template
DNA were performed with each set of primers and probes on
the same 96-well plates to generate standard curves. All
samples were amplified in triplicate. The relative amounts of
MHC I HC and bovine actin mRNA were determined by using
the standard curves.
Detection ofM lie class I ll C hy immunoblottinq
Cells were removed from the flasks by trypsinization, washed
with PBS, then lysed in lysis buffer (100 mM Tris HCI, plI 7.5,
2% SOS, 2% glycerol) and insoluble material was removed by
centrifugation at 20000 g. Lysate (10 Jig) were electrophoresed
in 4-12% NuPAGE gels (InVitrogen), and proteins were
transferred onto nitrocellulose membrane (Invitrogen) using a
semidry blotting apparatus at 20V 1150A for 1h. The
membranes were blocked in 5% milkjTBS/Twecn-20 (0.5%)
at room temperature (RT) for 1h before incubation with mAb
IL-A88 specific for bovine HC (Toye et al., 19(0) or rnAb AB-I
(Calbiochem) specific for actin. After repeated washing with
TBS/Tween-20 (0.5%), the membranes were incubated with
anti-mouse Ig-HRP (Amersham Pharmacia Biotech, UK)
for mAb IL-A88, and anti-mouse IgM-HRP (Oncogene
Calbiochem-Novabiochem International) for mAb AB-I, in
5% milkjTBS/Tween-20 (0.5%) for 1h at RT. The membranes
were washed three times with TBS/Tween-20 (0.5%) and
bound antibody was detected by enhanced chemolumincscence
staining (ECL) (Arncrsharn Pharrnacia Biotech).
Detection ofMll C class I by flow cytometry
After removal of the medium, the cells were washed once with
PBS, then detached from the flask with trypsin 'EDT A and
pelle ted at 200 g for 5 min at RT. The cell pellet was
resuspended in DMEM, 10% FCS, for I hat 37C to allow
surface antigens to be re-expressed. The cells were washed and
resuspended in PBS, 1% BSA (PBS-B) at lfl'cclls.ml.
For the detection of surface M HC class I, 100 Jd of cells were
aliquoted and incubated with an equal volume ofmAb IL-AI9
(Ben said et al., 1989) for 30 min at 4e. The cells were washed
three times in PBS-B and incubated with anti-mouse IgG-
FITC (Sigma) at 4"C for 30 min in the dark. The cells were
washed and resuspended in 500111PBS-B and analysed by flow
cytometry. If the flow cytometry analysis was not carried out
immediately, the cells were resuspended in 500JIl of 3.4~o
paraformaldehyde (PFA) in PBS and kept at 4 C. For the
detection of intracellular MHC class I, the cells were washed in
PBS-B and permeabilized with 0.1 ~o saponin in PBS-B for
Oncogene
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30min at RT. Following a further wash in PBS-B, the
permeabilized cells were stained with mAb IL-AI9 as
described above. All samples were examined in a Beckman
Coulter EPICS Elite analyser equipped with an ion argon laser
with 15 mY of excitation at 488 nm. The data were analysed
using Expo 2 software.
Detection ofMHC class I and GA by two-colour
immunofluorescence
Cells were grown until 80% confluent in single-well chamber
slides. After removal of medium, cells were washed twice with
serum-free DMEM, 25 mM HEPES (DMEM-H) and incu-
bated in 200 pi of 5 pM BODIPY-TR-ceramide, which localizes
to the GA, in DMEM-H for 30 min at 4°C. Cells were then
washed with DMEM-H for 30 min at 37°C. After removal of
the medium, cells were washed twice with PBS and fixed in
fixing solution (19 ml PBS, I ml 37% formaldehyde and 0.4 g
sucrose) for IOmin at RT. For the detection of endogenous
MHC class I, after fixation, cells were washed twice and
incubated in permeabilizing solution (19ml PBS, 1ml 10%
NP40 and 0.4 g sucrose) at RT for 10min and washed as
above, then incubated with mAb IL-A88 for I h at RT and
washed three times as above. The cells were then incubated
with anti-mouse IgG-FITC (Sigma) at 4°C for I h in the dark.
Following three final washes with PBS, the slides were
mounted in Citifluor " and analysed with a Leica TCS SP2
fluorescence confocal microscope. The merge between FITC
and BODIPY-TR-ceramide fluorescent signals was achieved
with the Leica TCS SP2 accompanying software.
In vitro transcription/translation and coimmunoprecipitation
In vitro transcription/translation reactions were performed
using the TNTA T7 Quick Coupled Transcription/Translation
System (Prom ega, UK) in presence of Redivue L-[35S]Methio-
nine (Amersham Pharmacia Biotech, UK), following the
manufacturer's instructions. Briefly, I pg of pcDNA3.1( -)/
HA4E5, pcDNA 3.1(-)/4E5 mutants, pcDNA3-HD6 or
pcDNA3-JSP.I was mixed in a 50 pi reaction containing
TNT~ mix (TNT~ lysate with energy generating system,
T7 RNA polymerase, nucleotides, salts, recombinant RNasinll>
ribonuclease inhibitors) in presence of canine microsomal
membranes (CMM) (Promega, UK) at 30DC for 1.5 h. Half of
each transcription/translation reaction product was immuno-
precipitated with either 10 pi rabbit antiserum Ab 274, raised
against the C-terminus of the BPY-4 E5 protein (Pennie et al.,
1993; Anderson et al., 1997) or with 5 pi of mAb HA.II
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Abstract
The major histocompatibility complex (MHC) class I region in mammals contains both classical and non-classical MIIC class I genes.
Classical MHC class I molecules present antigenic peptides to cytotoxic T lymphocytes, whereas non-classical MIIC class I molecules have a
variety of functions. Both classical and non-classical MHC molecules interact with natural killer cell receptors and may under some circumstances
prevent cell death by natural killer cytotoxicity. The E5 oncoprotein of BPV-4 down-regulates the expression of classical Mile class I on the cell
surface and retains the complex in the Golgi apparatus. The inhibition of classical MHC class I to the cell surface results from both the impaired
acidification of the Golgi, due to the interaction of E5 with subunit c of the H+ V-ATPase, and to the physical binding of E5 to the heavy chain of
MHC class I. Despite the profound effect of E5 on classical MHC class I, E5 does not retain a non-classical MIIC class I in the Golgi, does not
inhibit its transport to the cell surface and does not bind its heavy chain. We conclude that, as is the case for lIPV-16 E5, BPV-4 E5 does not down-
regulate certain non-classical MHC class I, potentially providing a mechanism for the escape of the infected cell from attack by both cytotoxic T
lymphocytes and NK cells.
© 2006 Elsevier B.V. All rights reserved.
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Introduction
Viruses have to evade the innate and adaptive host immune
response to establish infection and persist at least until new
progeny virus is released. Many viruses have developed the
ability of down-regulating the major histocompatibility com-
plex (MHC) class I (Piguet, 2005), thus avoiding lysis by
cytotoxic T lymphocytes (CTL; effector cells capable of
recognizing and destroying transformed or infected cells),
while not interfering with expression of some non-classical
MHC class I genes. Some non-classical MHC class I molecules,
in common with classical class I molecules, engage both
inhibitory and activating receptors of natural killer (NK) cells,
components of the innate immune response, which may
* Correspondingauthor. Fax: +44 1413305602.
E-mail address:s.campo@vet.gla.ac.uk (M.S. Campo).
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recognize and destroy cells with low levels of MHC class I.
The absence of down-regulation of some non-classical Mile
class I genes, or their up-regulation, by virus may result in the
failure ofNK cells to kill virus-infected cells and allows virus to
escape both CTL and NK killing (Cohen et al., 1999; Tomasec
et al., 2000; Wang et al., 2002).
Papillomaviruses (PV) are small oncogenic viruses that
infect mucosal and cutaneous epithelia causing benign
hyperproliferative lesions (papillomas, warts, condylomas).
Infection by PV is under immunological control, this is
demonstrated by epidemiological studies showing that, in both
human and animal hosts with genetic, iatrogenic or acquired
cell-mediated immune deficiencies, PV lesions show increased
persistence and enhanced neoplastic progression (see O'Brien
and Campo, 2002 for review). However, even in immunocom-
petent individuals, despite expressing abundant viral protein,
PV persist for a significant period of time, usually spanning
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several months, and even years, before activation of the host
immune system. This lack of recognition suggests that the host
immune system is unaware of, and/or disabled by, PV infection.
Indeed, the ability ofPV to persist has been attributed to several
causes: the nature of the virus life cycle, which takes place
wholly in the epithelium and therefore prevents high levels of
the viral proteins having access to the immune cells; the entry of
PV to a latent state with very low levels of expression of viral
antigens; and, as demonstrated recently, the ability of the virus
to directly subvert and evade the host immune response (Frazer
et al., 1999; O'Brien and Campo, 2002; Tindle, 2002). It is
likely that the contribution of each of these factors results in a
delay or prevention of resolution of infection.
It is becoming clear that the oncoproteins of PV can
interfere with the host immunosurveillance and response
(O'Brien and Campo, 2002). We have shown that the ES
oncoprotein of both BPV and HPV inhibits the transport of
MHC class I to the cell surface and retains it in the Golgi
apparatus (Araibi et al., 2004; Ashrafi et al., 2002, 2005;
Marchetti et al., 2002). Additionally, we have shown that
BPV-4 ES interacts physically with bovine MHC class I
heavy chain (HC) and that both this interaction and the down-
regulation of the complex require the C-terminus domain of
ES (Marchetti et al., 2006).
Although effectively down-regulating surface classical
MHC class I, HPV-16 ES does not interfere with the
transport of non-classical MHC class I to the cell surface
(Ashrafi et al., 2005). It is not known if this is the case also
for BPV ES.
Recently, nine putative non-classical class I sequences
(N*5000l-N* 5050 J, see http://www.ebi.ac.uklipdlmhctbolaJ)
have been identified in cattle cDNAs, most of which have not
yet been functionally characterized. N*5000J (GenBank
accession: AY188807) was first identified in 1995 when it
was termed HDS9 (Ellis et al., 1996) and subsequently was
mapped to a region of the cattle MHC containing several
classical class I genes (Di Palma et al., 2002). N*5000l
encodes an HC with a truncated cytoplasmic domain (8 rather
than 28 amino acids) and in this sense resembles human
HLA-G (Geraghty et al., 1987).
Here, we show that BPV-4 ES cannot down-regulate
expression of N*SOOOIMHC class I complex or interact with
N*SOOOI HC, suggesting that, like other viruses, BPV is
potentially capable of evading CTL and NK killing of infected
cells.
Results
We have shown that BPV-4 ES binds to bovine class I HC
and have mapped the HC-interacting domain of ES to its C-
terminus end (Marchetti et al., 2006). We have also shown that
HPV-16 ES down-regulates classical HLA I (MHC class I) but
not non-classical HLA-E (Ashrafi et al., 2005). To determine
whether BPV-4 ES, like HPV-16 ES, is incapable of down-
regulating certain non-classical MHC genes, we took advantage
of a recently described gene in the bovine MHC class I cluster,
N*5000l (Di Palma et al., 2002).
N*5000J has an early stop codon in the sequence encoding
the intracytoplasmic domain (producing a C-terminal truncated
HC), has a number of base pairs substitutions leading to unusual
amino acids (see Fig. 1), has a large deletion in the 3'UTR and
significant differences in the promoter region compared to
classical class I genes (data not shown). It is prone to alternative
splicing, in common with some other non-classical class I
genes, and the isoform most often found was used in this study
(Fig. 1). This isoform contains a small section of intron 4
resulting in 4 additional amino acids at the end of the alpha 3
domain. N*SOOOI is recognized by mAb IL-A88, an mAb that
recognizes a monomorphic determinant on all bovine classical
MHC class I molecules (Toye et al., 1990) (Fig. 4). mAb IL-
A88 was used throughout the present work.
Generation of mouse P8J5 cells expressing bovine Mile
class I
It is not possible to analyze the expression or the function
of N*5000J in bovine cells (in vivo) because there is no
specific antibody for its protein. To investigate the properties
of this gene, its cDNA was introduced into the mouse cell line
P8IS, giving rise to P8IS-N· SOOOI cells. P81S-N·0 130 I cells
were generated in a similar way. There was no need to co-
transfect the bovine 132microglobulin H~~m) gene with the
bovine MHe He genes into P81S cells because the bovine
class I HC associates with mouse ~~~m.and when the complex
reaches the cell surface, it rapidly exchanges mouse I\~m with
bovine 132mprovided by the fetal calf serum in the culture
medium (Ellis et al., 2005). Both N·OI30J and N·5000J are
expressed in P81S cells and transported to the cell surface (see
below and Fig. 3).
Stable introduction and expression of BPV-4 £5 into
P8J5-N*OJ30l and P8J5-N·50001 cells
Any interaction between ES and N·SOOOI cannot be studied
in bovine cells, such as our well-characterized PalF cell lines as
there are not specific antibodies for this HC and the mAb IL-
A88, which recognizes N·SOOOI, recognizes all other MHe
class I HC. The P8IS-N·01301 and P8IS-N*SOOOI cells gave
us an opportunity to analyze the functional relationship between
ES and N·SOOOI independently from the interaction between
ES and N·01301. We introduced ES into these cells. either
expressed from the murine MuLV transcriptional promoter in
pZipneo (pz4ES) or expressed from the IE promoter of IICMV
in pcDNA3 (pc4ES). The corresponding empty vectors were
also introduced into the P81S-N·01301 and P81S-N*SOOOl
cells as controls. We generated the following cell lines: P815-
N*01301-pz4ES, P81S-N*01301-pc4ES, P81S-N·01301-pZip.
P8IS-N·OI301-pcDNA, P81S-N*50001-pz4E5. P8I5-
N*SOOOI-pc4ES, P815-N·SOOOl-pZip and P81S-N·SOOOl-
pcDNA.
We determined the expression of ES by quantitative RT-
peR. There was little or no difference in ES expression whether
expressed from the MLV LTR or the CMV IE promoter. either
in P81S-N*01301 or in P81S-N·SOOOl cells (Fig. 2).
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Fig. I.Alignment of the predicted amino acid sequences ofN*01301 and N*SOOOI (splice variant). Dots indicate identity. *Indicates stop codon. Divergent amino
acids (bold) are seen only in N*50001 (or other cattle non-classical class I alleles) and are not seen in cattle classical class I alleles (www.ebi.ac.uk/ipd/mhc/bola/). Four
additional amino acids at the end of the alpha 3 domain of N*50001 are the result of incorrect splicing of intron 4.
The expression of N*01301 or N*50001 was analyzed by
flow cytometry, As expected, E5 induced a remarkable down-
regulation ofN*OI301-containing MHC class I (Fig. 3). There
was very little surface MHC class I, with a reduction of more
than five-fold compared to control cells carrying empty vector,
and also the amount of total (surface plus intracytoplasmic)
MHC class I was less than half of that in control cells. The
Expression of bovine MHC class I in P8I5 cells expressing
BPV-4 E5
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Fig. 2. BPV-4 E5 ORF is transcribed at comparable levels in all PSI5 cells. E5 and ~-actin RNA was measured by Q-RT-PCR. The histograms represent the average
with standard deviation of six independent measurements. Note that the levels of E5 RNA are three orders of magnitude lower than those of ~\-uctin RNA.
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measured by inhibiting the translation of new proteins with
cyclohexamide and by following the turnover of HC by western
blotting. In control cells, N"'O130 I was stable and could still be
detected after 24 h of treatment; in remarkable contrast, in the
4E5-expressing cells, N"'01301 was unstable and was practi-
cally undetectable after 10 h (Fig. 48). There was no difference
between the stability of N"'5000 I in control or 4E5-expressing
cells; in both cases, N"'50001 HC was still detectable after 24 h
of treatment, comparable to that of N*01301 in control cells
(Fig. 48). These results confirm the general inhibition of
classical MHC class I expression by E5, from stability of the HC
protein to the transport of the class I complex to the cell surface
(Ashrafi et al., 2002, 2005; Marchetti ct al., 2002, 2006). The
results also show that E5 has no effect on the expression, half-
life and transport of non-classical N*50001-MHC class I.
Localization of classical and non-classical MHC class I in
P815-4E5 cells
In PaIF-4E5 cells, E5 retains the MHC class I in the Golgi
apparatus (Marchetti et al., 2002). We wondered whether the
reduction in surface N*O 130 I-MHC class I was also due to the
retention of residual complex in the Golgi. We performed two-
color confocal immunofluorescence in the various P815 cell
lines where MHC class I was detected with mAb IL-A88 and an
FITC-conjugated secondary antibody and the Golgi apparatus
was detected with 80DIPY Ceramide Texas Red. In all control
cells, whether expressing N*01301 or N*50001, MHC was
both associated with the Golgi membranes and clearly on the
cell surface (Fig. 5). In contrast, the cellular localization of
N*01301- and N*50001-MHC class I was markedly different in
P815 cells expressing c4E5 or z4E5. Classical N*OI30I-MHC
class I was totally associated with Golgi membranes, and no
complex was detectable on the cell surface with this technique
(Fig. 5), whereas, in sharp contrast, N*50001-MHC was c1carly
on the cell surface, in addition to the Golgi membranes (Fig. 5),
and its localization pattern was no different from the one in
control cells. Again, no reaction was observed in parental P815
cells (data not shown).
The localization of N*50001 was analyzed also in bovine
PalF control cells (transformed but without E5) and in PaIF-4E5
cells (transformed and expressing E5) (Ashrafi et al., 2000;
Pennie et al., 1993). FLAG-taggcd N*50001 was detected both
in the Golgi apparatus and on the cell surface in both control and
PaIF-4E5 cells, while a GFP fusion form of classical HC 82705
was wholly confined to the misshapen Golgi apparatus in the
PaIF-4E5 cells, but not in the control cells (data not shown), as
previously reported (Marchetti et al., 2002). The results
obtaincd in both P815 and PalF cells show beyond doubt that
E5 is incapable of inhibiting the transport of N*50001-MHC
complex from the Golgi compartment to the surface of the cell.
Physical interaction between E5 and HC
E5 and N*01301 HC interact physically, and we have
proposed that this interaction contributes to the down-regulation
of the HC and the retention of the complex in the Golgi
(Marchetti et al., 2006). Therefore, we asked whether E5 would
complex with N*50001 HC and used in vitro co-precipitation
assays as in vitro interaction between E5 and HC is a faithful
read-out for in vivo interaction (Marchetti et al., 2006; Ashrafi
et al., in press). As before, we in vitro transcribed/translated E5
N*01301 and N"'50001 HC and precipitated the HC with rnAb
IL-A88. Whereas E5 co-precipitated with N*OI301 HC, it did
not do so with N*50001 HC (Fig. 6A). The lack ofintcraction
between E5 and N*50001 was confirmed by a competition
experiment in which unlabeled N*50001 was added to labeled
E5 and labeled N*01301. Unlabeled N*50001 failed to prevent
the interaction between E5 and N*01301 (Fig. 6A), confirming
that it cannot bind to E5.
As described above, N*50001 lacks the C-terminus
intracytoplasmic tail of classical MHC class I HC and is 19
amino acids shorter than N*01301 (Fig. I). Given the absence
of interaction between E5 and N*50001, we wondered
whether the intracytoplasmic domain of class I HC was
responsible for binding to E5. We made a C-terminus
truncation mutant of N*O 130 I HC lacking the final 19
amino acid residues and performed in vitro co-IP experiments
with 4E5. This mutant co-precipitated with 4E5 (data not
shown), showing that the interaction between HC and 4E5
does not involve the C-terminus intracytoplasmic domain of
HC. Furthermore, N*01301 HC bound E5 whether tagged
with V5-His at its C-terminus, like N*50001, or not (data not
shown), demonstrating that the C-terminus epitope has no
effect on the interaction.
We corroborated the in vitro interaction between E5 and HC
in a "pull-down co-immunoprecipitation" experiment. Protein
lysates for P815 parental cells, P815-N*OI301 and P815-
N*50001 cells were incubated with labeled E5 and immuno-
precipitated with mAb IL-A88. As expected, no E5 could be
precipitated from P815 control cells or P815-N*50001 cells
while E5 co-precipitated with N*01301 HC in P815-N*0130i
cells (Fig. 68).
Taken together, the results presented above lead to the firm
conclusion that E5 does not interfere with the biosynthetic
pathway of non-classical N*SOOOI MHC class I.
Discussion
Viruses and classical and non-classical MHC class I
It is well-documented that many viruses evade the host
immune system by interfering with the antigen processing and
presentation pathways (Piguet, 2005). These viral mechanisms
often target MHC class I, and there are several examples of
discrimination between classical and non-classical class I.
While classical class I expression is most often down-
regulated by viral interference at one or more points in the
pathway between transcription and cell-surface expression,
expression of non-classical class I genes usually remains
normal (Cohen et al., 1999; Tomasee et al., 2000; Wang et al.,
2002). It has been proposed that this enables the virus-
infected cell to evade cytotoxic T cell responses while at the
same time sending inhibitory signals to NK cells via
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Fig. 5. BPV4 E5 induces retention of classical, but not non-classical, MHe class I in the Golgi apparatus. (A) Immunofluorescent detection of classical and non-
classical MHC class I in P8l5 control cells or cells expressing E5.
expression of one or more non-classical class I genes. This
relates to engagement of inhibitory NK receptors by non-
classical class I molecules (Borrego et aI., 2005; Hofmeister
and Weiss, 2003).
Non-classical MHC class I in cattle
There is considerable evidence that N*SOOOI and related
alleles in cattle are encoded by a non-classical MHC class I
mAb ILASS: anti-bovine MHC I HC
B 2 3 4
I: input N"01301
2: IPN",()1301
3: IP E5+ N"0130 t
4: input E5
5: IP E5+N*sOOOl
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Fig. 6. BPV4 £5 interacts with classical N°0130l heavy chain but fails to interact with non-classical N°SOOOI heavy chain. (A) 3sS-labeled in vitro transcribed/
translated ES and N°O 130 1 He or N*SOOO1 HC were immunoprecipitated with mAb IL-A88, against MHe class I heavy chain; the precipitate was run in a NuPAGE
gel, and the dried gel exposed on a screen on a Storm 840 apparatus. Classical N°O 1301 HC interacts with £5 (lane 3), while non-classical N°SOOO1HC fails to interact
with £S (lane S) and to compete with classical N°O 130 I HC for binding to ES (lane 9). Several additional bands are visible which derive from the translation of the
proteins (see input lanes) which may be due to dimers or multimers of £S or to degradation products of He. (B) "Pull-down co-immunoprecipitation" between £S and
N°O I30 I HC. Protein extracts from P815, P8IS-N'0 I30 I and P8 IS-N'SOOOI cells were incubated with 3sS-labeled in vitro transcribed/translated £5 and precipitated
with mAb IL-A88. ES is precipitated from P8lS-N°0 I30 I cells (lane 2) but not from P81S parental or P8lS-N°SOOO I cells (lanes 3 and 4) .
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gene. The classification of N*5000J (and related alleles) as non-
classical is based on several criteria, namely association with a
number of unrelated MHC haplotypes (at least one of this set of
alJeles is present on all MHC haplotypes examined; Ellis,
unpublished data), lack of significant polymorphism, a
truncated cytoplasmic domain (8 rather than 28 amino acids),
unusual amino acid substitutions throughout, a characteristic
motif within the transmembrane domain, a large deletion in the
3' VTR and significant differences in the 5' upstream region in
comparison to classical class I genes. These alleles may be
widely transcribed, and there is currently no evidence to suggest
tissue-specific expression (Davies et al., 2004); Ellis, unpub-
lished data). In addition, a number of alternatively spliced
transcripts of N*5000J can be found (Ellis, unpublished data), a
characteristic seen in non-classieal class I genes in other species,
most notably HLA-G (Riteau et al., 200 I). N*5000J and related
alJeles are transcribed at relatively low levels in peripheral blood
lymphocytes and at slightly higher levels in trophoblast tissue
during pregnancy (Davies et al., 2004), in common with some
other putative non-classical cattle MHC class I alleles.
BPV-4 £5 and MHC class I
Because there is no monoclonal antibody available which
exclusively recognizes non-classical class I molecules, to study
the relationship of BPV-4 E5 with classical and non-classical
MHC I, we separately expressed a classical, N*0130J, and a
non-classical, N*5000J, allele in mouse P815 cells and
Subsequently introduced E5 in these cells. This proved to be a
powerful system which has confirmed that E5 down-regulates
classical MHC class I, while it does not interfere with the
biosynthetic pathway of this non-classical MHC class I.
BPV-4 £5 and classical MHC class I
As in bovine PalF cells (Marchetti et al., 2006), E5 down-
regulates classical MHe class I at more than one level.
However, in PalF cells, E5 was co-expressed with E6, E7 and
activated ras (Ashrafi et al., 2000), leaving open the possibility,
albeit remote, that down-regulation of MlfC class I was due to a
functional interaction between the viral and cellular oncopro-
teins. In P815 cells, E5 profoundly inhibits classical MHC class
I in the absence of other viral or cellular oncoproteins. E5
impacts on classical MHC class I at several levels: transcription
of the HC gene, expression of protein and transport of the
complex to the cell surface (Marchetti et al., 2006). Transcrip-
tion of the bovine N*O130 I HC cannot be analyzed in P815
cells: E5 inhibits transcription from the homologous promoter
of the HC gene, while in P815 cells the N*O130 I HC gene is
under the control ofthe CMV IE promoter, which is not affected
by E5 (data not shown). In P815 cells, in addition to blocking
MHC class I in the Golgi apparatus, E5 induces the degradation
of N*OI301 He. In control cells, the half-life of the He is
approximately 20 h, whereas in the presence ofES its half-life is
dramatically reduced to less than 5 h. We do not yet know how
£5 induces degradation of He. However, we have commented
before (Marchetti et al., 2006) on the similarities between E5
and HIV I Nef, and it is interesting to note that Nef re-directs
He to the Iysosomes for degradation through the simultaneous
interaction with He and with the adaptor protein I (AP-I)
complex (Roeth et al., 2004) and that inhibitors oflysosomes (in
conjunction with interferon treatment) restore the expression of
He in PaIF-4E5 cells (Marchetti et al., 2006). It is thus possible
that ES too interacts with both HC and AP-I inducing lysosomal
degradation of HC, but this remains to be elucidated.
BPV-4 £5 and non-classical MHC class I
In marked contrast to its inhibitory effect on classical MHC
class I, E5 does not affect the non-classical MHC class I
N*50001. This conclusion is based on numerous pieces of
evidence. N*SOOOI reaches the cell surface, N*50001 HC is
expressed to the same levels as in control cells and its half-life is
not affected, and crucially ES does not interact with N*5000 I
He. This last point is further corroborated by the inability of
N*SOOOI HC to inhibit the formation of the complex between
E5 and N*01301 HC in vitro. Moreover, the finding that the
half-life of N*5000 I He is not affected by E5 supports our
hypothesis that binding to HC is needed for HC degradation.
A major difference between classieal N*OI301 and non-
classieal N*50001 He is the truncation of the intracytoplasmic
domain in the latter, but the interaction with 4E5 does not take
place via this domain. This finding contrasts with the binding of
Nef to the intracytoplasmic domain of HLA-A and with the
observation that the inability of Nef to bind some non-classical
HLA resides in amino acid differences in the intracytoplasmic
domain of HLA-E and the absence of the domain in HLA-G
(Pizzato et al., 2004; Williams et al., 2002). There are several
amino acid differences throughout the extracellular domains
between classical N*OI301 and non-classical N*50001 He
(Fig. I), but which one of these differences is responsible for the
differential interaction with ES remains to be established.
Biological significance of the lack of down-regulation of
non-classical MHC class J by £5
The lack of significant polymorphism in the non-classical
MHC class I allele described here strongly suggests that this
complex is not involved in antigen presentation and is thus more
likely to interact with NK receptors, as has been observed for a
number of non-classical class I gene products in human and
other species. Cattle have recently been shown to have a family
of genes with homology to the human KIRs (McQueen and
Parham, 2002; Storset et al., 2003), and several other putative
NK receptors have been identified (Storset et al., 2004), but thus
far interactions between these putative NK receptors and MHe
class I molecules have not been demonstrated.
Thus, while it is possible to speculate that the lack of
interaction of E5 with N*50001 constitutes a viral mechanism
for evading NK recognition, this remains to be confirmed.
Nevertheless, down-regulation of classical MHe class I and
lack of down-regulation of non-classical MHe class I by E5
strongly suggest that the viral protein is instrumental for the
establishment of viral infection by allowing the infected cell to
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escape both the adaptive and innate immune response of the
host.
Materials and methods
Plasm ids
N*0J301 cDNA, encoding heavy chain (HC) N*01301
(formerly HD6), was cloned both in pcDNA3 (Ellis et al., 1999)
and pcDNA6-V5-His (Invitrogen, Paisley, UK). Full-length
clones of N*50001 cDNA (AYI88807), encoding N*50001,
were generated by PCR from cattle PBMC cDNA. This class I
gene is very prone to alternative spicing, and the most common
splice variant was used in this study. Multiple clones were
sequenced, and a clone containing the consensus sequence was
introduced into pcDNA6-V5-His (Fig. 1).
pz4E5 and pc4E5 are plasmids carrying the ORF of BPV-4
E5 under the transcriptional control of the murine MLV LTR
or the IE promoter of HCMV respectively. These plasmids
have been described before (Ashrafi et al., 2002; Pennie et al.,
1993).
Cells
P815 cells are a mouse mastocytoma cell line (ATCC). They
are grown in suspension in RPMI 1640 supplemented with 10%
FCS. Stable transfectants expressing N*O130 1 were produced
by transfection of pcDNA6-V5-His N*01301 and maintained
under blasticidin selection. These cells are designed P815-
N*01301. Stable P815 transfectants expressing N*50001 were
generated as described before (Ellis et al., 1999), and positive
cells were identified using blasticidin selection, screening by
western blotting with an anti-V5 monoclonal antibody (mAb)
(Invitrogen) and flow cytometry. These cells are designated
P815-N*50001. Both P815-N*OI301 and P815-N*50001 were
transfected with either pz4E5 or pc4E5, or the corresponding
empty vectors, with an Amaxa nucleofector (Amaxa GmbH)
using the kits and following the instructions supplied by the
manufacturers. Cells were selected by G418 resistance, and
stable transfectants were isolated.
Quantitative RT-PCR (Q-RT-PCR)
RNA was extracted from P815 cells using RNeasy mini Kit
(Qiagen, UK), and residual DNA was inactivated using DNase I
treatment (Invitrogen). Q-RT-PCR for BPV-4 E5 and mouse ~-
actin mRNA was carried out using the Taqman EZ RT-PCR Kit
(Applied Biosystems, Foster City, CA). Each reaction was
performed in triplicate using 100 ng of RNA. Oligonucleotide
primers, designed using Primer Express (v 1.7, Perkin-Elmer,
Oak Brook, IL), were as follows: BPV-4 E5 F5'-TGTCT-
TTGTGGCTTATCTATGTTTTGT-3'; BPV-4 E5 R5'-CCGAG-
TAATAGTAGAAATTAACAGAAGGTACAC-3'; and FAM/
TAMRA probe 5'-CTTTTCTGGTGTGCTTTTAATTTTC-
TTGCACTGTTA-3'. [3-actin F5'-GCTCTGGCTCCTAGCAC-
CAT-3'; ~~-actinR5'-GCCACCGATCCACACAGAGT-3' and
181
FAMITAMRA probe 5'-AAGATCATTGCTCCTCCTGAGC-
GAAAG-3'.
PCR reactions were performed using an ABI prism 7700
sequencer. Standard curves were generated using 10-fold serial
dilutions of each template DNA, which were used for
quantifying the relative levels ofE5 and ~>,-actinRNA.
Flow cytometric analysis of MHC class 1 expression
P815-N*0 BOland P815-N*5000 1 cells either expressing
BPV-4 E5 or carrying empty vector were grown in suspension
in T175 cm2 flasks until subconfluent. Following centrifuga-
tion, the cell pellet was washed with PBS and resuspended in
PBS/l % bovine serum albumin (PBS-B) at a concentration of
106 cells/ml. For the detection of surface MHC class I
molecules, aliquot of 106 cells was incubated for 1 h at 4 "C
with monoclonal antibody (mAb) IL-A88, specific for bovine
MHC class I (Toye et al., 1990) in PBS-B. After washing twice
with PBS, cells were incubated with 1:100 dilution of anti-
mouse IgG-FITC (Sigma, UK) for 30 min at 4 °C in the dark.
The cells were washed as above, resuspended in 500 III PBS and
analyzed by flow cytometry. If the flow cytometry analysis was
not carried out immediately, the cells were resuspended in
500 III of 3% parafonnaldehyde in PBS and kept at 4°C. P815
cells not expressing bovine MHC class 1were used as control,
as well as cells incubated without primary antibody. For the
detection of intracellular MHC class I, the cells were
penneabilized with 0.1% saponin in PBS-B for 30 min at RT
and then incubated with primary antibody as described above.
All samples were examined in a Beckman coulter EPICS Elite
analyzer equipped with an ion argon laser with 15 mV of
excitation at 488 nm. Data were analyzed using Expo 2
software.
Localization of MHC class I in P815 cells by
immunofluorescence
An eight-well slide (Chamber Slides Lab-tek, VWR
International) was washed with alcohol, air-dried and treated
with 40 Ill/well poly-t, lysine hydrobromide (Sigma) for 10 min
to allow adhesion of the cells. After removal of poly-t, lysine,
the slide was washed with distilled water and air-dried. P815
cells were pelleted, washed twice in PBS and resuspended in
fixing solution (5% formaldehyde in PBS containing 2%
sucrose) for 10 min. After two washes, the cells were plated in
PBS containing 1% FCS, at 1 x 102 cells/well, and left for
15 min to settle down. After removal of PBS, the cells were
treated with penneabilizing solution (0.01% Tween-20 in PBS)
for 10 min. The Golgi apparatus was visualized with 1:1000
dilution of BODIPY Ceramide Texas Red (TR) (in 2.5%
HEPES in serum-free RPMI 1640 medium) for 30 min at 4°C.
BODIPY Cerami de specifically locates to the Golgi apparatus.
After removal of BODIPY Ceramidc, cells were incubated in
2.5% HEPES in serum-free RPMI 1640 medium for 30 min at
37°C. For detection ofMHC class I, cells were first incubated
with IL-A88 antibody for 1 hat RT followed by incubation with
1:1000 dilution of anti-mouse IgG-FITC for 1 h in dark with
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two washes in between. The cells were washed three times, and
the slide was mounted with a 60 mm coverslip using citifluor.
Imaging
Images were captured using a Leica TCS SP2 true confocal
scanner microscope (Leica Microsystems, Heidelberg, Ger-
many) at a wavelength of 488 nm (MHC class I: FITC) or
543 nm (Golgi apparatus: Texas Red). The merge between the
fluorescent signals was achieved using the accompanying
software.
Immunoblotting
P815 cells were lysed in 300 III of lysis buffer (0.5% NP40,
50 mM Tris pH 7.8, ISO mM NaCI) containing a protease
inhibitor cocktail (Roche, Lewes, UK). Following incubation
on ice for 30 min, the cell debris was eliminated by
centrifugation and the protein concentration was measured
using the BCAICUS04 assay. To determine the stability of
classical and non-classical bovine MHC class I heavy chain in
P815 cells, aliquots of2 x 106 cells were treated with 100 ug/ml
cyclohexamide (Sigma) or the solvent DMSO (Sigma) for
different periods of time at 37 QC.The cells were wash cd with
ice-cold PBS, pelleted and resuspended in 100 J..tI of lysis buffer
as described above.
The protein samples were mixed with 4x NuPAGE SDS
sample buffer (40% Glycerol, 500 mM Tris-HCI (pH 6.8), 8%
SDS, 0.075% Serva blue G250, 0.025% phenol red) and lOx
NuPAGE Reducing Agent (0.5 M DTT). The samples were
heated at 70 QCfor 10 min before loading in NuPAGE 4-12%
Bis- Tris-HCI (pH 6.4) polyacrylamide gels (Invitrogen Ltd).
Electrophoresis was performed in MES SDS Running buffer
(Invitrogen Ltd) at a constant voltage of 200 V for 60 min.
Separated protein samples were transferred to nitrocellulose
membranes by wet electrophoretic transfer using a Xcell II
blotting apparatus (Invitrogen Ltd) as per manufacturer's
instructions. The blotting was performed at a constant voltage
of 30 V for 80 min in Ix NuPAGE transfer buffer containing
10% methanol. Transfer was checked by staining the nitrocel-
lulose membrane with Ponceau S solution (Sigma).
Membranes were blocked in 5% milk in Tris-buffered saline
(TBS) containing 0.05% Tween 20 (T-TBS) for I h at RT or
overnight at 4 QC.For detection ofMHC class I, the membranes
were incubated with mAb IL-A88 in 5% milk in T-TBS for 2 h
at RT. After two washes in T-TBS, the membranes were
incubated with I :5000 dilution of horseradish-peroxidase-
linked sheep anti-mouse IgG whole antibody (Amersham
Biosciences) in 5% milk in T-TBS for I h at RT. Bound
antibody was detected by incubating the membrane for 5 min at
RT with ECL plus western blotting detection system (Amer-
sham Biosciences) according to the manufacturer's instructions.
After exposure, bound antibody was removed from the
membranes with stripping buffer (lOO mM 2-Mercaptoethanol,
2% SDS, 62.5 mM Tris-HCI pH 6.7) at 50 QCfor 30 min. After
washing in T-TBS, the membranes were blocked in 5% milk in
T-TBS for 1 h at RT prior to re-probing with 1:20,000 dilution
of anti-actin antibody (mAb Ab-I; CALBIOCHEM). After
incubation with mAb Ab-I, the membranes were washed two
times in T-TBS and incubated with anti-mouse IgG linked to
horseradish peroxidase as described above.
Co-immunoprecipitation
In vitro transcription/translation and co-immunoprecipitation
In vitro transcription/translation reactions were performed
using the TNT T7 Quick Coupled TranscriptionlTranslation
System (Promega, UK) in the presence of Redivue L-e5S]
Methionine (Amersham Pharrnacia Biotech, UK) following
the manufacturer's instructions. Briefly, 1 Ilg of pc4E5,
pcDNA3-N*01301 or pcDNA6-V5-His-N*01301, or pcDNA6-
V5-His-N*50001 was mixed in a 50 III reaction containing
TNT mix (TNT lysate with energy generating system, T7
RNA polymerase, nuclcotidcs, salts, recombinant RNasin
ribonuclease inhibitors) in the presence of canine microsomal
membranes (CMM) (Promega, UK) at 30 QC for 1.5 h. Half
of each transcription/translation reaction product was immu-
noprecipitated with either 10 III rabbit antiserum Ab 274,
raised against the C-terminus of the BPV-4 E5 protein
(Anderson et al., 1997; Pennie et al., 1993) or with 3 III mAb
IL-A88. The other half of each reaction was left without
antibody as a negative control. For co-immunoprecipitation
experiments, the individual transcription/translation products
were mixed in equivalent amounts and immunoprecipitated
with double the amount of either antibody. For competition
experiments, no [35S] Methionine was added to the reaction
containing pcDNA3-N*5000J and the unlabeled N*5000I
was added to labeled E5 for an hour before the addition
of labeled N*01301 as above. After incubation overnight at
4 QC,protein G-sepharose bead suspension (Sigma) was added
for I h at 4 QC. Following two washes in a high salt buffer
(50 mM Tris-HCI pH 7.5, 500 mM NaCl, I% NonidetP-40,
0.05% NaDoc) and one wash in a low salt buffer (50 mM
Tris-HCI pH 7.5, 1% NonidetP-40, 0.05% NaDoc), the
sepharose beads were resuspended in 20 III of SDS loading
buffer, heated at 75 QC for 10 min, and then were
electrophoresed in 4-12% NuPAGE gels (Invitrogen). Gels
were fixed with glacial acetic acid and methanol, incubated for
IS min in Amplify Fluorographic reagent (Amersham, UK),
dried and exposed for autoradiography at -70 QCovemight or
exposed on a screen for quantification on a Storm 840 apparatus
using a ImageQuant v5.2 software.
Pull-down co-immunoprecipitation
Protein Iysates were obtained from P8I5, P8I5-N*OI30I
and P815-N*5000I cells. Cells were lysed in RIPA buffer
containing a cocktail of protease inhibitors (Roche, Lewes,
UK). Protein Iysates (100 ug) were incubated with in vitro
3sS-labeled E5 overnight at 4 QCand immunoprecipitated with
mAb IL-ASS as described above. Immunoprecipitates were
electrophoresed in 4-12% NuPAGE gels (Invitrogen). Gels
were fixed with glaeial acetic acid and methanol, incubated for
IS min in Amplify Fluorographic reagent (Amersham, UK),
dried and exposed for autoradiography at -70 QCovemight.
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E5 protein of human papillomavirus 16 down regulates HLA class I and interacts
with the heavy chain via its first hydrophobic domain
G. Hossein Ashrafi, Mohammad Haghshenas, Barbara Marchetti and M. Saveria Campo"
Division of Pathological Sciences, Institute of Comparative Medicine, University of Glasgow, Glasgow, Scotland, United Kingdom
Human papillomavirus type 16 ES protein (HPV-16 ES) is
expressed early in papillomavirus infection and is localised pri-
marily in the cell Golgi apparatus (GA) and endoplasmic reticu-
lum. ES prevents transport of the major histocompatibility class 1
(MHC I; HLA class 1 in humans) to the cell surface and retains
the complex in the GA. We report that these effects are due, at
least in part, to the interaction between ES and HLA 1 heavy chain
(HC). We also demonstrate that the down-regulation of surface
HLA 1 and interaction with HC are mediated by the first hvdro-
phobic domain of ES. Although ES downregulates classical '"LA
selectively as it does not downregulate non-classical "LA, the
interaction with the HC of classical "LA 1is not specific for a par-
ticular haplotype of "LA I. This suggests that ES can interfere
with antigen presentation by most, if not all, classical HLA 1hap-
lotypes, with potentially serious consequences as the ability of
infected cells to present antigenic peptides to effector T cells would
be compromised.
Cl 2006 Wiley-Liss, Inc.
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Human papillomaviruses (HPVs) infect mucosal and cutaneous
epithelia a~d induce lesions that can persist and progress to can-
c.er. Th~ mildest forms of HPV dise~se are benign hyperprolifera-
nve lesions, known as warts or papillomas, In most cases, these
lesions are cleared after several months following activation of the
host immune system against viral antigen. I However, due to the
ability of certain types of HPVs to avoid immune clearance, occa-
sionally, the lesions do not regress and can progress to cancer.
This is especially true for HPV type 16, which is involved in the
majority of cases of HPV-induced cervical cancers.f The ability of
the virus to avoid immune clearance is due to several factors de-
pendent on the virus life cycle, but also on active mechanisms
operated by the viral proteins to counteract the host immune
attack. Elimination of virally infected cells requires cytotoxic T-
lymphocytes (CTL) that can recognise and kill virally infected
cells via ligation of their receptor to major histocompatibility class
1 complex (MHC I; HLA I in humans) bound to viral peptides on
the surface of infected cells.'
One of the potential effectors of HPV-16 escape from host immu-
nosurveillance is the viral oncoprotein E5.4 E5 is a hydrophobic
membrane protein 83 amino acids long, possessing 3 well-defined
hydrophobic regions. E5 is expressed early in papillomavirus infec-
tion in the deep layers of the infected epithelium':" (Araibi et al.,
unpublished results) and is localised mainly in the endoplasmic
reticulum (ER) and Golgi apparatus (GA) membranes," We have
previously shown that HPV-16 E5 downregulates the expression of
surface HLA I by retaining the complex in the GA, and this downre-
gulation is selective, as E5 does not interfere with nonclassical
MHC. This may allow the virus to establish itself by avoiding clear-
ance of virus-infected cells by both CTL and natural killer cells."
Here we show that E5 physically interacts with the heavy chain
(HC) of HLA I and that interaction and downregulation of surface
HLA I are mediated by the first hydrophobic domain of E5.
Material and methods
Construction of HPV-J6 £5 mutants
The plasmid pcDNA-Neo (Invitrogen, UK), encoding 0418 re-
sistance and containing the universal IE promoter of CMV, was
~UICC
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used to express HPV-16 E5 wild type (wt) or mutant forms, all
tagged with the hemagglutinin (HA) epitope YPYDVPDY A at
their N-terminus. HPV-16 E5 deletion mutants R79, A54, V36
and R30 (gift of Dr Alonso, Deutsches Krebsforschungszentrum,
Heidelberg, Germany) were generated by introducing double stop
codons at the respective nucleotide positions of the HPV 16 E5
sequence." HPV-16 E5 Dell mutant protein was made by deletion
of the first hydrophobic domain (amino acids 1-30) by PCR
amplification using forward primer from nt 91 to lOS of the HPV-
16 E5 ORF (S'-CATIGCTAGC ATGTACCCAT ACOATGTICC
AGATIACOCT CCGCTGCITITGTCT-3') and reverse primer
from nt 252 to 231 (5'-TCGCOAATICTIATOTAATIAAAA
AGCGTG-3') including sites for Eeo RI and Nhe I respectively.
The resulting PCR products were inserted between the Eco RI
and Nhe I sites of pcDNA-Neo. All clones were verified by
sequencing.
Construction of GFP-E5 fusion proteins
pEGFP-C I (Cion tech, UK) is a eukaryotic expression plasmid,
which encodes the green fluorescent protein (OFP). It was used to
clone full length HPV-16 E5 and its mutants to generate GFP-E5
wt and OFP-E5 mutant fusion proteins by PCR. The forward
primer was from nt I to 22 of the E5 ORF for E5 wt and mutants
R79, A54, V36 and R30, and from nt 91 to 112 for the Dell mu-
tant. The reverse primers were from nt 252 to 231 for Dell, from
237 to 216 for R79, from 162 to 141 for A54, from III to 90 for
~36 and from 93 to 72 for R30. The forward and reverse primers
included an Eco RI and a Bgl II site respectively. The resulting
PCR products were inserted between the Eco RI and Bgl II sites of
pEGFP-CI. All clones were verified by sequencing.
Cell culture and transfection
The immortalised human keratinocyte (HaCaT) cell line was
grown in Dulbecco's modified Eagle medium (DMEM) high glu-
cose without calcium chloride (Life Technologies, UK), supple-
mented with 10% foetal calf serum, as previously described."
Cells (I X 106) were stably transfected with 4 mg pcDNA, pc-
l6E5 or pc-16E5 mutants by using Lipofectamine Plus (Invi-
trogen). Following transfection, HaCaT cells were selected in me-
dium containing 500 ug/ml G4l8 for 21 days. G4l8-resistant colo-
nies were marked, picked and expanded into cell lines for analysis.
Real time/quantitative RT-PCR
RNA was isolated from HaCaT cells using the RNAeasy Mini
kit (Qiagen, Sussex, UK), and residual DNA was removed by
DNAase I treatment according to the manufacturer's guidelines
(Invitrogen). Real-time RT-PCR for E5, E5 mutants and ~·actin
mRNA was carried out using the Taqman EZ RT-PCR kit
(Applied Biosystems, Foster City, CA) with gene-specific primers
and FAMrrAMRA probe designed by primer express vl.7 soft-
ware. RNA (100 ng) was used per each reaction, done in triplicate.
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Primers were as follows: forward (F) primer for E5 wt, R79, A54,
Y36 and R30 was 5'-TGACAAATCT TGATACTGCATCCA-3';
reverse (R) primer for E5, R79 and A54 was 5'-TGACAAATCT
TGATACTGCATCCA-3'; R primer for Y36 and R30 was 5'-
TAATAGGCAG ACACACAAA-3',
The probe was 5'-AACATTACTG GCGTGCTTTT TGCTTT-
GCT-3' in all cases. For l3-actin, primers and probe were commer-
cially available (Applied Biosystems). Standard curves were gen-
erated using ID-fold serial dilutions of each template DNA, to
quantify the relative levels of E5 and l3-actin mRNA.
Semi-quantitative RT·PCR
Real time RT-PCR did not work for E5 Dell, as no appropriate
forward primer could be identified outside the first hydrophobic
domain that matched the probe. Therefore, to quantify the levels
of E5 Dell, semi-quantitative RT-PCR was performed." The Dell
F primer was 5'-CTGCTTTTGT CTGTGTCTACATA-3' and the
R primer was 5'-TATAATATAT ACAATAAAACACCTAA-3'.
RT-PCR was performed using an ABI prism 7700 sequence detec-
tor for 20, 25, 30 or 35 cycles. The same amplification protocol
was used with E5 wt and R30 as controls. The RT-PCR products
were run on gels, the bands scanned with MagicScanner 32·v4.3
and quantified with Image Quant v5.2 software.
Western blotting
Fifty microgram of protein Iysates from HaCaT cell harbouring
empty vector (Control), expressing Dell or E5, were electropho-
resed and transferred to nitrocellulose membrane. The membranes
were blocked and incubated with mAb HA II (1/500 dilution'
Sigma) for I hr, washed and incubated with antimouse IgM-HRP
(1/5,000; Oncogene CalblOchem-Novabiochem International). Af-
ter I hr, the membranes were washed and bound antibody was
detected by enhanced chemoluminescence staining (Amersham
Pharmacia Biotech, UK).
Flow cytometry
Detection of HLA I by flow cytometry was performed essen-
tially as previously described." Briefly, HaCaT cells and cells
expressing E5 and mutants were incubated with antihuman HLA
class I monoclonal antibody (mAb) W6/32 (1/100; Serotec) at 4°C
for 30 min, and then with antimouse IgG-FITC (1/100; Sigma) at
4°C for 30 min in the dark. After washing, the cells were analysed
by flow cytometry. If the flow cytometry analysis was not per-
formed immediately, the cells were re-suspended in 500 ml of
3.4% paraformaldehyde in PBS and kept at 4°C. For the detection
of intracellular HLA I, the cells were permeabilised with 0.5%
Saponin (Sigma) in PBS-B and incubated with the primary anti-
body as described earlier. All samples were examined in a Beck-
man Coulter EPICS Elite analyser equipped with an ion argon
laser with IS mY of excitation at 488 nm. The data were analysed
using Expo 2 software.
Immunofluorescence
Detection of HLA I by immunofluorescence was performed
essentially as previously described." Briefly, cells were washed
and fixed in fixing solution (19 ml PBS, Iml 37% formaldehyde
and 0.4 g sucrose) for 10 min at room temperature (RT). After fix-
ation, cells were incubated in permeabilising solution (19 ml PBS,
I ml 10% NP40 and 0.4 g sucrose) at RT for 10 min, incubated
with mAb W6/32 (I:50 dilution) for I hr at RT and then with anti-
mouse IgG-FITC (l/500;Sigma) at 4°C for I hr in the dark.
Followin-A,3 final washes with PBS, the slides were mounted in
Citifluor (glycerolJPBS solution, Sigma) and analysed with a
Leica TCS SP2 fluorescence confocal microscope (Leica-micro-
systems, Heidelberg, Germany).
Co-localisation olGA and £5
HaCaT cells were transiently transfected with 0.1 ).Ig of either
pEGFP-E5 or pEGFP·E5 mutants, or with control empty plasmid.
using Lipofectamine Plus ™ Reagent according to the manufac-
turer's instructions. Seventy-two hours after transfection, cells
were plated approximately 25-50% confluent and grown over-
night. Cells were washed twice with serum-free DMEM, 25 mM
Hepes (OMEM-H) and incubated in 200).11 of 5 11MBOOIPY·TR·
ceramide, which localises to the GA, in DMEM-H for 30 min at
4°C. Cells were washed twice with PBS and fixed in fixing solu-
tion as earlier, and washed 3 times with PBS. Cells were incubated
with 4'6'-diamino-2-phenylindole (OAPI) for 10 min, to stain the
nucleus, washed in PBS-FCS and then with distilled water, dried
and mounted in Citifluor™ (Sigma). Cells were analysed with a
Leica TCS SP2 confocal scanner microscope. Images were ac-
quired and merged using Leica confocal software.
Co-immunoprecipitation of £5 and liLA HC in HaCaT cells
Control or E5-HaCaT cells were lysed in RIPA buffer (50 mM
Tris HCI, pH 7.5,150 mM NaCl, 1% Nonidet P40, 0.5% NaDoc,
0.1 % SOS) containing a cocktail of protease inhibitors (Roche,
Lewes, UK). Protein lysate (100 ug) was immunoprecitated with
50 III of mAb HA II (I: 10 dilution; Sigma) against the HA-tag of
E5 and then incubated at 4°C overnight. After that, protein
G-sepharose bead suspension (Sigma) was added for I hr at 4°C.
Following 4 washes in RIPA buffer, the sepharose beads were
resuspended in 20 III of SOS loading buffer, heated at 75°C for
ID min and then electrophoresed in 12% NuPAGE gels (Invi-
trogen). Proteins were transferred onto nitrocellulose membranes
and immunoblotted with ID III mAb HCIO against HLA-A, B, C
(I: I ,000 dilution; Cancer Research, UK).
In vitro transcription/translation and coimmunoprecipitation
HLA HC A2 cDNA sequence in pAL356 was excised and re-
cloned in pBluescript II SK (+) (Stratagene); HLA HC Al or B8
cDNA sequences in pRSV5-neo were excised and re-cloned in
pGEM-1lZf (Promega, UK). All HLA HC plasmids were a gift
from Dr S. Man, University of Cardiff, UK. HPY·16 E5 or E5
mutants and A I, A2 or B8 were in vitro transcribed-translated
using the TNT" T7 Quick Coupled Transcription!Translation Sys-
tem (Promega) in presence of Redivue L-C5S] methionine (Arner-
sham Pharmacia Biotech) following the manufacturer instructions,
and as described previously.!" Half of each transcription/translation
reaction product was immunoprecipitated with 3 III of mAb HA II
(I: 10 dilution; Sigma) or, in the case of R30, 3 III of a polycIonal
antiserum raised against the N-terminus of E5 (gift of Prof D.
DiMaio, Yale University, USA; Hwang et al., 1995), or 10 III mAb
HC 10 against HLA-A, B, C (1 :250 dilution; Cancer Research, UK)
and then incubated at 4°C overnight. The other half of each reac-
tion was left without antibody as a negative control. For coimmu-
noprecipitation, the individual transcription/translation products
(25 III each of HLA HC and E5 reactions) were mixed in equivalent
amounts and immunoprecipitated with double the amount of either
antibody. For competition experiments, unlabelled R30 or Dell
was added to labelled HLA-A2 overnight before the addition of
labelled E5 and antibody as earlier. After incubation overnight at
4°C, protein G-sepharose bead suspension (Sigma) was added for
I hr at 4°C. Following 2 washes in a high salt buffer (50 mM Tris
HCI, pH 7.5, 500 mM NaCl, 1% Nonidet P40, 0.05% NaDoc) and
I wash in a low salt buffer (50 mM Tris HCI, pH 7.5, 1% Noni-
detP-400, 0.05% NaDoc), the beads were resuspended in 20 III of
SOS loading buffer, heated at 75°C for 10 min and electrophoresed
in 4-12% NuPAGE gels (Invitrogen). Gels were fixed withJlacial
acetic acid and methanol, incubated for 15 min in Amplify" Fluo-
rographic reagent (Amersham, UK), dried and exposed for autora-
diography at -70°C overnight or exposed to a screen in a Storm
840 apparatus using a ImageQuant v5.2 software.
Results
flPV·16 £5 and HLA J HC interact physically
HPY·16 E5 prevents the transport of HLA class I to the cell sur-
face by retaining the complex in the GA.4 We have recently
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FIGURE1 _ E5 and HLA I HC interact physically. (a) Coimmuno~recipitation of E~ and HLA I HC in HaCaT cells. Proteins from HaCaT
cells harbouring empty vector (c) expressmg Dell or E5, were either Immunoblolted with mAb HC I0 to detect HC, or first immunopr cini d
with mAb HAll and immunoblotted with mAb HCIO. Dell is a deletion mutant of E5, which does not interact with HLA HC (see Iet 1)It~e
double HC band more visible when coimmunoprecipitated with E5 (lane 7), may represent 2 or more of the HC allele expressed b at~r. I?e
The heavy bands in the immunoprecipitations ar~ Ig. Despite equal amou~ts of protem 10 the lanes, equal amounts/dilutions of aniibo~ cean~
equal exposure time the Ig bands have been consistently more pronounced m the Immunopreclpltates from E5-expressmg HaCaT cell T/
Son for this effect is 'nol known. Please note that the 2 Dell IP lanes 5 and 6 represent 2 independent experiments. WB and JP of E5 sd he ~a-
Dell (lanes 2-5) were run in a separate but essentially identical gel and aligned for ease of comparison. (b) In vitro coprecipitation bet t e Endib d/ Id' . . h f 35S hi e ween 5
and HLA-A2 HC E5 and HC of HLA-A2 were transcrt e trans ate In vuro III I e presence 0 -met ionme and canine microsom . d. . B C) (I ) N . . d . es mlxe
together and coprecipitated with mAb HCIO (anti HLA-A, - ,- + anes. 0 precIpitate was observe m the absence of the anti bod (- I
6) or of A2 HC (lanes 4 and 5). A faint A2 band is visible in lane 2, despite the absence of antibody. (c) E5 wt and E5 Dell are express ~ ane
parable levels. Immunoblots of the same protein Iysates in A, prob~d ,;,ith m~b HA II. (d-g) E5 i~teracts with HC from different HL~ la~~o;:::
types. E5 and HC ofHLA-AI and -B8 were transcribed/translated In vitro as m panel band coprecipitated with either mAb HCIO (anti-HLlA
-B, -C; panels d and e) or mAb HAll (antl-HA eplloiJe of E5; pa~elsrand g). AI, B8 and E5 were precipitated by their specific antibodies (+
lanes); A I and E5, or B8 and ES copreclpltated when incubated with either mAb HClO (panels d and e; + lanes 7) or mAb HAll (panels/and
g; + lanes 7) and the coimmunopreclpltated bands were much stronger than In the absence of the antibody (- lanes). The E5 and HA b d
indicated by black dots; the other bands originate from the translated E5 protein (see input lanes) and may represent multimers of E5. an s are
shown that BPV-4 E5 physically interacts with the He of the bo-
vine MHe 1 providing an additional mechanism to the alkalinisa-
tion of the ciA for the retention of the complex in the GA.
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To
investigate whether this was the case also for HPV-16 E5, we per-
formed coimmunoprecipitation experiments between E5 and HLA
I He with monoclonal antibody (mAb) HAll (against the HA tag
of E5), in E5-expressing and control Haf'a'T keratinocytes, which
are known to express HLA-A3, A31 860 B51. A clear band was
present in t.he precipitate from ES-e~pressing cells, while no band
correspondmg to He was detected In t~7 precipitate from control
cells (FIg. la, lanes 4 and 7). ln addition to being detected b
mAb Hel 0, specific for HLA class I, the band corresponded to th~
He detected In the protem lysate by Western blotting (Fig I
lanes I and 2), leading to its identification as He, and to the 'co~~
elusion that E5 and HLA-A3 He (and possibly A31 B60 BSI
suggested by the double He band) exist in a physical comple~ f~
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FIGURE 2 _ Deletion mutants ofE5 express to the same levels and have similar cellular localisation to E5 wt. (a) Diagrammatic representation
of E5 wt, showing the 3 hydrophobic domains, and E5 mutants, showing the missing domains of ES; (b) Quantitative RT-PCR for ES wt, E5 mu-
tant and actin RNA, showing that the E5 mutants express at comparable levels; note that the right-hand y-axis represents the amount of E5 RNA
and is I X 10-4 that of the left-hand y-axis, which represents the amount of actin RNA; (c) Semi-quantitative RT-PCR for ES wt. E5 mutant
and actin RNA, showing that E5 Dell mutant express at levels comparable with E5 wt. The y-axis represents the band intensity after 25 amplifi-
cation cycles as measured by ImageQuant v5.2 software. (d) GFP-fusion forms of E5 wt or E5 mutants, transiently transfected in HaCaT kerati-
nocytes, were visualised at the confocal microscope, along with the GA stained with BODIPY-TR-ceramide and the nucleus stained with DAP!.
Only the merged images are presented (in greyscale), which show that E5 wt and mutants localise in the GA and ER. As the HaCaT cells were
transiently transfected with the GFP plasmids, GFP-E5 fusion proteins are expressed only in a minority of cells.
E5-expressing HaCaT cells (Dell is a noninteracting mutant of
E5, which is described later). The relative faintness of the HC
band coprecipitated with E5 is due to the very low level of E5 in
these cells: E5 is expressed at approximately 4 orders of magni-
tude lower than actin (see Fig. 2b and Ref. 4). Additionally, we
~erformed an in vitro coimmunoprecipitation experiment between
sS-labelled E5 and HLA-A2 He, as a similar experiment had al-
ready validated the interaction between BPY -4 E5 and bovine
MHC I ne." Physical interaction between E5 and He was con-
firmed by the coimmunoprecipitation of 3sS-labelled E5 and HLA-
A2 with mAb HC-lO (Fig. Ib, lane 7). Moreover, the formation of
a complex between E5 and HLA-A2 HC in vitro indicates that the
interaction is not specific for a particular HLA 1haplotype.
£5 interacts with the He of different HLA I haplotypes
To investigate whether E5 interacts with different l-!C, and. as
the in vitro interaction between E5 and HC reflects the mteracuon
occurring in vivo, we performed in vitro coprecipitation experi-
ments with E5 and Al or B8 He. In both cases, E5 and He copre-
cipitated when either mAb HCIO or mAb HAll was used
(Figs. ld-lg, lanes 7). Although a faint band corresponding to Al
or B8 HC was detected with mAb HAll even In the absence of
E5, the band was stronger when E5 was present, particularly in the
case of B8, giving confidence that the coprecipitation reflects a
genuine interaction. As E5 interacts with A3 in HaeaT cells and
with AI, A2 and B8 in vitro, we conclude that the interaction
between E5 and He is likely to take part with most, if not all, clas-
sic HLA I alleles.
Characterisation of £5 mutants
HPV-16 E5 is a transmembrane protein containing 3 well-
defined hydrophobic regions, of which the first one is the lon-
gest.12•13 To determine the E5 domain responsible for downregula-
tion of surface HLA I, deletion mutants of E5, lacking helical do-
main 1,2 or 3, were assayed for their ability to retain HLA I in the
GA. Mutant R79 lacks the last 5 C-terminal amino acids, A54
lacks the complete third hydrophobic domain, Y36 and R30 lack
the second and third hydrophobic domains and Dell lacks the first
hydrophobic domain (Fig. 2a). Before any analysis of the E5
mutants was carried out, we made sure that their expression and
cellular localisation were not different from those of E5 wt.
Expression of £5 in stably transfected cells. We verified that
the E5 proteins were being transcribed to a similar extent using
quantitative RT-peR (Q-RT-peR). RNA was isolated from 3
clones each of HaCa'I' keratinocytes stably transfected with E5 wt
or mutants. The level of E5 or E5 mutant RNA (with the exception
of E5 Dell, see later) was determined and compared to the level
of (3-actin RNA. Representative re ults from 1 clone each of E5
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FIGURE 3 _ The first hydrophobic domain of E5 mediates the downregulation of surface I-!LA I. (a), HaCaT parental cells, HaCaT carrying
empty vector, or expressing E5 wt or mutants were analysed by How cytometry for surface (white bars) and total HLA T (grey bars). The average
mean fluorescence was calculated from the How cytometry analyses of 2 duplicate measurements from at least 3 clones of each cell line. The
background (the reading of cells stained with no primary antibody and only secondary antibody) was 0.4 in all cases. Standard deviation is
shown. Dell fails to downregulate surface HLA r. The dotted line indicates the level of surface HLA T in parental and control cells. The HLA I
values for Dell are boxed. (b) The same cells were stained with mAb W6/32 and analysed by cytoimmunoHuorescence. Dell mutant failed to
retain HLA I in the GA (highlighted with 0). Although only a few cells are shown, the localisation of HLA I was the same in all cells of each
clone. N, nucleus.
wt and mutants are shown in Figure 2b. The levels of E5 wt or mu-
tant RNA were very low, approximately 4 orders of magnitude
less than actin RNA as previously found"; however, they were
comparable among clones, ranging approximately [Tom 0.02 to
0.03 pg per 100 ng RNA.
Dell RNA could not be amplified by Q-RT-PCR because no
forward primer compatible with the probe could be identified out-
side the first hydrophobic domain, so semi-quantitative RT-PCR
was used instead. Also in this case, there was no appreciable dif-
ference in the amounts of RNA between E5 wt and mutants,
including Dell (Fig.2c).
Cellular localisation of £5 proteins. Given the very low
expression levels of E5, it is not possible to determine the cellular
location of the protein by cytoimmunofluorescence. Therefore, we
decided to analyse E5 location by the use of GFP-E5 fusion pro-
teins. The correct cellular localisation of GFP-E5 fusion proteins
has been reported.l" HaCaT cells were transiently transfected with
plasm ids encoding GFP-fusions of E5 or E5 mutants or empty
EGFP vector; the GA was visualised by using the Golgi marker
BODlPY-TR-ceramide and the nucleus was stained with DAP!.
The localisation of the GFP-fusion proteins was determined by
three-colour confocal microscopy. There was no discernible dif-
ference in localisation between E5 and its mutants; in all cases,
the ES proteins were localised in the endomembranes, mainly the
GA, as shown by the merged images (Fig. 2d).
The first hydrophobic domain of £5 is responsible for surface
HLA I downregulation
As E5 wt and mutants were expressed to comparable levels and
localised to similar cellular compartments, we next investigated
which ES domain(s) was responsible for prevention of transport
of MHC class I to the cell surface and retention of the complex in
the GA. Using flow cytometry, we determined the levels of both
surface and total (surface plus intracellular) HLA I in parental
HaCaT, control cells harbouring empty vector, cells stably
expressing E5 wt or mutants. Control cells were not different from
parental cells, with approximately half as much surface HLA I
than total HLA I (Fig. 3a). In clones expressing E5 wt, the levels
of surface HLA I were reduced to approximately half that of con-
trol cells, as previously reported"; likewise, clones expressing the
E5 mutants containing the first hydrophobic domain (R79, A54,
V36, R30) had reduced levels of surface HLA [ to the same extent
as E5 wt (Fig. 3a). In contrast, expre sion of E5 Dell, lacking the
first hydrophobic domain, did not have any effect on the levels of
surface HLA [ (Fig. 3a). The failure of E5 Dell to downregulate
surface HLA I could be due to impaired stability of the protein.
However, Westem blotting of protein lysates from ES wt- or E5
Dell-expressing HaCaT cells showed that this is not the case as
ES wt and E5 Dell were present at comparable levels (Fig. Ic,
lanes I and 3).
From these results, we conclude that the first N-terminus 30
amino acid of E5 are responsible for the downregulation of HLA I.
This conclusion was confirmed by the locali ation of HLA 1 in
HaCaT cells expressing the E5 proteins. Cells carrying empty vec-
tor, expressing ES wt or ES mutants, were stained with mAb W6/
32 and analysed for HLA I by cytoirnmunofluorescence. In cells
expressing ES wt or mutants R79, A54, V36 or R30 (all containing
the first hydrophobic domain), HLA class I was detected only
intracellularly (Fig. 3b); in contrast, in cells expressing E5 Dell
HLA I was detected both on the cell surface and intracellularly, as
in control cells (Fig. 3b). These results, together with those
obtained by flow cytornetry, confirm that ES amino acids 1-30 are
responsible for the retention of HLA class I complex in the GA.
HPV-16 £5 binds HLA I He via its first helical domain
ES interacts with HLA 1 HC (Fig. I) and prevents the transport
of HLA I to the cell surface via its first hydrophobic domain
(Fig. 3). To investigate whether the same E5 domain was responsi-
ble for the interaction with HC, we performed in vivo and in vitro
coimmunoprecipitation experiments as earlier. In HaCaT cells
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FIGURE 4 _ Dell does not bind HC. (a) E5 wt, A54 and A2 HC were transcribed/translated in vitro in the presence of 35S-methionineand ca-
nine microsomes, mixed together and coprecipitated with mAb HCl 0 (+ lanes). Coprecipitates were observed only in the presence of antibody
and of A2 HC. (b) R30, Dell and A2 HC were processed as earlier. The only E5 mutant that did not interact with A2 was Dell (lane 5). (c) R30
and HLA-A2 HC were transcribed/translated ;/1 vitro as above and precipitated with an antibody against the N-terminus of E515 (+ lanes).
Coprecipitates were observed only in the presence of antibody. (d) E5 wt and HLA-A2 HC were transcribed/translated and labelled in vitro as
earlier; unlabelled R30 or Dell were added to the reactions, and proteins precipitated with mAb HC I0 (+ lanes). R30 competed with E5 wt and
prevented its binding to HC (lane 4), while Dell failed to do so (lane 9). Lanes I and 2 are the same as lanes 13 and 14, repealed for ease of com-
parison. In all panels, the coprecipitated E5. £5 mutants and HC bands are indicated by black dots; the other band originate from the translated
E5 protein (see input lanes) and may represent multimers of E5.
expressing E5 Dell, immunoprecipitation with mAb HAil failed
to precipitate HC (Fig. la, lanes 5 and 6), although in immuno-
blots HC was easily detected by mAb HClO (Fig. la, lane 3) and
E5 Dell and E5 wt were expressed at comparable levels at both
mRNA and protein levels (Figs. Ie (lanes I and 3) and 2c).
In in vitro coimmunoprecipitations, E5 wt and all the mutants
containing the first helical domain (including R30, which contains
only the first N-terminus 30 amino acids) coprecipitated with
HLA-A2 HC (Figs. 4a (lane 7) and 4b (lane 2), shown only for
A54 and R30). Despite the presence of nonspecific bands also in
the lanes without antibody (some deriving from the translation of
E5 and its mutants, possibly representing multimers of E5; see
input lanes), mAb HC-lO coprecipitated in each case both A2 and
the E5 proteins (marked with a black dot in Fig. 4). In contrast,
Dell failed to coprecipitate with HLA-A2 HC (Fig. 4b, lane 5).
Coimmunoprecipitation between R30 and HLA-A2 HC was con-
firmed by using an antibody raised against the N-tenninus of E5. t5
Also in this case, HLA-A2 HC coprecipitated with R30 (Fig. 4c,
lane 2), validating the results obtained with mAb HAil and
HClO. These data indicate that the interaction between E5 and HC
takes place via the N-tenninus first 30 amino acids. This was con-
firmed by competition experiments. The addition of unlabelled
R30 (containing the first 30 amino acids) to the reaction prevented
the interaction between E5 and A2 HC (Fig. 4d, lane 4), whereas
the addition of unlabelled Dell (amino acids 31-83) failed to com-
pete with E5 and did not affect the E5-HC interaction (Fig. 4d,
lane 9).
Taken together, these results conclusively show that E5 both
physically interacts with HC and downregulates surface HLA I via
its first hydrophobic domain.
Discussion
As i the case for the E5 oncoprotein of BPV,9-11.16the E5 on-
coprotein of HPV -16 prevents the transport of HLA I to the cell
surface and retains the complex in the GA.4 We have argued that
the Golgi retention of MHC I by BPV -4 E5 is due to at least 2
events: the impaired acidification of the GA and the physical inter-
action of E5 with the HC of MHC I.
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HPV-J6 £5 interacts with He
The interaction between E5 and the MHC I HC is not confined
to Spy E5. HPY-16 E5 forms a stable complex with the HC of
the HLA-A3 (and/or A31 S60 S51) of HaCaT keratinocytes, and
in vitro also with the HC of HLA-Al, -A2 and -S8. This interac-
tion is therefore not specific for a particular HLA I haplotype/al-
lele but it is likely to occur with most, if not all, HLA I. Complex'
formation between E5 and HC is responsible for downregulation
of surface HLA I, as a mutant of E5, which fails to bind HC, also
fails to prevent the transport of HLA I to the cell surface, as dis-
cussed later.
However, while the haplotype/allele of classical HLA I is not
critical for E5-HC complex formation, E5 fails to downregulate
nonclassical HLA 1.4 These findings parallel those obtained with
SPY-4 E5. SPY-4 E5 downregulates classical MHC I independ-
ently of its type 16 and interacts with different HC,IO but fails to
downregulate nonclassical MHC I and to interact with the HC of a
nonclassical MHC I (our unpublished results). It remains to be
seen if HPY -16 E5 is capable of binding the HC of nonclassical
HLAI.
The first N-terminus hydrophobic domain of £5 is essential for
downregulation of HLA J
HPY-16 E5 interacts also with 16 k subunit c, a component of
the vacuolar H+ -ATPase.17 Previously published deletion
mutants of E5 have been proficiently used to map the domain of
E5 mediating this interaction (see later"), These mutants and the
new N-terminus deletion mutant of E5 showed the importance of
the first N-terminus 30 amino acids in the interaction with and
downregulation of, HLA I. The absence of the middle and last
hydrophobic domains does not prevent downregulation of surface
HLA I, and the 30 amino acid-long N-terminus hydrophobic pep-
tide is sufficient to prevent the traffic of HLA I to the cell sur-
face. In contrast, the absence of the first hydrophobic N-terminus
domain completely abolishes surface HLA I downregulation. The
impaired function of this Dell mutant is not due to diminished
expression or inappropriate cellular localisation, as both expres-
sion and localisation are comparable to those of E5 wt or the
other mutants. Furthermore, Dell fails to interact with the HLA I
HC both in HaCaT cells and in vitro, the latter observation con-
firming that the inability of Dell to complex with HC is not due
to improper expression or location. Of importance is the fact that
R30, comprising only the first 30 amino acids, is capable of inter-
acting with and downregulating HLA I to the same extent as E5
wt, thus largely eliminating the possibility that the failure of
Dell to downregulate HLA I is due to improper configuration,
instability or any other feature which may be peculiar to this de-
letion mutant.
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We have recently reported that SPY E5 interacts with the HC
of bovine MHC I via its C-terminus domain.!" This contrasts with
the results presented here with HPY -16 E5 but this difference is
not surprising. Despite their differences in length and presumed
conformation, SPY E5 and HPY E5 share numerous functional
similarities, one of them being the interference with the proper
function of 16 k duct in (and therefore of the vacuolar ATPase).7
Spy E5 and HPY-16 E5 interact with 16 k subunit c via different
E5 domains: SPY E5 interacts via its 17th amino acid residue (Q
in BPY-I E5, N in SPY-4 E5IK.19), whereas HPY-16 E5 interacts
via its second and third hydrophobic domains.s.2o Thus, the same
effects, such as downregulation of MHC I and disablement of the
proton pump, can be achieved by distinct physical interactions
with HC and subunit c, respectively.
The interaction between HPY-16 E5 and 16 k subunit c has
been deemed responsible for the impaired functioning of the pump
and the conse~uent lack of acidification of the en do membrane
compartments. 1.22 Alkaline pH in the endolysosomes leads to
delayed degradation and faster recycling of the epidermal growth
factor receptor,22.23 thus promoting increased cell proliferation.
Studies with deletion mutants, including those employed by us
here, have mapped the 16 k-interacting domain of HPY-16 E5 to a
relatively large region of E5 encompassing the second and third
hydrophobic domains.s.2o The observation that HPY-16 E5 inter-
acts with HC and 16 k via different domains suggests that E5 can
in principle bind the 2 cellular partners at the same time, thus
simultaneously promoting immunomodulation and cell transfor-
mation, partly explaining the pleiotropic effects of E5 expression,
We have commented before on the functional similarity between
HPY-16 E5 and HIY-I Nef. Both proteins prevent transport of clas-
sical HLA I to the cell surface in their natural host cells type,24 bind
to the HLA I HC via the same domains needed for HLA Idownre-
gulariorr'" and neither downregulate nonclassical HLA f6; both
bind 16k subunit C27 and induce cytoskeletal rearrangements.Pv"
and induce epidermal hyperplasia when expressed in the basal layer
of the skin of transgenic mice.30•31 These similarities are intriguing
and point to a process of 'convergent evolution' of these 2 proteins
encoded by such different viruses,
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